6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 36_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 1_CD Accounting_NN policies_NNS The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN in_IN accordance_NN with_IN applicable_JJ accounting_NN standards_NNS and_CC under_IN United_NNP Kingdom_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS UK_NNP GAAP_NNP ._.
The_DT particular_JJ accounting_NN policies_NNS adopted_VBN by_IN the_DT Directors_NNS ,_, are_VBP described_VBN below_IN ._.
The_DT accounting_NN policies_NNS ,_, applied_VBD consistently_RB throughout_IN the_DT year_NN and_CC the_DT preceding_JJ year_NN ,_, are_VBP described_VBN below_IN ._.
Certain_JJ balances_NNS reported_VBN in_IN 2003_CD have_VBP been_VBN reclassified_VBN to_TO conform_VB to_TO the_DT 2004_CD presentation_NN including_VBG restricted_VBN cash_NN from_IN cash_NN at_IN bank_NN and_CC in_IN hand_NN to_TO restricted_VBN cash_NN and_CC the_DT inclusion_NN of_IN equity_NN method_NN investments_NNS ._.
a_DT Accounting_NN convention_NN The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN ._.
b_NN Basis_NN of_IN consolidation_NN The_DT consolidated_JJ financial_JJ statements_NNS incorporate_VBP the_DT financial_JJ statements_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC all_DT its_PRP$ subsidiary_NN undertakings_NNS drawn_VBN up_RP to_TO 31_CD December_NNP each_DT year_NN ._.
c_NN Acquisitions_NNS and_CC disposals_NNS On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, including_VBG an_DT interest_NN in_IN an_DT associated_VBN undertaking_NN ,_, fair_JJ values_NNS are_VBP attributed_VBN to_TO the_DT Groups_NNS share_NN of_IN net_JJ separable_JJ assets_NNS ._.
Where_WRB the_DT cost_NN of_IN the_DT acquisition_NN exceeds_VBZ the_DT fair_JJ values_NNS attributable_JJ to_TO such_JJ net_JJ assets_NNS ,_, the_DT difference_NN is_VBZ treated_VBN as_IN purchased_VBN goodwill_NN and_CC capitalized_VBN in_IN the_DT balance_NN sheet_NN in_IN the_DT year_NN of_IN acquisition_NN ._.
The_DT profit_NN or_CC loss_NN on_IN the_DT disposal_NN of_IN a_DT previously_RB acquired_VBN business_NN includes_VBZ the_DT attributable_JJ amount_NN of_IN any_DT purchased_VBN goodwill_NN relating_VBG to_TO that_DT business_NN not_RB previously_RB charged_VBN through_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT results_NNS and_CC cash_NN flows_NNS relating_VBG to_TO a_DT business_NN are_VBP included_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN and_CC the_DT consolidated_JJ cash_NN flow_NN statement_NN from_IN the_DT date_NN of_IN acquisition_NN up_IN to_TO the_DT date_NN of_IN disposal_NN ._.
d_LS Intangible_JJ assets_NNS goodwill_NN For_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, including_VBG an_DT interest_NN in_IN an_DT associated_VBN undertaking_NN ,_, purchased_VBD goodwill_NN is_VBZ capitalized_VBN in_IN the_DT year_NN in_IN which_WDT it_PRP arises_VBZ and_CC amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ economic_JJ life_NN up_IN to_TO a_DT maximum_NN of_IN 20_CD years_NNS ._.
The_DT Directors_NNS regard_VBP 20_CD years_NNS as_IN a_DT reasonable_JJ maximum_NN for_IN the_DT estimated_VBN useful_JJ economic_JJ life_NN of_IN goodwill_NN since_IN it_PRP is_VBZ difficult_JJ to_TO make_VB projections_NNS exceeding_VBG this_DT period_NN ._.
Provision_NNP is_VBZ made_VBN for_IN any_DT impairment_NN ._.
The_DT asset_NN is_VBZ deemed_VBN to_TO be_VB impaired_VBN to_TO the_DT extent_NN that_IN the_DT carrying_VBG amount_NN exceeds_VBZ the_DT recoverable_JJ amount_NN ._.
The_DT impairment_NN is_VBZ recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Goodwill_NN is_VBZ denominated_VBN in_IN the_DT currency_NN in_IN which_WDT the_DT acquisition_NN is_VBZ made_VBN ._.
Capitalised_VBN purchased_VBN goodwill_NN in_IN respect_NN of_IN subsidiaries_NNS is_VBZ included_VBN within_IN intangible_JJ assets_NNS ._.
Capitalised_NNP purchased_VBD goodwill_NN relating_VBG to_TO associates_NNS is_VBZ included_VBN within_IN the_DT carrying_VBG value_NN of_IN the_DT associate_NN ._.
Goodwill_NN arising_VBG on_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, prior_RB to_TO the_DT implementation_NN of_IN FRS_NNP 10_CD ,_, which_WDT was_VBD written-off_JJ to_TO the_DT profit_NN and_CC loss_NN reserve_NN as_IN a_DT matter_NN of_IN accounting_NN policy_NN ,_, remains_VBZ eliminated_VBN in_IN that_DT reserve_NN and_CC will_MD be_VB charged_VBN or_CC credited_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN as_IN appropriate_JJ on_IN the_DT subsequent_JJ disposal_NN of_IN the_DT business_NN to_TO which_WDT it_PRP relates_VBZ ._.
e_LS Intangible_JJ assets_NNS intellectual_JJ property_NN Intellectual_NNP property_NN ,_, including_VBG trademarks_NNS ,_, for_IN products_NNS with_IN an_DT immediate_JJ defined_VBN revenue_NN stream_NN and_CC acquired_VBN for_IN valuable_JJ consideration_NN ,_, is_VBZ capitalized_VBN and_CC amortised_VBN in_IN equal_JJ annual_JJ instalments_NNS over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT product_NN generally_RB not_RB exceeding_VBG 20_CD years_NNS ._.
Where_WRB a_DT product_NN exceeds_VBZ 20_CD years_NNS the_DT Group_NNP believes_VBZ that_IN the_DT product_NN is_VBZ well-established_JJ in_IN its_PRP$ market_NN ._.
The_DT Company_NN anticipates_VBZ these_DT products_NNS to_TO be_VB sold_VBN for_IN the_DT forseeable_JJ future_NN because_IN of_IN the_DT market_NN positioning_NN of_IN the_DT product_NN and_CC the_DT likelihood_NN of_IN a_DT competitor_NN entering_VBG the_DT relevant_JJ market_NN ._.
Intellectual_NNP property_NN acquired_VBD for_IN valuable_JJ consideration_NN but_CC with_IN no_DT defined_VBN revenue_NN stream_NN is_VBZ written-off_JJ on_IN acquisition_NN ._.
f_LS Tangible_JJ assets_NNS Depreciation_NN is_VBZ not_RB provided_VBN on_IN freehold_JJ land_NN ._.
All_DT other_JJ tangible_JJ fixed_JJ assets_NNS are_VBP shown_VBN at_IN cost_NN less_JJR accumulated_VBN depreciation_NN and_CC any_DT provision_NN for_IN impairment_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight_JJ line_NN basis_NN at_IN rates_NNS calculated_VBN to_TO write-off_NN the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN at_IN the_DT following_JJ annual_JJ rates_NNS :_: Freehold_NNP buildings_NNS 2-5_CD %_NN per_IN annum_NN Office_NNP furniture_NN and_CC fittings_NNS 10-25_CD %_NN per_IN annum_NN Equipment_NNP and_CC other_JJ 10-25_CD %_NN per_IN annum_NN 36_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 37_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 1_CD Accounting_NN policies_NNS continued_VBD g_NNP Investments_NNP Except_IN as_IN stated_VBN below_IN ,_, investments_NNS held_VBD as_IN fixed_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provision_NN for_IN any_DT impairment_NN ._.
In_IN the_DT consolidated_JJ accounts_NNS ,_, shares_NNS in_IN joint_JJ ventures_NNS are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
The_DT consolidated_JJ profit_NN and_CC loss_NN account_NN includes_VBZ the_DT Groups_NNS share_NN of_IN pre-tax_JJ profits_NNS and_CC attributable_JJ taxation_NN ._.
In_IN the_DT consolidated_JJ balance_NN sheet_NN ,_, the_DT investment_NN in_IN joint_JJ ventures_NNS is_VBZ shown_VBN as_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS of_IN the_DT joint_JJ ventures_NNS ._.
Current_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
h_NN Stocks_NNS Stocks_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Cost_NN incurred_VBN in_IN bringing_VBG each_DT product_NN to_TO its_PRP$ present_JJ location_NN and_CC condition_NN is_VBZ based_VBN on_IN purchase_NN costs_NNS calculated_VBN on_IN a_DT first-in_NN ,_, first-out_JJ basis_NN ,_, including_VBG transport_NN ._.
Net_JJ realisable_JJ value_NN is_VBZ based_VBN on_IN estimated_VBN normal_JJ selling_NN price_NN less_RBR further_JJ costs_NNS expected_VBN to_TO be_VB incurred_VBN to_TO completion_NN and_CC disposal_NN ._.
Provision_NNP is_VBZ made_VBN for_IN obsolete_JJ ,_, slow_JJ moving_VBG or_CC defective_JJ items_NNS where_WRB appropriate_JJ ._.
i_FW Deferred_JJ taxation_NN Current_JJ tax_NN ,_, including_VBG UK_NNP corporation_NN tax_NN and_CC foreign_JJ tax_NN ,_, is_VBZ provided_VBN at_IN amounts_NNS expected_VBN to_TO be_VB paid_VBN or_CC recovered_VBN using_VBG the_DT tax_NN rates_NNS and_CC laws_NNS that_WDT have_VBP been_VBN enacted_VBN or_CC substantively_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN is_VBZ recognized_VBN in_IN respect_NN of_IN all_DT timing_NN differences_NNS that_WDT have_VBP originated_VBN but_CC not_RB reversed_VBD at_IN the_DT balance_NN sheet_NN date_NN where_WRB transactions_NNS or_CC events_NNS that_WDT result_VBP in_IN an_DT obligation_NN to_TO pay_VB more_JJR tax_NN in_IN the_DT future_NN or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN in_IN the_DT future_NN have_VB occurred_VBN at_IN the_DT balance_NN sheet_NN date_NN ._.
Timing_NN differences_NNS are_VBP differences_NNS between_IN the_DT Groups_NNS taxable_JJ profits_NNS and_CC its_PRP$ results_NNS as_IN stated_VBN in_IN the_DT financial_JJ statements_NNS that_WDT arise_VBP from_IN the_DT inclusion_NN of_IN gains_NNS and_CC losses_NNS in_IN tax_NN assessments_NNS in_IN periods_NNS different_JJ from_IN those_DT in_IN which_WDT they_PRP are_VBP recognized_VBN in_IN the_DT financial_JJ statements_NNS ._.
A_DT net_JJ deferred_VBN tax_NN asset_NN is_VBZ regarded_VBN as_IN recoverable_JJ and_CC therefore_RB recognized_VBN only_RB when_WRB ,_, on_IN the_DT basis_NN of_IN all_DT available_JJ evidence_NN ,_, it_PRP can_MD be_VB regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN there_EX will_MD be_VB suitable_JJ taxable_JJ profits_NNS from_IN which_WDT the_DT future_JJ reversal_NN of_IN the_DT underlying_VBG timing_NN differences_NNS can_MD be_VB deducted_VBN ._.
Deferred_JJ tax_NN is_VBZ not_RB provided_VBN on_IN timing_NN differences_NNS arising_VBG on_IN unremitted_JJ earnings_NNS of_IN subsidiaries_NNS and_CC associates_NNS where_WRB there_EX is_VBZ no_DT commitment_NN to_TO remit_VB these_DT earnings_NNS ._.
Deferred_JJ tax_NN is_VBZ measured_VBN at_IN the_DT rates_NNS that_WDT are_VBP expected_VBN to_TO apply_VB in_IN the_DT periods_NNS in_IN which_WDT the_DT timing_NN differences_NNS are_VBP expected_VBN to_TO reverse_VB ,_, based_VBN on_IN tax_NN rates_NNS and_CC laws_NNS that_WDT have_VBP been_VBN enacted_VBN or_CC substantively_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT deferred_JJ tax_NN balances_NNS are_VBP not_RB discounted_VBN ._.
j_NN Turnover_NN The_DT Group_NNP recognizes_VBZ turnover_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT arrangement_NN :_: delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN :_: the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ fixed_VBN or_CC determinable_JJ :_: and_CC collectibility_NN is_VBZ reasonably_RB assured_VBN ._.
Revenues_NNS are_VBP stated_VBN net_NN of_IN VAT_NNP and_CC similar_JJ taxes_NNS ,_, trade_NN discounts_NNS and_CC intra-Group_JJ transactions_NNS ._.
The_DT principal_JJ components_NNS of_IN the_DT Groups_NNS turnover_NN and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP set_VBN out_RP below_IN :_: Revenue_NN from_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS or_CC at_IN the_DT time_NN of_IN delivery_NN depending_VBG on_IN the_DT terms_NNS of_IN sale_NN ._.
Provisions_NNS for_IN certain_JJ rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO net_JJ turnover_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN :_: Licensing_NN and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN licence_NN agreements_NNS and_CC from_IN collaborative_JJ research_NN and_CC development_NN arrangements_NNS :_: 37_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 38_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 1_CD Accounting_NN policies_NNS continued_VBD Initial_JJ licence_NN fees_NNS are_VBP not_RB considered_VBN to_TO be_VB separable_JJ from_IN the_DT associated_VBN research_NN and_CC development_NN activities_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP non-refundable_JJ and_CC not_RB creditable_JJ against_IN research_NN and_CC development_NN services_NNS to_TO be_VB rendered_VBN ._.
Initial_JJ licence_NN fees_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT licence_NN term_NN or_CC the_DT period_NN of_IN the_DT associated_VBN research_NN and_CC development_NN agreement_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ licence_NN fees_NNS are_VBP not_RB for_IN a_DT defined_VBN period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT licence_NN relates_VBZ :_: During_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS ,_, the_DT Group_NNP receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenue_NN is_VBZ recognized_VBN on_IN achievement_NN of_IN milestones_NNS :_: and_CC The_DT Group_NNP also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB receivable_NN ._.
If_IN milestone_NN payments_NNS are_VBP creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, the_DT milestones_NNS are_VBP deferred_VBN and_CC released_VBN over_IN the_DT period_NN in_IN which_WDT the_DT royalties_NNS are_VBP anticipated_VBN to_TO be_VB paid_VBN ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
k_NN Research_NN and_CC development_NN Research_NN and_CC development_NN expenditure_NN includes_VBZ funded_VBN and_CC unfunded_JJ expenditure_NN and_CC is_VBZ written-off_JJ in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
l_NN Pensions_NNS The_DT Group_NNP contributes_VBZ to_TO personal_JJ defined_VBN contribution_NN pension_NN plans_NNS of_IN employees_NNS ._.
Contributions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP become_VBP payable_JJ ._.
Differences_NNS between_IN contributions_NNS payable_JJ and_CC contributions_NNS actually_RB paid_VBN are_VBP shown_VBN as_IN either_DT accruals_NNS or_CC prepayments_NNS in_IN the_DT balance_NN sheet_NN ._.
m_NNP Foreign_NNP currency_NN Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN at_IN the_DT rate_NN of_IN exchange_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Monetary_NNP assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS at_IN the_DT balance_NN sheet_NN date_NN are_VBP reported_VBN at_IN the_DT rates_NNS of_IN exchange_NN prevailing_VBG at_IN that_DT date_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS are_VBP translated_VBN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS arising_VBG on_IN translation_NN of_IN the_DT opening_NN net_JJ assets_NNS and_CC on_IN foreign_JJ currency_NN borrowings_NNS ,_, to_TO the_DT extent_NN that_IN they_PRP hedge_VBP the_DT Groups_NNS investments_NNS in_IN such_JJ operations_NNS ,_, are_VBP reported_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
All_DT other_JJ exchange_NN differences_NNS are_VBP included_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
n_JJ Leases_NNP Assets_NNPS acquired_VBD under_IN finance_NN leases_NNS are_VBP capitalized_VBN at_IN their_PRP$ fair_JJ value_NN on_IN the_DT inception_NN of_IN the_DT leases_NNS and_CC depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN the_DT lease_NN and_CC the_DT useful_JJ economic_JJ lives_NNS of_IN the_DT assets_NNS ._.
The_DT finance_NN charges_NNS are_VBP allocated_VBN over_IN the_DT period_NN of_IN the_DT lease_NN in_IN proportion_NN to_TO the_DT capital_NN amount_NN outstanding_JJ and_CC are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Operating_VBG lease_NN rentals_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN equal_JJ amounts_NNS over_IN the_DT lease_NN term_NN ._.
o_NN Finance_NNP costs_VBZ Finance_NNP costs_NNS of_IN debt_NN are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT term_NN of_IN the_DT debt_NN at_IN a_DT constant_JJ rate_NN on_IN the_DT carrying_VBG amount_NN ._.
p_NN Debt_NNP Debt_NNP is_VBZ initially_RB stated_VBN at_IN the_DT amount_NN of_IN the_DT net_JJ proceeds_NNS after_IN deduction_NN of_IN issue_NN costs_NNS ._.
The_DT carrying_VBG amount_NN is_VBZ increased_VBN by_IN the_DT finance_NN cost_NN in_IN respect_NN of_IN the_DT accounting_NN period_NN and_CC reduced_VBN by_IN payments_NNS made_VBN in_IN the_DT period_NN ._.
Convertible_JJ debt_NN is_VBZ treated_VBN as_IN a_DT liability_NN as_RB long_RB as_IN there_EX is_VBZ no_DT genuine_JJ commercial_JJ possibility_NN that_IN the_DT option_NN to_TO issue_VB ordinary_JJ shares_NNS or_CC American_JJ Depositary_NNP Shares_NNP will_MD be_VB exercised_VBN ._.
q_NNP Government_NNP grants_NNS Government_NNP grants_NNS in_IN respect_NN of_IN funded_JJ research_NN and_CC development_NN expenditure_NN are_VBP credited_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN the_DT related_JJ expenditure_NN is_VBZ incurred_VBN ._.
38_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 39_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 1_CD Accounting_NN policies_NNS continued_VBD r_NN Derivative_JJ financial_JJ instruments_NNS The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO reduce_VB exposure_NN to_TO foreign_JJ exchange_NN risk_NN and_CC interest_NN rate_NN movements_NNS ._.
The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS for_IN speculative_JJ purposes_NNS ._.
For_IN a_DT forward_RB foreign_JJ exchange_NN contract_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ foreign_JJ currency_NN assets_NNS or_CC liabilities_NNS or_CC to_TO a_DT probable_JJ commitment_NN ._.
It_PRP must_MD involve_VB the_DT same_JJ currency_NN or_CC similar_JJ currencies_NNS as_IN the_DT hedged_VBN item_NN and_CC must_MD also_RB reduce_VB the_DT risk_NN of_IN foreign_JJ currency_NN exchange_NN movements_NNS on_IN the_DT Groups_NNS operations_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG on_IN these_DT contracts_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ,_, or_CC as_IN adjustments_NNS to_TO the_DT carrying_VBG amount_NN of_IN fixed_JJ assets_NNS ,_, only_RB when_WRB the_DT hedged_VBN transaction_NN has_VBZ itself_PRP been_VBN reflected_VBN in_IN the_DT Groups_NNS accounts_NNS ._.
For_IN an_DT interest_NN rate_NN swap_NN to_TO be_VB treated_VBN as_IN a_DT hedge_NN the_DT instrument_NN must_MD be_VB related_VBN to_TO actual_JJ assets_NNS or_CC liabilities_NNS or_CC a_DT probable_JJ commitment_NN and_CC must_MD change_VB the_DT nature_NN of_IN the_DT interest_NN rate_NN by_IN converting_VBG a_DT fixed_JJ rate_NN to_TO a_DT variable_JJ rate_NN or_CC vice_NN versa_RB ._.
Interest_NN differentials_NNS under_IN these_DT swaps_NNS are_VBP recognized_VBN by_IN adjusting_VBG net_JJ interest_NN payable_JJ over_IN the_DT periods_NNS of_IN the_DT contracts_NNS ._.
If_IN an_DT instrument_NN ceases_VBZ to_TO be_VB accounted_VBN for_IN as_IN a_DT hedge_NN ,_, for_IN example_NN because_IN the_DT underlying_VBG hedged_JJ position_NN is_VBZ eliminated_VBN ,_, the_DT instrument_NN is_VBZ marked_VBN to_TO market_NN and_CC any_DT resulting_JJ profit_NN or_CC loss_NN recognized_VBN at_IN that_DT time_NN ._.
s_PRP Associates_NNPS In_IN the_DT Group_NNP financial_JJ statements_NNS investments_NNS in_IN associates_NNS are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN ._.
The_DT consolidated_JJ profit_NN and_CC loss_NN account_NN includes_VBZ the_DT Groups_NNS share_NN of_IN associates_NNS profits_NNS less_RBR losses_NNS while_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS of_IN the_DT associates_NNS is_VBZ shown_VBN in_IN the_DT consolidated_JJ balance_NN sheet_NN ._.
Goodwill_NN arising_VBG on_IN the_DT acquisition_NN of_IN associates_NNS is_VBZ accounted_VBN for_IN in_IN accordance_NN with_IN the_DT policy_NN set_VBN out_RP above_IN ._.
Any_DT unamortised_JJ goodwill_NN is_VBZ included_VBN in_IN the_DT carrying_VBG value_NN of_IN the_DT investments_NNS in_IN associates_NNS ._.
t_VB Employee_NNP share_NN schemes_NNS In_IN accordance_NN with_IN UITF_NNP Abstract_NNP 17_CD Employee_NN share_NN schemes_NNS ,_, the_DT cost_NN of_IN awards_NNS to_TO employees_NNS that_WDT take_VBP the_DT form_NN of_IN shares_NNS or_CC rights_NNS to_TO shares_NNS is_VBZ recognized_VBN as_IN a_DT charge_NN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
The_DT amount_NN recognized_VBN ,_, which_WDT is_VBZ the_DT difference_NN between_IN the_DT market_NN value_NN at_IN date_NN of_IN grant_NN of_IN the_DT underlying_JJ share_NN and_CC any_DT exercise_NN price_NN ,_, is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN the_DT shares_NNS are_VBP vested_VBN ,_, with_IN a_DT corresponding_JJ credit_NN to_TO reserves_NNS ._.
u_NNP Related_NNP party_NN transactions_NNS In_IN accordance_NN with_IN the_DT exemptions_NNS in_IN FRS_NNP 8_CD related_JJ party_NN disclosures_NNS ,_, transactions_NNS between_IN Group_NNP companies_NNS have_VBP not_RB been_VBN disclosed_VBN since_IN Group_NNP accounts_NNS are_VBP prepared_JJ and_CC include_VBP the_DT results_NNS of_IN all_DT subsidiary_NN undertakings_NNS ._.
v_FW Significant_JJ accounting_NN estimates_NNS Sales_NNS deductions_NNS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP and_CC other_JJ Government_NN agencies_NNS ,_, contractual_JJ rebates_NNS with_IN health-maintenance_NN organizations_NNS HMOs_NNS ,_, product_NN returns_NNS ,_, trade_NN discounts_NNS and_CC allowances_NNS for_IN the_DT coupon_NN sampling_VBG program_NN ._.
Statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS and_CC contractual_JJ rebates_NNS with_IN HMOs_NNS are_VBP based_VBN on_IN price_NN differentials_NNS between_IN a_DT base_NN price_NN and_CC the_DT selling_NN price_NN ._.
As_IN a_DT result_NN ,_, the_DT rebates_NNS increase_NN as_IN a_DT percentage_NN of_IN the_DT selling_NN price_NN over_IN the_DT life_NN of_IN the_DT product_NN ._.
Provision_NNP for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO turnover_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS with_IN estimates_NNS of_IN future_JJ utilisation_NN derived_VBN from_IN historical_JJ trends_NNS ._.
c_NN Turnover_NN and_CC profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN Licensing_NN and_CC Product_NN sales_NNS development_NN Royalties_NNP Other_JJ revenues_NNS Total_JJ Year_NN to_TO 31_CD December_NNP 2004 000 000 000_CD 000_CD 000_CD Turnover_NN 619,969_CD 7,391_CD 123,405_CD 3,766_CD 754,531_CD Cost_NN of_IN product_NN sales_NNS 84,477_CD 84,477_CD Distribution_NN costs_NNS 181,463_CD 181,463_CD Funded_VBN research_NN and_CC development_NN costs_NNS 14_CD 14_CD 354,029_CD 7,377_CD 123,405_CD 3,766_CD 488,577_CD Unfunded_JJ research_NN and_CC development_NN costs_NNS 112,520_CD Depreciation_NN ,_, amortisation_NN and_CC impairment_NN 199,963_CD Expenses_NNS not_RB allocated_VBN general_JJ overheads_NNS 110,399_CD Operating_NN profit_NN 65,695_CD Share_NN of_IN associates_NNS operating_VBG profit_NN 37_CD Profit_NN on_IN disposal_NN of_IN fixed_JJ asset_NN investment_NN 8,264_CD Loss_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS 23,191_CD Finance_NNP income_NN ,_, net_JJ 6,630_CD Profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 57,435_CD Licensing_NNP and_CC Product_NNP sales_NNS development_NN Royalties_NNP Other_JJ revenues_NNS Total_JJ Year_NN to_TO 31_CD December_NNP 2003 000 000 000_CD 000_CD 000_CD Turnover_NN 635,545_CD 2,232_CD 122,110_CD 1,181_CD 761,068_CD Cost_NN of_IN product_NN sales_NNS 102,384_CD 102,384_CD Distribution_NN costs_NNS 156,070_CD 156,070_CD Funded_VBN research_NN and_CC development_NN costs_NNS 3,273_CD 3,273_CD 377,091_CD 1,041_CD 122,110_CD 1,181_CD 499,341_CD Unfunded_JJ research_NN and_CC development_NN costs_NNS 128,381_CD Depreciation_NN ,_, amortisation_NN and_CC impairment_NN 582,889_CD Expenses_NNS not_RB allocated_VBN general_JJ overheads_NNS 88,006_CD Operating_NN loss_NN 299,935_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 2,806_CD Profit_NN on_IN disposal_NN of_IN fixed_JJ asset_NN investment_NN 698_CD Finance_NNP income_NN ,_, net_JJ 3,702_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 298,341_CD 40_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 41_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 2_CD Turnover_NN and_CC segment_NN information_NN continued_VBD d_SYM Analysis_NN of_IN net_JJ operating_NN expenses_NNS 2004 2003 000 000_CD Distribution_NN costs_NNS 181,463_CD 156,070_CD Research_NNP and_CC development_NN 112,534_CD 131,654_CD Administrative_JJ expenses_NNS 310,362_CD 670,895_CD 604,359_CD 958,619_CD 3_CD Operating_NN profit_NN loss_NN Operating_NN profit_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG crediting_VBG :_: 2004 2003 000 000_CD Depreciation_NN and_CC amounts_NNS written_VBN off_RP tangible_JJ fixed_JJ assets_NNS owned_VBN 12,409_CD 18,772_CD held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 107_CD 597_CD Amortisation_NNP and_CC amounts_VBZ written_VBN off_RP intellectual_JJ property_NN 29,164_CD 30,405_CD Amortisation_NNP and_CC amounts_VBZ written_VBN off_RP goodwill_NN 158,283_CD 533,115_CD Research_NNP and_CC development_NN 112,534_CD 131,654_CD Reorganisation_NN costs_NNS 26,529_CD 14,597_CD Government_NN grants_NNS 14_CD 2,169_CD Operating_NN lease_NN rentals_NNS plant_NN and_CC machinery_NN 3,580_CD 3,591_CD other_JJ 3,541_CD 3,868_CD Auditors_NNS remuneration_NN for_IN audit_NN services_NNS 1_CD Group_NNP 1,715_CD 630_CD 1_CD Company_NN 60_CD 20_CD Auditors_NNS remuneration_NN for_IN non-audit_JJ services_NNS 2_CD Group_NNP audit_NN related_VBN 1,172_CD 1,015_CD 3_CD Group_NNP tax_NN 2,583_CD 1,145_CD 4_CD Group_NNP other_JJ 100_CD 177_CD 4_CD Company_NN other_JJ 75_CD 1_CD Audit_NNP fees_NNS consisted_VBD of_IN audit_NN work_NN only_RB the_DT Companys_NNPS auditors_NNS can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN statutory_JJ audits_NN and_CC in_IN 2004_CD included_VBD the_DT audit_NN in_IN relation_NN to_TO internal_JJ control_NN over_IN US_NNP GAAP_NNP Form_NN 10-K_JJ financial_JJ reporting_NN ._.
2_CD Audit_NNP related_JJ fees_NNS consist_VBP of_IN work_NN generally_RB only_RB the_DT Companys_NNPS auditors_NNS can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN procedures_NNS relating_VBG to_TO regulatory_JJ filings_NNS ._.
3_CD Tax_NNP fees_NNS consisted_VBD principally_RB of_IN assistance_NN with_IN matters_NNS related_VBN to_TO compliance_NN ,_, planning_NN and_CC advice_NN in_IN various_JJ tax_NN jurisdictions_NNS ._.
4_CD All_DT other_JJ fees_NNS relate_VBP to_TO assistance_NN in_IN CSR_NNP and_CC executive_JJ remuneration_NN ._.
41_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 42_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 4_CD Directors_NNS remuneration_NN ,_, interests_NNS and_CC transactions_NNS Aggregate_JJ remuneration_NN The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2004 2003 000 000_CD Emoluments_NNP 2,592_CD 2,256_CD Money_NN purchase_NN pension_NN contributions_NNS 278_CD 4,676_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 118_CD 114_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 86_CD 276_CD Compensation_NNP for_IN loss_NN of_IN office_NN 1,335_CD 3,074_CD 8,657_CD No_DT fees_NNS were_VBD payable_JJ to_TO third_JJ parties_NNS in_IN respect_NN of_IN Directors_NNS services_NNS for_IN either_DT year_NN ._.
The_DT number_NN of_IN Directors_NNS who_WP were_VBD members_NNS of_IN a_DT Company_NN pension_NN scheme_NN was_VBD as_IN follows_VBZ :_: 2004_CD 2003_CD Number_NNP Number_NNP Money_NNP purchase_NN schemes_NNS 3_CD 4_CD Contributions_NNS paid_VBN by_IN the_DT Group_NNP in_IN respect_NN of_IN these_DT Directors_NNS can_MD be_VB found_VBN in_IN the_DT Directors_NNS remuneration_NN report_NN ._.
The_DT above_JJ amounts_NNS for_IN remuneration_NN include_VBP the_DT following_VBG in_IN respect_NN of_IN the_DT highest_JJS paid_VBN Director_NNP :_: 2004 2003 000 000_CD Aggregate_NNP emoluments_NNS 1,419_CD 311_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 21_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 183_CD Compensation_NNP for_IN loss_NN of_IN office_NN 1,335_CD 1,419_CD 1,850_CD Further_JJ disclosures_NNS relating_VBG to_TO Directors_NNS remuneration_NN and_CC interests_NNS in_IN transactions_NNS can_MD be_VB found_VBN in_IN the_DT Directors_NNS remuneration_NN report_NN ._.
5_CD Staff_NN costs_NNS Particulars_NNPS of_IN employee_NN costs_NNS including_VBG executive_JJ Directors_NNS remuneration_NN are_VBP shown_VBN below_IN :_: 2004 2003 000 000_CD Wages_NNS and_CC salaries_NNS 97,754_CD 85,026_CD Social_NNP security_NN costs_NNS 8,366_CD 8,527_CD Pension_NN contributions_NNS 4,914_CD 9,824_CD 111,034_CD 103,377_CD The_DT increase_NN in_IN wages_NNS and_CC salaries_NNS was_VBD ,_, in_IN part_NN ,_, driven_VBN by_IN employee_NN retention_NN and_CC relocation_NN payments_NNS that_WDT were_VBD paid_VBN during_IN the_DT year_NN as_IN part_NN of_IN the_DT US_NNP reorganisation_NN ._.
The_DT average_JJ monthly_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: 2004_CD 2003_CD Number_NNP Number_NNP Manufacturing_NNP and_CC distribution_NN 358_CD 374_CD Sales_NNS and_CC marketing_NN 837_CD 797_CD General_NNP and_CC administrative_JJ 265_CD 327_CD Research_NNP and_CC development_NN 432_CD 407_CD 1,892_CD 1,905_CD 42_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 43_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 6_CD Finance_NNP income_NN ,_, net_JJ 2004 2003 000 000_CD Investment_NN income_NN 2,607_CD 2,804_CD Interest_NN receivable_NN 11,917_CD 10,361_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS 7,856_CD 9,404_CD Finance_NNP leases_NNS and_CC hire_VB purchase_NN contracts_NNS 38_CD 59_CD 7,894_CD 9,463_CD Finance_NNP charges_NNS ,_, net_JJ Investment_NN income_NN 2,607_CD 2,804_CD Interest_NN receivable_NN 11,917_CD 10,361_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS 7,894_CD 9,463_CD 6,630_CD 3,702_CD In_IN August_NNP 2004_CD 202.6_CD million_CD of_IN the_DT convertible_JJ debt_NN was_VBD redeemed_VBN at_IN cost_NN by_IN the_DT note_NN holders_NNS and_CC as_IN a_DT result_NN costs_NNS of_IN 3.8_CD million_CD were_VBD expensed_VBN in_IN the_DT year_NN ._.
These_DT costs_NNS were_VBD being_VBG amortised_VBN through_IN the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT life_NN of_IN the_DT loan_NN notes_NNS ._.
These_DT costs_NNS have_VBP been_VBN partly_RB offset_VBN by_IN a_DT reduction_NN in_IN interest_NN payable_JJ for_IN the_DT period_NN from_IN redemption_NN of_IN the_DT loan_NN notes_VBZ up_RP to_TO 31_CD December_NNP 2004_CD ._.
Interest_NN payable_JJ and_CC similar_JJ charges_NNS includes_VBZ net_JJ exchange_NN gains_NNS on_IN foreign_JJ currency_NN borrowings_NNS less_RBR deposits_NNS of_IN 1.1_CD million_CD 2003_CD :_: 3.9_CD million_CD ._.
7_CD Tax_NNP on_IN profit_NN loss_NN on_IN ordinary_JJ activities_NNS The_DT tax_NN charge_NN comprises_VBZ :_: 2004 2003 000 000_CD Current_JJ tax_NN UK_NNP corporation_NN tax_NN 925_CD Foreign_NNP corporation_NN tax_NN 82,673_CD 76,830_CD Adjustment_NNP to_TO prior_JJ year_NN tax_NN charge_NN Foreign_JJ corporation_NN tax_NN 2,119_CD 512_CD Total_JJ current_JJ tax_NN 81,479_CD 77,342_CD Deferred_JJ tax_NN Origination_NNP and_CC reversal_NN of_IN timing_NN differences_NNS :_: Current_JJ year_NN 3,341_CD 17,040_CD Adjustment_NNP to_TO prior_JJ year_NN 7,272_CD 4,712_CD Total_JJ deferred_JJ tax_NN 10,613_CD 12,328_CD Total_JJ tax_NN on_IN profit_NN loss_NN on_IN ordinary_JJ activities_NNS 70,866_CD 65,014_CD 43_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 44_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 7_CD Tax_NNP on_IN profit_NN loss_NN on_IN ordinary_JJ activities_NNS continued_VBD The_DT differences_NNS between_IN the_DT total_JJ current_JJ tax_NN shown_VBN above_IN and_CC the_DT amount_NN calculated_VBN by_IN applying_VBG the_DT standard_JJ rate_NN of_IN UK_NNP corporation_NN tax_NN to_TO the_DT profit_NN before_IN tax_NN is_VBZ as_IN follows_VBZ :_: 2004 2003 000 000_CD Group_NNP profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN tax_NN 57,435_CD 298,341_CD Tax_NNP on_IN profit_NN loss_NN on_IN ordinary_JJ activities_NNS at_IN standard_JJ UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN 2003_CD :_: 30_CD %_NN 17,230_CD 89,502_CD Effects_NNPS of_IN :_: Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 7,318_CD 12,063_CD Non_NNP deductible_JJ goodwill_NN 47,813_CD 161,195_CD Additional_JJ tax_NN benefits_NNS non_VBP taxable_JJ income_NN 1,662_CD 891_CD Movement_NNP of_IN tax_NN losses_NNS 4,080_CD 1,385_CD Capital_NN taxes_NNS and_CC withholding_NN taxes_NNS 150_CD 1,548_CD Different_JJ tax_NN rates_NNS on_IN overseas_JJ earnings_NNS 5,358_CD 26,008_CD Deferred_JJ tax_NN liability_NN non_NN permanent_JJ timing_NN differences_NNS 10,613_CD 12,328_CD Effect_NN of_IN discontinued_VBN operations_NNS 10,686_CD Adjustments_NNS to_TO tax_NN charge_NN in_IN respect_NN of_IN previous_JJ periods_NNS 9,391_CD 5,224_CD Group_NNP current_JJ tax_NN charge_NN for_IN period_NN 81,479_CD 77,342_CD The_DT Group_NNP earns_VBZ a_DT significant_JJ proportion_NN of_IN its_PRP$ profits_NNS in_IN the_DT US_NNP ._.
The_DT US_NNP statutory_JJ federal_JJ tax_NN rate_NN is_VBZ higher_JJR than_IN that_DT of_IN the_DT UK_NNP with_IN profits_NNS being_VBG taxed_VBN at_IN 35_CD %_NN ._.
Other_JJ jurisdictions_NNS have_VBP lower_JJR effective_JJ tax_NN rates_NNS ._.
In_IN the_DT future_NN ,_, changes_NNS in_IN US_NNP tax_NN law_NN may_MD affect_VB the_DT Group_NNP tax_NN charge_NN ._.
No_DT tax_NN deduction_NN is_VBZ available_JJ on_IN the_DT impairment_NN of_IN goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
As_IN of_IN 31_CD December_NNP 2004_CD the_DT Company_NN has_VBZ not_RB made_VBN a_DT UK_NNP tax_NN provision_NN on_IN approximately_RB 729.2_CD million_CD of_IN unremitted_JJ earnings_NNS of_IN its_PRP$ international_JJ subsidiaries_NNS ._.
The_DT Company_NN does_VBZ not_RB provide_VB for_IN income_NN taxes_NNS on_IN the_DT unremitted_JJ earnings_NNS of_IN subsidiaries_NNS located_VBN outside_IN the_DT UK_NNP ,_, where_WRB such_JJ earnings_NNS have_VBP been_VBN retained_VBN indefinitely_RB for_IN reinvestment_NN ,_, or_CC where_WRB it_PRP is_VBZ managements_NNS intention_NN that_IN the_DT earnings_NNS will_MD be_VB remitted_VBN in_IN a_DT tax_NN free_JJ liquidation_NN ,_, or_CC as_IN dividends_NNS with_IN taxes_NNS substantially_RB offset_VBN by_IN foreign_JJ tax_NN credits_NNS ._.
It_PRP is_VBZ not_RB practical_JJ to_TO determine_VB the_DT amount_NN of_IN unrecognised_JJ deferred_JJ tax_NN liabilities_NNS for_IN temporary_JJ differences_NNS related_VBN to_TO these_DT investments_NNS ._.
8_CD Loss_NN attributable_JJ to_TO Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT loss_NN for_IN the_DT financial_JJ year_NN dealt_VBD with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN was_VBD 17,492,000_CD 2003_CD :_: profit_NN of_IN 194,246,000_CD ._.
As_IN provided_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN in_IN respect_NN of_IN the_DT Company_NN ._.
9_CD Dividends_NNPS paid_VBD and_CC proposed_VBD 2004 2003 000 000_CD Equity_NNP shares_NNS :_: First_NNP interim_JJ paid_VBN of_IN 1_CD penny_NN per_IN share_NN 2003_CD :_: nil_NN 4,967_CD Second_JJ interim_JJ proposed_VBN of_IN 2_CD pence_NN per_IN share_NN 2003_CD :_: nil_NN 9,952_CD 14,919_CD 44_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 45_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 10_CD Loss_NN per_IN share_NN Basic_JJ EPS_NNP is_VBZ based_VBN on_IN the_DT net_JJ profit_NN or_CC loss_NN attributable_JJ to_TO ordinary_JJ shareholders_NNS divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT year_NN ._.
Diluted_JJ EPS_NNP is_VBZ based_VBN on_IN the_DT net_JJ profit_NN or_CC loss_NN attributable_JJ to_TO ordinary_JJ shareholders_NNS divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT year_NN and_CC adjusted_VBN for_IN the_DT effect_NN of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS that_WDT were_VBD outstanding_JJ during_IN the_DT year_NN ._.
Share_NN options_NNS to_TO purchase_VB approximately_RB 16.6_CD million_CD ordinary_JJ shares_NNS for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD were_VBD not_RB dilutive_JJ and_CC were_VBD therefore_RB excluded_VBN from_IN the_DT computation_NN of_IN diluted_JJ loss_NN per_IN share_NN 2003_CD :_: 17.0_CD million_CD ._.
Warrants_NNS to_TO purchase_VB approximately_RB 1.3_CD million_CD ordinary_JJ shares_NNS for_IN the_DT year_NN to_TO 31_CD December_NNP 2003_CD were_VBD not_RB dilutive_JJ and_CC were_VBD therefore_RB excluded_VBN from_IN the_DT computation_NN of_IN diluted_JJ loss_NN per_IN share_NN ._.
The_DT $_$ 370_CD million_CD convertible_JJ loan_NN note_NN is_VBZ excluded_VBN from_IN the_DT calculation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN fully_RB diluted_VBN loss_NN per_IN share_NN for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD and_CC 2003_CD as_IN it_PRP was_VBD not_RB dilutive_JJ ._.
Basic_JJ and_CC diluted_JJ 2004 2003 000 000_CD Loss_NN for_IN the_DT financial_JJ year_NN 13,431_CD 363,355_CD Number_NN of_IN shares_NNS 2004_CD 2003_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS :_: For_IN Basic_JJ and_CC diluted_JJ EPS_NNP 496,306,604_CD 498,212,826_CD 11_CD UITF_NNP 38_CD Accounting_NN for_IN ESOP_NNP Trusts_NNPS The_DT Employee_NNP Share_NNP Ownership_NNP Plan_NNP ESOP_NNP reserve_NN arises_VBZ in_IN connection_NN with_IN the_DT ESOP_NNP trust_NN ,_, a_DT discretionary_JJ trust_NN established_VBN to_TO facilitate_VB the_DT operation_NN of_IN the_DT Groups_NNS long-term_JJ incentive_NN scheme_NN for_IN senior_JJ management_NN ._.
The_DT amount_NN of_IN the_DT reserve_NN represents_VBZ the_DT deduction_NN in_IN arriving_VBG at_IN shareholders_NNS funds_NNS for_IN the_DT consideration_NN paid_VBN for_IN the_DT Companys_NNP shares_NNS purchased_VBN by_IN the_DT trust_NN which_WDT had_VBD not_RB vested_VBN unconditionally_RB to_TO employees_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT Deferred_NNP Bonus_NNP Plan_NNP the_DT Plan_NNP provides_VBZ for_IN participants_NNS to_TO use_VB up_RP to_TO 50_CD %_NN of_IN their_PRP$ annual_JJ bonus_NN to_TO buy_VB shares_NNS in_IN the_DT Company_NN ._.
The_DT Company_NN will_MD match_VB any_DT shares_NNS bought_VBD ,_, but_CC the_DT matched_VBN shares_NNS will_MD vest_NN ,_, for_IN executive_NN Directors_NNS ,_, only_RB if_IN the_DT Companys_NNPS EPS_NNP grows_VBZ by_IN more_JJR than_IN 15_CD %_NN in_IN excess_NN of_IN RPI_NNP over_IN a_DT three-year_JJ period_NN 9_CD %_NN in_IN excess_NN of_IN RPI_NNP for_IN other_JJ eligible_JJ employees_NNS ._.
Recent_JJ fiscal_JJ changes_NNS in_IN the_DT US_NNP have_VBP made_VBN the_DT Plan_NNP less_RBR attractive_JJ to_TO participants_NNS and_CC the_DT Remuneration_NNP Committee_NNP has_VBZ determined_VBN that_IN it_PRP will_MD discontinue_VB the_DT Plan_NN after_IN bonus_NN awards_NNS for_IN the_DT 2004_CD financial_JJ year_NN ._.
The_DT number_NN and_CC market_NN value_NN of_IN the_DT ordinary_JJ shares_NNS held_VBN by_IN the_DT ESOP_NNP trust_NN at_IN 31_CD December_NNP 2004_CD was_VBD :_: 2004 2004 2003 2003_CD Number_NNP Market_NNP value_NN Number_NNP Market_NNP value_NN 000 000 000 000_CD Shares_NNP allocated_VBN but_CC not_RB vested_JJ 50_CD 128_CD Unallocated_JJ shares_NNS 29_CD 52_CD 137_CD 45_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 46_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 12_CD Intangible_JJ assets_NNS intellectual_JJ property_NN Group_NNP Company_NNP 000_CD 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2004_CD 275,210_CD 23,668_CD Additions_NNPS 26,765_CD 84_CD Disposals_NNS 5,181_CD 700_CD Foreign_JJ exchange_NN 12,944_CD As_IN at_IN 31_CD December_NNP 2004_CD 283,850_CD 23,052_CD Amortisation_NNP As_IN at_IN 1_CD January_NNP 2004_CD 103,662_CD 4,338_CD Charge_NNP for_IN the_DT year_NN 20,709_CD 1,962_CD Impairment_NN 8,455_CD 70_CD Disposals_NNS 3,695_CD Foreign_JJ exchange_NN 5,314_CD As_IN at_IN 31_CD December_NNP 2004_CD 123,817_CD 6,230_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2003_CD 171,548_CD 19,330_CD As_IN at_IN 31_CD December_NNP 2004_CD 160,033_CD 16,822_CD During_IN the_DT year_NN ,_, the_DT Group_NNP purchased_VBD :_: the_DT exclusive_JJ rights_NNS to_TO REMINYL_NNP in_IN the_DT United_NNP Kingdom_NNP and_CC Ireland_NNP for_IN $_$ 30_CD million_CD 16.3_CD million_CD ,_, of_IN which_WDT $_$ 19.0_CD million_CD 10.5_CD million_CD is_VBZ deferred_VBN consideration_NN at_IN 31_CD December_NNP 2004_CD :_: and_CC the_DT rights_NNS to_TO the_DT global_JJ patents_NNS for_IN FOSRENOL_NNP from_IN AnorMED_NNP Inc_NNP for_IN a_DT consideration_NN of_IN up_RB to_TO $_$ 31_CD million_CD ,_, dependent_JJ upon_IN achievement_NN of_IN certain_JJ milestones_NNS ._.
As_IN at_IN 31_CD December_NNP 2004_CD ,_, two_CD of_IN these_DT milestones_NNS had_VBD been_VBN achieved_VBN resulting_VBG in_IN the_DT capitalization_NN of_IN $_$ 19.0_CD million_CD 10.5_CD million_CD ._.
13_CD Intangible_JJ assets_NNS goodwill_NN Group_NNP Company_NNP 000_CD 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2004_CD 2,773,269_CD Disposal_NNP 2,741_CD Foreign_JJ exchange_NN 1,047_CD As_IN at_IN 31_CD December_NNP 2004_CD 2,769,481_CD Amortisation_NNP As_IN at_IN 1_CD January_NNP 2004_CD 1,407,686_CD Charge_NNP for_IN the_DT year_NN 77,098_CD Impairment_NNP 81,185_CD Disposals_NNPS 410_CD Foreign_JJ exchange_NN 134_CD As_IN at_IN 31_CD December_NNP 2004_CD 1,565,425_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2003_CD 1,365,583_CD As_IN at_IN 31_CD December_NNP 2004_CD 1,204,056_CD At_IN 31_CD December_NNP 2004_CD ,_, an_DT impairment_NN charge_NN was_VBD booked_VBN in_IN relation_NN to_TO goodwill_NN that_WDT was_VBD created_VBN on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP ._.
A_DT discounted_JJ cash_NN flow_NN model_NN was_VBD used_VBN to_TO estimate_VB the_DT recoverable_JJ value_NN of_IN the_DT business_NN and_CC the_DT impairment_NN is_VBZ included_VBN within_IN net_JJ operating_NN expenses_NNS in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ._.
A_DT range_NN of_IN discount_NN rates_NNS between_IN 7.5-10_CD %_NN was_VBD applied_VBN to_TO probabilityadjusted_JJ forecasts_NNS ._.
The_DT net_JJ book_NN value_NN of_IN the_DT Groups_NNS assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN agreements_NNS is_VBZ shown_VBN below_IN :_: 2004 2003 000 000_CD Buildings_NNS 3,277_CD Equipment_NNP and_CC other_JJ 35_CD 3,312_CD All_DT finance_NN leases_NNS and_CC hire_VB purchase_NN arrangements_NNS were_VBD short_JJ leases_NNS with_IN a_DT life_NN of_IN less_JJR than_IN 50_CD years_NNS ._.
b_NN Company_NN Office_NNP furniture_NN Equipment_NNP and_CC fittings_NNS and_CC other_JJ Total_JJ 000 000 000_CD Cost_NN As_IN at_IN 1_CD January_NNP 2004_CD 97_CD 13,012_CD 13,109_CD Additions_NNPS 9,378_CD 9,378_CD Disposals_NNS 94 284 378_CD As_IN at_IN 31_CD December_NNP 2004_CD 3_CD 22,106_CD 22,109_CD Depreciation_NN As_IN at_IN 1_CD January_NNP 2004_CD 97_CD 5,088_CD 5,185_CD Charge_NNP 2,589_CD 2,589_CD Disposals_NNS 94 279 373_CD As_IN at_IN 31_CD December_NNP 2004_CD 3_CD 7,398_CD 7,401_CD Net_JJ book_NN value_NN As_IN at_IN 31_CD December_NNP 2003_CD 7,924_CD 7,924_CD As_IN at_IN 31_CD December_NNP 2004_CD 14,708_CD 14,708_CD The_DT net_JJ book_NN value_NN of_IN the_DT Companys_NNP equipment_NN includes_VBZ nil_NN 2003_CD :_: 35,000_CD in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN agreements_NNS ._.
47_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 48_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 15_CD Fixed_VBN asset_NN investments_NNS Group_NNP Company_NNP 2004 2003 2004 2003_CD 000 000 000 000_CD Subsidiary_NNP undertakings_NNS 3,419,605_CD 3,419,192_CD Associates_NNPS 12,849_CD Other_JJ investments_NNS 39,872_CD 33,269_CD 559_CD 559_CD 52,721_CD 33,269_CD 3,420,164_CD 3,419,751_CD Principal_NN Group_NNP investments_NNS The_DT parent_NN Company_NN and_CC the_DT Group_NNP have_VBP investments_NNS in_IN the_DT following_JJ subsidiary_NN undertakings_NNS which_WDT principally_RB affected_VBD the_DT results_NNS or_CC net_JJ assets_NNS of_IN the_DT Group_NNP ._.
To_TO avoid_VB a_DT statement_NN of_IN excessive_JJ length_NN ,_, details_NNS of_IN investments_NNS which_WDT are_VBP not_RB significant_JJ have_VBP been_VBN omitted_VBN ._.
Country_NN of_IN incorporation_NN or_CC principal_NN business_NN address_NN Principal_NN activity_NN Holding_VBG %_NN Subsidiary_NNP undertakings_NNS Shire_NNP LLC_NNP US_NNP Licensing_NNP ,_, development_NN ,_, production_NN 100_CD %_NN and_CC distribution_NN of_IN pharmaceuticals_NNS Shire_NNP US_NNP Inc._NNP ._.
US_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceutical_NNP Contracts_NNPS Limited_NNP UK_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP France_NNP SA_NNP France_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP K_NNP G_NNP Germany_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Italia_NNP SpA_NNP Italy_NNP Marketing_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Spain_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceuticals_NNP Ireland_NNP Limited_NNP Ireland_NNP Marketing_NNP and_CC distribution_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP BioChem_NNP Inc._NNP ._.
Canada_NNP Marketing_NNP ,_, research_NN and_CC development_NN 100_CD %_NN of_IN pharmaceuticals_NNS ,_, including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS Shire_NNP International_NNP Licensing_NNP BV_NNP Netherlands_NNP Licensing_NNP and_CC development_NN of_IN pharmaceuticals_NNS 100_CD %_NN Shire_NNP Pharmaceutical_NNP Development_NNP Limited_NNP UK_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG 100_CD %_NN on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS Shire_NNP Pharmaceuticals_NNP Development_NNP US_NNP Inc._NNP ._.
US_NNP Development_NNP of_IN pharmaceuticals_NNS ,_, including_VBG 100_CD %_NN on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS Shire_NNP Laboratories_NNPS Inc._NNP ._.
US_NNP Development_NNP and_CC licensing_NN of_IN pharmaceuticals_NNS ,_, 100_CD %_NN including_VBG on_IN behalf_NN of_IN other_JJ Group_NNP companies_NNS Shire_NNP Finance_NNP Limited_NNP Cayman_NNP Islands_NNP Issuer_NNP of_IN convertible_JJ notes_NNS 100_CD %_NN Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
US_NNP Manufacturer_NNP of_IN pharmaceuticals_NNS 100_CD %_NN Held_VBN directly_RB by_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc._NN ._.
All_DT subsidiary_NN undertakings_NNS have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
48_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 49_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 15_CD Fixed_VBN asset_NN investments_NNS continued_VBD Subsidiary_NNP undertakings_NNS Amounts_NNP Shares_NNP in_IN due_JJ from_IN subsidiary_NN subsidiary_NN undertakings_NNS undertakings_NNS Total_JJ 000 000 000_CD Company_NN Cost_NN At_IN 1_CD January_NNP 2004_CD 3,208,042_CD 211,150_CD 3,419,192_CD Additions_NNS 25,337_CD 25,337_CD Disposals_NNPS 17,181_CD 17,181_CD Foreign_JJ exchange_NN 7,743_CD 7,743_CD At_IN 31_CD December_NNP 2004_CD 3,216,198_CD 203,407_CD 3,419,605_CD In_IN October_NNP 2004_CD the_DT Company_NN subscribed_VBN for_IN shares_NNS in_IN a_DT directly_RB held_VBN subsidiary_NN and_CC satisfied_VBD the_DT subscription_NN with_IN the_DT shares_NNS of_IN another_DT directly_RB held_VBN subsidiary_NN ,_, valued_VBN at_IN cost_NN ._.
In_IN addition_NN ,_, in_IN August_NNP 2004_CD ,_, the_DT Company_NN provided_VBD additional_JJ investment_NN to_TO another_DT directly_RB owned_VBN subsidiary_NN ._.
Associates_NNP Group_NNP Company_NNP 000_CD 000_CD Cost_NN At_IN 1_CD January_NNP 2004_CD Reclassification_NN from_IN other_JJ investments_NNS 20,699_CD At_IN 31_CD December_NNP 2004_CD 20,699_CD Provisions_NNS for_IN impairment_NN At_IN 1_CD January_NNP 2004_CD Reclassification_NN from_IN other_JJ investments_NNS 7,850_CD At_IN 31_CD December_NNP 2004_CD 7,850_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2003_CD At_IN 31_CD December_NNP 2004_CD 12,849_CD In_IN the_DT fourth_JJ quarter_NN of_IN 2004_CD ,_, the_DT Company_NN reviewed_VBD the_DT nature_NN of_IN certain_JJ investments_NNS previously_RB accounted_VBD for_IN as_IN other_JJ investments_NNS and_CC determined_VBD that_IN they_PRP should_MD be_VB accounted_VBN for_IN as_IN associates_NNS ._.
Accordingly_RB ,_, from_IN 1_CD October_NNP 2004_CD these_DT investments_NNS have_VBP been_VBN accounted_VBN for_IN as_IN associates_NNS ._.
Between_IN 1_CD January_NNP and_CC 30_CD September_NNP 2004_CD these_DT investments_NNS were_VBD impaired_VBN by_IN 2.2_CD million_CD in_IN net_JJ operating_NN expenses_NNS 2003_CD :_: 5.7_CD million_CD ._.
The_DT following_VBG information_NN is_VBZ given_VBN in_IN respect_NN of_IN the_DT Groups_NNS share_NN of_IN all_DT associates_NNS ._.
2004_CD 000_CD Turnover_NN 43_CD Fixed_VBN assets_NNS Current_JJ assets_NNS 19,302_CD Creditors_NNPS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 23_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN 49_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 50_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 15_CD Fixed_VBN asset_NN investments_NNS continued_VBD Included_VBN above_IN is_VBZ the_DT Groups_NNS share_NN of_IN GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP which_WDT is_VBZ detailed_VBN individually_RB below_IN ._.
2004_CD 000_CD Turnover_NN 22_CD Loss_NN before_IN tax_NN 530_CD Taxation_NNP Loss_NN after_IN tax_NN 530_CD Fixed_VBN assets_NNS Current_JJ assets_NNS 5,425_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 5_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Other_JJ investments_NNS Group_NNP Company_NNP 000_CD 000_CD Cost_NN At_IN 1_CD January_NNP 2004_CD 48,569_CD 559_CD Additions_NNS 39,771_CD Disposals_NNPS 7,445_CD Foreign_JJ exchange_NN 1,151_CD Reclassification_NN to_TO associates_NNS 20,699_CD At_IN 31_CD December_NNP 2004_CD 59,045_CD 559_CD Provisions_NNS for_IN impairment_NN At_IN 1_CD January_NNP 2004_CD 15,300_CD Impairment_NNP 11,723_CD Reclassification_NNP to_TO associates_NNS 7,850_CD At_IN 31_CD December_NNP 2004_CD 19,173_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2003_CD 33,269_CD 559_CD At_IN 31_CD December_NNP 2004_CD 39,872_CD 559_CD Investments_NNP in_IN private_JJ companies_NNS At_IN 31_CD December_NNP 2004_CD the_DT Group_NNP held_VBD 1.3_CD million_CD 2003_CD :_: 23.3_CD million_CD of_IN investments_NNS in_IN private_JJ companies_NNS ._.
In_IN April_NNP 2004_CD Shire_NNP announced_VBD that_IN it_PRP had_VBD contributed_VBN cash_NN ,_, equipment_NN and_CC intellectual_JJ property_NN to_TO the_DT start-up_NN of_IN a_DT new_JJ Canadian-based_JJ pharmaceutical_JJ research_NN and_CC development_NN organization_NN ,_, ViroChem_NNP Pharma_NNP Inc._NNP in_IN return_NN for_IN a_DT 14_CD %_NN equity_NN interest_NN ._.
The_DT transaction_NN followed_VBD the_DT closure_NN of_IN the_DT Lead_JJ Optimisation_NN business_NN in_IN August_NNP 2003_CD and_CC the_DT decision_NN to_TO exit_NN the_DT vaccines_NNS business_NN ._.
In_IN addition_NN ,_, Shire_NNP contributed_VBD 2.8_CD million_CD to_TO various_JJ partnerships_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
Distributions_NNS from_IN these_DT partnerships_NNS totalled_VBD 0.7_CD million_CD 2003_CD :_: nil_NN ._.
During_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN 8.6_CD million_CD due_JJ to_TO a_DT decrease_NN in_IN the_DT market_NN value_NN of_IN its_PRP$ investment_NN in_IN private_JJ companies_NNS ._.
In_IN addition_NN ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN 2.2_CD million_CD 2003_CD :_: 5.7_CD million_CD against_IN the_DT investment_NN in_IN the_DT GeneChem_NNP Funds_NNPS following_VBG reviews_NNS of_IN the_DT Funds_NNPS investment_NN portfolios_NNS that_WDT identified_VBD permanent_JJ declines_NNS in_IN the_DT value_NN of_IN certain_JJ private_JJ and_CC publicly_RB quoted_VBN securities_NNS held_VBN by_IN the_DT Funds_NNS ._.
At_IN 31_CD December_NNP 2003_CD ,_, Shire_NNP held_VBD an_DT investment_NN in_IN a_DT private_JJ company_NN that_WDT was_VBD entering_VBG the_DT later_JJ stages_NNS of_IN an_DT Initial_JJ Public_NNP Offering_NNP IPO_NNP ._.
At_IN 31_CD December_NNP 2003_CD the_DT anticipated_JJ flotation_NN price_NN was_VBD used_VBN to_TO value_VB the_DT investment_NN ._.
In_IN March_NNP 2004_CD ,_, this_DT private_JJ company_NN gained_VBD its_PRP$ listing_NN ,_, but_CC the_DT initial_JJ listing_NN price_NN was_VBD below_IN the_DT anticipated_JJ flotation_NN price_NN used_VBN at_IN 31_CD December_NNP 2003_CD ._.
The_DT Company_NN recorded_VBD an_DT impairment_NN of_IN 2.3_CD million_CD included_VBN in_IN the_DT 8.6_CD million_CD above_IN to_TO decrease_VB the_DT value_NN of_IN the_DT investment_NN to_TO the_DT initial_JJ IPO_NNP price_NN ,_, because_IN it_PRP believed_VBD the_DT decline_NN in_IN price_NN was_VBD permanent_JJ ._.
The_DT total_JJ value_NN of_IN the_DT Groups_NNS investments_NNS in_IN private_JJ companies_NNS that_WDT underwent_VBD an_DT IPO_NNP during_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD was_VBD 5.4_CD million_CD 2003_CD :_: nil_NN ._.
50_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 51_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 15_CD Fixed_VBN asset_NN investments_NNS continued_VBD Investments_NNP in_IN public_JJ companies_NNS At_IN 31_CD December_NNP 2004_CD the_DT Group_NNP held_VBD 38.6_CD million_CD 2003_CD :_: 8.9_CD million_CD of_IN investments_NNS in_IN public_JJ companies_NNS ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ,_, the_DT Group_NNP received_VBD 31.3_CD million_CD $_$ 60.0_CD million_CD in_IN the_DT form_NN of_IN subscription_NN receipts_NNS upon_IN the_DT completion_NN of_IN the_DT disposal_NN of_IN its_PRP$ vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP ,_, a_DT Canadian_JJ biotechnology_NN company_NN ._.
See_VB Note_VB 16_CD for_IN further_JJ information_NN ._.
During_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD ,_, the_DT Company_NN sold_VBD an_DT investment_NN and_CC realized_VBD a_DT gain_NN on_IN the_DT sale_NN of_IN 8.3_CD million_CD 2003_CD :_: nil_NN ._.
The_DT Company_NN recorded_VBD an_DT impairment_NN of_IN 0.9_CD million_CD 2003_CD :_: $_$ nil_CD to_TO its_PRP$ investment_NN in_IN a_DT public_JJ company_NN ._.
The_DT company_NN concerned_VBN announced_VBD the_DT resignation_NN of_IN a_DT key_JJ member_NN of_IN senior_JJ management_NN and_CC Shire_NNP believes_VBZ that_IN the_DT decline_NN in_IN the_DT investee_NN companys_VBZ share_NN price_NN following_VBG the_DT announcement_NN indicates_VBZ long-term_JJ impairment_NN ._.
16_CD Acquisitions_NNS and_CC disposals_NNS a_DT Acquisitions_NNP The_NNP Group_NNP made_VBD no_DT acquisitions_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
b_NN Disposals_NNS Vaccines_NNS business_NN On_IN 9_CD September_NNP 2004_CD the_DT Company_NN completed_VBD its_PRP$ disposal_NN of_IN the_DT vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP ,_, a_DT Canadian_JJ biotechnology_NN company_NN ._.
The_DT total_JJ consideration_NN for_IN the_DT sale_NN was_VBD $_$ 120_CD million_CD 65.1_CD million_CD comprising_VBG $_$ 30_CD million_CD 15.6_CD million_CD of_IN cash_NN received_VBN at_IN completion_NN ,_, $_$ 30_CD million_CD 15.6_CD million_CD of_IN cash_NN held_VBN in_IN escrow_NN and_CC due_JJ on_IN the_DT first_JJ anniversary_NN of_IN closing_NN and_CC $_$ 60_CD million_CD 31.3_CD million_CD received_VBN at_IN completion_NN in_IN the_DT form_NN of_IN 4,931,864_CD subscription_NN receipts_NNS of_IN IDB_NNP ._.
Each_DT subscription_NN receipt_NN entitles_VBZ Shire_NNP to_TO acquire_VB ,_, at_IN any_DT time_NN during_IN the_DT period_NN from_IN 10_CD January_NNP 2005_CD to_TO 9_CD July_NNP 2006_CD ,_, for_IN no_DT additional_JJ consideration_NN ,_, one_CD fully_RB paid_VBN common_JJ share_NN of_IN IDB_NNP ._.
Prior_RB to_TO 10_CD January_NNP 2005_CD ,_, if_IN IDB_NNP were_VBD to_TO raise_VB up_RP to_TO $_$ 60_CD million_CD from_IN equity_NN related_VBN issuances_NNS then_RB they_PRP were_VBD required_VBN to_TO repurchase_VB the_DT subscription_NN receipts_NNS from_IN Shire_NNP for_IN $_$ 60_CD million_CD in_IN cash_NN ._.
On_IN 21_CD December_NNP 2004_CD ,_, IDB_NNP gave_VBD notification_NN that_IN it_PRP intended_VBD to_TO complete_VB a_DT convertible_JJ debt_NN issuance_NN on_IN 7_CD January_NNP 2005_CD and_CC subsequently_RB repurchased_VBD the_DT subscription_NN receipts_NNS from_IN Shire_NNP on_IN 7_CD January_NNP 2005_CD ._.
In_IN addition_NN to_TO the_DT $_$ 120_CD million_CD consideration_NN ,_, IDB_NNP is_VBZ required_VBN to_TO reimburse_VB Shire_NNP in_IN full_JJ for_IN the_DT net_JJ cost_NN of_IN operating_VBG the_DT vaccines_NNS business_NN from_IN 30_CD June_NNP 2004_CD ._.
As_IN part_NN of_IN the_DT transaction_NN ,_, Shire_NNP entered_VBD into_IN an_DT agreement_NN to_TO provide_VB IDB_NNP with_IN a_DT loan_NN facility_NN of_IN up_RB to_TO $_$ 100_CD million_CD 52.1_CD million_CD ,_, which_WDT can_MD be_VB drawn_VBN down_RB over_IN the_DT four_CD years_NNS following_VBG completion_NN ._.
It_PRP is_VBZ expected_VBN that_IN IDB_NNP will_MD draw_VB down_RP the_DT entire_JJ $_$ 100_CD million_CD loan_NN ._.
This_DT facility_NN can_MD be_VB used_VBN by_IN IDB_NNP to_TO fund_VB the_DT development_NN of_IN injectable_JJ flu_NN and_CC pipeline_NN products_NNS within_IN the_DT vaccines_NNS business_NN acquired_VBD from_IN Shire_NNP ._.
Drawings_NNS under_IN the_DT loan_NN facility_NN will_MD be_VB segregated_VBN into_IN two_CD components_NNS :_: drawings_NNS for_IN injectable_JJ flu_NN development_NN with_IN a_DT minimum_JJ drawing_NN of_IN $_$ 30_CD million_CD 15.6_CD million_CD ._.
Such_JJ drawings_NNS under_IN the_DT loan_NN facility_NN will_MD be_VB repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ non-Canadian_JJ injectable_JJ flu_NN products_NNS ,_, subject_JJ to_TO minimum_JJ annual_JJ repayments_NNS in_IN respect_NN of_IN the_DT $_$ 30_CD million_CD minimum_JJ drawing_NN ,_, to_TO be_VB made_VBN between_IN 2007_CD and_CC 2017_CD :_: and_CC drawings_NNS for_IN pipeline_NN development_NN of_IN up_RB to_TO $_$ 70_CD million_CD 36.5_CD million_CD ._.
Such_JJ drawings_NNS under_IN the_DT loan_NN facility_NN will_MD be_VB repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ pipeline_NN products_NNS developed_VBD using_VBG these_DT drawings_NNS and_CC will_MD have_VB no_DT fixed_VBN repayment_NN schedule_NN ._.
The_DT combined_VBN drawings_NNS of_IN the_DT two_CD components_NNS of_IN the_DT loan_NN facility_NN can_MD not_RB exceed_VB $_$ 100_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2004_CD ,_, IDB_NNP had_VBD drawn_VBN down_RB $_$ 56.8_CD million_CD 29.6_CD million_CD ,_, $_$ 30.0_CD million_CD 15.6_CD million_CD for_IN injectable_JJ flu_NN development_NN and_CC $_$ 26.8_CD million_CD 14.0_CD million_CD for_IN pipeline_NN development_NN ._.
The_DT transaction_NN gave_VBD rise_NN to_TO an_DT overall_JJ loss_NN on_IN sale_NN of_IN the_DT vaccines_NNS business_NN of_IN 23.2_CD million_CD ,_, which_WDT was_VBD recognized_VBN in_IN the_DT second_JJ quarter_NN of_IN 2004_CD ._.
This_DT comprises_VBZ a_DT profit_NN on_IN disposal_NN of_IN net_JJ assets_NNS of_IN 13.3_CD million_CD together_RB with_IN a_DT provision_NN for_IN a_DT loss_NN of_IN $_$ 70_CD million_CD 36.5_CD million_CD out_IN of_IN the_DT $_$ 100_CD million_CD 52.1_CD million_CD loan_NN facility_NN available_JJ to_TO IDB_NNP ._.
This_DT provision_NN is_VBZ made_VBN on_IN the_DT basis_NN that_WDT loan_NN repayments_NNS based_VBN only_RB on_IN the_DT future_JJ sales_NNS of_IN pipeline_NN products_NNS in_IN development_NN provide_VBP no_DT certainty_NN of_IN recovery_NN ._.
51_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 52_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 16_CD Acquisitions_NNS and_CC disposals_NNS continued_VBD The_DT following_JJ table_NN summarises_VBZ the_DT major_JJ categories_NNS of_IN assets_NNS and_CC liabilities_NNS attributed_VBD to_TO the_DT vaccines_NNS business_NN at_IN the_DT date_NN of_IN disposal_NN ._.
2004_CD 000_CD Goodwill_NNP 2,331_CD Tangible_JJ fixed_JJ assets_NNS 38,960_CD Stocks_NNS 3,376_CD Accounts_NNPS receivable_JJ 5,315_CD Prepaid_JJ expenses_NNS and_CC other_JJ debtors_NNS 205_CD Cash_NN 1,078_CD Debtors_NNS :_: due_JJ after_IN more_JJR than_IN one_CD year_NN 229_CD Creditors_NNPS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 7,416_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN 392_CD Loan_NN provision_NN 36,460_CD Other_JJ provisions_NNS 4,423_CD Acquisition_NNP costs_NNS 3,684_CD Loss_NN on_IN sale_NN 23,191_CD 65,062_CD Satisfied_VBN by_IN :_: Cash_NN consideration_NN 18,184_CD Deferred_JJ consideration_NN 15,626_CD Subscription_NN receipts_NNS 31,252_CD 65,062_CD Cash_NN consideration_NN comprised_VBD 15.6_CD million_CD upon_IN completion_NN and_CC 2.6_CD million_CD in_IN relation_NN to_TO the_DT working_VBG capital_NN of_IN the_DT vaccines_NNS business_NN ._.
Qualia_NNP The_NNP Group_NNP completed_VBD its_PRP$ divestment_NN of_IN its_PRP$ investment_NN in_IN the_DT joint_JJ venture_NN ,_, Qualia_NNP Computing_NNP Inc._NNP on_IN 31_CD December_NNP 2003_CD ._.
This_DT was_VBD sold_VBN to_TO iCAD_NNP Inc._NNP for_IN a_DT total_JJ consideration_NN of_IN 3.1_CD million_CD $_$ 5.5_CD million_CD ._.
The_DT following_JJ table_NN summarises_VBZ the_DT major_JJ categories_NNS of_IN assets_NNS and_CC liabilities_NNS attributed_VBD to_TO the_DT joint_JJ venture_NN at_IN the_DT date_NN of_IN disposal_NN ._.
9_CD associates_NNS and_CC joint_JJ ventures_NNS the_DT following_JJ information_NN regarding_VBG the_DT Groups_NNS share_NN in_IN Qualia_NNP is_VBZ disclosed_VBN ,_, prior_RB to_TO its_PRP$ disposal_NN in_IN December_NNP 2003_CD :_: 2003_CD 000_CD Qualia_NNP Turnover_NN 3,594_CD Loss_NN before_IN tax_NN 2,806_CD Taxation_NNP Loss_NN after_IN tax_NN 2,806_CD Fixed_VBN assets_NNS Current_JJ assets_NNS Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 18_CD Stocks_NNS Group_NNP Company_NNP 2004 2003 2004 2003_CD 000 000 000 000_CD Raw_NNP materials_NNS and_CC consumables_NNS 3,672_CD 3,797_CD Work_NN in_IN progress_NN 6,163_CD 5,644_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 11,640_CD 15,841_CD 21,475_CD 25,282_CD There_EX is_VBZ no_DT material_NN difference_NN between_IN the_DT balance_NN sheet_NN value_NN of_IN stocks_NNS and_CC their_PRP$ replacement_NN cost_NN ._.
19_CD Deferred_JJ tax_NN Group_NNP Company_NNP 000_CD 000_CD Asset_NNP At_IN 1_CD January_NNP 2004_CD 35,267_CD Credited_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN 10,613_CD Exchange_NNP adjustment_NN 1,760_CD At_IN 31_CD December_NNP 2004_CD 44,120_CD Included_VBN in_IN the_DT above_JJ balance_NN at_IN 31_CD December_NNP 2004_CD is_VBZ an_DT asset_NN of_IN 4,023,000_CD 2003_CD :_: liability_NN of_IN 782,000_CD which_WDT is_VBZ receivable_JJ after_IN more_JJR than_IN one_CD year_NN ._.
2004 2003 000 000_CD Group_NNP Accelerated_VBD capital_NN allowances_NNS 12,222_CD 17,902_CD Other_JJ timing_NN differences_NNS 21,909_CD 9,226_CD Tax_NNP losses_NNS available_JJ 34,433_CD 44,725_CD Undiscounted_JJ deferred_JJ tax_NN asset_NN 44,120_CD 36,049_CD Accelerated_VBN capital_NN allowances_NNS 782_CD Total_JJ undiscounted_JJ deferred_JJ tax_NN asset_NN 44,120_CD 35,267_CD As_IN at_IN 31_CD December_NNP 2004_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Group_NNP will_MD realize_VB the_DT benefits_NNS of_IN the_DT recognized_VBN deferred_VBN tax_NN assets_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realisable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
53_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 54_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 19_CD Deferred_JJ tax_NN continued_VBD Unrecognised_JJ deferred_VBN tax_NN Group_NNP Company_NNP 2004 2003 2004 2003_CD 000 000 000 000_CD Accelerated_VBN capital_NN allowances_NNS 1,257_CD Other_JJ timing_NN differences_NNS 12,761_CD 7_CD Tax_NNP losses_NNS available_JJ 66,886_CD 93,948_CD 6,124_CD 10,346_CD 79,647_CD 93,948_CD 7,381_CD 10,353_CD As_IN at_IN 31_CD December_NNP 2004_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Group_NNP will_MD not_RB realize_VB the_DT benefits_NNS of_IN the_DT unprovided_JJ deferred_JJ tax_NN assets_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN unrealisable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
20_CD Debtors_NNP Group_NNP Company_NNP 2004 2003 2004 2003_CD 000 000 000 000_CD Due_JJ within_IN one_CD year_NN :_: Trade_NNP debtors_NNS 116,843_CD 120,841_CD 1_CD 43_CD Amounts_NNS due_JJ from_IN Group_NNP undertakings_NNS 116,463_CD 97,048_CD Other_JJ debtors_NNS 6,609_CD 9,172_CD 1,851_CD 1,472_CD Cash_NN held_VBN in_IN Escrow_NNP Note_NN 16_CD 15,626_CD Prepayments_NNS and_CC accrued_VBN income_NN 17,082_CD 11,033_CD 2,095_CD 1,792_CD SERP_NNP 929_CD 157,089_CD 141,046_CD 120,410_CD 100,355_CD Due_JJ after_IN more_JJR than_IN one_CD year_NN :_: Loan_NN to_TO IDB_NNP 15,626_CD Accrued_VBN interest_NN on_IN IDB_NNP loan_NN 205_CD Other_JJ debtors_NNS 418_CD 2,497_CD SERP_NNP 4,010_CD 6,727_CD 20,259_CD 9,224_CD Further_JJ details_NNS of_IN the_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP asset_NN are_VBP provided_VBN in_IN Note_NN 29_CD ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT gross_JJ asset_NN represented_VBN by_IN non-current_JJ marketable_JJ securities_NNS ._.
A_DT related_JJ liability_NN is_VBZ included_VBN within_IN Notes_NNP 22_CD and_CC 23_CD ._.
21_CD Current_JJ asset_NN investments_NNS Group_NNP Company_NNP 2004 2003 2004 2003_CD 000 000 000 000_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 78,056_CD 102,373_CD Commercial_JJ paper_NN 91,143_CD 67,522_CD 169,199_CD 169,895_CD There_EX were_VBD no_DT material_NN differences_NNS between_IN book_NN value_NN and_CC market_NN value_NN of_IN the_DT current_JJ asset_NN investments_NNS as_IN at_IN 31_CD December_NNP 2004_CD or_CC as_RB at_IN 31_CD December_NNP 2003_CD ._.
54_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 55_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 22_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Company_NNP 2004 2003 2004 2003_CD 000 000 000 000_CD Other_JJ creditors_NNS Bank_NNP loans_NNS 431_CD Obligations_NNS under_IN finance_NN leases_NNS 158_CD 35_CD Trade_NNP creditors_NNS 18,518_CD 11,895_CD 3,406_CD 308_CD Amounts_NNS due_JJ to_TO Group_NNP undertakings_NNS 307,094_CD 241,661_CD Corporation_NNP tax_NN 24,354_CD 10,395_CD Other_JJ taxation_NN and_CC social_JJ security_NN 2,723_CD 2,683_CD 766_CD 1,162_CD Other_JJ creditors_NNS 33,865_CD 7,662_CD 2,188_CD 168_CD Accruals_NNPS and_CC deferred_VBN income_NN 147,042_CD 106,945_CD 9,431_CD 7,706_CD SERP_NNP 992_CD 1,553_CD Proposed_VBN dividends_NNS 9,952_CD 9,698_CD 237,446_CD 141,722_CD 332,583_CD 251,040_CD Obligations_NNS under_IN finance_NN leases_NNS were_VBD secured_VBN on_IN the_DT assets_NNS to_TO which_WDT they_PRP relate_VBP ._.
See_VB Note_VB 29_CD for_IN details_NNS relating_VBG to_TO the_DT SERP_NNP ._.
23_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP Company_NNP 2004 2003 2004 2003_CD Notes_NNP 000 000 000 000_CD Convertible_JJ debt_NN i_FW 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD 60_CD 202,659_CD Other_JJ creditors_NNS Bank_NNP loans_NNS 424_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 3,238_CD Amounts_NNS due_JJ to_TO other_JJ Group_NNP undertakings_NNS 206,459_CD Other_JJ creditors_NNS 13,819_CD 2,353_CD Deferred_JJ tax_NN liability_NN 782_CD Accruals_NNPS and_CC deferred_VBN income_NN 4,726_CD 7,503_CD SERP_NNP 1,870_CD 3,439_CD 20,415_CD 17,739_CD 206,459_CD 20,475_CD 220,398_CD 206,459_CD See_VB Note_VB 29_CD for_IN details_NNS relating_VBG to_TO the_DT SERP_NNP ._.
55_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 56_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 23_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN continued_VBD Subject_JJ to_TO the_DT conditions_NNS below_IN ,_, borrowings_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Group_NNP Company_NNP 2004 2003 2004 2003_CD Notes_NNP 000 000 000 000_CD Convertible_JJ loan_NN notes_NNS :_: i_FW After_IN five_CD years_NNS 60_CD 202,659_CD Bank_NNP loans_NNS :_: Between_IN one_CD and_CC two_CD years_NNS 424_CD Obligations_NNS under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS :_: Between_IN one_CD and_CC two_CD years_NNS 142_CD After_IN five_CD years_NNS 3,096_CD 3,238_CD 60_CD 206,321_CD i_FW $_$ 400_CD million_CD 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD The_DT guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD ,_, were_VBD issued_VBN in_IN August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN of_IN the_DT Company_NN ._.
The_DT convertible_JJ notes_NNS were_VBD guaranteed_VBN by_IN Shire_NNP and_CC were_VBD convertible_JJ into_IN redeemable_JJ preference_NN shares_NNS of_IN the_DT Issuer_NN which_WDT upon_IN issuance_NN will_MD be_VB immediately_RB exchanged_VBN for_IN either_DT i_FW Shire_FW ordinary_JJ shares_NNS ,_, ii_FW Shire_FW ADSs_FW or_CC iii_FW at_IN the_DT Issuers_NNPS option_NN ,_, a_DT cash_NN amount_NN based_VBN upon_IN the_DT London_NNP Stock_NNP Exchange_NNP volume-weighted_JJ average_NN prices_NNS of_IN Shires_NNP ordinary_JJ shares_NNS on_IN the_DT fourth_JJ through_IN eighth_JJ business_NN days_NNS following_VBG conversion_NN ._.
At_IN the_DT choice_NN of_IN investors_NNS ,_, each_DT $_$ 1,000_CD of_IN nominal_JJ value_NN notes_NNS was_VBD convertible_JJ into_IN 49.62_CD Shire_NNP ordinary_JJ shares_NNS subject_JJ to_TO adjustment_NN or_CC 16.54_CD Shire_NNP ADSs_NNP subject_NN to_TO adjustment_NN at_IN any_DT time_NN up_RP to_TO 21_CD August_NNP 2011_CD ._.
Alternatively_RB ,_, investors_NNS had_VBD the_DT alterative_JJ to_TO receive_VB repayment_NN of_IN the_DT nominal_JJ principal_NN in_IN cash_NN either_CC at_IN the_DT maturity_NN date_NN of_IN 21_CD August_NNP 2011_CD or_CC by_IN exercising_VBG a_DT put_NN option_NN on_IN any_DT of_IN the_DT three_CD put_VBD dates_NNS being_VBG 21_CD August_NNP 2004_CD ,_, 21_CD August_NNP 2006_CD and_CC 21_CD August_NNP 2008_CD ._.
On_IN 21_CD August_NNP 2004_CD ,_, upon_IN exercise_NN of_IN the_DT put_NN option_NN by_IN substantially_RB all_DT of_IN the_DT convertible_JJ note_NN holders_NNS ,_, the_DT Company_NN redeemed_VBN 202.6_CD million_CD $_$ 370.1_CD million_CD at_IN par_NN ,_, from_IN available_JJ funds_NNS 2003_CD :_: $_$ 29.8_CD million_CD ,_, recording_VBG a_DT gain_NN of_IN $_$ 0.5_CD million_CD ._.
The_DT obligation_NN to_TO pay_VB the_DT remaining_VBG 60,000_CD $_$ 116,000_CD of_IN the_DT convertible_JJ loan_NN notes_NNS outstanding_JJ as_IN of_IN 31_CD December_NNP 2004_CD is_VBZ due_JJ in_IN 2011_CD ._.
24_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS The_DT Financial_NNP Review_NNP on_IN pages_NNS 7_CD to_TO 12_CD provides_VBZ an_DT explanation_NN of_IN the_DT role_NN that_WDT financial_JJ instruments_NNS have_VBP had_VBN during_IN the_DT year_NN ._.
The_DT explanation_NN summarises_VBZ the_DT objectives_NNS and_CC policies_NNS for_IN holding_VBG or_CC issuing_VBG financial_JJ instruments_NNS and_CC similar_JJ contracts_NNS ,_, and_CC the_DT strategies_NNS for_IN achieving_VBG those_DT objectives_NNS that_WDT have_VBP been_VBN followed_VBN during_IN the_DT year_NN ._.
The_DT numerical_JJ disclosures_NNS in_IN this_DT note_NN deal_NN with_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS as_IN defined_VBN in_IN FRS_NNP 13_CD derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS :_: disclosures_NNS ._.
Certain_JJ financial_JJ assets_NNS such_JJ as_IN investments_NNS in_IN subsidiary_NN companies_NNS are_VBP excluded_VBN from_IN the_DT scope_NN of_IN these_DT disclosures_NNS ._.
As_IN permitted_VBN by_IN FRS_NNP 13_CD ,_, short-term_JJ debtors_NNS and_CC creditors_NNS have_VBP been_VBN excluded_VBN from_IN the_DT disclosures_NNS ,_, other_JJ than_IN the_DT currency_NN disclosures_NNS ._.
56_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 57_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 24_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Interest_NN rate_NN profile_NN The_DT currency_NN and_CC interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS ,_, excluding_VBG short-term_JJ debtors_NNS at_IN 31_CD December_NNP 2004_CD ,_, are_VBP as_RB below_RB ._.
In_IN addition_NN to_TO cash_NN and_CC cash_NN equivalents_NNS ,_, there_EX are_VBP current_JJ asset_NN investments_NNS as_IN detailed_VBN in_IN Note_NN 21_CD ._.
Weighted_JJ average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ Financial_NNP Financial_NNP interest_NN period_NN interest_NN rate_NN interest_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Days_NNS %_NN %_NN 000 000 000_CD Pounds_NNP sterling_NN 4.11_CD 19,683_CD 19,683_CD US_NNP dollars_NNS 678_CD 2.01_CD 2.05_CD 657,933_CD 22,247_CD 680,180_CD Euro_NNP 0.30_CD 8,752_CD 8,752_CD Canadian_JJ dollars_NNS 2.52_CD 53,339_CD 53,339_CD Other_JJ 0.25_CD 10_CD 10_CD 739,717_CD 22,247_CD 761,964_CD The_DT benchmark_NN rates_NNS for_IN floating_VBG rate_NN assets_NNS are_VBP primarily_RB :_: US_NNP dollar_NN 7_CD day_NN ,_, 1_CD month_NN and_CC 3_CD month_NN LIBID_NNP ,_, and_CC Pounds_NNP sterling_NN 7_CD day_NN LIBID_NNP ._.
The_DT currency_NN and_CC interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS excluding_VBG short-term_JJ debtors_NNS at_IN 31_CD December_NNP 2003_CD are_VBP as_RB below_RB ._.
Weighted_JJ average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ Financial_NNP Financial_NNP interest_NN period_NN interest_NN rate_NN interest_NN rate_NN instruments_NNS instruments_NNS Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Floating_VBG rate_NN Fixed_VBN rate_NN Total_JJ Days_NNS %_NN %_NN 000 000 000_CD Pounds_NNP sterling_NN 7_CD 3.07_CD 3.50_CD 14,729_CD 3,875_CD 18,604_CD US_NNP dollars_NNS 204_CD 1.00_CD 1.32_CD 604,822_CD 113,889_CD 718,711_CD Euro_NNP 76_CD 0.89_CD 2.00_CD 9,027_CD 6,634_CD 15,661_CD Canadian_JJ dollars_NNS 70_CD 0.25_CD 2.99_CD 3,093_CD 35,392_CD 38,485_CD 0.25_CD 104 104 631_CD ,775_CD 159,790_CD 791,565_CD The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2004_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NN 000 000 000 000_CD US_NNP dollars_NNS Convertible_JJ debt_NN 60_CD 60_CD The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2003_CD was_VBD as_IN follows_VBZ :_: Floating_VBG Fixed_NNP Interest_NNP free_JJ Total_JJ Currency_NN 000 000 000 000_CD Canadian_JJ dollars_NNS Federal_NNP and_CC provincial_JJ government_NN loan_NN 855_CD 855_CD US_NNP dollars_NNS Convertible_JJ debt_NN 202,659_CD 202,659_CD Total_JJ 202,659_CD 855_CD 203,514_CD 57_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 58_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 24_CD Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Currency_NNP exposures_NNS The_DT Groups_NNS objectives_NNS in_IN managing_VBG the_DT currency_NN exposures_NNS arising_VBG from_IN its_PRP$ net_JJ investment_NN overseas_RB in_IN other_JJ words_NNS ,_, its_PRP$ structural_JJ currency_NN exposures_NNS are_VBP to_TO minimize_VB currency_NN related_VBN exposures_NNS ._.
Gains_NNS and_CC losses_NNS arising_VBG from_IN structural_JJ currency_NN exposures_NNS are_VBP recognized_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT Groups_NNS currency_NN exposures_NNS :_: in_IN other_JJ words_NNS ,_, those_DT transactional_JJ or_CC non-structural_JJ exposures_NNS that_WDT give_VBP rise_VB to_TO the_DT net_JJ currency_NN gains_NNS and_CC losses_NNS recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Such_JJ exposures_NNS comprise_VBP the_DT monetary_JJ assets_NNS and_CC monetary_JJ liabilities_NNS of_IN the_DT Group_NNP that_WDT are_VBP not_RB denominated_VBN in_IN the_DT operating_NN or_CC functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN involved_VBN ,_, other_JJ than_IN certain_JJ non-sterling_JJ borrowings_NNS treated_VBN as_IN hedges_NNS of_IN net_JJ investments_NNS in_IN overseas_JJ operations_NNS ._.
As_IN at_IN 31_CD December_NNP 2004_CD these_DT exposures_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS Pounds_NNP sterling_NN US_NNP dollars_NNS Euro_NNP Canadian_NNP dollars_NNS Other_JJ Total_NNP Functional_NNP currency_NN of_IN Group_NNP operation_NN 000 000 000 000_CD 000_CD 000_CD Pounds_NNS sterling_JJ 472,523_CD 11,355_CD 1_CD 149_CD 461,020_CD US_NNP dollars_NNS 178,025_CD 19,874_CD 35_CD 2_CD 158,114_CD Euro_NNP 523 269 792_CD Canadian_JJ dollars_NNS 95,278_CD 155,354_CD 20_CD 250,652_CD 272,780_CD 317,438_CD 8,499_CD 36_CD 147_CD 53,046_CD The_DT exposures_NNS at_IN 31_CD December_NNP 2003_CD for_IN comparison_NN purposes_NNS were_VBD as_IN follows_VBZ :_: Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS Pounds_NNP sterling_NN US_NNP dollars_NNS Euro_NNP Canadian_NNP dollars_NNS Other_JJ Total_NNP Functional_NNP currency_NN of_IN Group_NNP operation_NN 000 000 000 000_CD 000_CD 000_CD Pounds_NNS sterling_JJ 333,969_CD 681_CD 436_CD 80_CD 332,772_CD US_NNP dollars_NNS 12,447_CD 8,171_CD 20_CD 25_CD 20,663_CD Euro_NNP 2,201_CD 5,455_CD 7,656_CD Canadian_JJ dollars_NNS 49,183_CD 108,267_CD 26_CD 157,476_CD 63,831_CD 220,247_CD 8,878_CD 456 105 146_CD ,977_CD Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS at_IN 31_CD December_NNP 2004_CD is_VBZ shown_VBN below_IN :_: Convertible_JJ loan_NN notes_NNS Bank_NNP loans_NNS Total_JJ 000 000 000_CD Group_NNP Over_IN five_CD years_NNS 60_CD 60_CD See_VB Note_VB 23_CD i_FW for_IN further_JJ information_NN on_IN convertible_JJ loan_NN notes_NNS ._.
Borrowing_NN facilities_NNS The_DT Group_NNP had_VBD no_DT undrawn_JJ committed_JJ borrowing_NN facilities_NNS at_IN 31_CD December_NNP 2004_CD or_CC 2003_CD ._.
Fair_NNP values_VBZ The_DT quoted_VBN market_NN price_NN of_IN the_DT convertible_JJ loan_NN stock_NN 2011_CD as_RB at_IN 31_CD December_NNP 2004_CD was_VBD $_$ 100.53_CD compared_VBN with_IN an_DT issue_NN price_NN of_IN $_$ 100_CD ._.
If_IN the_DT remaining_VBG loan_NN is_VBZ not_RB converted_VBN into_IN equity_NN ,_, it_PRP would_MD be_VB repayable_JJ at_IN $_$ 100_CD per_IN note_NN ._.
The_DT total_JJ fair_JJ value_NN of_IN the_DT debt_NN as_IN at_IN 31_CD December_NNP 2004_CD ,_, based_VBN on_IN the_DT above_JJ quoted_VBN market_NN price_NN ,_, was_VBD 61,000_CD $_$ 116,000_CD compared_VBN to_TO a_DT carrying_VBG value_NN of_IN 60,000_CD ._.
In_IN addition_NN at_IN 31_CD December_NNP 2004_CD the_DT fair_JJ value_NN of_IN listed_VBN fixed_VBN asset_NN investments_NNS ,_, based_VBN on_IN their_PRP$ quoted_VBN market_NN price_NN ,_, was_VBD 8.3_CD million_CD above_IN carrying_VBG value_NN 2003_CD :_: 4.8_CD million_CD above_IN ._.
There_EX were_VBD no_DT other_JJ material_NN differences_NNS between_IN the_DT carrying_VBG values_NNS and_CC fair_JJ values_NNS of_IN all_DT other_JJ Group_NNP financial_JJ assets_NNS and_CC liabilities_NNS at_IN 31_CD December_NNP 2004_CD 2003_CD :_: nil_NN ._.
Gains_NNS and_CC losses_NNS on_IN foreign_JJ exchange_NN contracts_NNS As_IN at_IN 31_CD December_NNP 2004_CD the_DT Company_NN had_VBD two_CD outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN of_IN $_$ 39_CD million_CD used_VBN to_TO manage_VB the_DT risk_NN associated_VBN with_IN holding_VBG Canadian_JJ dollar_NN investments_NNS ._.
There_EX were_VBD no_DT material_NN gains_NNS or_CC losses_NNS on_IN these_DT contracts_NNS ._.
58_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 59_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 25_CD Called-up_JJ share_NN capital_NN Number_NNP Ordinary_NNP shares_NNS 000_CD 000_CD Authorised_VBN At_IN 31_CD December_NNP 2003_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 40,000_CD At_IN 31_CD December_NNP 2004_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 800,000_CD 40,000_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2004_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 477,895_CD 23,895_CD Issued_VBN on_IN exercise_NN of_IN options_NNS for_IN cash_NN consideration_NN 2,098_CD 105_CD Issued_VBN on_IN exchange_NN of_IN exchangeable_JJ shares_NNS 4,839_CD 242_CD Issue_NN of_IN ordinary_JJ share_NN capital_NN 84_CD 4_CD At_IN 31_CD December_NNP 2004_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT 484,916_CD 24,246_CD Number_NNP Special_JJ ordinary_JJ voting_NN shares_NNS 000_CD 000_CD Authorised_VBN At_IN 31_CD December_NNP 2003_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD At_IN 31_CD December_NNP 2004_CD special_JJ ordinary_JJ voting_NN shares_NNS of_IN 0.00001_CD p_NN 17,500_CD Allotted_NNP ,_, issued_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2004_CD 5,840_CD Cancelled_VBN following_VBG an_DT exchange_NN of_IN exchangeable_JJ shares_NNS for_IN ordinary_JJ shares_NNS 1,613_CD At_IN 31_CD December_NNP 2004_CD 4,227_CD Authorised_JJ share_NN capital_NN As_IN at_IN 31_CD December_NNP 2004_CD the_DT authorised_JJ share_NN capital_NN of_IN the_DT Company_NN was_VBD 40,000,000_CD divided_VBN into_IN 799,999,965_CD ordinary_JJ shares_NNS of_IN 5p_JJ each_DT and_CC 17,500,000_CD Special_JJ Ordinary_NNP Voting_NNP Shares_NNP of_IN 0.00001_CD p_NN each_DT ._.
Issue_NN of_IN ordinary_JJ shares_NNS During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD the_DT Company_NN allotted_VBD 4,839,249_CD ordinary_JJ shares_NNS with_IN a_DT nominal_JJ value_NN of_IN 241,962_CD on_IN the_DT exchange_NN of_IN exchangeable_JJ shares_NNS ,_, which_WDT were_VBD issued_VBN following_VBG the_DT acquisition_NN of_IN BioChem_NNP in_IN 2001_CD ._.
These_DT shares_NNS were_VBD issued_VBN at_IN a_DT premium_NN of_IN 52,360,000_CD ._.
Exchange_NNP of_IN exchangeable_JJ shares_NNS and_CC cancellation_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS The_DT Company_NN exchanged_VBD 1,613,083_CD exchangeable_JJ shares_NNS and_CC canceled_VBD the_DT equivalent_JJ number_NN of_IN special_JJ ordinary_JJ voting_NN shares_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
Each_DT exchangeable_JJ share_NN is_VBZ capable_JJ of_IN being_VBG exchanged_VBN for_IN ordinary_JJ shares_NNS or_CC ADSs_NNS ,_, at_IN a_DT rate_NN of_IN one_CD exchangeable_JJ share_NN for_IN three_CD ordinary_JJ shares_NNS or_CC one_CD exchangeable_JJ share_NN for_IN one_CD ADS_NNPS ,_, at_IN any_DT time_NN at_IN the_DT request_NN of_IN the_DT holder_NN ._.
Only_RB BioChem_NNP shareholders_NNS with_IN Canadian_JJ residency_NN had_VBD the_DT option_NN to_TO receive_VB exchangeable_JJ shares_NNS for_IN their_PRP$ shares_NNS of_IN BioChem_NNP at_IN the_DT time_NN of_IN acquisition_NN ._.
The_DT exchangeable_JJ shares_NNS were_VBD issued_VBN by_IN Shire_NNP Acquisition_NNP Inc._NNP a_DT company_NN incorporated_VBN under_IN the_DT Canada_NNP Business_NNP Corporations_NNS Act_NNP ,_, which_WDT is_VBZ a_DT wholly_RB owned_VBN subsidiary_NN of_IN the_DT Company_NN ,_, and_CC is_VBZ listed_VBN on_IN the_DT Toronto_NNP Stock_NNP Exchange_NNP ._.
Holders_NNS of_IN exchangeable_JJ shares_NNS are_VBP entitled_VBN to_TO vote_VB at_IN shareholder_NN meetings_NNS of_IN the_DT Company_NN and_CC are_VBP entitled_VBN to_TO a_DT dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN ordinary_JJ shares_NNS ,_, through_IN a_DT voting_NN trust_NN and_CC by_IN means_NNS of_IN the_DT special_JJ ordinary_JJ voting_NN shares_NNS in_IN Shire_NNP ._.
As_IN at_IN 31_CD December_NNP 2004_CD 4,226,476_CD exchangeable_JJ shares_NNS remained_VBD unconverted_JJ ._.
The_DT Company_NN can_MD redeem_VB all_DT outstanding_JJ exchangeable_JJ shares_NNS for_IN ordinary_JJ shares_NNS after_IN 11_CD May_NNP 2011_CD ,_, or_CC earlier_JJR if_IN the_DT total_JJ number_NN of_IN exchangeable_JJ shares_NNS falls_VBZ below_IN 1_CD million_CD ._.
The_DT exchangeable_JJ shares_NNS are_VBP included_VBN as_IN part_NN of_IN share_NN capital_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN to_TO present_VB a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT consolidated_JJ Groups_NNS capital_NN structure_NN ,_, which_WDT differs_VBZ from_IN the_DT Companies_NNS Act_NNP 1985_CD requirements_NNS to_TO reflect_VB these_DT amounts_NNS as_IN minority_NN interests_NNS ,_, as_IN they_PRP will_MD become_VB ,_, and_CC are_VBP equivalent_JJ ,_, to_TO ordinary_JJ shares_NNS ._.
Share_NN warrants_NNS On_IN 24_CD April_NNP 2002_CD the_DT Company_NN issued_VBN 741,812_CD share_NN warrants_NNS ,_, at_IN 4.88_CD per_IN warrant_NN ,_, and_CC on_IN 21_CD November_NNP 2002_CD the_DT Company_NN issued_VBD a_DT further_JJ 604,595_CD share_NN warrants_NNS ,_, at_IN 4.895_CD per_IN warrant_NN ,_, both_DT issues_NNS being_VBG made_VBN to_TO Technology_NNP Partnership_NNP Canada_NNP TPC_NNP ,_, pursuant_JJ to_TO an_DT agreement_NN between_IN BioChem_NNP and_CC the_DT Government_NN of_IN Canada_NNP GOC_NNP ._.
Each_DT warrant_NN grants_NNS a_DT right_NN to_TO subscribe_VB for_IN a_DT corresponding_JJ number_NN of_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN within_IN five_CD years_NNS from_IN the_DT date_NN of_IN issue_NN of_IN the_DT warrant_NN ._.
59_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 60_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 25_CD Called-up_JJ share_NN capital_NN continued_VBD The_DT Groups_NNS Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN share_NN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT following_JJ share_NN option_NN plans_NNS :_: the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plans_NNS Roberts_NNP Plans_NNP ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP and_CC the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ._.
The_DT highest_JJS and_CC lowest_JJS market_NN prices_NNS during_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD were_VBD 5.71_CD and_CC 4.36_CD respectively_RB ._.
62_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 63_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 25_CD Called-up_JJ share_NN capital_NN continued_VBD Notes_NNP i_FW Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three_CD years_NNS ,_, they_PRP are_VBP thereafter_RB tested_VBN quarterly_JJ by_IN reference_NN to_TO share_VB price_NN growth_NN over_IN the_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS will_MD become_VB exercisable_JJ ._.
ii_FW Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP vest_NN six_CD weeks_NNS prior_RB to_TO the_DT expiry_NN date_NN ._.
Options_NNS granted_VBN under_IN this_DT scheme_NN are_VBP subject_JJ to_TO performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT option_NN granted_VBN prior_RB to_TO August_NNP 2002_CD ,_, if_IN Shires_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN will_MD be_VB exercisable_JJ in_IN full_JJ ._.
If_IN it_PRP increases_VBZ by_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN the_DT same_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN may_MD be_VB exercised_VBN on_IN 60_CD %_NN of_IN the_DT shares_NNS covered_VBN by_IN the_DT option_NN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three-year_JJ measurement_NN period_NN ,_, they_PRP will_MD thereafter_RB be_VB tested_VBN quarterly_JJ by_IN reference_NN to_TO compound_VB annual_JJ share_NN price_NN growth_NN over_IN an_DT extended_JJ period_NN ._.
The_DT performance_NN criteria_NNS were_VBD reviewed_VBN in_IN 2002_CD to_TO ensure_VB the_DT criteria_NNS reflected_VBD the_DT market_NN in_IN which_WDT Shire_NNP operates_VBZ ._.
Given_VBN Shires_NNPS development_NN it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT EPS_NNP based_VBN measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS was_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD only_RB become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP EPS_NNP growth_NN over_IN a_DT three_CD year_NN period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Price_NNP Index_NNP RPI_NNP on_IN average_NN a_DT year_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN Directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN The_DT new_JJ EPS_NNP performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
After_IN consultation_NN with_IN some_DT of_IN its_PRP$ institutional_JJ shareholders_NNS ,_, the_DT Company_NN has_VBZ decided_VBN that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN from_IN 2004_CD onwards_NNS ,_, the_DT performance_NN condition_NN should_MD be_VB retested_VBN once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
The_DT retest_NN will_MD be_VB applied_VBN only_RB where_WRB Shires_NNP EPS_NNP growth_NN has_VBZ fallen_VBN short_JJ of_IN the_DT minimum_JJ annual_JJ average_JJ percentage_NN increase_NN over_IN the_DT three-year_JJ period_NN from_IN grant_NN ._.
Hence_RB the_DT level_NN of_IN EPS_NNP growth_NN in_IN the_DT next_JJ two_CD years_NNS needs_VBZ to_TO be_VB consequentially_RB higher_JJR to_TO meet_VB the_DT test_NN ._.
The_DT EPS_NNP used_VBD will_MD be_VB the_DT fully_RB diluted_VBN EPS_NNP calculated_VBN under_IN US_NNP GAAP_NNP reporting_NN ._.
iii_FW These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Shire_NNP Laboratories_NNPS Inc._NNP ._.
SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT US_NNP company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 23_CD March_NNP 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN the_DT Company_NN ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ SLI_NNP Plan_NNP ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN and_CC were_VBD not_RB subject_JJ to_TO performance_NN criteria_NNS ._.
iv_NN These_DT options_NNS have_VBP been_VBN granted_VBN over_IN shares_NNS in_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP ,_, a_DT US_NNP company_NN acquired_VBN by_IN the_DT Group_NNP on_IN 23_CD December_NNP 1999_CD ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN Roberts_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ Roberts_NNP Plan_NNP ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS ._.
v_FW Following_VBG the_DT acquisition_NN of_IN BioChem_NNP on_IN 11_CD May_NNP 2001_CD ,_, the_DT BioChem_NNP Plan_NNP was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChems_NNPS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN ._.
All_DT BioChem_NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN and_CC were_VBD not_RB subject_JJ to_TO any_DT performance_NN conditions_NNS ._.
vi_FW Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
Employees_NNS may_MD enter_VB into_IN three_CD or_CC five-year_JJ savings_NNS contracts_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT Scheme_NN is_VBZ not_RB subject_JJ to_TO any_DT performance_NN criteria_NNS ._.
vii_FW Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT offering_NN period_NN is_VBZ for_IN 27_CD months_NNS ._.
The_DT exercise_NN of_IN options_NNS under_IN this_DT plan_NN is_VBZ not_RB subject_JJ to_TO any_DT performance_NN condition_NN ._.
63_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 64_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 26_CD Reserves_NNPS Group_NNP Share_NN premium_NN Exchangeable_JJ Profit_NN and_CC account_NN shares_NNS Capital_NNP reserve_NN Other_JJ reserves_NNS loss_NN account_NN 000 000 000 000_CD 000_CD As_IN at_IN 1_CD January_NNP 2004_CD 3,218,695_CD 190,425_CD 3,135_CD 24,247_CD 1,151,897_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 52,358_CD 52,600_CD Issue_NN of_IN ordinary_JJ share_NN capital_NN 419_CD Options_NNS exercised_VBN 7,180_CD Foreign_JJ exchange_NN 55,510_CD Other_JJ 941_CD 941_CD Loss_NN for_IN the_DT financial_JJ year_NN 13,431_CD Dividends_NNPS paid_VBD and_CC proposed_VBD 14,919_CD As_IN at_IN 31_CD December_NNP 2004_CD 3,279,593_CD 137,825_CD 3,135_CD 24,247_CD 1,236,698_CD The_DT cumulative_JJ goodwill_NN resulting_VBG from_IN acquisitions_NNS that_WDT has_VBZ been_VBN written-off_JJ directly_RB to_TO reserves_NNS amounts_NNS to_TO 208,194,000_CD as_IN at_IN 31_CD December_NNP 2004_CD and_CC 31_CD December_NNP 2003_CD ._.
The_DT capital_NN and_CC other_JJ reserves_NNS arose_VBD in_IN relation_NN to_TO various_JJ Group_NNP reconstructions_NNS and_CC certain_JJ financing_NN transactions_NNS ,_, and_CC are_VBP not_RB distributable_JJ ._.
Company_NN Share_NN premium_NN Exchangeable_JJ Profit_NN and_CC account_NN shares_NNS Capital_NNP reserve_NN Other_JJ reserves_NNS loss_NN account_NN 000 000 000 000_CD 000_CD As_IN at_IN 1_CD January_NNP 2004_CD 3,219,636_CD 190,425_CD 2,054_CD 18,079_CD 130,437_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 52,358_CD 52,600_CD Issue_NN of_IN ordinary_JJ share_NN capital_NN 419_CD Options_NNS exercised_VBN 7,180_CD Foreign_JJ exchange_NN 11,735_CD Loss_NN for_IN the_DT financial_JJ year_NN 17,492_CD Dividends_NNPS paid_VBD and_CC proposed_VBD 14,536_CD As_IN at_IN 31_CD December_NNP 2004_CD 3,279,593_CD 137,825_CD 2,054_CD 18,079_CD 86,674_CD In_IN addition_NN to_TO the_DT dividends_NNS paid_VBN and_CC proposed_VBN by_IN the_DT Company_NN is_VBZ an_DT amount_NN of_IN 383,000_CD payable_JJ by_IN Shire_NNP Acquisition_NNP Inc._NNP to_TO the_DT holders_NNS of_IN the_DT Groups_NNS exchangeable_JJ shares_NNS see_VBP Note_NN 25_CD for_IN more_JJR details_NNS on_IN the_DT exchangeable_JJ shares_NNS ._.
27_CD Reconciliation_NNP of_IN movement_NN in_IN Group_NNP shareholders_NNS funds_NNS 2004 2003 000 000_CD Loss_NN for_IN the_DT financial_JJ year_NN 13,431_CD 363,355_CD Other_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 55,510_CD 47,157_CD 68,941_CD 410,512_CD Dividends_NNPS paid_VBD and_CC proposed_VBD 14,919_CD New_NNP shares_NNS issued_VBD 423_CD Repurchase_NN of_IN ordinary_JJ share_NN capital_NN 31,808_CD Repurchase_NN of_IN ordinary_JJ share_NN capital_NN in_IN to_TO Treasury_NNP Stock_NNP 137_CD Proceeds_NNS on_IN exercise_NN of_IN employee_NN share_NN options_NNS 7,285_CD 3,114_CD Net_JJ reduction_NN in_IN shareholders_NNS funds_NNS 76,289_CD 439,206_CD Opening_NN shareholders_NNS funds_NNS 2,308,500_CD 2,747,706_CD Closing_NN shareholders_NNS funds_NNS 2,232,211_CD 2,308,500_CD The_DT cumulative_JJ foreign_JJ exchange_NN differences_NNS on_IN translation_NN amount_NN to_TO 150,189,000_CD losses_NNS as_IN at_IN 31_CD December_NNP 2004_CD 2003_CD :_: losses_NNS of_IN 94,679,000_CD ._.
64_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 65_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 28_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS a_DT Leases_NNP The_NNP Group_NNP leases_VBZ property_NN ,_, computer_NN and_CC office_NN equipment_NN and_CC motor_NN vehicles_NNS on_IN short-term_JJ operating_NN leases_NNS ._.
The_DT rents_NNS payable_JJ under_IN property_NN leases_NNS are_VBP subject_JJ to_TO renegotiation_NN at_IN various_JJ intervals_NNS specified_VBN in_IN the_DT leases_NNS ._.
The_DT Group_NNP pays_VBZ for_IN substantially_RB all_DT of_IN the_DT insurance_NN ,_, maintenance_NN and_CC repair_NN of_IN these_DT assets_NNS ._.
The_DT minimum_JJ annual_JJ rentals_NNS under_IN the_DT foregoing_VBG operating_NN leases_NNS are_VBP as_IN follows_VBZ :_: 2004_CD 2003_CD Land_NNP and_CC Land_NNP and_CC buildings_NNS Equipment_NNP Motor_NNP vehicles_NNS buildings_NNS Equipment_NNP Motor_NNP vehicles_NNS 000 000 000 000_CD 000_CD 000_CD Group_NNP Operating_NN leases_NNS which_WDT expire_VBP :_: within_IN 1_CD year_NN 589 933 645_CD 30 538 973_CD within_IN 2-5_CD years_NNS 833_CD 1,442_CD 2,271_CD 1,010_CD 1,856_CD 1,756_CD after_IN 5_CD years_NNS 1,655_CD 1,600_CD 5_CD 3,077_CD 2,375_CD 2,916_CD 2,640_CD 2,399_CD 2,729_CD 2004_CD 2003_CD Land_NNP and_CC Land_NNP and_CC buildings_NNS Equipment_NNP Motor_NNP vehicles_NNS buildings_NNS Equipment_NNP Motor_NNP vehicles_NNS 000 000 000 000_CD 000_CD 000_CD Company_NN Operating_NN leases_NNS which_WDT expire_VBP :_: within_IN 1_CD year_NN 9_CD 35_CD within_IN 2-5_CD years_NNS 145_CD 28_CD 145_CD 34_CD 145_CD 37_CD 145_CD 69_CD b_NN Guarantees_NNS and_CC collateral_NN At_IN 31_CD December_NNP 2004_CD the_DT Company_NN had_VBD $_$ 5.3_CD million_CD 2.8_CD million_CD of_IN restricted_VBN cash_NN held_VBN as_IN collateral_NN for_IN certain_JJ equipment_NN leases_NNS ._.
c_NN Letters_NNS of_IN credit_NN As_IN at_IN 31_CD December_NNP 2004_CD ,_, the_DT Company_NN had_VBD outstanding_JJ ,_, an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Barclays_NNP Bank_NNP plc_NN in_IN the_DT amount_NN of_IN $_$ 15.0_CD million_CD 7.8_CD million_CD providing_VBG security_NN on_IN the_DT recoverability_NN of_IN insurance_NN claims_NNS ._.
The_DT Company_NN had_VBD restricted_VBN cash_NN of_IN $_$ 16.0_CD million_CD 8.3_CD million_CD in_IN connection_NN with_IN this_DT letter_NN of_IN credit_NN ._.
d_LS Capital_NNP commitments_NNS i_FW The_DT Company_NN has_VBZ undertaken_VBN to_TO subscribe_VB for_IN interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totaling_VBG $_$ 22.0_CD million_CD 11.5_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2004_CD an_DT amount_NN of_IN $_$ 48.6_CD million_CD 25.3_CD million_CD has_VBZ been_VBN subscribed_VBN ._.
ii_FW MTS_FW METHYPATCH_NNP In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN MTS_NNP METHYPATCH_NNP in_IN 2003_CD ,_, the_DT Company_NN is_VBZ committed_VBN to_TO pay_VB an_DT additional_JJ $_$ 50.0_CD million_CD 26.0_CD million_CD upon_IN regulatory_JJ approval_NN of_IN the_DT product_NN ._.
In_IN addition_NN the_DT Company_NN has_VBZ an_DT obligation_NN to_TO make_VB further_JJ milestone_NN payments_NNS ,_, which_WDT are_VBP linked_VBN to_TO the_DT future_JJ sales_NNS performance_NN of_IN the_DT product_NN ._.
These_DT payments_NNS could_MD total_VB $_$ 75.0_CD million_CD 39.1_CD million_CD ._.
iii_FW FOSRENOL_NNP patent_NN rights_NNS In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN the_DT global_JJ patents_NNS for_IN FOSRENOL_NNP ,_, Shire_NNP agreed_VBD to_TO pay_VB AnorMED_NNP $_$ 6.0_CD million_CD 3.1_CD million_CD when_WRB it_PRP is_VBZ approved_VBN in_IN certain_JJ European_JJ countries_NNS and_CC $_$ 6.0_CD million_CD upon_IN receipt_NN of_IN regulatory_JJ approval_NN in_IN Japan_NNP ._.
iv_NNP Manufacturing_NNP facility_NN The_DT Company_NN has_VBZ committed_VBN to_TO the_DT expansion_NN and_CC modification_NN of_IN its_PRP$ manufacturing_NN facility_NN at_IN Owings_NNP Mills_NNP ,_, Maryland_NNP to_TO facilitate_VB the_DT production_NN of_IN FOSRENOL_NNP ._.
The_DT Company_NN has_VBZ committed_VBN to_TO spend_VB a_DT further_JJ $_$ 10.6_CD million_CD 5.5_CD million_CD by_IN the_DT end_NN of_IN 2005_CD ._.
The_DT Company_NN has_VBZ an_DT additional_JJ commitment_NN of_IN $_$ 4.4_CD million_CD 2.3_CD million_CD for_IN the_DT design_NN and_CC construction_NN of_IN a_DT technology_NN center_NN at_IN Owings_NNP Mills_NNP ,_, Maryland_NNP ._.
v_FW Chesterbrook_NNP ,_, Pennsylvania_NNP fit_VBD out_RP The_DT Company_NN is_VBZ in_IN the_DT process_NN of_IN fitting_JJ out_IN its_PRP$ new_JJ US_NNP headquarters_NN at_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
At_IN 31_CD December_NNP 2004_CD the_DT Company_NN had_VBD an_DT outstanding_JJ commitment_NN of_IN $_$ 20.4_CD million_CD 10.6_CD million_CD ._.
65_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 66_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 28_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD e_SYM Contingent_JJ liabilities_NNS Shire_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ business_NN ,_, including_VBG those_DT set_VBN out_RP below_IN ._.
Although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS referred_VBD to_TO below_IN ,_, Shire_NNP believes_VBZ that_IN they_PRP will_MD not_RB have_VB a_DT materially_RB adverse_JJ effect_NN on_IN the_DT Groups_NNS financial_JJ position_NN ._.
i_FW Phentermine_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, is_VBZ a_DT defendant_NN in_IN 260_CD lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
SUS_NNP ,_, formerly_RB known_VBN as_IN Shire_NNP Richwood_NNP Inc._NNP has_VBZ been_VBN sued_VBN as_IN a_DT manufacturer_NN and_CC distributor_NN of_IN phentermine_NN ,_, an_DT anorectic_NN used_VBN in_IN the_DT short-term_JJ treatment_NN of_IN obesity_NN and_CC one_CD of_IN the_DT products_NNS addressed_VBN by_IN the_DT lawsuits_NNS ._.
The_DT suits_NNS relate_VBP to_TO phentermine_VB either_CC alone_RB or_CC together_RB with_IN fenfluramine_NN or_CC dexenfluramine_NN ._.
The_DT lawsuits_NNS generally_RB allege_VBP the_DT following_VBG claims_NNS :_: the_DT defendants_NNS marketed_VBN phentermine_NN and_CC other_JJ products_NNS for_IN the_DT treatment_NN of_IN obesity_NN and_CC misled_VBD users_NNS about_IN the_DT products_NNS and_CC dangers_NNS associated_VBN with_IN them_PRP :_: the_DT defendants_NNS failed_VBD adequately_RB to_TO test_NN phentermine_NN individually_RB and_CC when_WRB taken_VBN in_IN combination_NN with_IN the_DT other_JJ drugs_NNS :_: and_CC the_DT defendants_NNS knew_VBD or_CC should_MD have_VB known_VBN about_IN the_DT negative_JJ effects_NNS of_IN the_DT drugs_NNS and_CC should_MD have_VB informed_VBN the_DT public_JJ about_IN such_JJ risks_NNS and_CC or_CC failed_VBD to_TO provide_VB appropriate_JJ warning_NN labels_NNS ._.
SUS_NNP has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT total_NN of_IN 4,196_CD such_JJ phentermine_NN lawsuits_NNS ,_, in_IN respect_NN of_IN which_WDT SUS_NNP has_VBZ been_VBN dismissed_VBN as_IN a_DT defendant_NN in_IN 3,936_CD cases_NNS ._.
Eight_CD of_IN the_DT 4,196_CD cases_NNS name_NN Shire_NNP as_IN a_DT defendant_NN ,_, but_CC have_VBP not_RB been_VBN served_VBN as_IN required_VBN by_IN state_NN and_CC federal_JJ rules_NNS of_IN civil_JJ procedure_NN ._.
It_PRP is_VBZ expected_VBN that_IN Shire_NNP will_MD be_VB dismissed_VBN from_IN the_DT remaining_VBG cases_NNS based_VBN upon_IN lack_NN of_IN product_NN identification_NN or_CC agreement_NN of_IN the_DT parties_NNS ._.
SUS_NNP became_VBD involved_VBN with_IN phentermine_NN through_IN its_PRP$ acquisition_NN of_IN certain_JJ assets_NNS of_IN Rexar_NNP Pharmacal_NNP Corporation_NNP Rexar_NNP in_IN January_NNP 1994_CD ._.
In_IN addition_NN to_TO SUS_NNP potentially_RB incurring_VBG liability_NN as_IN a_DT result_NN of_IN its_PRP$ own_JJ production_NN of_IN Oby-Cap_NNP ,_, a_DT phentermine_JJ product_NN ,_, the_DT plaintiffs_NNS may_MD additionally_RB seek_VB to_TO impose_VB liability_NN on_IN SUS_NNP as_IN successor_NN to_TO Rexar_NNP ._.
SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB all_PDT the_DT lawsuits_NNS ._.
SUS_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB prescribed_VBN ,_, causes_VBZ the_DT alleged_JJ side_NN effects_NNS and_CC that_IN SUS_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Accordingly_RB ,_, SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Group_NNP in_IN respect_NN of_IN phentermine_NN ._.
Legal_JJ expenses_NNS to_TO date_NN have_VBP been_VBN paid_VBN by_IN Eon_NNP Labs_NNPS ,_, Inc._NNP ._.
Eon_NNP ,_, the_DT supplier_NN to_TO SUS_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN 30_CD November_NNP 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
ii_FW ADDERALL_NNP XR_NNP a_DT Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Shires_NNP extended_VBD release_NN once-daily_RB version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP ,_, is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ._.
In_IN January_NNP 2003_CD the_DT Company_NN was_VBD notified_VBN that_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Barr_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD Patent_NN ._.
The_DT notification_NN alleged_VBD that_IN the_DT 819_CD Patent_NN is_VBZ not_RB infringed_VBN by_IN Barrs_NNP extended_VBD release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, which_WDT is_VBZ the_DT subject_NN of_IN Barrs_NNP ANDA_NNP ._.
On_IN 24_CD February_NNP 2003_CD Shire_NNP Laboratories_NNPS Inc._NNP ._.
Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Barr_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP alleging_VBG that_IN Barrs_NNP ANDA_NNP infringes_VBZ the_DT 819_CD Patent_NN ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP infringes_VBZ the_DT 819_CD Patent_NN and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 819_CD Patent_NN ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
Barr_NNP has_VBZ counterclaimed_VBN for_IN a_DT declaration_NN that_IN its_PRP$ ANDA_NNP product_NN will_MD not_RB infringe_VB the_DT claims_NNS of_IN the_DT 819_CD Patent_NN ._.
Barr_NNP is_VBZ also_RB seeking_VBG its_PRP$ attorneys_NNS fees_NNS ,_, costs_NNS and_CC expenses_NNS ._.
On_IN 12_CD August_NNP 2003_CD ,_, Shire_NNP Laboratories_NNP was_VBD issued_VBN a_DT new_JJ US_NNP patent_NN No._NN ._.
6,605,300_CD the_DT 300_CD Patent_NN covering_VBG ADDERALL_NNP XR_NNP ._.
In_IN August_NNP 2003_CD Shire_NNP was_VBD notified_VBN that_IN Barr_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN and_CC alleging_VBG that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ ._.
In_IN September_NNP 2003_CD Shire_NNP Laboratories_NNPS filed_VBD a_DT lawsuit_NN in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN Barr_NNP alleging_VBG that_IN Barrs_NNP ANDA_NNP infringes_VBZ the_DT 300_CD Patent_NN ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP infringes_VBZ the_DT 300_CD Patent_NN and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 300_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
By_IN way_NN of_IN a_DT counterclaim_NN ,_, Barr_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ and_CC Barr_NNP has_VBZ also_RB asked_VBN for_IN its_PRP$ attorneys_NNS fees_NNS ,_, costs_NNS and_CC expenses_NNS ._.
The_DT lawsuits_NNS against_IN Barr_NNP with_IN respect_NN to_TO the_DT 819_CD and_CC 300_CD Patents_NNP were_VBD consolidated_VBN in_IN December_NNP 2003_CD and_CC a_DT trial_NN date_NN scheduled_VBN for_IN January_NNP 2006_CD ._.
On_IN 27_CD September_NNP 2004_CD ,_, Barr_NNP filed_VBD an_DT amended_VBN Answer_NNP ,_, Affirmative_NNP Defense_NNP and_CC Counterclaim_NNP in_IN which_WDT Barr_NNP added_VBD the_DT following_VBG counterclaims_NNS and_CC affirmative_JJ defences_NNS :_: invalidity_NN of_IN the_DT 819_CD patent_NN ,_, non-infringement_NN of_IN the_DT 300_CD Patent_NN and_CC unenforceability_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP due_JJ to_TO inequitable_JJ conduct_NN ._.
Shire_NNP has_VBZ asserted_VBN affirmative_JJ defenses_NNS ,_, alleging_VBG ,_, among_IN other_JJ things_NNS ,_, that_IN Barr_NNP has_VBZ waived_VBN its_PRP$ right_NN to_TO assert_VB the_DT counterclaims_NNS set_VBN forth_RB in_IN its_PRP$ 27_CD September_NNP 2004_CD amended_VBN answers_NNS ._.
66_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 67_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 28_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD Barr_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP FDA_NNP ._.
The_DT lawsuits_NNS triggered_VBD stays_NNS of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Companys_NNP receipt_NN of_IN Barrs_NNP notices_NNS to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suits_NNS ._.
Even_RB if_IN Barr_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT latest_JJS stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN Barr_NNP receives_VBZ a_DT favourable_JJ decision_NN before_IN the_DT expiration_NN of_IN the_DT stay_NN ,_, then_RB Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ,_, following_VBG the_DT expiry_NN of_IN the_DT Hatch-Waxman_NNP exclusivity_NN period_NN ._.
HatchWaxman_NNP exclusivity_NN was_VBD originally_RB due_JJ to_TO expire_VB in_IN October_NNP 2004_CD ._.
However_RB ,_, on_IN 28_CD October_NNP 2004_CD the_DT FDA_NNP granted_VBD an_DT additional_JJ six_CD months_NNS exclusivity_NN to_TO ADDERALL_NNP XR_NNP based_VBN upon_IN pediatric_JJ studies_NNS carried_VBD out_RP on_IN the_DT drug_NN product_NN ,_, meaning_VBG that_IN Barr_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN after_IN Hatch-Waxman_NNP exclusivity_NN expires_VBZ on_IN 11_CD April_NNP 2005_CD ._.
b_NN Impax_NNP Laboratories_NNP ,_, Inc._NNP ._.
In_IN November_NNP 2003_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Impax_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Impax_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 30mg_JJ strength_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP and_CC alleging_VBG that_IN the_DT 819_CD and_CC 300_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Impaxs_NNP extended_VBD release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, the_DT subject_NN of_IN Impaxs_NNP ANDA_NNP ._.
In_IN December_NNP 2003_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Impaxs_VBZ ANDA_NNP infringes_VBZ the_DT 819_CD and_CC 300_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Impax_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Impax_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
Impaxs_NNP affirmative_JJ defenses_NNS include_VBP non-infringement_JJ and_CC invalidity_NN of_IN both_DT the_DT 819_CD and_CC 300_CD Patents_NNP ._.
Impax_NNP is_VBZ also_RB requesting_VBG that_IN costs_NNS be_VB assessed_VBN against_IN the_DT Company_NN ._.
A_DT trial_NN date_NN of_IN 11_CD October_NNP 2005_CD has_VBZ been_VBN set_VBN ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP received_VBD an_DT additional_JJ notification_NN from_IN Impax_NNP advising_VBG of_IN the_DT filing_NN of_IN an_DT ANDA_NNP for_IN a_DT generic_JJ version_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ and_CC 25mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP in_IN addition_NN to_TO the_DT 30mg_JJ strength_NN ,_, the_DT subject_NN of_IN Impaxs_NNP initial_JJ ANDA_NNP ._.
In_IN January_NNP 2005_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Impaxs_VBZ amended_VBN ANDA_NNP infringes_VBZ the_DT 819_CD and_CC 300_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Impax_NNP from_IN commercialising_VBG its_PRP$ amended_VBN ANDA_NNP products_NNS before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Impax_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
Impaxs_NNP affirmative_JJ defenses_NNS include_VBP non-infringement_JJ ,_, invalidity_NN and_CC unenforceability_NN of_IN both_DT the_DT 819_CD and_CC 300_CD Patents_NNP ._.
Impax_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuits_NNS triggered_VBD stays_NNS of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT Companys_NNP receipt_NN of_IN Impaxs_NNP notices_NNS to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suits_NNS ._.
Even_RB if_IN Impax_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stays_NNS May_MD 2006_CD in_IN the_DT case_NN of_IN the_DT 30mg_JJ strength_NN and_CC June_NNP 2007_CD in_IN the_DT case_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ and_CC 25mg_JJ strengths_NNS or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_WDT Impax_NNP receives_VBZ a_DT favourable_JJ decision_NN before_IN the_DT expiration_NN of_IN the_DT stays_NNS ,_, then_RB Impax_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended_JJ release_NN mixed_JJ amphetamine_NN salt_NN products_NNS upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
The_DT FDA_NNP may_MD grant_VB 180_CD days_NNS of_IN market_NN exclusivity_NN to_TO the_DT first_JJ to_TO file_VB ._.
Hatch-Waxman_NNP exclusivity_NN was_VBD originally_RB due_JJ to_TO expire_VB in_IN October_NNP 2004_CD ._.
However_RB ,_, on_IN 28_CD October_NNP 2004_CD the_DT FDA_NNP granted_VBD an_DT additional_JJ six_CD months_NNS exclusivity_NN to_TO ADDERALL_NNP XR_NNP based_VBN upon_IN pediatric_JJ studies_NNS carried_VBD out_RP on_IN the_DT drug_NN product_NN ,_, meaning_VBG that_IN Impax_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN after_IN Hatch-Waxman_NNP exclusivity_NN expires_VBZ on_IN 11_CD April_NNP 2005_CD ._.
c_NN Colony_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Colony_NNP Pharmaceuticals_NNP Inc_NNP Colony_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
Shire_NNP has_VBZ decided_VBN not_RB to_TO sue_VB Colony_NNP ._.
In_IN any_DT event_NN ,_, Colony_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN Shires_NNP existing_VBG Hatch-Waxman_NNP exclusivity_NN on_IN 11_CD April_NNP 2005_CD and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
In_IN February_NNP 2005_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Teva_NNP Pharmaceuticals_NNP USA_NNP ,_, Inc._NNP ._.
Teva_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 10mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
Shire_NNP is_VBZ reviewing_VBG the_DT content_NN of_IN the_DT notice_NN received_VBD from_IN Teva_NNP and_CC is_VBZ considering_VBG what_WP action_NN ,_, if_IN any_DT ,_, it_PRP will_MD take_VB against_IN Teva_NNP ._.
In_IN any_DT event_NN ,_, Teva_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiry_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN on_IN 11_CD April_NNP 2005_CD and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
67_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 68_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 28_CD Guarantees_NNS ,_, commitments_NNS and_CC contingencies_NNS continued_VBD iv_JJ CARBATROL_NNP In_IN August_NNP 2003_CD the_DT Company_NN was_VBD notified_VBN that_IN Nostrum_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Nostrum_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT HatchWaxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 300mg_JJ strength_NN of_IN CARBATROL_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS US_NNP patents_NNS for_IN CARBATROL_NNP ,_, US_NNP patent_NN No._NN ._.
5,912,013_CD the_DT 013_CD Patent_NN and_CC US_NNP patent_NN No._NN ._.
The_DT notification_NN alleges_VBZ that_IN the_DT 013_CD and_CC 570_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP 300mg_CD extended_JJ release_NN carbamazepine_NN product_NN ,_, the_DT subject_NN of_IN Nostrums_NNPS ANDA_NNP ._.
This_DT dosage_JJ strength_NN represents_VBZ about_IN half_NN of_IN Shires_NNP current_JJ sales_NNS in_IN epilepsy_NN ._.
On_IN 18_CD September_NNP 2003_CD Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Nostrum_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP for_IN infringement_NN of_IN these_DT two_CD patents_NNS ._.
The_DT Company_NN was_VBD seeking_VBG a_DT ruling_NN that_WDT Nostrums_VBZ ANDA_NNP infringes_VBZ the_DT 013_CD and_CC 570_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ._.
The_DT Company_NN was_VBD also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Nostrum_NNP from_IN commercialising_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Nostrum_NNP should_MD engage_VB in_IN such_JJ commercialisation_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN 23_CD January_NNP 2004_CD the_DT Company_NN amended_VBD the_DT complaint_NN to_TO delete_VB the_DT allegations_NNS with_IN respect_NN to_TO the_DT 013_CD Patent_NN ._.
By_IN way_NN of_IN counterclaims_NNS Nostrum_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 570_CD and_CC 013_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP ANDA_NNP product_NN as_RB well_RB as_IN actual_JJ and_CC punitive_JJ damages_NNS for_IN alleged_JJ abuse_NN of_IN process_NN by_IN Shire_NNP ._.
On_IN 12_CD July_NNP 2004_CD the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP dismissed_VBD Nostrums_NNP abuse_NN of_IN process_NN counterclaim_NN for_IN failure_NN to_TO state_VB a_DT claim_NN upon_IN which_WDT relief_NN can_MD be_VB granted_VBN ._.
On_IN 10_CD December_NNP 2004_CD Nostrum_NNP filed_VBD a_DT summary_NN judgment_NN motion_NN seeking_VBG a_DT declaration_NN of_IN non-infringement_NN of_IN the_DT 570_CD Patent_NN ._.
Shires_NNP opposition_NN to_TO this_DT motion_NN was_VBD filed_VBN on_IN 14_CD January_NNP 2005_CD ._.
The_DT case_NN is_VBZ now_RB in_IN the_DT expert_NN discovery_NN phase_NN ._.
No_DT trial_NN date_NN has_VBZ been_VBN set_VBN ._.
Nostrum_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN CARBATROL_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuit_NN triggered_VBD a_DT stay_NN of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN Shires_NNP receipt_NN of_IN Nostrums_NNP notice_NN to_TO allow_VB the_DT court_NN to_TO resolve_VB the_DT suit_NN ._.
Even_RB if_IN Nostrum_NNP receives_VBZ tentative_JJ approval_NN from_IN the_DT FDA_NNP for_IN its_PRP$ ANDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB ,_, then_RB Nostrum_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ 300mg_JJ extended_JJ release_NN carbamazepine_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ._.
29_CD Pension_NN arrangements_NNS The_DT Group_NNP has_VBZ a_DT number_NN of_IN defined_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
The_DT Company_NN contribution_NN is_VBZ fixed_VBN as_IN a_DT set_VBN percentage_NN of_IN employees_NNS base_JJ salary_NN ._.
The_DT pension_NN cost_NN charge_NN for_IN the_DT defined_VBN contribution_NN schemes_NNS for_IN the_DT year_NN was_VBD 4,914,000_CD 2003_CD :_: 9,824,000_CD ._.
The_DT closing_NN creditor_NN in_IN respect_NN of_IN pension_NN premiums_NNS at_IN 31_CD December_NNP 2004_CD is_VBZ 118,000_CD 31_CD December_NNP 2003_CD :_: 605,000_CD ._.
The_DT defined_VBN benefit_NN plan_NN operated_VBN by_IN the_DT Group_NNP was_VBD a_DT Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP for_IN certain_JJ US_NNP employees_NNS of_IN the_DT acquired_VBN company_NN ,_, Roberts_NNP Pharmaceutical_NNP Corporation_NNP ,_, who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
The_DT plan_NN was_VBD discontinued_VBN in_IN 2000_CD and_CC there_EX were_VBD no_DT contributions_NNS payable_JJ in_IN respect_NN of_IN the_DT years_NNS 2004_CD and_CC 2003_CD ._.
The_DT Group_NNP paid_VBD a_DT lump_NN sum_NN of_IN 9.4_CD million_CD $_$ 18.0_CD million_CD into_IN the_DT SERP_NNP ,_, which_WDT was_VBD accounted_VBN for_IN as_IN a_DT fair_JJ value_NN adjustment_NN on_IN the_DT acquisition_NN of_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP to_TO make_VB good_JJ the_DT deficit_NN on_IN this_DT scheme_NN at_IN the_DT time_NN of_IN acquisition_NN ._.
This_DT lump_NN sum_NN payment_NN has_VBZ led_VBN to_TO the_DT Group_NNP having_VBG no_DT future_JJ liability_NN under_IN the_DT SERP_NNP ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS with_IN contributions_NNS no_RB longer_RB payable_JJ by_IN existing_VBG members_NNS ._.
The_DT asset_NN and_CC liability_NN of_IN 4.9_CD million_CD and_CC 2.9_CD million_CD respectively_RB are_VBP shown_VBN in_IN Notes_NNP 20_CD ,_, 22_CD and_CC 23_CD respectively_RB ._.
30_CD Notes_NNS to_TO the_DT consolidated_JJ cash_NN flow_NN statement_NN a_DT Reconciliation_NNP of_IN operating_NN profit_NN loss_NN to_TO net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 2004 2003 000 000_CD Group_NNP operating_NN profit_NN loss_NN 65,695_CD 299,935_CD Depreciation_NN and_CC amounts_NNS written_VBN off_RP tangible_JJ fixed_JJ assets_NNS 12,516_CD 19,369_CD Amortisation_NNP and_CC amounts_VBZ written_VBN off_RP intellectual_JJ property_NN 29,164_CD 30,405_CD Amortisation_NNP and_CC amounts_VBZ written_VBN off_RP goodwill_NN 158,283_CD 533,115_CD Loss_NN profit_NN on_IN sale_NN of_IN tangible_JJ fixed_JJ assets_NNS 205_CD 100_CD Profit_NN on_IN sale_NN of_IN intellectual_JJ property_NN 432_CD Provision_NNP for_IN investments_NNS 8,801_CD 9,491_CD Increase_VBP decrease_NN in_IN stocks_NNS 1,570_CD 3,320_CD Increase_VBP in_IN debtors_NNS 28,444_CD 27,868_CD Increase_VBP in_IN creditors_NNS 29,514_CD 12,478_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 273,732_CD 280,275_CD 68_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 69_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 30_CD Notes_NNS to_TO the_DT consolidated_JJ cash_NN flow_NN statement_NN continued_VBD b_NN Analysis_NN and_CC reconciliation_NN of_IN net_JJ debt_NN Other_JJ non-cash_JJ Exchange_NNP Start_NNP of_IN year_NN Cash_NN flow_NN changes_NNS movement_NN End_NN of_IN year_NN Year_NN ended_VBD 31_CD December_NNP 2004 000 000 000_CD 000_CD 000_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 621,670_CD 5,299_CD 23,606_CD 592,765_CD Debt_NN due_JJ within_IN one_CD year_NN 431_CD 429_CD 3_CD 1_CD Finance_NNP leases_NNS 158_CD 130_CD 28_CD 621,081_CD 4,740_CD 3_CD 23,579_CD 592,765_CD Debt_NN due_JJ after_IN one_CD year_NN 203,083_CD 199,489_CD 3_CD 3,537_CD 60_CD Finance_NNP leases_NNS 3,238_CD 3,234_CD 4_CD 414,760_CD 197,983_CD 20,038_CD 592,705_CD Current_JJ assets_NNS investments_NNS 169,895_CD 9,017_CD 9,713_CD 169,199_CD Net_JJ funds_NNS 584,655_CD 207,000_CD 29,751_CD 761,904_CD Other_JJ non-cash_JJ Exchange_NNP Start_NNP of_IN year_NN Cash_NN flow_NN changes_NNS movement_NN End_NN of_IN year_NN Year_NN ended_VBD 31_CD December_NNP 2003 000 000 000_CD 000_CD 000_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 558,432_CD 124,578_CD 61,340_CD 621,670_CD Debt_NN due_JJ within_IN one_CD year_NN 389 443 446_CD 39_CD 431_CD Finance_NNP leases_NNS 162 160 155_CD 1_CD 158_CD 557,881_CD 125,181_CD 601_CD 61,380_CD 621,081_CD Debt_NN due_JJ after_IN one_CD year_NN 244,325_CD 17,610_CD 446_CD 23,186_CD 203,083_CD Finance_NNP leases_NNS 3,757_CD 155_CD 364_CD 3,238_CD 309,799_CD 142,791_CD 37,830_CD 414,760_CD Current_JJ assets_NNS investments_NNS 196,364_CD 17,848_CD 8,621_CD 169,895_CD Net_JJ funds_NNS 506,163_CD 124,943_CD 46,451_CD 584,655_CD 2004 2003 000 000_CD Decrease_NN increase_NN in_IN cash_NN in_IN the_DT year_NN 5,299_CD 124,578_CD Cash_NN outflow_NN from_IN decrease_NN in_IN debt_NN and_CC lease_NN financing_NN 203,282_CD 18,213_CD Cash_NN outflow_NN inflow_NN from_IN decrease_NN in_IN liquid_JJ resources_NNS 9,017_CD 17,848_CD Change_NNP in_IN net_JJ debt_NN resulting_VBG from_IN cash_NN flows_NNS 207,000_CD 124,943_CD Translation_NN difference_NN 29,751_CD 46,451_CD Movement_NNP in_IN net_JJ funds_NNS in_IN year_NN 177,249_CD 78,492_CD Net_JJ funds_NNS at_IN beginning_NN of_IN year_NN 584,655_CD 506,163_CD Net_JJ funds_NNS at_IN end_NN of_IN year_NN 761,904_CD 584,655_CD c_NN Major_JJ non-cash_JJ transactions_NNS 2004 2003 000 000_CD Sale_NNP of_IN the_DT vaccines_NNS business_NN 4,931,864_CD subscription_NN receipts_NNS in_IN IDB_NNP 31,252_CD Cash_NN held_VBN in_IN Escrow_NNP 15,626_CD The_DT 4,931,864_CD subscription_NN receipts_NNS were_VBD redeemed_VBN on_IN 7_CD January_NNP 2005_CD for_IN a_DT value_NN of_IN 31.3_CD million_CD $_$ 60_CD million_CD ._.
The_DT receipts_NNS were_VBD received_VBN as_IN part_NN of_IN the_DT consideration_NN for_IN the_DT sale_NN of_IN the_DT vaccines_NNS business_NN ._.
See_VB Note_VB 16_CD for_IN further_JJ details_NNS on_IN the_DT sale_NN of_IN the_DT vaccines_NNS business_NN ._.
69_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 70_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 31_CD Related_VBN party_NN transactions_NNS The_DT Company_NN incurred_VBN professional_JJ fees_NNS with_IN Stikeman_NNP Elliott_NNP ,_, a_DT law_NN firm_NN in_IN which_WDT The_DT Hon_NNP James_NNP Grant_NNP is_VBZ a_DT partner_NN ,_, totaling_VBG $_$ 2.1_CD million_CD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 2003_CD :_: $_$ 0.8_CD million_CD ._.
In_IN April_NNP 2004_CD Shire_NNP BioChem_NNP Inc._NNP ._.
BioChem_NNP ,_, a_DT subsidiary_NN of_IN Shire_NNP ,_, sold_VBD a_DT Canadian_JJ property_NN to_TO NeuroChem_NNP Inc._NNP for_IN CAN$_NNP 10.5_CD million_CD ._.
Dr_NNP Bellini_NNP ,_, a_DT non-executive_JJ Director_NNP of_IN Biochem_NNP and_CC ,_, until_IN 10_CD May_NNP 2003_CD ,_, a_DT non-executive_JJ Director_NNP of_IN Shire_NNP and_CC Mr_NNP Nordmann_NNP ,_, a_DT nonexecutive_JJ Director_NNP of_IN Shire_NNP are_VBP both_DT directors_NNS of_IN NeuroChem_NNP Inc._NNP ._.
Dr_NNP Bellini_NNP had_VBD an_DT indirect_JJ substantial_JJ interest_NN in_IN the_DT issued_VBN share_NN capital_NN of_IN NeuroChem_NNP Inc._NNP at_IN the_DT time_NN of_IN the_DT transaction_NN ._.
In_IN April_NNP 2004_CD ,_, Biochem_NNP contributed_VBD cash_NN of_IN CAN$_NNP 5.0_CD million_CD ,_, equipment_NN and_CC intellectual_JJ property_NN to_TO the_DT start-up_NN of_IN a_DT new_JJ Canadianbased_JJ pharmaceutical_JJ research_NN and_CC development_NN organization_NN ,_, ViroChem_NNP Pharma_NNP Inc._NNP in_IN return_NN for_IN an_DT equity_NN interest_NN and_CC royalties_NNS on_IN the_DT sale_NN of_IN certain_JJ products_NNS subsequently_RB launched_VBN by_IN Virochem_NNP ._.
Biochem_NNP has_VBZ undertaken_VBN to_TO invest_VB an_DT additional_JJ CAN$_NNP 10.0_CD million_CD in_IN Virochem_NNP in_IN two_CD equal_JJ tranches_NNS of_IN CAN$_NNP 5.0_CD million_CD in_IN April_NNP 2005_CD and_CC April_NNP 2006_CD ._.
Dr_NNP Bellini_NNP ,_, a_DT non-executive_JJ Director_NNP of_IN Biochem_NNP and_CC ,_, until_IN 10_CD May_NNP 2003_CD ,_, a_DT non-executive_JJ Director_NNP of_IN Shire_NNP ,_, had_VBD ,_, at_IN the_DT time_NN of_IN the_DT transaction_NN ,_, an_DT indirect_JJ substantial_JJ interest_NN in_IN a_DT company_NN which_WDT is_VBZ a_DT co-investor_NN in_IN ViroChem_NNP Pharma_NNP Inc._NNP ._.
In_IN accordance_NN with_IN Financial_NNP Reporting_NNP Standard_NNP No._NN ._.
8_CD related_JJ party_NN disclosures_NNS ,_, transactions_NNS with_IN other_JJ companies_NNS in_IN ,_, and_CC investee_NN related_VBN parties_NNS of_IN ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP have_VBP not_RB been_VBN disclosed_VBN in_IN these_DT financial_JJ statements_NNS ._.
32_CD Subsequent_JJ events_NNS a_DT NRP_NNP 104_CD In_IN January_NNP 2005_CD ,_, Shire_NNP entered_VBD into_IN an_DT agreement_NN with_IN New_NNP River_NNP Pharmaceuticals_NNP Inc._NNP to_TO collaborate_VB in_IN developing_VBG ,_, manufacturing_VBG ,_, marketing_NN and_CC selling_VBG NRP104_NNP in_IN the_DT US_NNP ._.
In_IN the_DT rest_NN of_IN the_DT world_NN ,_, Shire_NNP acquired_VBD the_DT license_NN to_TO develop_VB and_CC commercialise_VB NRP104_NNP ._.
Shire_NNP paid_VBD an_DT initial_JJ sum_NN of_IN $_$ 50_CD million_CD 26.0_CD million_CD on_IN signing_NN ,_, and_CC there_EX is_VBZ a_DT further_JJ $_$ 50_CD million_CD due_JJ upon_IN acceptance_NN of_IN filing_NN of_IN the_DT New_NNP Drug_NNP Application_NNP by_IN the_DT FDA_NNP and_CC up_RB to_TO $_$ 300_CD million_CD 156.3_CD million_CD in_IN milestone_NN payments_NNS following_VBG the_DT first_JJ commercial_JJ sale_NN depending_VBG on_IN the_DT characteristics_NNS of_IN the_DT FDA_NNP approved_VBD product_NN labeling_VBG ._.
A_DT $_$ 5_CD million_CD 2.6_CD million_CD milestone_NN payment_NN is_VBZ payable_JJ following_VBG the_DT first_JJ commercial_JJ sale_NN in_IN specified_VBN European_JJ countries_NNS ._.
An_DT additional_JJ $_$ 100_CD million_CD 52.1_CD million_CD milestone_NN would_MD be_VB payable_JJ as_IN a_DT sales_NNS bonus_NN upon_IN achieving_VBG a_DT significant_JJ sales_NNS target_NN ._.
Shire_NNP may_MD be_VB entitled_VBN to_TO refunds_NNS of_IN amounts_NNS previously_RB paid_VBN in_IN the_DT event_NN of_IN a_DT delayed_JJ product_NN approval_NN ._.
b_NN ADDERALL_NNP XR_NNP in_IN Canada_NNP ADDERALL_NNP XR_NNP was_VBD made_VBN commercially_RB available_JJ for_IN the_DT treatment_NN of_IN children_NNS in_IN Canada_NNP during_IN February_NNP 2004_CD ._.
On_IN 9_CD February_NNP 2005_CD ,_, Shire_NNP announced_VBD that_IN Health_NNP Canada_NNP had_VBD suspended_VBN sales_NNS of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP where_WRB sales_NNS in_IN 2004_CD amounted_VBD to_TO $_$ 7.8_CD million_CD ._.
Following_VBG the_DT Health_NNP Canada_NNP announcement_NN ,_, the_DT FDA_NNP issued_VBD a_DT statement_NN in_IN which_WDT it_PRP advised_VBD that_IN after_IN consultation_NN with_IN the_DT Canadian_JJ authorities_NNS regarding_VBG the_DT basis_NN for_IN their_PRP$ action_NN ,_, it_PRP did_VBD not_RB feel_VB that_IN any_DT immediate_JJ changes_NNS were_VBD warranted_VBN in_IN the_DT FDA_NNP labeling_VBG or_CC approved_VBN use_NN of_IN ADDERALL_NNP XR_NNP in_IN the_DT US_NNP based_VBN on_IN its_PRP$ preliminary_JJ understanding_NN of_IN Health_NNP Canadas_NNP analyses_NNS of_IN adverse_JJ event_NN reports_NNS and_CC the_DT FDAs_NNS own_VBP knowledge_NN and_CC assessment_NN of_IN those_DT reports_NNS ._.
Although_IN Shire_NNP is_VBZ complying_VBG with_IN Health_NNP Canadas_NNP suspension_NN request_NN ,_, Shire_NNP strongly_RB disagrees_VBZ with_IN the_DT conclusions_NNS drawn_VBN by_IN Health_NNP Canada_NNP and_CC has_VBZ lodged_VBN an_DT appeal_NN and_CC taken_VBN other_JJ actions_NNS to_TO preserve_VB its_PRP$ legal_JJ rights_NNS and_CC options_NNS ._.
70_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 71_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP head_NN office_NN and_CC main_JJ operating_NN locations_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP Italia_NNP S._NNP p._NNP A._NN Chief_NNP Executive_NNP Officer_NNP :_: Matthew_NNP Emmens_NNP Managing_VBG Director_NNP :_: Gian_NNP Piero_NNP Reverberi_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP Via_NNP Provinciale_NNP Lucchese_NNP ,_, 70_CD Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP 50019_CD Sesto_NNP F._NNP No_NNP FI_NNP United_NNP Kingdom_NNP Italy_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Tel_NNP 39_CD 0_CD 55 3025050_CD Fax_NNP 44_CD 0_CD 1256 894708_CD Fax_NNP 39_CD 0_CD 55 3025051_CD Shire_NNP Pharmaceuticals_NNPS Ltd_NNP Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Managing_VBG Director_NNP :_: John_NNP Freeman_NNP Managing_VBG Director_NNP :_: Jos_NNP Antonio_NNP Senz_NNP fide_NNP Broto_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP P_NNP Pintor_NNP Rosales_NNP ,_, n_NN 40_CD ,_, Bajo_NNP Izda_NNP ._.
Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP 28008_CD Madrid_NNP United_NNP Kingdom_NNP Spain_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Tel_NNP 34 915 500 691_CD Fax_NNP 44_CD 0_CD 1256 894708_CD Fax_NNP 34 915 493 695_CD Shire_NNP Pharmaceuticals_NNP Ireland_NNP Ltd_NNP Shire_NNP US_NNP Inc._NNP ._.
General_NNP Manager_NNP :_: Brian_NNP Martin_NNP President_NNP :_: Matthew_NNP Emmens_NNP Building_NNP 1A_NNP ,_, Citylink_NNP Business_NNP Park_NNP 725_CD Chesterbrook_NNP Blvd._NNP ._.
Old_NNP Naas_NNP Road_NNP ,_, Dublin_NNP 12_CD Wayne_NNP ,_, Pennsylvania_NNP 19087-5637_CD Ireland_NNP USA_NNP Tel_NNP 353_CD 1_CD 429_CD 7700_CD Tel_NNP 1_CD 484 595 8800_CD Fax_NNP 353_CD 1_CD 429_CD 7701_CD Fax_NN 1_CD 484 595 8900_CD Shire_NNP Pharmaceutical_NNP Contracts_NNPS Ltd_NNP Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
Singapore_NNP representative_JJ office_NN EVP_NNP Global_NNP Supply_NNP Chain_NNP &_CC Quality_NNP :_: John_NNP Lee_NNP Managing_VBG Director_NNP :_: Tony_NNP Ooi_NNP 11200_CD Gundry_NNP Lane_NNP LiFung_NNP Centre_NNP Owings_NNP Mills_NNP ,_, Maryland_NNP 21117_CD 5_CD B_NNP ,_, Toh_NNP Guan_NNP Road_NNP East_NNP ,_, #_# 03-09A_CD USA_NNP Singapore_NNP 608829_CD Tel_NNP 1_CD 410 413 1000_CD Tel_NNP 65 6665 2795_CD Fax_NNP 1_CD 410 413 2000_CD Fax_NNP 65 6665 2797_CD Shire_NNP Laboratories_NNPS Inc._NNP ._.
Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP KG_NNP President_NNP and_CC Chief_NNP Executive_NNP Officer_NNP :_: Jack_NNP Khattar_NNP Managing_VBG Director_NNP :_: Leonhard_NNP Terp_NNP 1550_CD East_NNP Gude_NNP Drive_NNP Siegburger_NNP Strae_NNP 126_CD Rockville_NNP ,_, Maryland_NNP 20850_CD D-50679_NNP Kln_NNP USA_NNP Germany_NNP Tel_NNP 1_CD 301 838 2500_CD Tel_NNP 49_CD 221_CD 8_CD 80_CD 47_CD 30_CD Fax_NN 1_CD 301 838 2501_CD Fax_NNP 49_CD 221_CD 8_CD 80_CD 47_CD 41_CD Shire_NNP Pharmaceutical_NNP Development_NNP Inc._NNP ._.
Shire_NNP France_NNP S._NNP A._NNP Senior_NNP Vice_NNP President_NNP :_: Simon_NNP Tulloch_NNP Managing_VBG Director_NNP :_: Vincent_NNP Lucet_NNP 725_CD Chesterbrook_NNP Blvd._NNP ._.
88_CD ,_, rue_NN du_NNP Dme_NNP Wayne_NNP ,_, Pennsylvania_NNP 19087-5637_CD 92514_CD Boulogne-Billancourt_NNP Cedex_NNP USA_NNP France_NNP Tel_NNP 1_CD 484 595 8800_CD Tel_NNP 33_CD 0_CD 146_CD 10_CD 90_CD 00_CD Fax_NN 1_CD 484 595 8900_CD Fax_NNP 33_CD 0_CD 146_CD 08_CD 21_CD 49_CD Shire_NNP BioChem_NNP Inc._NNP ._.
Vice_NNP President_NNP and_CC General_NNP Manager_NNP :_: Claude_NNP Perron_NNP 2250_CD Alfred-Nobel_NNP Blvd._NNP ._.
Suite_NN 500_CD Ville_NNP Saint-Laurent_NNP ,_, Qubec_NNP H4S_NNP 2C9_NNP Canada_NNP Tel_NNP 1_CD 514 787 2300_CD Fax_NN 1_CD 514 787 2427_CD 71_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP 72_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shareholder_NN information_NN Registered_NNP office_NN address_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP United_NNP Kingdom_NNP Registered_NNP in_IN England_NNP No._NN ._.
2883758_CD Investor_NNP relations_NNS Europe_NNP and_CC Rest_VB of_IN the_DT World_NNP :_: Cla_NNP Rosenfeld_NNP Tel_NNP 44_CD 0_CD 1256 894160_CD Fax_NNP 44_CD 0_CD 1256 894708_CD Email_NNP investorrelations@uk_NNP ._.
com_NN North_NNP America_NNP :_: Brian_NNP Piper_NNP Tel_NNP 1_CD 484 595 8800_CD Fax_NN 1_CD 484 595 8151_CD Email_NNP bpiper@us_NNS ._.
com_NN Registrars_NNPS and_CC transfer_VB office_NN All_DT administrative_JJ enquiries_NNS relating_VBG to_TO shareholdings_NNS should_MD be_VB addressed_VBN to_TO Lloyds_NNP TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_VBN shareholders_NNS name_NN and_CC address_NN ._.
Lloyds_NNP TSB_NNP Registrars_NNPS Customer_NN Services_NNP ,_, The_DT Causeway_NNP Worthing_NNP ,_, West_NNP Sussex_NNP BN99_NNP 6DA_NNP United_NNP Kingdom_NNP Tel_NNP 44 870 600 3970_CD 72_CD 6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP IBC73_NNP Designed_NNP and_CC produced_VBN by_IN Bostock_NNP and_CC Pollitt_NNP Limited_NNP ,_, London_NNP Printed_NNP in_IN the_DT UK_NNP by_IN Butler_NNP and_CC Tanner_NNP The_DT paper_NN used_VBN in_IN this_DT publication_NN is_VBZ Elemental_JJ Chlorine_NNP Free_NNP ECF_NNP sourced_VBD from_IN sustainably_RB managed_VBN forests_NNS ._.
The_DT mill_NN is_VBZ accredited_VBN to_TO both_DT ISO14001_CD and_CC EMAS_NNP ._.
6169_CD UK_NNP GAAP_NNP 2004_CD ._.
qxd_NN 7_CD 12_CD 05_CD 1:57_CD PM_NNP Page_NNP BC2_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP United_NNP Kingdom_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Fax_NNP 44_CD 0_CD 1256 894708_CD www_NN ._.
com_NN 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP FC1_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2004_CD Delivering_VBG on_IN promises_NNS building_VBG a_DT foundation_NN for_IN future_JJ growth_NN 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP IFC2_NNP Mission_NNP Shires_NNP mission_NN is_VBZ to_TO develop_VB and_CC market_VB medicines_NNS that_WDT improve_VBP the_DT quality_NN of_IN life_NN for_IN patients_NNS and_CC their_PRP$ caregivers_NNS ._.
We_PRP focus_VBP on_IN meeting_NN our_PRP$ commitments_NNS and_CC obligations_NNS to_TO all_DT our_PRP$ stakeholders_NNS :_: patients_NNS ,_, physicians_NNS ,_, employees_NNS ,_, shareholders_NNS and_CC the_DT communities_NNS in_IN which_WDT we_PRP live_VBP and_CC work_VBP ._.
Contents_NNS 01_CD Financial_NNP highlights_VBZ 02_CD Chairmans_NNPS statement_NN We_PRP maintain_VBP the_DT highest_JJS professional_JJ and_CC 04_CD Chief_NNP Executives_NNS review_VBP 06_CD Product_NNP portfolio_NN ethical_JJ standards_NNS ,_, building_VBG value-added_JJ 08_CD Operating_NN review_NN 24_CD CSR_NNP :_: Corporate_NNP and_CC relationships_NNS with_IN physicians_NNS ._.
social_JJ responsibility_NN 28_CD Financial_NNP review_NN 32_CD The_NNP Board_NNP of_IN Directors_NNS We_PRP focus_VBP resources_NNS and_CC organize_VB our_PRP$ work_NN 34_CD The_DT Executive_NNP Committee_NNP 36_CD Directors_NNS remuneration_NN around_IN select_JJ therapeutic_JJ areas_NNS as_RB well_RB report_VB 46_CD Audit_NNP Committee_NNP report_NN as_IN implementing_VBG effective_JJ processes_NNS for_IN 48_CD Corporate_JJ governance_NN statements_NNS identifying_VBG compounds_NNS and_CC optimizing_VBG Financial_JJ statements_NNS our_PRP$ drug_NN development_NN activities_NNS to_TO bring_VB 53_CD Statement_NN of_IN Directors_NNS responsibilities_NNS the_DT best_JJS drugs_NNS to_TO market_NN ._.
54_CD Report_NNP of_IN independent_JJ registered_JJ public_JJ accounting_NN firm_NN We_PRP galvanize_VBP the_DT entire_JJ company_NN around_IN 55_CD Consolidated_NNP balance_NN sheets_NNS growing_VBG our_PRP$ business_NN and_CC executing_VBG 56_CD Consolidated_NNP statements_NNS of_IN operations_NNS our_PRP$ strategy_NN ,_, fostering_VBG a_DT rewarding_JJ and_CC 57_CD Consolidated_NNP statements_NNS of_IN changes_NNS in_IN shareholders_NNS enjoyable_JJ workplace_NN for_IN our_PRP$ employees_NNS ._.
equity_NN 58_CD Consolidated_NNP statements_NNS of_IN comprehensive_JJ income_NN Above_IN all_DT ,_, we_PRP have_VBP an_DT underlying_JJ passion_NN 59_CD Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS for_IN our_PRP$ work_NN ._.
61_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 97_CD Five-year_JJ review_NN Vision_NNP 98_CD Summary_NNP financial_JJ statement_NN We_PRP will_MD consistently_RB be_VB recognized_VBN as_IN 103_CD Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN the_DT leading_VBG global_JJ company_NN serving_VBG Other_JJ specialist_NN physicians_NNS and_CC their_PRP$ 105_CD Shire_NNP head_NN office_NN and_CC main_JJ operating_NN locations_NNS patients_NNS through_IN distinctive_JJ medicines_NNS 106_CD Shareholder_NN information_NN 107_CD Shire_NNP Trade_NNP Marks_NNP and_CC effective_JJ education_NN programs_NNS ._.
01_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP flap2_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Project_NNP development_NN pipeline_NN In_IN 2004_CD we_PRP received_VBD 6_CD regulatory_JJ approvals_NNS and_CC further_JJ regulatory_JJ filings_NNS are_VBP planned_VBN for_IN 2005_CD Indication_NNP Product_NNP Pre-clinical_JJ Phase_NN 1_CD Phase_NN 2_CD Phase_NN 3_CD Registration_NNP Central_NNP nervous_JJ system_NN 1_CD ADHD_NNP MTS_NNP METHYPATCH_NNP ADHD_NNP SPD503_CD ADHD_NNP NRP104_CD ADHD_NNP SPD465_CD ADHD_NNP SPD483_NNP Indication_NNP Product_NNP General_NNP products_NNS Hyperphosphatemia_NNP FOSRENOL_NNP Approved_VBD launch_NN underway_NN in_IN Europe_NNP and_CC US_NNP 2_CD ET_NNP XAGRID_NNP Approved_VBD launch_NN underway_NN in_IN Europe_NNP Indication_NNP Product_NNP Pre-clinical_JJ Phase_NN 1_CD Phase_NN 2_CD Phase_NN 3_CD Registration_NNP Gastro-intestinal_JJ 3_CD IBD_NNP SPD476_CD IBD_NNP SPD480_CD 1_CD Attention_NN Deficit_NN Hyperactivity_NNP Disorder_NNP ADHD_NNP 2_CD Essential_NNP Thrombocythemia_NNP ET_NNP 3_CD Inflammatory_NNP Bowel_NNP Disease_NNP IBD_NNP 4_CD Canadian_JJ marketing_NN authorization_NN is_VBZ currently_RB suspended_VBN 5_CD Janssen_NNP Pharmaceutica_NNP N._NNP V._NNP Janssen_NNP part_NN of_IN the_DT Johnson_NNP &_CC Johnson_NNP Group_NNP 6_CD Also_RB distributed_VBN in_IN other_JJ worldwide_JJ markets_NNS on_IN Shires_NNP behalf_NN 7_CD This_DT is_VBZ not_RB a_DT comprehensive_JJ list_NN of_IN trademarks_NNS for_IN this_DT product_NN as_IN various_JJ others_NNS are_VBP used_VBN in_IN smaller_JJR markets_NNS 8_CD Also_RB distributed_VBN in_IN other_JJ European_JJ markets_NNS on_IN Shires_NNP behalf_NN 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP flap3_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Marketed_VBN products_NNS Shire_NNP has_VBZ an_DT established_JJ portfolio_NN of_IN marketed_VBN products_NNS to_TO serve_VB specialist_NN physicians_NNS and_CC their_PRP$ patients_NNS Products_NNPS Principal_NN indications_NNS Marketed_VBN by_IN relevant_JJ territory_NN Central_NNP 4_CD ADDERALL_NNP XR_NNP ADHD_NNP Shire_NNP US_NNP and_CC Canada_NNP ADDERALL_NNP ADHD_NNP Shire_NNP US_NNP nervous_JJ CARBATROL_NNP Epilepsy_NNP Shire_NNP US_NNP system_NN EQUETRO_NNP Bipolar_NNP 1_CD disorder_NN Approved_VBN 2004_CD launch_NN planned_VBD Q2_CD 2005_CD REMINYL_NNP Alzheimer_NNP s_VBZ disease_NN Shire_NNP UK_NNP and_CC Republic_NNP of_IN Ireland_NNP 5_CD Janssen_NNP Rest_VB of_IN the_DT World_NNP Products_NNPS Principal_NN indications_NNS Marketed_VBN by_IN relevant_JJ territory_NN General_NNP 6_CD AGRYLIN_NNP Thrombocythemia_NNP secondary_JJ Shire_NNP US_NNP and_CC Canada_NNP to_TO a_DT myeloproliferative_JJ disorder_NN products_NNS XAGRID_NNP Thrombocythemia_NNP Shire_NNP Germany_NNP ,_, France_NNP ,_, UK_NNP and_CC 2_CD 7_CD second_JJ line_NN treatment_NN in_IN ET_NNP Republic_NNP of_IN Ireland_NNP FOSRENOL_NNP Hyperphosphatemia_NNP in_IN end-stage_JJ Shire_NNP US_NNP renal_JJ disease_NN PROAMATINE_NNP Symptomatic_NNP orthostatic_JJ Shire_NNP US_NNP and_CC Canada_NNP AMATINE_NNP hypotension_NN CALCICHEW_NNP Adjunct_NNP in_IN osteoporosisShire_NNP UK_NNP and_CC Republic_NNP of_IN Ireland_NNP Products_NNPS Principal_NN indications_NNS Marketed_VBN by_IN relevant_JJ territory_NN Royalty_NNP 3TC_NNP EPIVIR_NNP HIV_NNP Shire_NNP and_CC GSK_NNP Canada_NNP :_: GSK_NNP Rest_VB of_IN the_DT World_NNP revenues_NNS COMBIVIR_NNP HIV_NNP Shire_NNP and_CC GSK_NNP Canada_NNP :_: GSK_NNP Rest_VB of_IN the_DT World_NNP TRIZIVIR_NNP HIV_NNP Shire_NNP and_CC GSK_NNP Canada_NNP :_: GSK_NNP Rest_VB of_IN the_DT World_NNP ZEFFIX_NNP Hepatitis_NNP B_NNP infection_NN Shire_NNP and_CC GSK_NNP Canada_NNP :_: EPIVIR_NNP HBV_NNP GSK_NNP Rest_VBP of_IN the_DT World_NNP 7_CD HEPTOVIR_NNP Products_NNPS Principal_NN indications_NNS Marketed_VBN by_IN relevant_JJ territory_NN GastroPENTASA_NNP Ulcerative_NNP colitisShire_NNP US_NNP 8_CD COLAZIDE_NNP Ulcerative_NNP colitis_VBZ Shire_NNP UK_NNP intestinal_JJ Future_NNP expansion_NN and_CC growth_NN opportunities_NNS 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 02_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chairmans_NNPS statement_NN 2004_CD was_VBD dedicated_VBN to_TO creating_VBG the_DT structure_NN that_WDT will_MD enable_VB us_PRP to_TO grow_VB the_DT Company_NN of_IN our_PRP$ head_NN office_NN ,_, and_CC Wayne_NNP ,_, Pennsylvania_NNP in_IN the_DT US_NNP ._.
These_DT geographies_NNS give_VBP us_PRP a_DT firm_NN presence_NN in_IN two_CD of_IN the_DT worlds_NNS largest_JJS pharmaceutical_JJ markets_NNS ._.
In_IN line_NN with_IN this_DT strategy_NN ,_, we_PRP are_VBP also_RB well_RB advanced_VBN in_IN implementing_VBG a_DT new_JJ organizational_JJ structure_NN that_WDT allows_VBZ Shire_NNP to_TO operate_VB crossfunctionally_RB through_IN dedicated_VBN ,_, global_JJ teams_NNS ._.
These_DT teams_NNS are_VBP accountable_JJ for_IN delivering_VBG results_NNS in_IN each_DT of_IN our_PRP$ main_JJ therapeutic_JJ areas_NNS Central_NNP Nervous_NNP System_NNP CNS_NNP ,_, Gastro-Intestinal_NNP GI_NNP and_CC General_NNP Products_NNPS GP_NNP ._.
This_DT structure_NN enables_VBZ people_NNS from_IN different_JJ geographic_JJ and_CC functional_JJ areas_NNS to_TO work_VB together_RB closely_RB and_CC collaboratively_RB to_TO solve_VB problems_NNS and_CC to_TO create_VB new_JJ and_CC better_RBR products_NNS ._.
More_RBR importantly_RB ,_, it_PRP provides_VBZ Shire_NNP with_IN the_DT flexibility_NN and_CC nimbleness_NN required_VBN for_IN continued_JJ growth_NN in_IN an_DT industry_NN marked_VBN by_IN rapid_JJ change_NN and_CC ever-increasing_JJ competition_NN ._.
During_IN the_DT year_NN ,_, renewed_VBN emphasis_NN has_VBZ also_RB been_VBN placed_VBN on_IN business_NN development_NN activities_NNS M&A_NNP ._.
The_DT pharmaceutical_JJ environment_NN continues_VBZ We_PRP have_VBP a_DT newly_RB charged_VBN global_JJ team_NN with_IN a_DT to_TO be_VB more_RBR challenging_JJ than_IN in_IN the_DT past_NN ._.
clear_JJ mandate_NN to_TO examine_VB all_DT opportunities_NNS for_IN In_IN what_WP some_DT have_VBP called_VBN the_DT perfect_JJ storm_NN ,_, partnership_NN that_WDT fit_VBP our_PRP$ strategic_JJ focus_NN ._.
It_PRP is_VBZ our_PRP$ big_JJ pharma_NN companies_NNS have_VBP faced_VBN significant_JJ intention_NN to_TO fill_VB our_PRP$ earlier-stage_JJ pipeline_NN with_IN inchallenges_NNS including_VBG technical_JJ ,_, regulatory_JJ and_CC licensed_JJ projects_NNS that_IN we_PRP will_MD then_RB manage_VB through_IN economic_JJ issues_NNS ._.
to_TO approval_NN and_CC launch_NN over_IN the_DT next_JJ few_JJ years_NNS ._.
Dr_NNP James_NNP Cavanaugh_NNP Chairman_NNP Rather_NNP than_IN inhibiting_VBG Shires_NNP future_NN ,_, this_DT 2004_CD results_NNS environment_NN has_VBZ actually_RB provided_VBN an_DT attractive_JJ Shires_NNP highly_RB focused_VBD growth_NN strategy_NN produced_VBD platform_NN for_IN Shire_NNP to_TO occupy_VB ._.
Under_IN the_DT leadership_NN solid_JJ results_NNS in_IN 2004_CD ._.
Revenues_NNS were_VBD up_RB 13_CD %_NN of_IN our_PRP$ Chief_NNP Executive_NNP Officer_NNP ,_, Matthew_NNP Emmens_NNP ,_, to_TO $_$ 1,363.2_CD million_CD ._.
Net_JJ income_NN of_IN $_$ 269.0_CD million_CD we_PRP have_VBP a_DT strategy_NN that_IN differentiates_VBZ us_PRP from_IN 2003_CD :_: $_$ 276.1_CD million_CD was_VBD impacted_VBN by_IN the_DT big_JJ pharma_NN :_: we_PRP concentrate_VBP our_PRP$ resources_NNS on_IN $_$ 44.2_CD million_CD loss_NN on_IN disposal_NN of_IN the_DT vaccines_NNS specialist_NN physicians_NNS who_WP treat_VBP serious_JJ diseases_NNS ._.
business_NN and_CC $_$ 48.5_CD million_CD of_IN reorganization_NN costs_NNS ._.
The_DT ability_NN to_TO develop_VB and_CC register_VB distinctive_JJ products_NNS and_CC then_RB deploy_JJ small-scale_JJ sales_NNS Shires_VBZ cash_NN position_NN remained_VBD strong_JJ with_IN forces_NNS helps_VBZ us_PRP build_VB relationships_NNS with_IN high_JJ net_JJ cash_NN of_IN $_$ 1,457.5_CD million_CD ,_, compared_VBN with_IN prescribers_NNS in_IN niche_NN markets_NNS and_CC achieve_VB $_$ 1,037.7_CD million_CD in_IN 2003_CD ._.
This_DT cash_NN will_MD be_VB used_VBN significant_JJ market_NN shares_NNS ._.
Additionally_RB ,_, our_PRP$ Company_NN is_VBZ focusing_VBG on_IN fewer_JJR ,_, Corporate_JJ governance_NN later-stage_NN ,_, low-risk_JJ projects_NNS that_WDT have_VBP the_DT best_JJS Good_JJ corporate_JJ governance_NN and_CC prudent_JJ chances_NNS of_IN reaching_VBG the_DT market_NN ._.
We_PRP intend_VBP to_TO enterprise-wide_JJ risk_NN management_NN have_VBP taken_VBN maximize_VB our_PRP$ return_NN on_IN Research_NNP &_CC Development_NNP on_IN critical_JJ importance_NN for_IN corporations_NNS the_DT world_NN R&D_NNP investments_NNS and_CC optimize_VB our_PRP$ sales_NNS network_NN over_IN ._.
Shire_NNP understands_VBZ the_DT key_JJ risks_NNS that_IN it_PRP faces_VBZ by_IN extending_VBG our_PRP$ global_JJ reach_NN ._.
Accordingly_RB ,_, and_CC has_VBZ taken_VBN appropriate_JJ steps_NNS to_TO manage_VB them_PRP we_PRP have_VBP established_VBN leading_VBG strategic_JJ functions_NNS as_IN our_PRP$ business_NN has_VBZ grown_VBN in_IN size_NN and_CC therefore_RB at_IN two_CD main_JJ sites_NNS :_: Basingstoke_NNP in_IN the_DT UK_NNP ,_, location_NN complexity_NN ._.
Our_PRP$ implementation_NN of_IN a_DT rigorous_JJ risk_NN management_NN process_NN has_VBZ added_VBN and_CC will_MD continue_VB to_TO add_VB value_NN to_TO our_PRP$ business_NN ._.
02_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 03_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chairmans_NNPS statement_NN Shires_NNP highly_RB Our_PRP$ Board_NNP is_VBZ committed_VBN to_TO the_DT highest_JJS standards_NNS Talented_VBN people_NNS of_IN corporate_JJ governance_NN ._.
As_IN a_DT FTSE_NNP 100_CD Shires_NNP accomplishments_NNS over_IN the_DT past_JJ few_JJ focused_VBN strategy_NN company_NN ,_, we_PRP are_VBP subject_JJ to_TO the_DT UK_NNP Listing_NNP years_NNS speak_VBP volumes_NNS about_IN its_PRP$ talented_JJ team_NN continued_VBD to_TO produce_VB Rules_NNS and_CC The_DT Combined_NNP Code_NNP on_IN Corporate_NNP of_IN employees_NNS worldwide_JJ ,_, who_WP have_VBP firmly_RB solid_JJ results_NNS in_IN 2004_CD Governance_NNP ._.
We_PRP are_VBP required_VBN by_IN the_DT UK_NNP Listing_NNP embraced_VBD the_DT Companys_NNP vision_NN ._.
They_PRP are_VBP to_TO and_CC the_DT Company_NN is_VBZ Rules_NNS to_TO report_VB annually_RB on_IN our_PRP$ compliance_NN be_VB thanked_VBN and_CC congratulated_VBN for_IN their_PRP$ many_JJ set_NN for_IN future_JJ growth_NN with_IN the_DT Combined_NNP Code_NNP and_CC on_IN our_PRP$ risk_NN contributions_NNS and_CC ongoing_JJ support_NN ._.
Where_WRB we_PRP fail_VBP to_TO comply_VB with_IN the_DT provisions_NNS of_IN the_DT Combined_VBN We_PRP had_VBD 1,833_CD employees_NNS as_IN of_IN December_NNP 31_CD ,_, Code_NNP ,_, we_PRP are_VBP required_VBN to_TO explain_VB why_WRB ._.
Shires_NNP 2004_CD ,_, with_IN strong_JJ skills_NNS sets_VBZ spanning_VBG compliance_NN with_IN the_DT provisions_NNS of_IN the_DT Combined_VBN pharmaceutical_JJ research_NN ,_, sales_NNS and_CC marketing_NN ,_, Code_NNP is_VBZ described_VBN in_IN the_DT corporate_JJ governance_NN operations_NNS and_CC management_NN and_CC administration_NN ,_, statements_NNS on_IN pages_NNS 48_CD to_TO 52_CD ._.
among_IN others_NNS ._.
As_IN many_JJ as_IN 300_CD new_JJ people_NNS joined_VBD Shire_NNP this_DT year_NN to_TO work_VB in_IN our_PRP$ newly_RB As_IN a_DT NASDAQ_NNP company_NN ,_, we_PRP are_VBP subject_JJ to_TO the_DT established_VBN US_NNP Corporate_NNP Headquarters_NNP in_IN rules_NNS of_IN the_DT Sarbanes-Oxley_NNP Act_NNP ,_, implemented_VBD Philadelphia_NNP ._.
In_IN addition_NN ,_, over_IN 100_CD employees_NNS in_IN 2002_CD ._.
In_IN order_NN for_IN Shire_NNP to_TO comply_VB with_IN Section_NN relocated_VBN from_IN our_PRP$ offices_NNS in_IN Kentucky_NNP and_CC 404_CD of_IN Sarbanes-Oxley_NNP ,_, Shire_NNP ,_, along_IN with_IN all_DT Maryland_NNP ._.
We_PRP believe_VBP that_IN our_PRP$ new_JJ operating_NN Securities_NNP Exchange_NNP Commission_NNP SEC_NNP regulated_VBD model_NN ,_, designed_VBN to_TO build_VB an_DT integrated_VBN and_CC companies_NNS ,_, must_MD review_VB its_PRP$ material_NN financial_JJ global_JJ company_NN based_VBN on_IN therapeutic_JJ areas_NNS ,_, reporting_VBG processes_NNS and_CC then_RB document_NN ,_, review_NN makes_VBZ Shire_NNP an_DT attractive_JJ new_JJ type_NN of_IN and_CC test_VB all_DT internal_JJ controls_NNS over_IN financial_JJ pharmaceutical_JJ company_NN in_IN which_WDT people_NNS can_MD reporting_VBG to_TO ensure_VB that_IN these_DT operate_VBP effectively_RB ._.
Consequently_RB we_PRP In_IN 2004_CD ,_, Shire_NNP completed_VBD a_DT global_JJ review_NN of_IN its_PRP$ were_VBD able_JJ to_TO recruit_VB a_DT wide_JJ range_NN of_IN very_RB highsystems_NNS of_IN internal_JJ control_NN over_IN financial_JJ reporting_NN caliber_NN people_NNS many_JJ from_IN well-established_JJ so_RB as_IN to_TO enable_VB compliance_NN with_IN Section_NN 404_CD industry_NN players_NNS ._.
Our_PRP$ model_NN will_MD further_RBR enhance_VB by_IN the_DT end_NN of_IN 2004_CD ._.
Shire_NNP undertook_VBD this_DT review_NN opportunities_NNS for_IN our_PRP$ employees_NNS within_IN Shire_NNP ._.
during_IN a_DT year_NN of_IN considerable_JJ internal_JJ change_NN We_PRP are_VBP currently_RB developing_VBG consistent_JJ and_CC as_IN a_DT result_NN of_IN the_DT restructuring_NN exercise_NN ._.
competitive_JJ policies_NNS and_CC programs_NNS to_TO position_VB I_PRP am_VBP particularly_RB pleased_JJ ,_, therefore_RB ,_, that_IN this_DT Shire_NNP as_IN one_CD of_IN the_DT top_JJ global_JJ pharmaceutical_JJ process_NN has_VBZ run_VBN smoothly_RB and_CC that_IN no_DT material_NN companies_NNS and_CC FTSE_NNP 100_CD companies_NNS for_IN which_WDT weaknesses_NNS were_VBD identified_VBN ._.
We_PRP are_VBP continuing_VBG to_TO ensure_VB that_IN we_PRP have_VBP the_DT right_JJ resources_NNS to_TO manage_VB the_DT exciting_JJ Shires_NNP Board_NNP is_VBZ comprised_VBN of_IN eight_CD members_NNS from_IN products_NNS and_CC projects_NNS that_IN we_PRP have_VBP underway_JJ both_DT Europe_NNP and_CC North_NNP America_NNP with_IN extensive_JJ or_CC will_MD be_VB bringing_VBG on_IN board_NN ._.
knowledge_NN and_CC experience_NN in_IN business_NN and_CC the_DT pharmaceutical_JJ industry_NN ._.
We_PRP are_VBP continuing_VBG to_TO A_DT bright_JJ future_NN strengthen_VB our_PRP$ Board_NNP :_: during_IN 2004_CD David_NNP Kappler_NNP Shire_NNP has_VBZ considerable_JJ strengths_NNS :_: a_DT most_RBS joined_VBN as_IN a_DT non-executive_JJ Director_NNP and_CC assumed_VBD talented_JJ group_NN of_IN employees_NNS ,_, a_DT growing_VBG chairmanship_NN of_IN the_DT Audit_NNP Committee_NNP ._.
Mr_NNP Kappler_NNP presence_NN in_IN the_DT worlds_NNS key_JJ pharmaceutical_NN was_VBD formerly_RB Chief_NNP Financial_NNP Officer_NNP of_IN Cadbury_NNP markets_NNS and_CC a_DT leading_VBG portfolio_NN of_IN products_NNS Schweppes_NNP plc._NN ._.
Wilson_NNP Totten_NNP ,_, Chief_NNP Scientific_NNP with_IN many_JJ more_JJR in_IN the_DT pipeline_NN ._.
Over_IN the_DT next_JJ Officer_NNP ,_, left_VBD Shire_NNP during_IN 2004_CD and_CC has_VBZ resigned_VBN few_JJ years_NNS ,_, we_PRP intend_VBP to_TO build_VB on_IN our_PRP$ strengths_NNS from_IN the_DT Board_NNP ._.
I_PRP would_MD like_VB to_TO take_VB this_DT and_CC successes_NNS through_IN the_DT disciplined_JJ opportunity_NN to_TO thank_VB him_PRP for_IN his_PRP$ many_JJ years_NNS implementation_NN of_IN our_PRP$ growth_NN strategy_NN ._.
of_IN valuable_JJ contributions_NNS to_TO Shire_NNP ,_, including_VBG In_IN addition_NN to_TO growing_VBG our_PRP$ current_JJ franchises_NNS ,_, the_DT successful_JJ development_NN and_CC registration_NN we_PRP will_MD continue_VB to_TO search_VB for_IN and_CC develop_VB of_IN FOSRENOL_NNP in_IN both_DT Europe_NNP and_CC the_DT US_NNP ._.
new_JJ products_NNS that_WDT deliver_VBP significant_JJ value_NN for_IN shareholders_NNS ,_, physicians_NNS ,_, patients_NNS and_CC other_JJ stakeholders_NNS ._.
The_DT ultimate_JJ goal_NN is_VBZ to_TO become_VB a_DT more_RBR globally_RB focused_VBN and_CC integrated_VBN company_NN with_IN a_DT number_NN of_IN successful_JJ global_JJ products_NNS ._.
More_JJR than_IN ever_RB ,_, I_PRP am_VBP confident_JJ that_IN we_PRP will_MD achieve_VB this_DT goal_NN ._.
03_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 04_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chief_NNP Executives_NNS review_NN Everything_NN that_IN we_PRP have_VBP done_VBN this_DT year_NN has_VBZ positioned_VBN us_PRP to_TO leverage_NN on_IN our_PRP$ strengths_NNS and_CC create_VB an_DT organization_NN with_IN sustainable_JJ growth_NN Key_NNP milestones_NNS We_PRP achieved_VBD a_DT lot_NN this_DT year_NN ._.
Our_PRP$ operating_NN profits_NNS were_VBD good_JJ and_CC we_PRP made_VBD real_JJ progress_NN with_IN our_PRP$ new_JJ business_NN strategy_NN ,_, which_WDT I_PRP outlined_VBD in_IN this_DT section_NN of_IN last_JJ years_NNS report_NN ._.
In_IN particular_JJ :_: we_PRP increased_VBD product_NN sales_NNS and_CC received_VBD more_JJR income_NN from_IN royalties_NNS :_: we_PRP turned_VBD in_RP a_DT solid_JJ financial_JJ performance_NN ,_, with_IN revenues_NNS up_IN 13_CD %_NN :_: we_PRP paid_VBD our_PRP$ first_JJ dividend_NN :_: we_PRP moved_VBD our_PRP$ pipeline_NN forward_RB and_CC achieved_VBD six_CD new_JJ product_NN approvals_NNS or_CC line_NN extensions_NNS in_IN Europe_NNP and_CC the_DT US_NNP :_: and_CC we_PRP made_VBD the_DT business_NN more_RBR focused_JJ ,_, strengthened_VBD the_DT management_NN team_NN and_CC increased_VBD our_PRP$ R&D_NNP capabilities_NNS ._.
You_PRP may_MD remember_VB that_IN last_JJ year_NN I_PRP described_VBD how_WRB we_PRP intended_VBD to_TO change_VB the_DT structure_NN of_IN the_DT Company_NN so_IN that_IN we_PRP could_MD work_VB more_RBR laterally_RB and_CC internationally_RB across_IN the_DT organization_NN ,_, rather_RB than_IN in_IN isolated_JJ silos_NNS ._.
We_PRP wanted_VBD simpler_JJR reporting_NN lines_NNS and_CC a_DT business_NN model_NN that_WDT brought_VBD our_PRP$ drug_NN development_NN and_CC commercial_JJ activities_NNS closer_RBR together_RB and_CC that_DT is_VBZ what_WP we_PRP Matthew_NNP Emmens_NNP now_RB have_VBP ._.
As_IN a_DT result_NN ,_, we_PRP are_VBP more_RBR competitive_JJ ,_, Chief_NNP Executive_NNP Officer_NNP more_RBR accountable_JJ and_CC more_RBR attuned_JJ to_TO the_DT particular_JJ needs_NNS of_IN the_DT specialist_NN doctors_NNS who_WP are_VBP our_PRP$ main_JJ customers_NNS ._.
Our_PRP$ technological_JJ and_CC R&D_JJ efforts_NNS are_VBP now_RB concentrated_VBN on_IN highpotential_JJ treatments_NNS that_WDT are_VBP in_IN the_DT latter_JJ stages_NNS of_IN development_NN ,_, which_WDT significantly_RB reduces_VBZ our_PRP$ risk_NN profile_NN ._.
As_IN a_DT result_NN ,_, we_PRP had_VBD six_CD projects_NNS in_IN registration_NN at_IN the_DT end_NN of_IN the_DT first_JJ quarter_NN 2004_CD ,_, two_CD more_JJR in_IN Phase_NN 3_CD of_IN development_NN and_CC two_CD in_IN Phase_NN 2_CD and_CC by_IN the_DT end_NN of_IN the_DT year_NN wed_VBD received_VBN six_CD drugs_NNS approvals_NNS in_IN Europe_NNP and_CC in_IN the_DT US_NNP ,_, including_VBG :_: FOSRENOL_NNP in_IN both_DT the_DT US_NNP and_CC in_IN Europe_NNP :_: PENTASA_NNP 500mg_CD in_IN the_DT US_NNP :_: ADDERALL_NNP XR_NNP for_IN adult_NN patients_NNS in_IN the_DT US_NNP :_: EQUETRO_NNP in_IN the_DT US_NNP :_: and_CC XAGRID_NNP in_IN Europe_NNP ._.
04_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 05_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Chief_NNP Executives_NNS review_NN We_PRP will_MD add_VB to_TO current_JJ Shire_NNP has_VBZ a_DT particularly_RB strong_JJ portfolio_NN of_IN lateCorporate_NNP social_JJ responsibility_NN stage_NN projects_NNS ._.
Methylphenidate_NNP transdermal_JJ We_PRP take_VBP a_DT practical_JJ and_CC contemporary_JJ approach_NN therapeutic_JJ areas_NNS as_IN system_NN MTS_NNP METHYPATCH_NNP for_IN ADHD_NNP is_VBZ now_RB to_TO corporate_JJ social_JJ responsibility_NN and_CC this_DT is_VBZ well_RB as_IN pursue_VB new_JJ in_IN registration_NN and_CC we_PRP plan_VBP to_TO register_VB three_CD an_DT area_NN where_WRB a_DT lot_NN has_VBZ been_VBN achieved_VBN in_IN the_DT opportunities_NNS to_TO grow_VB more_JJR products_NNS in_IN the_DT US_NNP by_IN 2006_CD :_: SPD503_CD last_JJ year_NN ,_, for_IN instance_NN :_: our_PRP$ business_NN in_IN the_DT guanfacine_NN and_CC SPD465_CD longer-acting_JJ US_NNP and_CC Europe_NNP ADDERALL_NNP XR_NNP ,_, both_DT for_IN the_DT treatment_NN of_IN we_PRP appointed_VBD a_DT global_JJ Environment_NNP and_CC ADHD_NNP and_CC SPD476_NNP for_IN ulcerative_JJ colitis_NNS ._.
Health_NNP and_CC Safety_NNP Officer_NNP for_IN the_DT Company_NN :_: Shires_NNS strategy_NN we_PRP completed_VBD a_DT risk_NN management_NN exercise_NN :_: We_PRP are_VBP a_DT specialty_NN pharmaceutical_JJ company_NN and_CC that_IN focuses_VBZ on_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN ._.
Geographically_NNP ,_, our_PRP$ key_NN we_PRP took_VBD on_RP a_DT range_NN of_IN community_NN initiatives_NNS markets_NNS are_VBP the_DT US_NNP and_CC the_DT larger_JJR European_JJ in_IN both_DT Philadelphia_NNP and_CC Basingstoke_NNP ._.
markets_NNS of_IN the_DT United_NNP Kingdom_NNP ,_, France_NNP ,_, Germany_NNP ,_, Italy_NNP and_CC Spain_NNP ._.
Angus_NNP Russell_NNP ,_, our_PRP$ Chief_NNP Financial_NNP Officer_NNP ,_, leads_VBZ the_DT committee_NN that_WDT looks_VBZ after_IN corporate_JJ We_PRP deliberately_RB concentrate_VBP our_PRP$ R&D_NNP resources_NNS social_JJ responsibility_NN and_CC monitors_VBZ the_DT progress_NN on_IN products_NNS that_WDT are_VBP in_IN the_DT late_JJ stages_NNS of_IN were_VBD making_VBG ._.
As_IN last_JJ year_NN ,_, we_PRP will_MD be_VB issuing_VBG development_NN ._.
This_DT is_VBZ where_WRB we_PRP expect_VBP to_TO get_VB a_DT separate_JJ report_NN on_IN this_DT whole_JJ area_NN which_WDT you_PRP the_DT optimum_JJ combination_NN of_IN better_JJR returns_NNS ,_, can_MD download_RB from_IN the_DT website_NN or_CC request_NN from_IN more_JJR predictability_NN and_CC lower_JJR risk_NN ._.
We_PRP are_VBP quite_RB our_PRP$ Corporate_JJ Communications_NNPS department_NN ._.
open_JJ about_IN the_DT fact_NN that_IN we_PRP dont_VBP compete_VB with_IN the_DT very_RB large_JJ pharmaceutical_JJ companies_NNS The_DT future_NN the_DT products_NNS we_PRP want_VBP are_VBP those_DT that_WDT could_MD In_IN last_JJ years_NNS report_VBP I_PRP said_VBD that_IN we_PRP were_VBD going_VBG to_TO achieve_VB sales_NNS of_IN between_IN US$_$ 150_CD million_CD and_CC reinforce_VB our_PRP$ position_NN in_IN the_DT market_NN and_CC make_VB US$_$ 500_CD million_CD at_IN their_PRP$ peak_NN ._.
In_IN practice_NN we_PRP Shire_VBP one_CD of_IN the_DT leading_VBG specialty_NN pharmaceutical_JJ do_VBP this_DT by_IN seeking_VBG to_TO add_VB new_JJ projects_NNS to_TO the_DT companies_NNS in_IN the_DT world_NN ._.
Thats_NNS what_WDT weve_NN done_VBN pipeline_NN every_DT year_NN ._.
We_PRP look_VBP for_IN projects_NNS where_WRB and_CC will_MD strive_VB to_TO maintain_VB ._.
we_PRP can_MD exploit_VB the_DT intellectual_JJ property_NN involved_VBN fully_RB ,_, which_WDT means_VBZ that_IN we_PRP actively_RB look_VBP for_IN Our_PRP$ profits_NNS are_VBP very_RB strong_JJ ,_, the_DT business_NN is_VBZ licensing_VBG opportunities_NNS ._.
This_DT is_VBZ why_WRB I_PRP stepped_VBD up_RP growing_VBG and_CC thats_VBZ despite_IN all_DT the_DT work_NN done_VBN our_PRP$ business_NN development_NN efforts_NNS this_DT year_NN ,_, by_IN to_TO reorganize_VB the_DT Company_NN this_DT year_NN ._.
This_DT time_NN bringing_VBG in_IN Barbara_NNP Deptula_NNP to_TO head_VB up_RP business_NN last_JJ year_NN I_PRP predicted_VBD a_DT promising_JJ future_NN and_CC we_PRP development_NN ._.
In_IN addition_NN ,_, Eliseo_NNP Salinas_NNP joined_VBD can_MD see_VB the_DT proof_NN of_IN this_DT in_IN six_CD product_NN approvals_NNS us_PRP to_TO head_VB up_RP the_DT R&D_NNP function_NN ._.
and_CC the_DT strength_NN and_CC depth_NN of_IN our_PRP$ pipeline_NN ._.
Patent_NN challenges_NNS Our_PRP$ strategy_NN is_VBZ simple_JJ but_CC it_PRP is_VBZ compelling_JJ and_CC In_IN todays_NNS markets_NNS ,_, we_PRP know_VBP that_IN manufacturers_NNS it_PRP is_VBZ working_VBG ._.
This_DT is_VBZ largely_RB due_JJ to_TO the_DT dedication_NN of_IN generic_JJ drugs_NNS will_MD challenge_VB our_PRP$ portfolio_NN ._.
and_CC professionalism_NN of_IN all_DT Shire_NNP employees_NNS ,_, and_CC But_CC as_IN I_PRP said_VBD last_JJ year_NN ,_, we_PRP are_VBP determined_VBN this_DT report_NN gives_VBZ me_PRP the_DT chance_NN to_TO thank_VB them_PRP all_DT ._.
to_TO defend_VB our_PRP$ intellectual_JJ property_NN vigorously_RB and_CC we_PRP will_MD continue_VB to_TO file_VB new_JJ patents_NNS on_IN our_PRP$ projects_NNS and_CC products_NNS ._.
05_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 06_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Product_NNP portfolio_NN With_IN the_DT approvals_NNS secured_VBN in_IN 2004_CD ,_, a_DT number_NN of_IN new_JJ products_NNS entered_VBD the_DT portfolio_NN ._.
FOSRENOL_NNP and_CC XAGRID_NNP are_VBP Shires_NNP first_JJ global_JJ products_NNS ADDERALL_NNP XR_NNP AGRYLIN_NNP CARBATROL_NNP ADDERALL_NNP XR_NNP mixed_JJ amphetamine_NN salts_NNS AGRYLIN_NNP anagrelide_NN hydrochloride_NN CARBATROL_NNP carbamazepine_NN extendedis_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN ADHD_NNP and_CC is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN release_NN capsules_NNS is_VBZ marketed_VBN for_IN the_DT is_VBZ a_DT once-daily_JJ formulation_NN of_IN ADDERALL_NNP ._.
thrombocythemia_NN ,_, secondary_JJ to_TO a_DT treatment_NN of_IN epilepsy_NN ,_, combining_VBG proven_VBN It_PRP offers_VBZ convenience_NN to_TO patients_NNS and_CC myeloproliferative_JJ disorder_NN ._.
Research_NNP medication_NN with_IN advanced_JJ drug_NN delivery_NN caregivers_NNS ,_, and_CC the_DT potential_NN for_IN improved_VBN indicates_VBZ that_IN a_DT key_JJ benefit_NN of_IN AGRYLIN_NNP technology_NN to_TO enable_VB a_DT convenient_JJ twicepatient_NN compliance_NN ._.
is_VBZ its_PRP$ platelet_NN selectivity_NN ,_, targeting_VBG only_RB daily_JJ treatment_NN ._.
those_DT cells_NNS that_WDT develop_VBP into_IN platelets_NNS ._.
REMINYL_NNP SOLARAZE_NNP VANIQA_NNP REMINYL_NNP galantamine_NN hydrobromide_NN SOLARAZE_NNP diclofenac_JJ sodium_NN 3_CD %_NN gel_NN VANIQA_NNP eflornithine_NN 11.5_CD %_NN cream_NN is_VBZ indicated_VBN for_IN the_DT symptomatic_JJ treatment_NN is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN actinic_NN is_VBZ indicated_VBN for_IN the_DT treatment_NN of_IN facial_JJ of_IN mild_JJ to_TO moderately_RB severe_JJ dementia_NN keratosis_NN ,_, a_DT pre-cancerous_JJ skin_NN condition_NN ._.
VANIQA_NNP inhibits_VBZ an_DT of_IN the_DT Alzheimer_NNP type_NN ._.
REMINYL_NNP differs_VBZ enzyme_NN involved_VBN in_IN the_DT production_NN of_IN from_IN other_JJ compounds_NNS in_IN its_PRP$ class_NN in_IN that_IN the_DT hair_NN shaft_NN by_IN the_DT hair_NN follicle_NN ._.
VANIQA_NNP it_PRP has_VBZ a_DT dual_JJ mechanism_NN of_IN action_NN ._.
has_VBZ been_VBN shown_VBN to_TO reduce_VB the_DT rate_NN of_IN facial_JJ hair_NN growth_NN ._.
06_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 07_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Product_NNP portfolio_NN EQUETRO_NNP FOSRENOL_NNP PENTASA_NNP EQUETRO_NNP carbamazepine_NN extendedFOSRENOL_NNP lanthanum_NN carbonate_NN PENTASA_NNP mesalamine_NN is_VBZ indicated_VBN for_IN release_NN capsules_NNS is_VBZ indicated_VBN for_IN the_DT is_VBZ indicated_VBN to_TO reduce_VB serum_NN phosphate_VB the_DT induction_NN of_IN remission_NN and_CC treatment_NN treatment_NN of_IN acute_JJ manic_NN and_CC mixed_JJ in_IN patients_NNS with_IN end-stage_JJ renal_JJ disease_NN ._.
of_IN patients_NNS with_IN mild_JJ to_TO moderately_RB active_JJ episodes_NNS associated_VBN with_IN bipolar_NN 1_CD Approved_VBN in_IN 2004_CD ,_, FOSRENOL_NNP will_MD ulcerative_VB colitis_NN ,_, using_VBG a_DT unique_JJ delivery_NN disorder_NN ._.
Advanced_NNP drug_NN delivery_NN become_VB one_CD of_IN the_DT first_JJ global_JJ products_NNS mechanism_NN ._.
technology_NN enables_VBZ the_DT convenience_NN for_IN Shire_NNP ._.
XAGRID_NNP ZEFFIX_NNP 3TC_NNP XAGRID_NNP anagrelide_NN hydrochloride_NN ZEFFIX_NNP lamivudine_NN is_VBZ indicated_VBN for_IN 3TC_NNP lamivudine_NN ,_, also_RB marketed_VBN as_IN EPIVIR_NNP ,_, is_VBZ indicated_VBN for_IN the_DT reduction_NN of_IN elevated_VBN the_DT treatment_NN of_IN chronic_JJ hepatitis_NN B_NN in_IN combination_NN with_IN other_JJ anti-retroviral_JJ platelet_NN counts_NNS in_IN at-risk_JJ essential_JJ infection_NN associated_VBN with_IN evidence_NN of_IN agents_NNS is_VBZ indicated_VBN for_IN the_DT treatment_NN thrombocythemia_NN patients_NNS who_WP are_VBP hepatitis_NNP B_NNP viral_JJ replication_NN and_CC acute_JJ of_IN human_JJ immuno-deficiency_NN virus_NN HIV_NNP intolerant_NN to_TO their_PRP$ current_JJ therapy_NN or_CC whose_WP$ liver_NN inflammation_NN ._.
Lamivudine_NNP is_VBZ a_DT component_NN elevated_VBD platelet_NN counts_NNS are_VBP not_RB reduced_VBN to_TO of_IN the_DT combination_NN HIV_NNP treatments_NNS ,_, an_DT acceptable_JJ level_NN by_IN their_PRP$ current_JJ therapy_NN ._.
07_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 08_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Central_NNP nervous_JJ system_NN Simon_NNP Tulloch_NNP Senior_NNP Vice_NNP President_NNP and_CC CNS_NNP Strategic_NNP Therapeutic_NNP Area_NNP Leader_NNP 08_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 09_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Shire_NNP will_MD continue_VB to_TO build_VB upon_IN its_PRP$ successful_JJ ADHD_NNP platform_NN ,_, thereby_RB helping_VBG thousands_NNS of_IN patients_NNS suffering_VBG from_IN the_DT disease_NN 09_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 10_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Our_PRP$ business_NN strategy_NN going_VBG forward_RB is_VBZ to_TO continue_VB to_TO optimize_VB our_PRP$ current_JJ portfolio_NN of_IN products_NNS and_CC to_TO in-license_JJ projects_NNS in_IN clinical_JJ development_NN Disorders_NNS of_IN the_DT CNS_NNP are_VBP a_DT very_RB important_JJ for_IN delivering_VBG results_NNS for_IN those_DT products_NNS ._.
The_DT new_JJ segment_NN of_IN the_DT global_JJ pharmaceutical_JJ market_NN structure_NN allows_VBZ people_NNS from_IN different_JJ geographic_JJ one_NN that_WDT is_VBZ still_RB relatively_RB underserved_VBD ._.
Shire_NNP has_VBZ and_CC functional_JJ areas_NNS to_TO work_VB together_RB to_TO solve_VB developed_VBN a_DT strong_JJ heritage_NN in_IN this_DT area_NN by_IN problems_NNS collaboratively_RB ._.
The_DT new_JJ STAT_NNP structure_NN successfully_RB finding_VBG ,_, developing_VBG and_CC marketing_VBG also_RB puts_VBZ us_PRP in_IN a_DT better_JJR position_NN to_TO focus_VB on_IN drugs_NNS that_WDT meet_VBP the_DT needs_NNS of_IN specialist_NN making_VBG a_DT global_JJ success_NN of_IN our_PRP$ products_NNS and_CC physicians_NNS in_IN treating_VBG patients_NNS suffering_VBG from_IN to_TO build_VB truly_RB global_JJ franchises_NNS ._.
disorders_NNS such_JJ as_IN attention_NN deficit_NN hyperactivity_NN disorder_NN ADHD_NNP and_CC bipolar_NN 1_CD disorder_NN ._.
Shires_NNP CNS_NNP STAT_NNP is_VBZ already_RB delivering_VBG solid_JJ My_PRP$ experience_NN with_IN results_NNS ._.
During_IN the_DT year_NN considerable_JJ progress_NN ADDERALL_NNP XR_NNP has_VBZ been_VBN Shire_NNP has_VBZ a_DT world-class_JJ team_NN of_IN researchers_NNS was_VBD made_VBN in_IN finalizing_VBG the_DT CNS_NNP team_NN structure_NN very_RB positive_JJ ._.
I_PRP have_VBP an_DT and_CC scientists_NNS focused_VBD on_IN the_DT later_JJ stages_NNS of_IN and_CC in_IN rolling_VBG out_RP the_DT CNS_NNP business_NN plan_NN ._.
adult_NN patient_NN with_IN ADHD_NNP product_NN development_NN and_CC a_DT strong_JJ business_NN We_PRP have_VBP achieved_VBN major_JJ successes_NNS with_IN our_PRP$ who_WP has_VBZ only_RB responded_VBD development_NN group_NN with_IN global_JJ reach_NN actively_RB key_JJ CNS_NNP marketed_VBD products_NNS and_CC projects_NNS under_IN to_TO ADDERALL_NNP XR_NNP ._.
In_IN my_PRP$ seeking_VBG new_JJ opportunities_NNS to_TO bring_VB marketed_VBN and_CC development_NN ,_, such_JJ as_IN receiving_VBG US_NNP marketing_NN opinion_NN it_PRP is_VBZ a_DT valuable_JJ development_NN products_NNS into_IN Shires_NNP portfolio_NN ._.
The_DT approval_NN for_IN EQUETRO_NNP only_RB ten_CD months_NNS after_IN tool_NN in_IN managing_NN patients_NNS Company_NN can_MD add_VB significant_JJ value_NN to_TO potential_JJ its_PRP$ New_NNP Drug_NNP Application_NNP NDA_NNP submission_NN ._.
partners_NNS with_IN its_PRP$ expertise_NN in_IN drug_NN development_NN ,_, its_PRP$ knowledge_NN of_IN regulatory_JJ processes_NNS and_CC ADHD_NNP :_: a_DT core_NN business_NN for_IN Shire_NNP Dr_NNP David_NNP Baron_NNP its_PRP$ excellent_JJ sales_NNS and_CC marketing_NN capability_NN ._.
ADDERALL_NNP XR_NNP mixed_JJ amphetamine_NN salts_NNS ,_, Professor_NNP and_CC Chair_NNP ,_, By_IN leveraging_VBG these_DT strengths_NNS and_CC employing_VBG Shires_NNP patented_VBD novel_JJ formulation_NN of_IN ADDERALL_NNP Department_NNP of_IN Psychiatry_NNP ,_, our_PRP$ considerable_JJ financial_JJ resources_NNS we_PRP have_VBP that_DT provides_VBZ all-day_JJ treatment_NN for_IN ADHD_NNP with_IN Temple_NNP University_NNP School_NNP the_DT ability_NN to_TO take_VB on_RP both_DT new_JJ projects_NNS or_CC one_CD daily_JJ dose_NN ,_, continues_VBZ to_TO build_VB market_NN share_NN of_IN Medicine_NNP existing_VBG products_NNS and_CC maximize_VB their_PRP$ potential_JJ ,_, since_IN being_VBG launched_VBN in_IN late_JJ 2001_CD ._.
In_IN July_NNP 2004_CD ,_, for_IN example_NN in_IN new_JJ indications_NNS or_CC populations_NNS ._.
it_PRP became_VBD the_DT most_RBS prescribed_JJ ADHD_NNP treatment_NN One_CD example_NN of_IN product_NN optimization_NN in_IN CNS_NNP in_IN the_DT United_NNP States_NNPS with_IN a_DT 25_CD %_NN share_NN of_IN the_DT US_NNP is_VBZ ADDERALL_NNP XR_NNP which_WDT was_VBD developed_VBN as_IN a_DT prescription_NN ADHD_NNP market_NN ._.
Sales_NNS of_IN ADDERALL_NNP long-acting_JJ version_NN of_IN ADDERALL_NNP for_IN children_NNS ,_, XR_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD were_VBD then_RB later_RB developed_VBD for_IN the_DT treatment_NN of_IN US_NNP $_$ 606.7_CD million_CD compared_VBN with_IN $_$ 474.5_CD million_CD adults_NNS with_IN ADHD_NNP ._.
Our_PRP$ business_NN strategy_NN going_VBG forward_RB is_VBZ to_TO The_DT size_NN of_IN the_DT US_NNP ADHD_NNP market_NN increased_VBD continue_VBP to_TO optimize_VB our_PRP$ current_JJ portfolio_NN by_IN 17_CD %_NN in_IN 2004_CD and_CC it_PRP is_VBZ anticipated_VBN to_TO continue_VB of_IN products_NNS and_CC to_TO in-license_JJ projects_NNS in_IN growing_VBG as_IN awareness_NN of_IN the_DT condition_NN increases_VBZ clinical_JJ development_NN which_WDT have_VBP meaningful_JJ in_IN pediatric_JJ ,_, adolescent_JJ and_CC adult_JJ populations_NNS ._.
commercial_JJ value_NN to_TO Shire_NNP by_IN virtue_NN of_IN their_PRP$ ADDERALL_NNP XR_NNP has_VBZ developed_VBN a_DT strong_JJ clinical_JJ uniqueness_NN and_CC hence_RB their_PRP$ benefit_NN reputation_NN among_IN doctors_NNS for_IN being_VBG highly_RB for_IN patients_NNS ,_, strong_JJ patent_NN protection_NN and_CC effective_JJ ._.
ADDERALL_NNP XR_NNP has_VBZ been_VBN supported_VBN significant_JJ market_NN opportunity_NN ._.
by_IN a_DT focused_JJ marketing_NN strategy_NN ,_, implemented_VBN by_IN our_PRP$ specialist_NN sales_NNS force_NN that_WDT calls_VBZ on_IN key_JJ A_DT responsive_JJ organization_NN psychiatrists_NNS ,_, pediatricians_NNS and_CC neurologists_NNS ._.
Our_PRP$ new_JJ organizational_JJ structure_NN based_VBN Our_PRP$ sales_NNS force_NN targets_VBZ the_DT highest_JJS prescribing_VBG around_IN Strategic_NNP Therapeutic_NNP Area_NNP Teams_NNP specialists_NNS and_CC is_VBZ backed_VBN by_IN a_DT well-structured_JJ and_CC STATs_NNS ,_, supported_VBN by_IN strong_JJ functions_NNS such_JJ comprehensive_JJ professional_JJ education_NN program_NN ._.
as_IN marketing_NN ,_, business_NN development_NN and_CC R&D_NNP ,_, Educating_VBG the_DT medical_JJ community_NN about_IN ADHD_NNP will_MD allow_VB Shire_NNP to_TO better_RBR manage_VB our_PRP$ existing_VBG and_CC the_DT various_JJ treatments_NNS available_JJ is_VBZ a_DT critical_JJ products_NNS and_CC identify_VB and_CC add_VB innovative_JJ new_JJ success_NN factor_NN for_IN Shire_NNP in_IN this_DT field_NN ._.
The_DT STAT_NNP structure_NN should_MD also_RB enable_VB us_PRP to_TO respond_VB quickly_RB and_CC In_IN October_NNP 2004_CD ,_, the_DT United_NNP States_NNPS Food_NNP &_CC Drug_NNP more_RBR effectively_RB to_TO changing_VBG market_NN dynamics_NNS ._.
Administration_NNP FDA_NNP granted_VBD an_DT additional_JJ six_CD Within_IN each_DT of_IN the_DT STATs_NNS we_PRP have_VBP dedicated_VBN months_NNS US_PRP market_NN exclusivity_NN to_TO ADDERALL_NNP XR_NNP ,_, cross-functional_JJ global_JJ teams_NNS organized_VBN by_IN until_IN April_NNP 11_CD ,_, 2005_CD ,_, under_IN the_DT Hatch-Waxman_NNP product_NN who_WP are_VBP responsible_JJ and_CC accountable_JJ regulations_NNS ._.
ADDERALL_NNP XR_NNP is_VBZ also_RB protected_VBN by_IN 10_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 11_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Shire_NNP intends_VBZ to_TO serve_VB each_DT of_IN the_DT ADHD_NNP areas_NNS with_IN clinically_RB beneficial_JJ products_NNS ADDERALL_NNP XR_NNP patents_NNS that_WDT expire_VBP in_IN 2018_CD ._.
As_IN Shire_NNP has_VBZ with_IN clinically_RB beneficial_JJ products_NNS ._.
Accordingly_RB ,_, mixed_JJ amphetamine_NN salts_NNS previously_RB announced_VBD ,_, a_DT number_NN of_IN generic_JJ drug_NN we_PRP are_VBP developing_VBG the_DT following_VBG drugs_NNS :_: is_VBZ indicated_VBN for_IN the_DT treatment_NN manufacturers_NNS have_VBP filed_VBN abbreviated_JJ NDAs_NNS with_IN of_IN ADHD_NNP and_CC is_VBZ a_DT once-daily_RB the_DT FDA_NNP ,_, seeking_VBG to_TO market_NN generic_JJ versions_NNS SPD503_VBP a_DT modified_VBN release_NN formulation_NN of_IN formulation_NN of_IN ADDERALL_NNP ._.
Litigation_NN proceedings_NNS are_VBP in_IN guanfacine_NN :_: a_DT non-scheduled_JJ ,_, non-stimulant_JJ It_PRP offers_VBZ convenience_NN to_TO progress_VB against_IN some_DT of_IN these_DT manufacturers_NNS product_NN ._.
Thanks_NNS to_TO progress_VB in_IN development_NN patients_NNS and_CC caregivers_NNS ,_, and_CC and_CC are_VBP described_VBN in_IN more_JJR detail_NN in_IN Note_NN 20_CD during_IN 2004_CD ,_, Shire_NNP could_MD file_VB an_DT NDA_NNP for_IN the_DT potential_NN for_IN improved_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS ._.
Shire_NNP registration_NN in_IN the_DT US_NNP for_IN SPD503_NNP in_IN 2005_CD ,_, patient_JJ compliance_NN remains_VBZ committed_JJ to_TO protecting_VBG its_PRP$ patents_NNS ._.
subject_JJ to_TO agreement_NN with_IN the_DT FDA_NNP ._.
In_IN February_NNP 2005_CD ,_, Health_NNP Canada_NNP announced_VBD the_DT Methylphenidate_NNP transdermal_NN system_NN suspension_NN of_IN sales_NNS of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP ._.
MTS_NNP METHYPATCH_NNP :_: a_DT transdermal_JJ delivery_NN The_DT FDA_NNP subsequently_RB issued_VBD a_DT statement_NN in_IN product_NN for_IN the_DT methylphenidate_NN market_NN :_: which_WDT it_PRP advised_VBD that_IN after_IN consultation_NN with_IN the_DT Shire_NNP is_VBZ on_IN track_NN to_TO submit_VB a_DT response_NN to_TO the_DT Canadian_JJ authorities_NNS regarding_VBG the_DT basis_NN for_IN their_PRP$ April_NNP 2003_CD non-approvable_JJ letter_NN from_IN the_DT action_NN ,_, it_PRP did_VBD not_RB feel_VB that_IN any_DT immediate_JJ changes_NNS FDA_NNP ,_, including_VBG new_JJ clinical_JJ data_NNS ,_, in_IN mid-2005_NN ._.
were_VBD warranted_VBN in_IN the_DT FDA_NNP labeling_VBG or_CC approved_VBN use_NN of_IN ADDERALL_NNP XR_NNP ,_, based_VBN on_IN its_PRP$ preliminary_JJ NRP104_NNP ,_, a_DT prodrug_NN of_IN amphetamine_NN :_: understanding_NN of_IN Health_NNP Canadas_NNP analysis_NN in_IN January_NNP 2005_CD ,_, Shire_NNP signed_VBD a_DT collaborative_NN of_IN adverse_JJ event_NN reports_NNS and_CC the_DT FDAs_NNS own_JJ agreement_NN with_IN New_NNP River_NNP Pharmaceuticals_NNP knowledge_NN and_CC assessment_NN of_IN those_DT reports_NNS ._.
Inc._NNP ._.
New_NNP River_NNP for_IN the_DT global_JJ commercialization_NN Although_IN Shire_NNP is_VBZ complying_VBG with_IN Health_NNP of_IN NRP104_NNP ,_, a_DT product_NN in_IN Phase_NN 3_CD development_NN Canadas_NNP suspension_NN request_NN ,_, the_DT Company_NN for_IN the_DT treatment_NN of_IN ADHD_NNP and_CC other_JJ potential_JJ strongly_RB disagrees_VBZ with_IN the_DT conclusions_NNS drawn_VBN indications_NNS ._.
Shire_NNP expects_VBZ the_DT NDA_NNP for_IN NRP104_NNP by_IN Health_NNP Canada_NNP ,_, and_CC has_VBZ lodged_VBN an_DT appeal_NN to_TO be_VB filed_VBN for_IN US_NNP registration_NN in_IN late_JJ 2005_CD and_CC taken_VBN other_JJ actions_NNS to_TO preserve_VB its_PRP$ legal_JJ to_TO early_JJ 2006_CD ._.
NRP104_CD is_VBZ a_DT new_JJ chemical_NN rights_NNS and_CC obligations_NNS ._.
entity_NN an_DT amphetamine_NN prodrug_NN where_WRB an_DT amphetamine_NN is_VBZ linked_VBN to_TO a_DT specific_JJ amino_JJ acid_NN ._.
The_DT US_NNP ADHD_NNP market_NN is_VBZ segmented_JJ into_IN three_CD NRP104_NNP is_VBZ intended_VBN to_TO provide_VB better_JJR overdose_JJ types_NNS of_IN treatments_NNS amphetamine-based_JJ protection_NN and_CC a_DT reduced_VBN potential_NN for_IN abuse_NN products_NNS ,_, methylphenidate_NN products_NNS ,_, and_CC nonthan_JJ currently_RB marketed_VBN amphetamine_NN stimulant_NN products_NNS ._.
As_IN we_PRP look_VBP to_TO the_DT future_NN ,_, Shire_NNP products_NNS ,_, while_IN providing_VBG effective_JJ treatment_NN intends_VBZ to_TO serve_VB each_DT of_IN these_DT therapeutic_JJ needs_NNS of_IN ADHD_NNP symptoms_NNS when_WRB taken_VBN as_IN directed_VBN ._.
11_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 12_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Shire_NNP will_MD continue_VB to_TO strengthen_VB its_PRP$ US_NNP ADHD_NNP franchise_NN and_CC explore_VB ways_NNS to_TO build_VB a_DT successful_JJ European_JJ ADHD_NNP franchise_NN In_IN March_NNP 2005_CD ,_, New_NNP River_NNP published_VBD the_DT results_NNS proper_JJ diagnosis_NN and_CC treatment_NN can_MD usually_RB of_IN a_DT Phase_NN 2_CD trial_NN with_IN NRP104_NNP ._.
A_DT total_NN of_IN 52_CD alter_VBP the_DT course_NN of_IN the_DT illness_NN ._.
Each_DT year_NN it_PRP is_VBZ children_NNS aged_VBN 6-12_CD with_IN ADHD_NNP were_VBD enrolled_VBN in_IN estimated_VBN that_IN more_JJR than_IN two_CD million_CD American_NNP a_DT double-blind_JJ ,_, placeboand_JJ active-controlled_JJ ,_, adults_NNS ,_, about_IN 1_CD %_NN of_IN the_DT population_NN aged_VBN 18_CD randomized_VBN ,_, crossover_NN study_NN that_IN compared_VBN and_CC older_JJR ,_, are_VBP afflicted_VBN with_IN bipolar_JJ disorder_NN ._.
NRP104s_NNS efficacy_NN ,_, duration_NN and_CC incidence_NN The_DT market_NN for_IN pharmaceuticals_NNS to_TO treat_VB bipolar_NN of_IN adverse_JJ events_NNS to_TO placebo_NN ._.
disorder_NN in_IN the_DT United_NNP States_NNPS is_VBZ currently_RB valued_VBN at_IN about_IN $_$ 1.9_CD billion_CD and_CC is_VBZ expected_VBN to_TO grow_VB The_DT primary_JJ efficacy_NN endpoint_NN in_IN this_DT study_NN was_VBD to_TO $_$ 2.4_CD billion_CD by_IN 2007_CD ._.
EQUETRO_NNP is_VBZ an_DT extendedthe_NN SKAMP-Deportment_JJ Swanson_NNP ,_, Kotkin_NNP ,_, release_NN preparation_NN Agler_NNP ,_, M._NNP Flynn_NNP and_CC Pelham_NNP rating_NN scale_NN ._.
In_IN the_DT Shire_NNP intends_VBZ to_TO grow_VB its_PRP$ market_NN share_NN in_IN this_DT of_IN carbamazepine_NN which_WDT study_NN ,_, patients_NNS treated_VBD with_IN NRP104_CD showed_VBD a_DT high-potential_JJ treatment_NN area_NN ._.
The_DT FDA_NNP approved_VBD is_VBZ better_RBR tolerated_JJ than_IN statistically_RB significant_JJ improvement_NN on_IN primary_JJ EQUETRO_NNP carbamazepine_NN extended-release_NN immediate_JJ release_NN forms_NNS ._.
endpoint_NN compared_VBN to_TO placebo_NN across_IN all_DT three_CD capsules_NNS ,_, previously_RB known_VBN as_IN SPD417_NNP I_PRP expect_VBP EQUETRO_NNP to_TO doses_NNS p_VBP values_NNS 0.0001_CD ._.
and_CC Bipotrol_NNP ,_, for_IN the_DT treatment_NN of_IN acute_JJ manic_JJ be_VB a_DT significant_JJ advance_NN and_CC mixed_JJ episodes_NNS associated_VBN with_IN bipolar_NN 1_CD in_IN the_DT pharmacotherapy_JJ The_DT significant_JJ therapeutic_JJ effects_NNS of_IN NRP104_NNP disorder_NN ,_, in_IN December_NNP 2004_CD ._.
The_DT US_NNP marketing_NN of_IN bipolar_NN disorder_NN ._.
continued_VBN throughout_IN the_DT last_JJ assessment_NN approval_NN from_IN the_DT FDA_NNP came_VBD just_RB ten_CD months_NNS time_NN point_NN i._FW e._FW 12_CD hours_NNS post-morning_JJ dose_NN ,_, after_IN submission_NN ,_, which_WDT represents_VBZ a_DT significant_JJ Wade_NNP Berrettini_NNP MD_NNP ,_, PhD_NNP compared_VBD to_TO placebo_NN ,_, suggesting_VBG a_DT 12-hour_JJ achievement_NN ._.
In_IN addition_NN ,_, the_DT unique_JJ three-bead_JJ Karl_NNP E_NNP Rickels_NNP duration_NN of_IN drug_NN action_NN ._.
extended-release_NN delivery_NN system_NN of_IN EQUETRO_NNP Professor_NNP of_IN Psychiatry_NNP provides_VBZ for_IN convenient_JJ twice-daily_JJ administration_NN ._.
University_NNP of_IN Pennsylvania_NNP NRP104_NNP was_VBD generally_RB well_RB tolerated_JJ ,_, with_IN School_NNP of_IN Medicine_NNP adverse_JJ events_NNS of_IN a_DT nature_NN consistent_JJ with_IN EQUETRO_NNP has_VBZ patents_NNS around_IN its_PRP$ formulation_NN ,_, Director_NNP ,_, Center_NNP for_IN those_DT in_IN the_DT approved_VBN labeling_VBG for_IN ADDERALL_NNP and_CC will_MD have_VB at_IN least_JJS three_CD years_NNS of_IN market_NN Neurobiology_NNP and_CC Behavior_NNP XR_NNP and_CC other_JJ stimulant_NN therapies_NNS ._.
exclusivity_NN under_IN the_DT US_NNP Hatch-Waxman_NNP Act_NNP ._.
It_PRP will_MD be_VB available_JJ for_IN prescribing_VBG in_IN the_DT US_NNP SPD465_NNP :_: a_DT long-acting_JJ amphetamine_JJ product_NN ._.
Shire_NNP has_VBZ Shire_NNP is_VBZ developing_VBG a_DT longer-acting_JJ amphetamine_NN obtained_VBD a_DT dedicated_JJ sales_NNS force_NN to_TO promote_VB product_NN for_IN patients_NNS such_JJ as_IN adults_NNS who_WP need_VBP EQUETRO_NNP in_IN the_DT US_NNP ._.
therapeutic_JJ coverage_NN throughout_IN a_DT long_JJ day_NN ._.
Epilepsy_NNP :_: an_DT existing_VBG business_NN for_IN Shire_NNP with_IN CARBATROL_NNP Shire_NNP will_MD continue_VB to_TO build_VB and_CC strengthen_VB Epilepsy_NNP is_VBZ one_CD of_IN the_DT most_RBS common_JJ chronic_NN its_PRP$ position_NN as_IN the_DT leading_VBG ADHD_NNP specialty_NN neurological_JJ disorders_NNS ,_, affecting_VBG approximately_RB pharmaceutical_JJ company_NN in_IN the_DT US_NNP by_IN optimizing_VBG 2.5_CD million_CD people_NNS in_IN the_DT US_NNP alone_RB ._.
CARBATROL_NNP ,_, its_PRP$ existing_VBG portfolio_NN and_CC adding_VBG to_TO its_PRP$ pipeline_NN ._.
Shires_NNP extended-release_NN formulation_NN of_IN We_PRP will_MD also_RB be_VB working_VBG to_TO explore_VB ways_NNS to_TO build_VB carbamazepine_NN ,_, uses_VBZ the_DT patented_JJ MICROTROL_NNP a_DT successful_JJ ADHD_NNP franchise_NN in_IN Europe_NNP ,_, where_WRB delivery_NN system_NN technology_NN ._.
This_DT twice-daily_JJ the_DT market_NN is_VBZ evolving_VBG ._.
A_DT number_NN of_IN our_PRP$ projects_NNS extended-release_VBP formulation_NN is_VBZ more_RBR patientin_JJ development_NN have_VBP the_DT potential_NN to_TO serve_VB the_DT friendly_JJ than_IN immediate-release_JJ formulations_NNS on_IN emerging_VBG European_JJ ADHD_NNP market_NN ._.
the_DT market_NN ,_, which_WDT require_VBP three_CD to_TO four_CD doses_NNS a_DT day_NN ._.
CARBATROL_NNP can_MD also_RB be_VB sprinkled_VBN on_IN food_NN ._.
Bipolar_NNP disorder_NN :_: a_DT new_JJ CNS_NNP disease_NN area_NN In_IN 2004_CD ,_, US_NNP prescription_NN growth_NN of_IN 11_CD %_NN was_VBD for_IN Shire_NNP with_IN EQUETRO_NNP achieved_VBD and_CC CARBATROL_NNP had_VBD a_DT 46_CD %_NN share_NN Bipolar_NNP disorder_NN is_VBZ a_DT leading_VBG neuropsychiatric_NN of_IN the_DT total_JJ US_NNP extended-release_NN carbamazepine_NN disorder_NN according_VBG to_TO the_DT World_NNP Health_NNP prescription_NN market_NN ._.
Litigation_NN relating_VBG to_TO an_DT Organization_NNP WHO_WP ._.
Also_RB known_VBN as_IN manic_JJ application_NN by_IN a_DT generic_JJ drug_NN manufacturer_NN depression_NN ,_, it_PRP is_VBZ characterized_VBN by_IN episodes_NNS of_IN to_TO market_VB a_DT generic_JJ version_NN of_IN CARBATROL_NNP is_VBZ mania_NN and_CC depression_NN with_IN periods_NNS of_IN normal_JJ in_IN progress_NN ._.
More_RBR detail_NN is_VBZ provided_VBN in_IN Note_NN 20_CD mood_NN in_IN between_IN ._.
The_DT disorder_NN can_MD have_VB to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
devastating_VBG effects_NNS on_IN an_DT individuals_NNS life_NN but_CC 12_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 13_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: CNS_NNP Each_DT year_NN it_PRP is_VBZ estimated_VBN that_IN more_JJR than_IN two_CD million_CD American_JJ adults_NNS are_VBP afflicted_VBN with_IN bipolar_JJ disorder_NN EQUETRO_NNP carbamazepine_NN Alzheimers_NNP disease_NN :_: the_DT first_JJ During_IN 2004_CD 5_CD the_DT National_NNP Institute_NNP for_IN Clinical_NNP extended-release_NN capsules_NNS CNS_NNP success_NN for_IN Shire_NNP with_IN REMINYL_NNP Excellence_NNP NICE_NNP has_VBZ been_VBN reviewing_VBG its_PRP$ is_VBZ indicated_VBN for_IN the_DT treatment_NN Alzheimers_NNP disease_NN ,_, one_CD of_IN the_DT most_RBS common_JJ guidance_NN for_IN the_DT drug_NN treatment_NN of_IN Alzheimers_NNP of_IN acute_JJ manic_NN and_CC mixed_JJ forms_NNS of_IN dementia_NN ,_, affects_VBZ approximately_RB disease_NN ,_, which_WDT includes_VBZ the_DT three_CD acetylepisodes_NNS associated_VBN with_IN 18_CD million_CD people_NNS worldwide_JJ ,_, mainly_RB those_DT cholinesterase_JJ inhibitors_NNS donepezil_NN ,_, rivastigmine_JJ bipolar_NN 1_CD disorder_NN ._.
It_PRP is_VBZ a_DT progressive_JJ disorder_NN and_CC galantamine_NN ._.
drug_NN delivery_NN technology_NN that_WDT gradually_RB robs_VBZ individuals_NNS of_IN their_PRP$ ability_NN to_TO enables_VBZ the_DT convenience_NN remember_VBP ,_, learn_VBP new_JJ information_NN and_CC perform_VB NICE_NNP published_VBD a_DT preliminary_JJ Appraisal_NNP of_IN twice-daily_JJ dosing_NN basic_JJ activities_NNS of_IN daily_JJ living_NN ._.
This_DT document_NN states_VBZ that_IN donepezil_NN ,_, rivastigmine_JJ REMINYL_NNP slows_VBZ the_DT progression_NN of_IN the_DT symptoms_NNS and_CC galantamine_NN are_VBP not_RB recommended_VBN for_IN of_IN Alzheimers_NNP disease_NN for_IN up_RB to_TO four_CD years_NNS ._.
use_NN in_IN the_DT treatment_NN of_IN mild_JJ to_TO moderate_JJ REMINYL_NNP is_VBZ an_DT acetylcholinesterase_NN inhibitor_NN with_IN Alzheimers_NNP disease_NN by_IN the_DT National_NNP Health_NNP an_DT additional_JJ nicotinic_JJ mode_NN of_IN action_NN ._.
It_PRP is_VBZ one_CD Service_NN in_IN England_NNP and_CC Wales_NNP for_IN new_JJ patients_NNS ,_, of_IN the_DT fastest-growing_JJ products_NNS for_IN treating_VBG mild_JJ due_JJ to_TO NICEs_NNS economic_JJ assessment_NN ._.
to_TO moderately_RB severe_JJ dementia_NN of_IN the_DT Alzheimer_NNP Pharmaceutical_NNP manufacturers_NNS ,_, physicians_NNS ,_, type_NN ._.
Developed_VBN by_IN Johnson_NNP &_CC Johnson_NNP patients_NNS and_CC parliamentarians_NNS have_VBP already_RB Pharmaceutical_NNP Research_NNP and_CC Development_NNP voiced_VBD their_PRP$ objection_NN to_TO this_DT proposal_NN ._.
It_PRP is_VBZ under_IN a_DT co-development_NN and_CC licensing_NN agreement_NN expected_VBD that_IN NICEs_NNP final_JJ recommendation_NN with_IN Shire_NNP ,_, it_PRP is_VBZ licensed_VBN for_IN use_NN in_IN 69_CD countries_NNS ._.
will_MD be_VB published_VBN by_IN June_NNP 1_CD ,_, 2005_CD ._.
With_IN the_DT exception_NN of_IN the_DT UK_NNP and_CC the_DT Republic_NNP of_IN Ireland_NNP ,_, REMINYL_NNP is_VBZ marketed_VBN by_IN Janssen-Cilag_NNP worldwide_NN ._.
Janssen-Cilag_NNP pays_VBZ Shire_NNP a_DT royalty_NN on_IN its_PRP$ net_JJ sales_NNS of_IN REMINYL_NNP ._.
Shire_NNP and_CC JanssenCilag_NNP co-promoted_VBD REMINYL_NNP in_IN the_DT UK_NNP and_CC Republic_NNP of_IN Ireland_NNP until_IN May_NNP 2004_CD ,_, when_WRB full_JJ marketing_NN and_CC promotion_NN rights_NNS in_IN these_DT countries_NNS was_VBD acquired_VBN by_IN Shire_NNP ._.
Shire_NNP is_VBZ seeking_VBG to_TO expand_VB its_PRP$ REMINYL_NNP franchise_NN ,_, including_VBG the_DT introduction_NN of_IN a_DT once-a-day_JJ formulation_NN ,_, during_IN the_DT first_JJ half_NN of_IN 2005_CD ._.
13_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 14_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: General_NNP products_NNS &_CC royalty_NN revenues_NNS General_JJ products_NNS royalty_NN &_CC revenues_NNS David_NNP Milton_NNP Senior_NNP Vice_NNP President_NNP and_CC General_NNP Products_NNPS Strategic_NNP Therapeutic_NNP Area_NNP Leader_NNP 14_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 15_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: General_NNP products_NNS &_CC royalty_NN revenues_NNS I_PRP found_VBD FOSRENOL_NNP a_DT much_RB more_RBR convenient_JJ product_NN to_TO take_VB compared_VBN to_TO my_PRP$ previous_JJ treatments_NNS ,_, not_RB only_RB because_IN I_PRP had_VBD to_TO take_VB fewer_JJR tablets_NNS but_CC also_RB because_IN FOSRENOL_NNP was_VBD far_RB more_RBR palatable_JJ ._.
These_DT benefits_NNS helped_VBD me_PRP to_TO deal_VB with_IN my_PRP$ illness_NN more_RBR easily_RB until_IN I_PRP received_VBD a_DT successful_JJ kidney_NN transplant_NN ._.
Simon_NNP Jenkins_NNP FOSRENOL_NNP patient_JJ FOSRENOL_NNP lanthanum_NN carbonate_NN is_VBZ indicated_VBN to_TO reduce_VB serum_NN phosphate_NN in_IN patients_NNS with_IN end-stage_JJ renal_JJ disease_NN ._.
Approved_VBN in_IN 2004_CD ,_, FOSRENOL_NNP will_MD s_PRP become_VB one_CD of_IN the_DT first_JJ global_JJ products_NNS for_IN Shire_NNP 15_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 16_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: General_NNP products_NNS &_CC royalty_NN revenues_NNS FOSRENOL_NNP is_VBZ strategically_RB very_RB important_JJ to_TO our_PRP$ business_NN and_CC nearly_RB 2,000_CD patients_NNS have_VBP taken_VBN the_DT drug_NN so_RB far_RB Shire_NNP aims_VBZ to_TO deliver_VB superior_JJ results_NNS by_IN FOSRENOL_NNP is_VBZ the_DT first_JJ Shire_NNP compound_NN taken_VBN developing_VBG and_CC marketing_VBG products_NNS that_WDT meet_VBP from_IN the_DT laboratory_NN bench_NN to_TO approval_NN and_CC the_DT needs_NNS of_IN specialist_NN physicians_NNS and_CC their_PRP$ commercialization_NN and_CC it_PRP is_VBZ strategically_RB very_RB patients_NNS ._.
It_PRP does_VBZ so_RB by_IN leveraging_VBG its_PRP$ extensive_JJ important_JJ for_IN our_PRP$ business_NN ._.
The_DT drug_NN has_VBZ been_VBN expertise_NN in_IN R&D_NNP and_CC regulatory_JJ affairs_NNS ,_, as_RB well_RB as_IN studied_VBN more_RBR extensively_RB than_IN any_DT other_JJ its_PRP$ dedicated_JJ sales_NNS forces_NNS strategically_RB located_VBN in_IN phosphate-binder_NN prior_RB to_TO launch_NN and_CC up_RB to_TO five_CD North_NNP America_NNP and_CC Europe_NNP ._.
Our_PRP$ diverse_JJ portfolio_NN years_NNS of_IN pharmacological_JJ data_NNS has_VBZ already_RB been_VBN includes_VBZ specialist_NN products_NNS and_CC projects_NNS that_WDT collected_VBD ._.
Nearly_RB 2,000_CD patients_NNS have_VBP taken_VBN the_DT fit_NN well_RB into_IN this_DT strategic_JJ model_NN and_CC to_TO which_WDT we_PRP drug_NN so_RB far_RB ._.
Hyperphosphatemia_NNP is_VBZ believe_VB we_PRP can_MD add_VB considerable_JJ value_NN ._.
a_DT very_RB serious_JJ condition_NN Starting_VBG in_IN the_DT first_JJ quarter_NN of_IN 2005_CD ,_, FOSRENOL_NNP for_IN ESRD_NNP patients_NNS ._.
Effective_JJ During_IN 2004_CD ,_, we_PRP focused_VBD on_IN the_DT impending_JJ market_NN is_VBZ available_JJ in_IN the_DT US_NNP in_IN 250mg_CD and_CC 500mg_CD reduction_NN of_IN phosphate_NN launches_NNS of_IN two_CD key_JJ products_NNS in_IN our_PRP$ General_NNP strengths_NNS ._.
It_PRP is_VBZ formulated_VBN as_IN a_DT chewable_JJ tablet_NN levels_NNS in_IN patients_NNS with_IN Products_NNPS portfolio_NN FOSRENOL_NNP for_IN the_DT treatment_NN that_WDT does_VBZ not_RB need_VB water_NN to_TO be_VB swallowed_VBN ,_, kidney_NN disease_NN could_MD make_VB of_IN hyperphosphatemia_NN in_IN end-stage_JJ renal_JJ disease_NN an_DT important_JJ benefit_NN for_IN ESRD_NNP patients_NNS who_WP a_DT real_JJ impact_NN on_IN their_PRP$ lives_NNS ._.
ESRD_NNP and_CC XAGRID_NNP in_IN essential_JJ thrombocythemia_NN have_VBP to_TO restrict_VB fluid_JJ intake_NN ._.
The_DT launch_NN in_IN the_DT US_NNP In_IN my_PRP$ opinion_NN ,_, existing_VBG ET_NNP which_WDT are_VBP poised_VBN to_TO become_VB our_PRP$ first_JJ truly_RB has_VBZ already_RB showed_VBN promising_JJ signs_NNS of_IN success_NN ._.
therapies_NNS have_VBP numerous_JJ global_JJ products_NNS ._.
The_DT new_JJ General_NNP Products_NNPS According_VBG to_TO IMS_NNP data_NNS ,_, FOSRENOL_NNP captured_VBD shortcomings_NNS from_IN longStrategic_NNP Therapeutic_NNP Area_NNP Team_NNP STAT_NNP is_VBZ allowing_VBG a_DT share_NN of_IN 13.8_CD %_NN of_IN the_DT new_JJ prescriptions_NNS written_VBN term_NN safety_NN issues_NNS to_TO high_JJ us_PRP to_TO harness_VB Shires_NNP resources_NNS in_IN the_DT most_RBS for_IN phosphate_NN binders_NNS in_IN ESRD_NNP patients_NNS in_IN the_DT pill_NN burdens_NNS and_CC poor_JJ effective_JJ way_NN ,_, by_IN having_VBG global_JJ ,_, cross-functional_JJ US_NNP market_NN by_IN April_NNP 1_CD ,_, 2005_CD ,_, only_RB four_CD months_NNS intestinal_JJ tolerability_NN ._.
I_PRP believe_VBP leadership_NN responsible_JJ and_CC accountable_JJ for_IN after_IN launch_NN ._.
FOSRENOL_NNP moves_VBZ us_PRP closer_JJR drug_NN development_NN through_IN to_TO commercialization_NN ._.
to_TO the_DT ideal_JJ phosphate_NN binder_NN ,_, It_PRP will_MD ensure_VB successful_JJ campaigns_NNS on_IN both_DT FOSRENOL_NNP is_VBZ reaching_VBG the_DT market_NN as_IN rates_NNS since_IN it_PRP can_MD be_VB integrated_VBN sides_NNS of_IN the_DT Atlantic_NNP for_IN these_DT exciting_JJ of_IN ESRD_NNP in_IN the_DT US_NNP and_CC Europe_NNP are_VBP forecast_VBN to_TO easily_RB into_IN patients_NNS day_NN to_TO new_JJ products_NNS and_CC others_NNS to_TO follow_VB in_IN future_NN ._.
soar_VB ,_, largely_RB as_IN a_DT result_NN of_IN the_DT growing_VBG worldwide_JJ day_NN schedules_NNS and_CC has_VBZ a_DT incidence_NN of_IN diabetes_NN one_CD of_IN the_DT leading_VBG proven_JJ efficacy_NN and_CC safety_NN Renal_NNP :_: FOSRENOL_NNP set_VBD for_IN launch_NN causes_NNS of_IN renal_JJ disease_NN ._.
The_DT WHO_WP estimates_VBZ profile_NN from_IN a_DT number_NN of_IN After_IN nine_CD years_NNS of_IN R&D_NNP ,_, clinical_JJ studies_NNS and_CC the_DT incidence_NN of_IN diabetes_NN worldwide_NN will_MD rise_VB from_IN well-designed_JJ clinical_JJ trials_NNS ._.
regulatory_JJ reviews_NNS ,_, Shire_NNP has_VBZ already_RB started_VBN 171_CD million_CD affected_JJ people_NNS in_IN 2000_CD to_TO about_IN launching_VBG FOSRENOL_NNP lanthanum_NN carbonate_NN 366_CD million_CD by_IN 2030_CD ._.
FOSRENOL_NNP is_VBZ a_DT new_JJ phosphate-binder_NN Consultant_NN Nephrologist_NNP and_CC that_IN reduces_VBZ elevated_JJ blood_NN levels_NNS of_IN phosphate_NN Approximately_RB 70_CD %_NN of_IN ESRD_NNP patients_NNS undergoing_VBG Clinical_JJ Director_NNP of_IN the_DT Renal_NNP in_IN patients_NNS with_IN ESRD_NNP ._.
regular_JJ dialysis_NN suffer_VBP from_IN hyperphosphatemia_NN Unit_NN at_IN The_DT Royal_NNP Infirmary_NNP ,_, elevated_VBD concentrations_NNS of_IN phosphate_NN in_IN the_DT Manchester_NNP ,_, UK_NNP The_NNP FDA_NNP approved_VBD FOSRENOL_NNP in_IN October_NNP 2004_CD ,_, plasma_NN ._.
Changes_NNS in_IN mineral_NN metabolism_NN and_CC the_DT seven_CD months_NNS after_IN Shire_NNP received_VBD approval_NN for_IN use_NN of_IN calcium_NN containing_VBG phosphate-binders_NNS the_DT drug_NN from_IN the_DT Swedish_JJ regulatory_JJ authorities_NNS ._.
have_VBP been_VBN associated_VBN with_IN the_DT deposition_NN of_IN Following_VBG FDA_NNP approval_NN ,_, Shire_NNP immediately_RB calcium_NN and_CC phosphates_NNS ._.
started_VBD promoting_VBG FOSRENOL_NNP at_IN the_DT American_NNP Society_NNP of_IN Nephrology_NNP annual_JJ conference_NN in_IN St._NNP Calcification_NNP of_IN the_DT heart_NN ,_, heart_NN valves_NNS Louis_NNP ,_, Missouri_NNP ,_, where_WRB it_PRP received_VBD considerable_JJ and_CC coronary_JJ arteries_NNS is_VBZ frequently_RB observed_JJ attention_NN ._.
With_IN FDA_NNP approval_NN ,_, we_PRP are_VBP escalating_VBG in_IN patients_NNS with_IN ESRD_NNP ._.
Hyperphosphatemia_NNP our_PRP$ efforts_NNS to_TO ensure_VB a_DT successful_JJ US_NNP launch_NN and_CC is_VBZ associated_VBN with_IN significant_JJ clinical_JJ problems_NNS ,_, to_TO realize_VB the_DT full_JJ value_NN of_IN this_DT product_NN through_IN including_VBG the_DT development_NN of_IN cardiovascular_JJ the_DT establishment_NN of_IN specialized_VBN sales_NNS teams_NNS disease_NN ,_, which_WDT accounts_VBZ for_IN nearly_RB 50_CD %_NN of_IN all_DT in_IN the_DT US_NNP ,_, backed_VBN by_IN comprehensive_JJ educational_JJ deaths_NNS in_IN ESRD_NNP patients_NNS ._.
Patients_NNS with_IN and_CC promotional_JJ campaigns_NNS ._.
Regulatory_NNP hyperphosphatemia_NN have_VBP a_DT 52_CD %_NN higher_JJR relative_JJ approvals_NNS in_IN a_DT number_NN of_IN other_JJ EU_NNP member_NN risk_NN of_IN dying_VBG from_IN coronary_JJ artery_NN disease_NN ,_, states_NNS have_VBP been_VBN sought_VBN pursuant_JJ to_TO the_DT mutual_JJ a_DT 34_CD %_NN higher_JJR relative_JJ risk_NN of_IN dying_VBG from_IN other_JJ recognition_NN process_NN ._.
Following_VBG the_DT conclusion_NN cardiac_JJ diseases_NNS and_CC a_DT 26_CD %_NN higher_JJR relative_JJ risk_NN of_IN pricing_NN and_CC reimbursement_NN discussions_NNS with_IN of_IN sudden_JJ death_NN ._.
individual_JJ countries_NNS ,_, the_DT launch_NN of_IN FOSRENOL_NNP will_MD begin_VB in_IN European_JJ territories_NNS during_IN 2005_CD ._.
16_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 17_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: General_NNP products_NNS &_CC royalty_NN revenues_NNS In_IN the_DT past_JJ eight_CD years_NNS in_IN the_DT US_NNP ,_, AGRYLIN_NNP has_VBZ developed_VBN a_DT proven_JJ track_NN record_NN for_IN lowering_VBG the_DT platelet_NN count_NN in_IN patients_NNS suffering_VBG from_IN myeloproliferative_JJ disorders_NNS AGRYLIN_NNP lets_VBZ me_PRP get_VB on_IN with_IN my_PRP$ life_NN ._.
Teresa_NNP Adcock_NNP AGRYLIN_NNP patient_JJ AGRYLIN_NNP anagrelide_NN Hyperphosphatemia_NNP also_RB causes_VBZ persistent_JJ at_IN the_DT beginning_NN of_IN 2005_CD ._.
XAGRID_NNP is_VBZ also_RB hydrochloride_NN is_VBZ indicated_VBN and_CC severe_JJ hyperparathyroidism_NN hormone_NN marketed_VBN in_IN the_DT US_NNP under_IN the_DT trade_NN name_NN for_IN the_DT treatment_NN of_IN imbalance_NN that_IN in_IN turn_NN causes_NNS changes_NNS in_IN mineral_NN AGRYLIN_NNP anagrelide_NN hydrochloride_NN ,_, and_CC thrombocythemia_NN ,_, secondary_JJ balance_NN associated_VBN with_IN bone_NN disease_NN renal_JJ therefore_RB the_DT product_NN is_VBZ the_DT second_JJ truly_RB global_JJ to_TO a_DT myeloproliferative_JJ osteodystrophy_NN ._.
Bone_NN disease_NN is_VBZ common_JJ in_IN product_NN for_IN Shire_NNP ._.
Shire_NNP sales_NNS teams_NNS are_VBP in_IN place_NN disorder_NN ._.
Research_NNP indicates_VBZ patients_NNS with_IN chronic_JJ ESRD_NNP and_CC is_VBZ associated_VBN or_CC being_VBG established_VBN to_TO commercialize_VB the_DT that_IN a_DT key_JJ benefit_NN of_IN AGRYLIN_NNP with_IN bone_NN pain_NN ,_, skeletal_JJ deformity_NN ,_, bone_NN product_NN ,_, backed_VBN by_IN comprehensive_JJ educational_JJ is_VBZ its_PRP$ platelet_NN selectivity_NN ,_, weakness_NN and_CC fractures_NNS ._.
targeting_VBG only_RB those_DT cells_NNS that_WDT develop_VBP into_IN platelets_NNS FOSRENOL_NNP has_VBZ been_VBN shown_VBN in_IN numerous_JJ XAGRID_NNP has_VBZ been_VBN designated_VBN an_DT orphan_JJ clinical_JJ studies_NNS to_TO offer_VB a_DT promising_JJ option_NN for_IN medicinal_JJ product_NN ,_, providing_VBG it_PRP with_IN up_RB to_TO ten_VB hyperphosphatemia_NN management_NN compared_VBN with_IN years_NNS market_NN exclusivity_NN in_IN Europe_NNP ._.
These_DT studies_NNS estimates_VBZ that_IN over_IN 40,000_CD patients_NNS suffer_VBP confirm_VBP that_IN it_PRP is_VBZ an_DT effective_JJ and_CC well-tolerated_JJ from_IN ET_NNP across_IN the_DT European_NNP Union_NNP ._.
XAGRID_NNP phosphate-binder_NN ,_, lowering_VBG serum_NN phosphate_NN to_TO is_VBZ the_DT only_JJ platelet-selective_JJ treatment_NN with_IN target_NN levels_NNS within_IN eight_CD weeks_NNS and_CC maintaining_VBG approval_NN throughout_IN the_DT European_NNP Union_NNP ,_, this_DT long_JJ term_NN ,_, with_IN some_DT patients_NNS treated_VBD for_IN Iceland_NNP and_CC Norway_NNP ._.
We_PRP are_VBP therefore_RB hopeful_JJ that_IN FOSRENOL_NNP will_MD become_VB a_DT widely_RB used_VBN treatment_NN AGRYLIN_NNP is_VBZ also_RB being_VBG sold_VBN successfully_RB in_IN Israel_NNP ,_, for_IN hyperphosphatemia_NN in_IN ESRD_NNP patients_NNS ._.
South_NNP Africa_NNP ,_, Brazil_NNP and_CC the_DT Pacific_NNP Rim_NNP and_CC has_VBZ also_RB been_VBN available_JJ on_IN a_DT named_VBN patient_NN XAGRID_NNP AGRYLIN_NNP basis_NN in_IN a_DT number_NN of_IN European_JJ countries_NNS for_IN XAGRID_NNP anagrelide_NN hydrochloride_NN Shires_VBZ several_JJ years_NNS ._.
Shire_NNP ,_, therefore_RB ,_, already_RB has_VBZ an_DT treatment_NN for_IN ET_NNP received_VBD approval_NN from_IN the_DT established_VBN business_NN base_NN and_CC a_DT product_NN profile_NN European_JJ Medicines_NNP Evaluation_NNP Agency_NNP in_IN for_IN XAGRID_NNP among_IN key_JJ opinion_NN leaders_NNS ._.
With_IN 2004_CD for_IN second-line_NN ,_, monotherapy_JJ treatment_NN the_DT recent_JJ EU_NNP approval_NN ,_, it_PRP has_VBZ been_VBN successfully_RB in_IN patients_NNS suffering_VBG from_IN ET_NNP ,_, in_IN the_DT European_JJ launched_VBN in_IN six_CD EU_NNP countries_NNS as_RB well_RB as_IN Union_NNP ,_, Iceland_NNP and_CC Norway_NNP ._.
Promotional_JJ and_CC educational_JJ disorder_NN of_IN bone_NN marrow_NN associated_VBN with_IN the_DT activities_NNS are_VBP well_RB underway_JJ to_TO further_JJ build_VB increased_VBN production_NN of_IN blood_NN platelets_NNS ._.
XAGRID_NNP launch_NN commenced_VBD across_IN Europe_NNP 17_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 18_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: General_NNP products_NNS &_CC royalty_NN revenues_NNS In_IN the_DT past_JJ eight_CD years_NNS in_IN the_DT US_NNP ,_, AGRYLIN_NNP VANIQA_NNP has_VBZ developed_VBN a_DT proven_JJ track_NN record_NN for_IN In_IN 2004_CD ,_, VANIQA_NNP ,_, an_DT innovative_JJ new_JJ product_NN lowering_VBG the_DT platelet_NN count_NN in_IN patients_NNS suffering_VBG designed_VBN to_TO slow_VB unwanted_JJ facial_JJ hair_NN growth_NN from_IN myeloproliferative_JJ disorders_NNS ._.
Platelets_NNS are_VBP in_IN women_NNS ,_, was_VBD launched_VBN by_IN Shire_NNP in_IN the_DT UK_NNP ,_, involved_VBN in_IN blood_NN clotting_NN and_CC lowering_VBG the_DT the_DT Republic_NNP of_IN Ireland_NNP ,_, Germany_NNP ,_, France_NNP ,_, Italy_NNP elevated_VBD count_NN helps_VBZ decrease_VB symptoms_NNS such_JJ and_CC Spain_NNP ._.
The_DT market_NN response_NN to_TO date_NN has_VBZ as_IN blood_NN vessel_NN blockages_NNS and_CC bleeding_VBG events_NNS ._.
Sales_NNS continued_VBD to_TO grow_VB in_IN 2004_CD ,_, totalling_VBG $_$ 152.5_CD million_CD ,_, up_RB 15_CD %_NN from_IN the_DT previous_JJ year_NN ._.
Anti-infectives_NNS :_: HIV_NNP and_CC hepatitis_NNP B_NNP XAGRID_NNP is_VBZ platelet_JJ selective_JJ ,_, $_$ 34_CD million_CD of_IN 2004_CD AGRYLIN_NNP sales_NNS were_VBD Shire_NNP receives_VBZ royalties_NNS from_IN GlaxoSmithKline_NNP targeting_VBG only_RB those_DT cells_NNS attributed_VBD to_TO Europe_NNP ._.
plc_NN GSK_NNP on_IN the_DT worldwide_JJ sales_NNS of_IN 3TC_NNP that_WDT develop_VBP into_IN platelets_NNS :_: lamivudine_NN ,_, a_DT key_JJ component_NN in_IN most_JJS of_IN the_DT it_PRP is_VBZ well_RB tolerated_VBN by_IN most_JJS Orphan_JJ drug_NN exclusivity_NN for_IN AGRYLIN_NNP in_IN the_DT HIV_NNP combination_NN treatment_NN regimes_VBZ ,_, such_JJ as_IN patients_NNS and_CC is_VBZ a_DT welcome_JJ US_NNP expired_VBD in_IN March_NNP 2004_CD and_CC a_DT subsequent_JJ COMBIVIR_NNP and_CC TRIZIVIR_NNP ._.
In_IN Canada_NNP ,_, Shire_NNP addition_NN to_TO the_DT drugs_NNS we_PRP six-month_JJ US_NNP market_NN exclusivity_NN period_NN granted_VBN markets_NNS 3TC_NNP jointly_RB with_IN GSK_NNP ._.
Lamivudine_NNP is_VBZ also_RB have_VBP available_JJ to_TO treat_VB ET_NNP ._.
by_IN the_DT FDA_NNP Pediatric_NNP Board_NNP ending_VBG September_NNP marketed_VBD for_IN the_DT treatment_NN of_IN chronic_JJ hepatitis_NN B_NNP 2004_CD has_VBZ also_RB expired_VBN ._.
Shire_NNP is_VBZ therefore_RB as_IN HEPTOVIR_NNP in_IN Canada_NNP ,_, EPIVIR_NNP HBV_NNP in_IN the_DT US_NNP ,_, Dr_NNP Claire_NNP Harrison_NNP anticipating_VBG the_DT launch_NN of_IN generic_JJ versions_NNS and_CC ZEFFIX_NNP elsewhere_RB in_IN the_DT world_NN ._.
Shire_NNP also_RB Consultant_NN Hematologist_NNP of_IN the_DT product_NN in_IN the_DT US_NNP market_NN ._.
receives_VBZ royalties_NNS on_IN sales_NNS of_IN lamivudine_NN by_IN at_IN Guys_NNP and_CC St_NNP Thomas_NNP GSK_NNP for_IN hepatitis_NNP B._NNP In_IN 2004_CD ,_, royalty_NN income_NN for_IN Foundation_NNP Trust_NNP Other_JJ general_JJ products_NNS lamivudine_NN ,_, including_VBG ZEFFIX_NNP and_CC 3TC_NNP ,_, totalled_VBD $_$ 183.2_CD million_CD ._.
SOLARAZE_NNP SOLARAZE_NNP is_VBZ a_DT leading_VBG topical_JJ treatment_NN for_IN In_IN July_NNP 2004_CD ,_, global_JJ research_NN ,_, development_NN and_CC actinic_JJ keratosis_NN AK_NNP which_WDT ,_, if_IN left_VBN untreated_JJ ,_, marketing_NN rights_NNS for_IN TROXATYL_NNP troxacitabine_NN could_MD lead_VB to_TO squamous_JJ cell_NN carcinoma_NN ,_, a_DT form_NN were_VBD out-licensed_JJ to_TO Structural_NNP GenomiX_NNP Inc._NNP of_IN skin_NN cancer_NN ._.
It_PRP is_VBZ marketed_VBN by_IN Shire_NNP in_IN five_CD In_IN addition_NN ,_, in_IN January_NNP 2005_CD ,_, Shire_NNP out-licensed_JJ European_JJ countries_NNS and_CC marketed_VBN in_IN another_DT its_PRP$ HIV_NNP compound_NN ,_, SPD754_NNP ,_, to_TO Avexa_NNP Limited_NNP ,_, a_DT seven_CD countries_NNS through_IN Shire_NNP distributors_NNS ._.
publicly-listed_JJ Australian_JJ specialty_NN anti-infectives_NNS SOLARAZE_NNP gel_NN offers_VBZ an_DT alternative_NN to_TO existing_VBG company_NN ._.
These_DT transactions_NNS represented_VBD some_DT treatment_NN options_NNS ,_, which_WDT may_MD cause_VB burning_NN of_IN the_DT final_JJ steps_NNS in_IN our_PRP$ divestment_NN program_NN or_CC peeling_VBG during_IN the_DT treatment_NN of_IN AK_NNP lesions_NNS ._.
designed_VBN to_TO ensure_VB focus_NN on_IN later-stage_JJ pipeline_NN It_PRP is_VBZ particularly_RB useful_JJ for_IN patients_NNS with_IN AK_NNP on_IN investment_NN in_IN our_PRP$ core_NN therapeutic_JJ areas_NNS ._.
the_DT face_NN or_CC scalp_NN ,_, where_WRB other_JJ treatments_NNS such_JJ as_IN cryotherapy_JJ freezing_NN would_MD be_VB too_RB painful_JJ Vaccines_NNS or_CC risk_VB leaving_VBG scarring_NN ._.
Shire_NNP completed_VBD the_DT sale_NN of_IN its_PRP$ vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP in_IN September_NNP CALCICHEW_NNP 2004_CD for_IN proceeds_NNS of_IN $_$ 120_CD million_CD $_$ 60_CD million_CD in_IN Shire_JJ markets_NNS the_DT CALCICHEW_NNP range_NN of_IN calcium_NN cash_NN and_CC $_$ 60_CD million_CD in_IN IDB_NNP subscription_NN receipts_NNS ._.
and_CC calcium_NN vitamin_NN D_NNP supplements_NNS in_IN the_DT UK_NNP The_NNP subscription_NN receipts_NNS were_VBD redeemed_VBN by_IN and_CC the_DT Republic_NNP of_IN Ireland_NNP as_IN adjuncts_NNS in_IN the_DT IDB_NNP for_IN $_$ 60_CD million_CD in_IN cash_NN in_IN January_NNP 2005_CD ._.
Shire_NNP treatment_NN of_IN osteoporosis_NN ,_, a_DT disease_NN characterized_VBD considers_VBZ IDB_NNP to_TO be_VB the_DT ideal_JJ company_NN to_TO take_VB by_IN a_DT progressive_JJ loss_NN of_IN bone_NN mass_NN that_WDT renders_VBZ the_DT vaccines_NNS business_NN into_IN its_PRP$ next_JJ stage_NN of_IN bone_NN fragile_JJ and_CC liable_JJ to_TO fracture_NN ._.
Shire_NNP decided_VBD to_TO exit_NN the_DT vaccines_NNS three_CD million_CD people_NNS in_IN the_DT UK_NNP are_VBP estimated_VBN to_TO business_NN ,_, because_IN it_PRP is_VBZ no_RB longer_RB core_NN to_TO our_PRP$ suffer_VBP with_IN this_DT condition_NN ._.
Osteoporosis_NNP affects_VBZ global_JJ strategy_NN of_IN focusing_VBG on_IN therapeutic_JJ both_DT sexes_NNS but_CC is_VBZ more_RBR rapid_JJ and_CC profound_JJ products_NNS meeting_VBG the_DT needs_NNS of_IN specialist_NN doctors_NNS ._.
in_IN women_NNS ,_, largely_RB as_IN a_DT result_NN of_IN the_DT decline_NN in_IN estrogen_NN production_NN following_VBG menopause_NN ._.
18_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 19_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: General_NNP products_NNS &_CC royalty_NN revenues_NNS XAGRID_NNP European_NNP launch_NN early_RB 2005_CD XAGRID_NNP anagrelide_NN hydrochloride_NN is_VBZ indicated_VBN for_IN the_DT reduction_NN of_IN elevated_JJ platelet_NN counts_NNS in_IN at-risk_JJ essential_JJ thrombocythemia_NN patients_NNS who_WP are_VBP intolerant_JJ to_TO their_PRP$ current_JJ therapy_NN or_CC whose_WP$ elevated_JJ platelet_NN counts_NNS are_VBP not_RB reduced_VBN to_TO an_DT acceptable_JJ level_NN by_IN their_PRP$ current_JJ therapy_NN 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 20_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Gastro-intestinal_JJ Gastrointestinal_NNP Greg_NNP Flexter_NNP Executive_NNP Vice_NNP President_NNP &_CC General_NNP Manager_NNP ,_, North_NNP America_NNP and_CC GI_NNP Strategic_NNP Therapeutic_NNP Area_NNP Leader_NNP 20_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 21_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Gastro-intestinal_JJ The_DT worldwide_JJ diagnosed_VBN population_NN for_IN ulcerative_JJ colitis_NN is_VBZ expected_VBN to_TO reach_VB 1.3_CD million_CD by_IN 2012_CD 21_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 22_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Gastro-intestinal_JJ The_DT gastro-intestinal_JJ GI_NNP therapeutic_JJ area_NN is_VBZ a_DT convenient_JJ and_CC less_RBR burdensome_JJ formulation_NN ,_, as_IN specialty_NN market_NN with_IN high_JJ ,_, unmet_JJ needs_NNS ._.
Its_PRP$ size_NN ,_, well_RB as_IN allowing_VBG physicians_NNS another_DT prescribing_NN in_IN terms_NNS of_IN both_DT revenue_NN and_CC the_DT number_NN of_IN option_NN ._.
Shire_NNP also_RB markets_VBZ COLAZIDE_NNP specialist_NN physicians_NNS practicing_VBG in_IN the_DT area_NN ,_, balsalazide_NN ,_, an_DT oral_JJ mesalamine_NN formulation_NN for_IN makes_NNS this_DT an_DT attractive_JJ market_NN that_IN fits_VBZ well_RB with_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS ,_, in_IN the_DT UK_NNP and_CC Shires_NNP specialty-driven_JJ model_NN ._.
We_PRP can_MD add_VB value_NN other_JJ European_JJ markets_NNS ._.
Both_DT products_NNS in_IN this_DT sector_NN by_IN using_VBG our_PRP$ particular_JJ capabilities_NNS ,_, performed_VBN according_VBG to_TO expectations_NNS in_IN 2004_CD ,_, resources_NNS and_CC expertise_NN to_TO bring_VB specialist_NN with_IN PENTASA_NNP holding_VBG a_DT 17.6_CD %_NN share_NN of_IN the_DT US_NNP projects_NNS through_IN the_DT development_NN and_CC mesalamine_NN market_NN and_CC COLAZIDE_NNP a_DT 6_CD %_NN share_NN The_DT commitment_NN to_TO patients_NNS registration_NN phases_NNS quickly_RB ._.
Our_PRP$ focused_VBN sales_NNS of_IN the_DT UK_NNP market_NN ._.
and_CC gastroenterology_NN that_WDT and_CC marketing_NN network_NN ,_, which_WDT targets_VBZ specialist_NN Shire_NNP has_VBZ demonstrated_VBN is_VBZ GI_NNP physicians_NNS ,_, is_VBZ well_RB positioned_VBN to_TO ensure_VB A_DT growing_VBG pipeline_NN :_: SPD476_CD and_CC SPD480_CD exemplary_JJ ._.
The_DT use_NN of_IN market_NN success_NN in_IN the_DT commercialization_NN phase_NN ._.
SPD476_CD ,_, a_DT novel_NN system_NN for_IN the_DT delivery_NN of_IN an_DT PENTASA_NNP in_IN patients_NNS with_IN unprecedented_JJ 1.2_CD g_NN mesalamine_NN ,_, is_VBZ in_IN Phase_NN 3_CD inflammatory_JJ bowel_NN disease_NN Shire_NNP already_RB has_VBZ a_DT long_JJ and_CC successful_JJ history_NN clinical_JJ development_NN and_CC nearing_VBG completion_NN such_JJ as_IN ulcerative_JJ colitis_NN of_IN working_VBG in_IN GI_NNP therapeutic_JJ areas_NNS with_IN PENTASA_NNP of_IN pivotal_JJ clinical_JJ trials_NNS ._.
This_DT technology_NN uses_VBZ allows_VBZ many_JJ of_IN them_PRP to_TO in_IN the_DT US_NNP and_CC COLAZIDE_NNP in_IN Europe_NNP and_CC we_PRP are_VBP a_DT proprietary_JJ system_NN for_IN targeting_VBG the_DT release_NN of_IN enjoy_VB a_DT better_JJR quality_NN of_IN life_NN ._.
planning_VBG to_TO expand_VB our_PRP$ presence_NN in_IN GI_NNP medicine_NN ._.
high_JJ concentrations_NNS of_IN mesalamine_NN throughout_IN With_IN proper_JJ management_NN The_DT establishment_NN of_IN a_DT Strategic_NNP Therapeutic_NNP the_DT length_NN of_IN the_DT colon_NN ,_, with_IN the_DT potential_JJ to_TO many_JJ patients_NNS and_CC physicians_NNS Area_NNP Team_NNP STAT_NNP dedicated_VBD to_TO this_DT segment_NN will_MD reduce_VB the_DT burden_NN for_IN ulcerative_JJ colitis_NN patients_NNS have_VBP seen_VBN lower_JJR incidence_NN enable_VB us_PRP to_TO work_VB better_JJR and_CC more_JJR collaboratively_RB of_IN having_VBG to_TO take_VB large_JJ numbers_NNS of_IN tablets_NNS ._.
Shires_NNS across_IN borders_NNS to_TO meet_VB common_JJ goals_NNS ._.
In_IN In_IN May_NNP 2002_CD Shire_NNP announced_VBD the_DT in-licensing_JJ commitment_NN to_TO research_NN addition_NN to_TO bringing_VBG a_DT more_RBR global_JJ focus_NN to_TO our_PRP$ of_IN the_DT rights_NNS to_TO this_DT technology_NN in_IN North_NNP America_NNP ,_, in_IN gastroenterology_NN will_MD product_NN strategy_NN ,_, it_PRP will_MD also_RB be_VB conducive_JJ to_TO Europe_NNP excluding_VBG Italy_NNP and_CC Japan_NNP under_IN an_DT expand_VB the_DT medical_JJ faster_JJR product_NN development_NN ,_, registration_NN and_CC agreement_NN with_IN Giuliani_NNP S._NNP p._NNP A._NN this_DT was_VBD armamentarium_NN to_TO combat_VB commercialization_NN ._.
At_IN the_DT same_JJ time_NN ,_, it_PRP will_MD extended_VBD to_TO the_DT Pacific_NNP Rim_NNP ,_, Australia_NNP and_CC New_NNP these_DT devastating_JJ diseases_NNS ._.
enable_VB Shire_NNP to_TO evaluate_VB potential_JJ GI_NNP products_NNS Zealand_NNP in_IN 2003_CD ._.
Filings_NNS for_IN regulatory_JJ approval_NN for_IN their_PRP$ multinational_JJ potential_NN more_RBR effectively_RB ._.
of_IN SPD476_NNP are_VBP scheduled_VBN to_TO be_VB made_VBN in_IN the_DT US_NNP Gary_NNP R_NNP Lichtenstein_NNP ,_, MD_NNP and_CC Europe_NNP in_IN the_DT second_JJ half_NN of_IN 2005_CD ,_, and_CC it_PRP will_MD Director_NNP Inflammatory_NNP We_PRP intend_VBP to_TO extend_VB and_CC optimize_VB new_JJ uses_NNS for_IN be_VB Shires_JJ third_JJ global_JJ product_NN after_IN FOSRENOL_NNP Bowel_NNP Disease_NNP Program_NNP our_PRP$ products_NNS through_IN the_DT STAT_NNP ,_, both_DT in_IN existing_VBG and_CC XAGRID_NNP AGRYLIN_NNP ._.
Division_NN of_IN Gastroenterology_NNP and_CC in_IN new_JJ territories_NNS and_CC to_TO build_VB a_DT truly_RB global_JJ University_NNP of_IN Pennsylvania_NNP ,_, franchise_NN in_IN this_DT promising_JJ market_NN segment_NN ._.
Although_IN mesalamine_NN is_VBZ an_DT existing_VBG and_CC wellPhiladelphia_NNP known_VBN treatment_NN for_IN ulcerative_JJ colitis_NNS ,_, we_PRP believe_VBP Ulcerative_JJ colitis_NNS :_: PENTASA_NNP and_CC COLAZIDE_NNP SPD476_NNP may_MD improve_VB its_PRP$ ease_NN of_IN use_NN by_IN being_VBG Ulcerative_JJ colitis_NN is_VBZ a_DT chronic_NN ,_, relapsing_VBG type_NN of_IN available_JJ in_IN a_DT once-daily_JJ or_CC twice-daily_JJ formulation_NN ._.
inflammatory_JJ bowel_NN disease_NN in_IN which_WDT part_NN ,_, or_CC all_DT ,_, This_DT will_MD help_VB patients_NNS adhere_VB to_TO their_PRP$ medication_NN of_IN the_DT large_JJ intestine_JJ becomes_VBZ inflamed_VBN and_CC and_CC live_VB better_JJR lives_NNS ._.
Patients_NNS experience_VBP intermittent_JJ attacks_NNS separated_VBN by_IN periods_NNS of_IN remission_NN ,_, and_CC SPD480_NNP is_VBZ a_DT rectally_RB administered_VBN mesalamine_NN can_MD suffer_VB from_IN diarrhoea_NN ,_, bleeding_VBG and_CC abdominal_JJ aerosol_NN foam_NN for_IN the_DT treatment_NN of_IN certain_JJ types_NNS pain_NN ._.
About_IN 30_CD %_NN of_IN people_NNS with_IN ulcerative_JJ colitis_NN of_IN ulcerative_JJ colitis_NNS and_CC is_VBZ also_RB in_IN the_DT advanced_JJ eventually_RB undergo_VB surgery_NN ,_, typically_RB after_IN 15_CD to_TO stages_NNS of_IN development_NN Phase_NN 2_CD ._.
This_DT formulation_NN ,_, 25_CD years_NNS of_IN disease_NN ._.
in-licensed_JJ from_IN Giuliani_NNP S._NNP p._NNP A._NN may_MD also_RB assist_VB patients_NNS to_TO adhere_VB to_TO their_PRP$ medication_NN ,_, as_IN it_PRP may_MD The_DT mainstay_NN treatment_NN for_IN inflammatory_JJ bowel_NN be_VB more_RBR acceptable_JJ and_CC easier_JJR to_TO use_VB than_IN disease_NN is_VBZ mesalamine_JJ 5-ASA_NN products_NNS ._.
Our_PRP$ leading_VBG ulcerative_JJ colitis_NN product_NN ,_, PENTASA_NNP ,_, delivers_VBZ mesalamine_NN throughout_IN the_DT small_JJ and_CC In_IN addition_NN to_TO developing_VBG SPD476_NNP and_CC SPD480_NNP ,_, large_JJ bowel_NN ._.
In_IN the_DT US_NNP ,_, Shire_NNP markets_NNS PENTASA_NNP Shire_NNP is_VBZ actively_RB evaluating_VBG a_DT variety_NN of_IN GI_NNP as_IN a_DT 250mg_JJ capsule_NN and_CC in_IN 2004_CD introduced_VBD a_DT licensing_NN and_CC acquisition_NN opportunities_NNS that_WDT will_MD 500mg_VB capsule_NN to_TO offer_VB patients_NNS a_DT more_RBR expand_VB our_PRP$ GI_NNP product_NN portfolio_NN and_CC contribute_VBP to_TO our_PRP$ future_JJ growth_NN ._.
22_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 23_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Operating_NN review_NN :_: Gastro-intestinal_JJ Shire_NNP believes_VBZ SPD476_NNP may_MD improve_VB the_DT ease_NN of_IN use_NN of_IN mesalamine_NN for_IN patients_NNS by_IN being_VBG available_JJ in_IN a_DT once-daily_JJ or_CC twice-daily_JJ formulation_NN With_IN symptoms_NNS under_IN control_NN ,_, I_PRP can_MD get_VB on_IN with_IN my_PRP$ life_NN ._.
PENTASA_NNP mesalamine_NN is_VBZ indicated_VBN for_IN the_DT induction_NN of_IN remission_NN and_CC treatment_NN of_IN patients_NNS with_IN mild_JJ to_TO moderately_RB active_JJ ulcerative_JJ colitis_NN ,_, using_VBG a_DT unique_JJ delivery_NN mechanism_NN 23_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 24_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN Our_PRP$ business_NN touches_NNS many_JJ peoples_NNS lives_VBZ Our_PRP$ business_NN touches_NNS many_JJ peoples_NNS lives_NNS :_: Customer_NN focus_NN our_PRP$ employees_NNS ,_, our_PRP$ shareholders_NNS ,_, the_DT physicians_NNS We_PRP are_VBP customer_NN driven_VBN ,_, focusing_VBG on_IN quality_NN who_WP prescribe_VBP our_PRP$ products_NNS and_CC most_RBS importantly_RB and_CC the_DT needs_NNS of_IN both_DT the_DT internal_JJ and_CC external_JJ the_DT patients_NNS whose_WP$ lives_NNS benefit_VBP from_IN Shires_NNP customer_NN ._.
Global_JJ teamwork_NN As_IN a_DT corporation_NN ,_, we_PRP work_VBP with_IN many_JJ suppliers_NNS We_PRP achieve_VB better_JJR outcomes_NNS as_IN a_DT team_NN ._.
who_WP provide_VBP invaluable_JJ services_NNS that_WDT enable_VBP us_PRP The_DT entire_JJ company_NN is_VBZ focused_VBN on_IN growing_VBG our_PRP$ to_TO complete_VB our_PRP$ day_NN to_TO day_NN tasks_NNS and_CC we_PRP have_VBP business_NN and_CC executing_VBG our_PRP$ strategy_NN as_IN a_DT team_NN ._.
operations_NNS in_IN communities_NNS where_WRB it_PRP is_VBZ important_JJ to_TO us_PRP to_TO be_VB respected_VBN and_CC recognized_VBN ._.
Openness_NN and_CC innovation_NN We_PRP believe_VBP that_IN anything_NN is_VBZ possible_JJ and_CC that_IN We_PRP know_VBP that_IN maintaining_VBG trust_NN among_IN the_DT prudent_JJ risks_NNS are_VBP worth_JJ taking_VBG ._.
people_NNS and_CC communities_NNS in_IN which_WDT we_PRP operate_VBP is_VBZ essential_JJ to_TO the_DT success_NN and_CC sustainability_NN Excellence_NN in_IN execution_NN of_IN Shire_NNP as_IN a_DT whole_NN ._.
Personal_JJ ownership_NN and_CC great_JJ processes_NNS lead_VBP to_TO excellence_NN in_IN decision-making_NN and_CC execution_NN ._.
This_DT is_VBZ what_WP Corporate_NNP Social_NNP Responsibility_NNP CSR_NNP means_VBZ to_TO us_PRP ._.
These_DT values_NNS guide_VBP our_PRP$ daily_JJ behaviors_NNS and_CC serve_VB as_IN principles_NNS for_IN our_PRP$ approach_NN to_TO CSR_NNP ._.
As_IN a_DT leading_VBG healthcare_NN provider_NN ,_, we_PRP recognize_VBP our_PRP$ responsibilities_NNS to_TO the_DT people_NNS who_WP depend_VBP The_DT CSR_NNP Committee_NNP on_IN our_PRP$ products_NNS and_CC to_TO the_DT communities_NNS in_IN which_WDT The_DT Shire_NNP CSR_NNP Committee_NNP the_DT Committee_NNP we_PRP operate_VBP ._.
We_PRP are_VBP and_CC will_MD remain_VB committed_JJ continues_VBZ to_TO steer_VB and_CC monitor_VB the_DT Companys_NNPS to_TO sound_VB CSR_NNP principles_NNS and_CC practices_NNS ._.
overall_JJ approach_NN to_TO CSR_NNP in_IN line_NN with_IN the_DT agreed_JJ policy_NN that_WDT is_VBZ available_JJ on_IN the_DT Shire_NNP website_NN ._.
We_PRP are_VBP again_RB producing_VBG a_DT stand-alone_JJ CSR_NNP report_NN that_WDT will_MD provide_VB more_JJR detail_NN of_IN the_DT Chaired_VBN by_IN Chief_NNP Financial_NNP Officer_NNP Angus_NNP Russell_NNP ,_, social_JJ and_CC environmental_JJ activities_NNS that_WDT were_VBD the_DT Committee_NNP comprises_VBZ individuals_NNS whose_WP$ daily_JJ undertaken_VBN during_IN 2004_CD this_DT will_MD be_VB available_JJ responsibilities_NNS involve_VBP leadership_NN or_CC management_NN as_IN a_DT printed_VBN report_NN as_RB well_RB as_IN online_NN from_IN our_PRP$ of_IN functions_NNS that_WDT can_MD have_VB significant_JJ impact_NN on_IN website_NN later_RB in_IN the_DT year_NN ._.
implementation_NN of_IN our_PRP$ CSR_NNP policy_NN ._.
Shire_NNP values_VBZ During_IN the_DT year_NN ,_, Shire_NNP established_VBD several_JJ At_IN the_DT core_NN of_IN our_PRP$ approach_NN to_TO CSR_NNP are_VBP our_PRP$ new_JJ global_JJ functions_NNS and_CC the_DT CSR_NNP Committee_NNP ,_, values_NNS ._.
During_IN 2004_CD we_PRP undertook_VBD an_DT exercise_NN recognizing_VBG that_IN some_DT of_IN these_DT functions_NNS were_VBD We_PRP know_VBP that_IN maintaining_VBG to_TO restate_VB and_CC update_VB these_DT values_NNS ,_, in_IN line_NN highly_RB relevant_JJ to_TO CSR_NNP ,_, invited_VBD the_DT heads_NNS of_IN trust_NN among_IN the_DT people_NNS and_CC with_IN our_PRP$ global_JJ restructuring_NN and_CC new_JJ strategic_JJ these_DT new_JJ functions_NNS to_TO join_VB the_DT Committee_NNP ._.
communities_NNS in_IN which_WDT we_PRP focus_VBP ._.
In_IN consultation_NN with_IN groups_NNS of_IN employees_NNS These_DT included_VBN global_JJ human_JJ resources_NNS ,_, facilities_NNS operate_VBP is_VBZ essential_JJ to_TO the_DT from_IN all_DT parts_NNS of_IN the_DT business_NN ,_, we_PRP agreed_VBD and_CC management_NN ,_, environment_NN and_CC occupational_JJ success_NN and_CC sustainability_NN adapted_VBD new_JJ descriptions_NNS for_IN our_PRP$ values_NNS with_IN health_NN and_CC safety_NN EHS_NNP ._.
Shires_NNP divestment_NN of_IN of_IN Shire_NNP as_IN a_DT whole_JJ an_DT emphasis_NN on_IN teamwork_NN and_CC global_JJ working_NN ._.
its_PRP$ vaccines_NNS business_NN and_CC internal_JJ restructuring_NN meant_VBD that_IN two_CD prior_JJ members_NNS of_IN the_DT Committee_NNP Integrity_NNP and_CC respect_NN were_VBD no_RB longer_JJR Shire_NNP employees_NNS ._.
Relationships_NNPS are_VBP the_DT foundation_NN of_IN our_PRP$ business_NN ._.
They_PRP are_VBP based_VBN on_IN unwavering_VBG ethics_NNS and_CC The_DT Committee_NNP met_VBD three_CD times_NNS in_IN 2004_CD ._.
As_IN an_DT respect_NN for_IN individuals_NNS ._.
Executive_NNP Committee_NNP and_CC Board_NNP Member_NNP ,_, Angus_NNP Russell_NNP reports_VBZ matters_NNS of_IN CSR_NNP relevance_NN to_TO both_DT the_DT Executive_NNP Committee_NNP and_CC the_DT Board_NNP and_CC offers_VBZ guidance_NN and_CC where_WRB necessary_JJ ,_, detailed_JJ briefings_NNS to_TO Board_NNP members_NNS ._.
24_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 25_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN The_DT Committees_NNS main_JJ responsibilities_NNS are_VBP to_TO :_: facilitate_VB an_DT effective_JJ and_CC cross-functional_JJ implementation_NN of_IN Shires_NNP CSR_NNP policy_NN :_: advise_VB and_CC inform_VB the_DT Board_NNP on_IN business_NN risks_NNS related_VBN to_TO Social_NNP ,_, Environmental_NNP and_CC Ethical_NNP SEE_VBP matters_NNS :_: evaluate_VB Shires_NNP compliance_NN with_IN and_CC the_DT continuing_VBG appropriateness_NN of_IN the_DT Companys_NNPS CSR_NNP policy_NN :_: and_CC review_NN and_CC approve_VB Shires_NNP CSR_NNP disclosures_NNS ._.
CSR_NNP risk_NN During_IN 2004_CD ,_, the_DT CSR_NNP Committee_NNP initiated_VBD a_DT review_NN of_IN the_DT Companys_NNP approach_NN to_TO identifying_VBG ,_, assessing_VBG and_CC mitigating_VBG CSR-related_JJ risks_NNS ._.
The_DT main_JJ purposes_NNS were_VBD to_TO continue_VB enhancing_VBG practices_NNS and_CC performance_NN and_CC further_JJ embedding_VBG the_DT processes_NNS within_IN Shires_NNP risk_NN management_NN framework_NN ._.
All-employee_JJ meetings_NNS have_VBP The_DT exercise_NN is_VBZ underway_JJ with_IN input_NN from_IN external_JJ specialist_NN consultants_NNS ._.
The_DT CSR_NNP Committee_NNP will_MD taken_VBN place_NN at_IN our_PRP$ major_JJ sites_NNS report_VBP to_TO the_DT Board_NNP and_CC Executive_NNP Committee_NNP on_IN with_IN the_DT chief_JJ executive_NN officer_NN this_DT in_IN 2005_CD ._.
and_CC executive_JJ committee_NN members_NNS leading_VBG each_DT meeting_NN Engagement_NNP with_IN stakeholders_NNS In_IN 2004_CD employee_NN communications_NNS received_VBD a_DT new_JJ emphasis_NN in_IN order_NN to_TO help_VB facilitate_VB Shires_NNP internal_JJ restructuring_NN ._.
All-employee_JJ meetings_NNS have_VBP taken_VBN place_NN at_IN our_PRP$ major_JJ sites_NNS with_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC members_NNS of_IN the_DT Executive_NNP Committee_NNP leading_VBG each_DT meeting_NN ._.
In_IN addition_NN ,_, global_JJ teleconferences_NNS have_VBP taken_VBN place_NN each_DT quarter_NN with_IN the_DT Companys_NNPS top_JJ 150_CD managers_NNS where_WRB business_NN issues_NNS are_VBP discussed_VBN and_CC executive_JJ management_NN share_VB their_PRP$ views_NNS on_IN progress_NN and_CC achievements_NNS ._.
Global_JJ emails_NNS have_VBP been_VBN issued_VBN regularly_RB and_CC face-to-face_RB dialogue_NN has_VBZ been_VBN encouraged_VBN with_IN line_NN managers_NNS ._.
We_PRP have_VBP also_RB produced_VBN two_CD new_JJ Shire_NNP videos_NNS articulating_VBG our_PRP$ global_JJ One_CD Shire_JJ culture_NN and_CC focus_NN during_IN the_DT year_NN ._.
25_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 26_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN Divesting_VBG our_PRP$ vaccines_NNS business_NN was_VBD a_DT key_JJ part_NN Some_DT of_IN the_DT patient_JJ groups_NNS that_IN we_PRP have_VBP of_IN Shires_NNP new_JJ business_NN strategy_NN ._.
All_DT employees_NNS supported_VBN and_CC or_CC had_VBD regular_JJ dialogue_NN with_IN of_IN the_DT vaccines_NNS business_NN were_VBD offered_VBN during_IN 2004_CD include_VBP :_: employment_NN with_IN the_DT new_JJ owner_NN ,_, ID_NNP Biomedical_NNP Corporation_NNP and_CC many_JJ have_VBP bright_JJ and_CC CHADD_NNP ,_, CADDRA_NNP ,_, Alzheimers_NNP Society_NNP ,_, attractive_JJ careers_NNS ahead_RB with_IN a_DT new_JJ focused_JJ Marie_NNP Curie_NNP ,_, National_NNP Osteoporosis_NNP Society_NNP ,_, and_CC committed_JJ owner_NN whose_WP$ core_NN business_NN Crohns_NNP Society_NNP ,_, Crohns_NNP and_CC Colitis_NNP Foundation_NNP is_VBZ the_DT development_NN of_IN vaccines_NNS ._.
of_IN America_NNP ,_, Susan_NNP G_NNP Komen_NNP BreastCancer_NNP Foundation_NNP ,_, American_NNP College_NNP of_IN Patients_NNPS are_VBP the_DT ultimate_JJ Shareholders_NNS have_VBP been_VBN kept_VBN informed_VBN of_IN Shires_NNP Gastroenterology_NNP ,_, Epilepsy_NNP Foundation_NNP of_IN beneficiaries_NNS of_IN Shires_NNP performance_NN through_IN regular_JJ communications_NNS America_NNP and_CC the_DT National_NNP Kidney_NNP Foundation_NNP ._.
It_PRP is_VBZ knowing_VBG that_DT and_CC disclosures_NNS ._.
Senior_JJ management_NN has_VBZ also_RB medicines_NNS have_VBP an_DT impact_NN on_IN regularly_RB presented_VBN at_IN investor_NN conferences_NNS and_CC As_IN a_DT global_JJ business_NN ,_, we_PRP work_VBP with_IN many_JJ patients_NNS lives_VBZ that_IN motivates_VBZ engaged_VBN in_IN face-to-face_JJ meetings_NNS ._.
These_DT relationships_NNS are_VBP important_JJ to_TO many_JJ of_IN Shires_NNP employees_NNS us_PRP and_CC the_DT appointment_NN of_IN a_DT new_JJ Global_JJ Head_NNP of_IN The_DT establishment_NN of_IN our_PRP$ new_JJ US_NNP headquarters_NN Procurement_NNP in_IN 2004_CD will_MD enable_VB us_PRP to_TO introduce_VB a_DT in_IN Philadelphia_NNP was_VBD a_DT major_JJ focus_NN in_IN 2004_CD ._.
more_RBR disciplined_JJ approach_NN to_TO this_DT important_JJ area_NN ._.
We_PRP have_VBP become_VBN members_NNS of_IN the_DT Philadelphia_NNP Chamber_NNP of_IN Commerce_NNP and_CC have_VBP engaged_VBN in_IN CSR_NNP objectives_NNS a_DT varied_JJ series_NN of_IN activities_NNS in_IN the_DT Philadelphia_NNP The_NNP Committee_NNP set_VBD specific_JJ CSR_NNP objectives_NNS in_IN community_NN where_WRB we_PRP were_VBD seeking_VBG to_TO attract_VB 2004_CD and_CC we_PRP will_MD report_VB on_IN them_PRP in_IN full_JJ in_IN our_PRP$ full_JJ new_JJ employees_NNS and_CC establish_VB our_PRP$ presence_NN CSR_NNP report_NN ._.
To_TO summarize_VB ,_, the_DT areas_NNS of_IN focus_NN and_CC reputation_NN ._.
A_DT full_JJ report_NN of_IN all_PDT these_DT initiatives_NNS in_IN 2004_CD in_IN each_DT of_IN the_DT Companys_NNPS key_JJ impact_NN will_MD be_VB found_VBN in_IN the_DT 2004_CD CSR_NNP report_NN ._.
areas_NNS were_VBD as_IN follows_VBZ :_: Specialist_NN doctors_NNS are_VBP our_PRP$ key_JJ customers_NNS and_CC Workplace_NNP we_PRP focus_VBP intently_RB on_IN the_DT development_NN of_IN strong_JJ Living_VBG up_RP to_TO what_WP we_PRP believe_VBP in_IN :_: encouraging_JJ relationships_NNS with_IN them_PRP through_IN the_DT provision_NN the_DT widest_JJS possible_JJ diversity_NN in_IN our_PRP$ workplace_NN :_: of_IN data_NNS and_CC information_NN on_IN the_DT therapeutic_JJ areas_NNS giving_VBG people_NNS the_DT chance_NN to_TO develop_VB their_PRP$ in_IN which_WDT we_PRP specialize_VBP ._.
Patients_NNS are_VBP the_DT ultimate_JJ beneficiaries_NNS of_IN Shires_NNP Example_NNP :_: new_JJ performance_NN management_NN business_NN ._.
It_PRP is_VBZ knowing_VBG that_IN medicines_NNS have_VBP system_NN introduced_VBN with_IN Shires_NNP corporate_JJ values_NNS an_DT impact_NN on_IN patients_NNS lives_VBZ that_IN motivates_VBZ many_JJ as_IN a_DT performance_NN measure_NN ._.
We_PRP have_VBP continued_VBN a_DT strong_JJ dialogue_NN with_IN the_DT patient_JJ groups_NNS and_CC Marketplace_NNP key_JJ opinion_NN leaders_NNS who_WP lead_VBP and_CC influence_VBP the_DT Helping_VBG to_TO educate_VB patients_NNS and_CC health_NN therapeutic_JJ areas_NNS in_IN which_WDT we_PRP have_VBP products_NNS ._.
professionals_NNS about_IN the_DT treatments_NNS we_PRP make_VBP and_CC the_DT diseases_NNS in_IN which_WDT we_PRP specialize_VBP :_: providing_VBG medicines_NNS for_IN those_DT who_WP can_MD not_RB afford_VB them_PRP :_: making_VBG sure_JJ our_PRP$ marketing_NN and_CC selling_NN is_VBZ done_VBN in_IN an_DT ethical_JJ and_CC appropriate_JJ way_NN ._.
Example_NN :_: Shire_NNP participated_VBD in_IN the_DT American_NNP Society_NNP of_IN Nephrology_NNP ASN_NNP Conference_NNP ,_, held_VBN in_IN St_NNP Louis_NNP ,_, Missouri_NNP ,_, USA_NNP ,_, from_IN October_NNP 29_CD until_IN November_NNP 1_CD ,_, 2004_CD in_IN advance_NN of_IN FOSRENOL_NNP launch_NN 26_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 27_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN CSR_NNP :_: Corporate_NNP social_JJ responsibility_NN We_PRP are_VBP pleased_VBN with_IN the_DT steady_JJ progress_NN we_PRP are_VBP making_VBG with_IN our_PRP$ approach_NN to_TO CSR_NNP Community_NNP Shire_NNP completed_VBD a_DT return_NN for_IN The_DT Giving_NNP List_NN ,_, Getting_VBG involved_VBN with_IN our_PRP$ local_JJ communities_NNS :_: published_VBN by_IN The_DT Guardian_NNP newspaper_NN and_CC talking_VBG more_RBR about_IN our_PRP$ community_NN activities_NNS was_VBD ranked_VBN broadly_RB in_IN line_NN with_IN its_PRP$ position_NN in_IN inside_IN the_DT Company_NN :_: collecting_VBG all_PDT the_DT information_NN the_DT FTSE_NNP 100_CD ._.
Shire_NNP is_VBZ taking_VBG part_NN in_IN the_DT London_NNP about_IN our_PRP$ community_NN involvement_NN in_IN one_CD place_NN ._.
Stock_NNP Exchanges_NNP pilot_NN online_NN CSR_NNP Index_NNP this_DT database_NN will_MD enable_VB the_DT Company_NN to_TO monitor_VB Examples_NNS :_: Sponsorship_NN of_IN Franklin_NNP Institute_NNP and_CC track_VB data_NNS gathered_VBN from_IN across_IN the_DT Shire_NNP Day_NNP free_JJ entrance_NN for_IN children_NNS :_: organization_NN in_IN order_NN to_TO provide_VB information_NN on_IN participation_NN by_IN CSR_NNP Chairman_NNP in_IN the_DT Business_NN a_DT more_RBR regular_JJ basis_NN to_TO the_DT numerous_JJ external_JJ in_IN the_DT Communitys_NNPS BITCs_NNP Seeing_VBG is_VBZ Believing_VBG researchers_NNS and_CC assessors_NNS who_WP contact_VBP the_DT program_NN and_CC subsequent_JJ donation_NN to_TO the_DT company_NN with_IN CSR_NNP questionnaires_NNS ._.
Kids_NNP Company_NNP ,_, a_DT charitable_JJ organization_NN that_WDT provides_VBZ refuge_NN and_CC help_NN for_IN children_NNS whose_WP$ Looking_VBG ahead_RB young_JJ lives_NNS have_VBP been_VBN blighted_JJ by_IN fear_NN ,_, violence_NN We_PRP are_VBP pleased_VBN with_IN the_DT steady_JJ progress_NN and_CC neglect_NN ._.
we_PRP are_VBP making_VBG with_IN our_PRP$ approach_NN to_TO CSR_NNP and_CC how_WRB we_PRP are_VBP gaining_VBG more_JJR recognition_NN for_IN our_PRP$ Environment_NNP initiatives_NNS following_VBG the_DT issue_NN of_IN our_PRP$ first_JJ CSR_NNP Integrating_VBG a_DT single_JJ Environmental_NNP Health_NNP &_CC Safety_NNP Report_NNP for_IN 2003_CD ._.
Shire_NNP is_VBZ committed_VBN to_TO CSR_NNP but_CC Community_NNP :_: Getting_VBG involved_JJ management_NN system_NN across_IN the_DT Company_NN not_RB complacent_JJ we_PRP are_VBP aware_JJ that_IN there_EX are_VBP with_IN our_PRP$ local_JJ communities_NNS :_: globally_RB :_: encouraging_JJ suppliers_NNS to_TO improve_VB their_PRP$ many_JJ ways_NNS in_IN which_WDT we_PRP can_MD improve_VB or_CC talking_VBG more_RBR about_IN our_PRP$ Health_NNP &_CC Safety_NNP practices_NNS :_: developing_VBG practical_JJ enhance_VB our_PRP$ activities_NNS ._.
community_NN activities_NNS inside_IN guidelines_NNS for_IN our_PRP$ offices_NNS ._.
the_DT Company_NN :_: collecting_VBG We_PRP welcome_JJ feedback_NN and_CC suggestions_NNS and_CC all_PDT the_DT information_NN about_IN Example_NNP :_: Appointment_NN of_IN a_DT Global_JJ Head_NNP of_IN will_MD be_VB happy_JJ to_TO receive_VB emails_NNS to_TO our_PRP$ dedicated_VBN our_PRP$ community_NN involvement_NN Environment_NNP ,_, Health_NNP &_CC Safety_NNP EHS_NNP :_: creation_NN address_NN :_: CSR@shire_NNP ._.
com_NN in_IN one_CD place_NN of_IN EHS_NNP principles_NNS as_IN part_NN of_IN a_DT Mission_NNP Statement_NNP for_IN distribution_NN to_TO Shire_NNP employees_NNS and_CC suppliers_NNS :_: establishment_NN of_IN a_DT global_JJ EHS_NNP network_NN amongst_IN suppliers_NNS to_TO ascertain_VB and_CC implement_VB best_JJS practices_NNS ._.
CSR_NNP indices_VBZ Shire_NNP continues_VBZ to_TO be_VB a_DT constituent_NN of_IN the_DT FTSE4Good_NNP Index_NNP despite_IN the_DT introduction_NN of_IN tougher_JJR criteria_NNS in_IN 2004_CD ._.
The_DT Company_NN has_VBZ taken_VBN part_NN ,_, for_IN the_DT second_JJ year_NN running_VBG ,_, in_IN the_DT BITC_NNP Corporate_NNP Responsibility_NNP Index_NNP ._.
Feedback_NNP ,_, following_VBG BITCs_NNP assessment_NN of_IN Shire_NNP in_IN 2003_CD ,_, has_VBZ been_VBN taken_VBN into_IN account_NN and_CC led_VBD to_TO an_DT increased_VBN focus_NN on_IN training_NN and_CC internal_JJ Guardian_NNP awareness_NN programs_NNS for_IN Shire_NNP employees_NNS Giving_NNP List_NN during_IN 2004_CD and_CC beyond_IN ._.
27_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 28_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN The_DT following_VBG review_NN should_MD be_VB read_VBN in_IN conjunction_NN with_IN the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS and_CC related_JJ notes_NNS appearing_VBG elsewhere_RB in_IN this_DT annual_JJ review_NN Results_NNS of_IN operations_NNS ADDERALL_NNP XR_NNP The_NNP Company_NNP in_IN this_DT Financial_JJ review_NN meaning_NN Sales_NNS of_IN ADDERALL_NNP XR_NNP for_IN the_DT year_NN to_TO December_NNP the_DT consolidated_JJ group_NN recorded_VBD net_JJ income_NN of_IN 31_CD ,_, 2004_CD were_VBD $_$ 606.7_CD million_CD ,_, an_DT increase_NN of_IN 28_CD %_NN $_$ 269.0_CD million_CD 2003_CD :_: $_$ 276.1_CD million_CD and_CC diluted_VBN compared_VBN to_TO prior_JJ year_NN 2003_CD :_: $_$ 474.5_CD million_CD ._.
earnings_NNS per_IN ordinary_JJ share_NN of_IN 53.3_CD 2003_CD :_: ADDERALL_NNP XR_NNP held_VBD a_DT 25_CD %_NN share_NN of_IN the_DT total_JJ 54.2_CD ._.
Net_JJ income_NN for_IN 2004_CD was_VBD impacted_VBN US_NNP ADHD_NNP market_NN in_IN December_NNP 2004_CD December_NNP by_IN both_DT the_DT loss_NN on_IN disposal_NN of_IN the_DT vaccines_NNS 2003_CD :_: 23_CD %_NN and_CC at_IN that_DT date_NN was_VBD the_DT leading_VBG business_NN of_IN $_$ 44.2_CD million_CD and_CC the_DT $_$ 48.5_CD million_CD brand_NN in_IN the_DT US_NNP ADHD_NNP market_NN ._.
As_IN previously_RB of_IN reorganization_NN costs_NNS recorded_VBN in_IN 2004_CD ._.
disclosed_VBN ,_, legal_JJ proceedings_NNS relating_VBG to_TO generic_JJ competitors_NNS seeking_VBG to_TO market_NN generic_JJ versions_NNS Total_JJ revenues_NNS of_IN ADDERALL_NNP XR_NNP are_VBP in_IN progress_NN ._.
Further_JJ For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, total_JJ information_NN can_MD be_VB found_VBN in_IN Note_NN 20_CD to_TO the_DT revenues_NNS increased_VBN by_IN 13_CD %_NN to_TO $_$ 1,363.2_CD million_CD consolidated_JJ financial_JJ statements_NNS ._.
Although_IN Angus_NNP Russell_NNP compared_VBD to_TO $_$ 1,211.6_CD million_CD in_IN 2003_CD ._.
Shire_NNP rigorously_RB defends_VBZ its_PRP$ patent_NN rights_NNS Chief_NNP Financial_NNP Officer_NNP against_IN generic_JJ and_CC other_JJ challenges_NNS ,_, the_DT loss_NN Revenue_NN is_VBZ primarily_RB derived_VBN from_IN sales_NNS of_IN or_CC expiration_NN of_IN patent_NN protection_NN on_IN this_DT product_NN pharmaceutical_JJ products_NNS and_CC royalties_NNS earned_VBN could_MD have_VB a_DT material_NN adverse_JJ effect_NN on_IN Shires_NNP on_IN products_NNS out-licensed_JJ to_TO third_JJ parties_NNS ._.
financial_JJ condition_NN and_CC results_NNS of_IN operations_NNS ._.
For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, 82_CD %_NN of_IN revenues_NNS were_VBD in_IN respect_NN of_IN pharmaceutical_JJ AGRYLIN_NNP product_NN sales_NNS 2003_CD :_: 83_CD %_NN ._.
Royalties_NNS comprised_VBD Sales_NNS of_IN AGRYLIN_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 17_CD %_NN of_IN total_JJ revenues_NNS in_IN both_DT 2003_CD and_CC 2004_CD ._.
2004_CD were_VBD $_$ 152.5_CD million_CD ,_, an_DT increase_NN of_IN 15_CD %_NN Income_NN from_IN out-licensing_JJ product_NN rights_NNS compared_VBN to_TO the_DT prior_JJ year_NN 2003_CD :_: $_$ 132.5_CD million_CD ._.
has_VBZ increased_VBN slightly_RB as_IN a_DT proportion_NN of_IN US_NNP sales_NNS were_VBD up_RB 13_CD %_NN in_IN the_DT year_NN and_CC AGRYLIN_NNP revenues_NNS and_CC represented_VBD 1_CD %_NN of_IN revenues_NNS had_VBD a_DT 28_CD %_NN share_NN of_IN the_DT total_JJ US_NNP AGRYLIN_NNP ,_, in_IN 2004_CD ._.
hydrea_NN and_CC generic_JJ hydroxyurea_NN prescription_NN market_NN in_IN December_NNP 2004_CD December_NNP 2003_CD :_: 27_CD %_NN ._.
a_DT Product_NNP sales_NNS For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, the_DT US_NNP pediatric_JJ exclusivity_NN expired_VBD in_IN September_NNP Companys_NNP product_NN sales_NNS increased_VBN by_IN 11_CD %_NN 2004_CD and_CC in_IN August_NNP 2004_CD Shire_NNP filed_VBD a_DT Citizens_NNPS to_TO $_$ 1,112.5_CD million_CD compared_VBN to_TO $_$ 1,004.3_CD million_CD Petition_NN with_IN the_DT FDA_NNP ._.
Shire_NNP has_VBZ petitioned_VBN that_IN in_IN the_DT prior_JJ year_NN ._.
The_DT main_JJ products_NNS driving_VBG this_DT any_DT generic_JJ anagrelide_NN product_NN should_MD be_VB growth_NN are_VBP shown_VBN in_IN the_DT table_NN below_IN :_: demonstrated_VBD to_TO be_VB bio-equivalent_JJ to_TO AGRYLIN_NNP ._.
Product_NN highlights_VBZ 1_CD ,_, 2_CD SalesSales_NNS US_NNP Rx_NNP US_NNP market_NN 1_CD 2_CD Product_NNP $_$ million_CD growth_NN growth_NN share_NN ADDERALL_NNP XR_NNP 606.7_CD 28_CD %_NN 21_CD %_NN 25_CD %_NN AGRYLIN_NNP US_NNP market_NN 105.7_CD 13_CD %_NN 6_CD %_NN 28_CD %_NN AGRYLIN_NNP International_NNP market_NN 46.8_CD 20_CD %_NN n_VBD a_DT n_NN a_DT PENTASA_NNP 115.0_CD 16_CD %_NN 2_CD %_NN 18_CD %_NN CARBATROL_NNP 54.3_CD 4_CD %_NN 11_CD %_NN 46_CD %_NN 1_CD Compared_VBN to_TO 2003_CD ._.
2_CD IMS_NNP Prescription_NNP Data_NNP Product_NNP specific_NN at_IN December_NNP 31_CD ,_, 2004_CD IMS_NNP Health_NNP is_VBZ a_DT leading_VBG global_JJ provider_NN of_IN business_NN intelligence_NN for_IN the_DT pharmaceutical_JJ and_CC healthcare_NN industries_NNS ._.
28_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 29_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN The_DT Company_NN is_VBZ anticipating_VBG the_DT launch_NN of_IN with_IN the_DT exception_NN of_IN the_DT UK_NNP and_CC the_DT Republic_NNP generic_JJ versions_NNS of_IN AGRYLIN_NNP in_IN the_DT US_NNP market_NN of_IN Ireland_NNP where_WRB Shire_NNP acquired_VBD the_DT exclusive_JJ but_CC no_DT generic_JJ products_NNS have_VBP come_VBN to_TO market_NN marketing_NN rights_NNS in_IN May_NNP 2004_CD ._.
to_TO date_NN ._.
The_DT launch_NN of_IN generic_JJ versions_NNS of_IN AGRYLIN_NNP may_MD negatively_RB affect_VB the_DT sales_NNS Cost_NN of_IN sales_NNS and_CC net_JJ operating_NN expenses_NNS of_IN AGRYLIN_NNP in_IN the_DT future_NN ._.
For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, the_DT cost_NN of_IN product_NN sales_NNS amounted_VBD to_TO 13_CD %_NN of_IN product_NN sales_NNS International_NNP sales_NNS all_DT sales_NNS outside_IN of_IN the_DT US_NNP 2003_CD :_: 14_CD %_NN ._.
The_DT decrease_NN can_MD be_VB attributed_VBN to_TO reported_VBN in_IN US_NNP dollars_NNS were_VBD up_RB 20_CD %_NN ,_, due_JJ to_TO product_NN mix_NN ,_, with_IN a_DT greater_JJR proportion_NN of_IN sales_NNS strong_JJ growth_NN in_IN Canadian_JJ and_CC European_JJ coming_VBG from_IN higher_JJR margin_NN products_NNS ._.
markets_NNS and_CC ,_, because_IN these_DT sales_NNS revenues_NNS are_VBP earned_VBN in_IN currencies_NNS other_JJ than_IN the_DT US_NNP dollar_NN ,_, R&D_NNP expenditure_NN increased_VBD from_IN $_$ 187.7_CD million_CD the_DT benefit_NN of_IN favorable_JJ translation_NN effects_NNS ._.
Sales_NNS in_IN 2003_CD to_TO $_$ 196.3_CD million_CD in_IN 2004_CD ,_, with_IN savings_NNS outside_IN the_DT US_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, from_IN the_DT closure_NN of_IN the_DT Canada-based_JJ Lead_JJ 2004_CD were_VBD $_$ 46.8_CD million_CD 2003_CD :_: $_$ 38.9_CD million_CD ._.
Optimization_NN business_NN in_IN 2003_CD partially_RB reinvested_VBN to_TO fund_VB late_JJ stage_NN Phase_NN 3_CD trials_NNS ._.
Shires_NNP AGRYLIN_NNP gained_VBD EU_NNP approval_NN in_IN November_NNP pipeline_NN is_VBZ now_RB well_RB advanced_VBN with_IN four_CD projects_NNS 2004_CD and_CC trades_VBZ under_IN the_DT name_NN XAGRID_NNP ._.
in_IN late_JJ stage_NN development_NN or_CC registration_NN ._.
In_IN The_DT product_NN will_MD have_VB up_RP to_TO ten_VB years_NNS market_NN addition_NN ,_, five_CD projects_NNS were_VBD approved_VBN during_IN the_DT exclusivity_NN in_IN accordance_NN with_IN current_JJ orphan_JJ second_JJ half_NN of_IN 2004_CD ._.
Expressed_VBN as_IN a_DT percentage_NN medicinal_JJ product_NN legislation_NN in_IN the_DT EU_NNP ._.
of_IN total_JJ revenues_NNS ,_, R&D_NNP expenditure_NN was_VBD 14_CD %_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD 2003_CD :_: 15_CD %_NN ._.
PENTASA_NNP Shire_NNP has_VBZ historically_RB invested_VBN between_IN 17-20_CD %_NN Sales_NNS of_IN PENTASA_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, of_IN revenues_NNS in_IN R&D_NNP ._.
With_IN the_DT refocusing_NN of_IN the_DT 2004_CD were_VBD $_$ 115.0_CD million_CD ,_, an_DT increase_NN of_IN 16_CD %_NN project_NN pipeline_NN this_DT year_NN and_CC the_DT successful_JJ compared_VBN to_TO prior_JJ year_NN 2003_CD :_: $_$ 99.3_CD million_CD ._.
out-licensing_NN of_IN certain_JJ products_NNS ,_, this_DT percentage_NN PENTASA_NNP had_VBD an_DT 18_CD %_NN share_NN of_IN the_DT total_JJ US_NNP oral_JJ fell_VBD in_IN 2004_CD ._.
Shire_NNP anticipates_VBZ that_IN the_DT level_NN of_IN mesalamine_NN olsalazine_NN prescription_NN market_NN in_IN R&D_NNP spend_VBP will_MD be_VB approximately_RB 15_CD %_NN excluding_VBG December_NNP 2004_CD December_NNP 2003_CD :_: 18_CD %_NN ._.
the_DT impact_NN of_IN payments_NNS relating_VBG to_TO NRP104_NNP going_VBG forward_RB ._.
CARBATROL_NNP Sales_NNS of_IN CARBATROL_NNP for_IN the_DT year_NN to_TO December_NNP Selling_NNP ,_, general_JJ and_CC administrative_JJ SG&A_NNP 31_CD ,_, 2004_CD were_VBD $_$ 54.3_CD million_CD ,_, an_DT increase_NN of_IN 4_CD %_NN expenses_NNS increased_VBD from_IN $_$ 409.7_CD million_CD in_IN 2003_CD compared_VBN to_TO prior_JJ year_NN 2003_CD :_: $_$ 52.4_CD million_CD ._.
CARBATROL_NNP had_VBD a_DT 46_CD %_NN share_NN of_IN the_DT total_JJ US_NNP This_DT is_VBZ primarily_RB due_JJ to_TO an_DT increase_NN in_IN marketing_NN extended_VBN release_NN carbamazepine_NN prescription_NN expenses_NNS ,_, related_VBN to_TO new_JJ product_NN launches_NNS market_NN in_IN December_NNP 2004_CD December_NNP 2003_CD :_: including_VBG FOSRENOL_NNP ,_, XAGRID_NNP and_CC ADDERALL_NNP 43_CD %_NN ._.
As_IN previously_RB disclosed_VBN ,_, legal_JJ proceedings_NNS XR_NNP adult_NN ,_, and_CC sales_NNS costs_NNS ,_, due_JJ to_TO the_DT relating_VBG to_TO CARBATROL_NNP are_VBP in_IN progress_NN ._.
recruitment_NN in_IN Q4_NNP 2004_CD of_IN a_DT sales_NNS force_NN of_IN about_IN Further_JJ information_NN can_MD be_VB found_VBN in_IN Note_NN 20_CD 85_CD people_NNS exclusively_RB to_TO promote_VB FOSRENOL_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
As_IN a_DT percentage_NN of_IN product_NN sales_NNS ,_, SG&A_NNP expenses_NNS were_VBD 41_CD %_NN 2003_CD :_: 37_CD %_NN ._.
The_DT b_NN Royalties_NNS depreciation_NN charge_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, Royalty_NN revenue_NN increased_VBD 13_CD %_NN to_TO $_$ 230.4_CD million_CD 2004_CD was_VBD $_$ 19.8_CD million_CD 2003_CD :_: $_$ 11.5_CD million_CD ._.
for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, compared_VBN The_DT increase_NN was_VBD primarily_RB due_JJ to_TO a_DT shortening_VBG to_TO $_$ 203.6_CD million_CD in_IN 2003_CD ._.
of_IN the_DT useful_JJ economic_JJ lives_NNS on_IN certain_JJ property_NN ,_, plant_NN and_CC equipment_NN as_IN a_DT result_NN of_IN the_DT US_NNP site_NN Shire_NNP receives_VBZ royalties_NNS from_IN GlaxoSmithKline_NNP rationalization_NN ._.
Amortization_NN charges_NNS were_VBD plc_JJ GSK_NNP on_IN worldwide_JJ sales_NNS of_IN 3TC_NNP and_CC $_$ 38.7_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ZEFFIX_NNP ._.
Other_JJ royalties_NNS are_VBP primarily_RB in_IN respect_NN 2003_CD :_: $_$ 26.4_CD million_CD ,_, with_IN the_DT increase_NN due_JJ to_TO the_DT of_IN REMINYL_NNP galantamine_NN hydrobromide_NN ,_, a_DT purchase_NN of_IN $_$ 49.2_CD million_CD of_IN intangible_JJ assets_NNS in_IN product_NN marketed_VBN in_IN the_DT US_NNP and_CC the_DT rest_NN of_IN the_DT 2004_CD and_CC the_DT reassessment_NN of_IN the_DT useful_JJ world_NN by_IN Janssen_NNP Pharmaceutica_NNP NV_NNP Janssen_NNP ,_, economic_JJ lives_NNS of_IN certain_JJ intangibles_NNS ._.
29_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 30_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN Intangible_JJ asset_NN impairments_NNS for_IN the_DT year_NN to_TO increased_VBN investment_NN in_IN trade_NN debtors_NNS and_CC December_NNP 31_CD ,_, 2004_CD were_VBD $_$ 13.5_CD million_CD 2003_CD :_: stock_NN levels_NNS which_WDT may_MD arise_VB as_IN sales_NNS levels_NNS $_$ 27.5_CD million_CD see_VBP Note_NN 12_CD to_TO the_DT consolidated_JJ increase_NN :_: financial_JJ statements_NNS for_IN further_JJ information_NN ._.
competitive_JJ and_CC technological_JJ developments_NNS :_: During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, $_$ 48.5_CD million_CD of_IN reorganization_NN costs_NNS were_VBD the_DT timing_NN and_CC cost_NN of_IN obtaining_VBG required_VBN recorded_VBN relating_VBG to_TO the_DT US_NNP site_NN consolidation_NN ._.
regulatory_JJ approvals_NNS for_IN new_JJ products_NNS :_: and_CC The_DT costs_NNS related_VBN to_TO employee_NN severance_NN $_$ 20.0_CD million_CD ,_, relocation_NN $_$ 13.8_CD million_CD and_CC other_JJ the_DT continuing_VBG revenues_NNS generated_VBD from_IN sales_NNS costs_NNS associated_VBN with_IN the_DT reorganization_NN of_IN key_JJ products_NNS ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD the_DT Company_NN recorded_VBN reorganization_NN As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD costs_NNS of_IN $_$ 23.9_CD million_CD ._.
These_DT related_VBN to_TO cash_NN ,_, restricted_VBN cash_NN and_CC short-term_JJ investments_NNS $_$ 13.2_CD million_CD of_IN costs_NNS in_IN connection_NN with_IN the_DT of_IN $_$ 1,457.5_CD million_CD 2003_CD :_: $_$ 1,414.0_CD million_CD ._.
closure_NN of_IN the_DT Lead_JJ Optimization_NN division_NN ,_, Total_JJ long-term_JJ debt_NN excluding_VBG capital_NN leases_NNS primarily_RB for_IN employee_NN severance_NN $_$ 6.4_CD million_CD as_IN of_IN December_NNP 31_CD ,_, 2004_CD was_VBD $_$ 116,000_CD and_CC the_DT write-off_NN of_IN property_NN ,_, plant_NN and_CC 2003_CD :_: $_$ 370.2_CD million_CD in_IN respect_NN of_IN guaranteed_JJ equipment_NN $_$ 6.0_CD million_CD ._.
In_IN addition_NN ,_, the_DT convertible_JJ notes_NNS ._.
Company_NN made_VBD the_DT decision_NN to_TO close_VB certain_JJ properties_NNS :_: a_DT write-down_NN of_IN $_$ 10.7_CD million_CD was_VBD During_IN the_DT third_JJ quarter_NN of_IN 2004_CD ,_, Shire_NNP redeemed_VBD made_VBN to_TO record_VB the_DT assets_NNS at_IN fair_JJ value_NN ._.
$_$ 370.1_CD million_CD of_IN the_DT $_$ 400_CD million_CD 2_CD %_NN guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD 2003_CD :_: $_$ 29.8_CD million_CD ._.
Discontinued_VBN operations_NNS The_DT Company_NN completed_VBD the_DT disposal_NN of_IN its_PRP$ Treasury_NNP policies_NNS and_CC financial_JJ risk_NN vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP management_NN IDB_NNP on_IN September_NNP 9_CD ,_, 2004_CD ._.
The_DT vaccines_NNS Shires_VBZ principal_JJ treasury_NN operations_NNS are_VBP business_NN impacted_VBD operating_NN profit_NN with_IN losses_NNS of_IN managed_VBN by_IN the_DT corporate_JJ treasury_NN function_NN $_$ 20.1_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD based_VBN in_IN the_DT UK_NNP ._.
All_DT treasury_NN operations_NNS are_VBP 2003_CD :_: $_$ 21.9_CD million_CD ._.
In_IN addition_NN the_DT Company_NN conducted_VBN within_IN a_DT framework_NN of_IN policies_NNS and_CC recorded_VBD a_DT loss_NN on_IN the_DT disposal_NN of_IN the_DT vaccines_NNS procedures_NNS approved_VBN by_IN the_DT Board_NNP ._.
As_IN a_DT business_NN of_IN $_$ 44.2_CD million_CD in_IN the_DT year_NN to_TO December_NNP matter_NN of_IN policy_NN ,_, the_DT Company_NN does_VBZ not_RB 31_CD ,_, 2004_CD ._.
See_VB Note_VB 3_CD ii_FW to_TO the_DT consolidated_JJ undertake_VBP speculative_JJ transactions_NNS that_WDT would_MD financial_JJ statements_NNS for_IN further_JJ information_NN ._.
increase_NN currency_NN or_CC interest_NN rate_NN exposure_NN ._.
The_DT Board_NNP reviews_NNS and_CC agrees_VBZ policies_NNS for_IN managing_VBG Capital_NNP structure_NN these_DT risks_NNS and_CC they_PRP are_VBP summarized_VBN below_IN ._.
The_DT Company_NN has_VBZ financed_VBN its_PRP$ operations_NNS since_IN inception_NN through_IN private_JJ and_CC public_JJ offerings_NNS Foreign_JJ currency_NN risk_NN of_IN equity_NN securities_NNS ,_, the_DT issuance_NN of_IN loan_NN notes_NNS The_DT Company_NN is_VBZ exposed_VBN to_TO movements_NNS in_IN and_CC convertible_JJ notes_NNS ,_, collaborative_JJ licensing_NN foreign_JJ exchange_NN rates_NNS against_IN the_DT US_NNP dollar_NN and_CC development_NN fees_NNS ,_, product_NN sales_NNS and_CC for_IN trading_NN transactions_NNS and_CC the_DT translation_NN of_IN investment_NN income_NN ._.
net_JJ assets_NNS and_CC earnings_NNS of_IN non-US_JJ subsidiaries_NNS ._.
The_DT main_JJ trading_NN currencies_NNS of_IN the_DT Company_NN The_DT Companys_NNPS funding_NN requirements_NNS depend_VBP are_VBP the_DT US_NNP dollar_NN ,_, the_DT Canadian_JJ dollar_NN ,_, Pounds_NNP on_IN a_DT number_NN of_IN factors_NNS ,_, including_VBG :_: sterling_NN and_CC the_DT Euro_NNP ._.
The_DT financial_JJ statements_NNS of_IN foreign_JJ entities_NNS are_VBP translated_VBN using_VBG the_DT the_DT Companys_NNP product_NN development_NN accounting_NN policies_NNS described_VBN in_IN Note_NN 2_CD k_NN to_TO programs_NNS ,_, business_NN and_CC product_NN acquisitions_NNS :_: the_DT consolidated_JJ financial_JJ statements_NNS ._.
the_DT level_NN of_IN resources_NNS required_VBN for_IN the_DT The_DT Company_NN reports_VBZ its_PRP$ results_NNS in_IN US_NNP dollars_NNS ._.
expansion_NN of_IN marketing_NN capabilities_NNS as_IN the_DT As_IN the_DT majority_NN of_IN the_DT Companys_NNP transactions_NNS product_NN base_NN expands_VBZ :_: are_VBP also_RB denominated_VBN in_IN US_NNP dollars_NNS ,_, this_DT reduces_VBZ the_DT impact_NN of_IN currency_NN movements_NNS on_IN the_DT Companys_NNPS results_NNS ._.
30_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 31_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Financial_NNP review_NN The_DT exposure_NN to_TO foreign_JJ exchange_NN risk_NN is_VBZ For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD net_JJ cash_NN managed_VBD and_CC monitored_VBD by_IN the_DT treasury_NN provided_VBN by_IN operating_VBG activities_NNS amounted_VBD to_TO function_VB ._.
Exposures_NNS are_VBP generally_RB managed_VBN $_$ 520.7_CD million_CD compared_VBN to_TO $_$ 379.1_CD million_CD in_IN 2003_CD ._.
through_IN natural_JJ hedging_NN via_IN the_DT currency_NN denomination_NN of_IN cash_NN balances_NNS ._.
As_IN of_IN December_NNP During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD net_JJ cash_NN 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD two_CD outstanding_JJ generated_VBN from_IN operations_NNS was_VBD used_VBN primarily_RB forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_NN to_TO fund_VB the_DT Companys_NNPS tax_NN payments_NNS ,_, capital_NN principal_NN amount_NN of_IN $_$ 39_CD million_CD hedging_NN expenditures_NNS including_VBG the_DT purchase_NN of_IN intangible_JJ investments_NNS held_VBN in_IN its_PRP$ Canadian_JJ subsidiary_NN ._.
assets_NNS and_CC property_NN ,_, plant_NN and_CC equipment_NN ,_, and_CC There_EX were_VBD no_DT material_NN gains_NNS or_CC losses_NNS on_IN the_DT repayment_NN of_IN debt_NN ._.
Capital_NNP expenditure_NN Market_NN risk_NN of_IN investments_NNS Expenditure_NN on_IN intangible_JJ assets_NNS of_IN $_$ 30.2_CD million_CD As_IN of_IN December_NNP 31_CD ,_, 2004_CD the_DT Company_NN had_VBD 2003_CD :_: $_$ 47.0_CD million_CD comprised_VBN payments_NNS $_$ 63.3_CD million_CD 2003_CD :_: $_$ 73.0_CD million_CD of_IN investments_NNS made_VBN to_TO acquire_VB additional_JJ rights_NNS for_IN REMINYL_NNP comprising_VBG equity_NN investment_NN funds_NNS ,_, private_JJ and_CC FOSRENOL_NNP ._.
companies_NNS and_CC public_JJ quoted_VBN companies_NNS ._.
The_DT public_JJ quoted_VBN companies_NNS are_VBP exposed_VBN to_TO market_NN Capital_NN expenditure_NN on_IN property_NN ,_, plant_NN and_CC risk_NN ._.
No_DT financial_JJ instruments_NNS or_CC derivatives_NNS have_VBP equipment_NN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD was_VBD been_VBN employed_VBN to_TO hedge_VB this_DT risk_NN ._.
This_DT expenditure_NN included_VBD the_DT ongoing_JJ implementation_NN of_IN an_DT Interest_NN rate_NN risk_VB Enterprise_NN Resource_NNP Planning_NNP system_NN by_IN the_DT The_DT majority_NN of_IN the_DT Companys_NNPS debt_NN was_VBD repaid_VBN Company_NN $_$ 9.1_CD million_CD and_CC further_JJ upgrades_NNS during_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD and_CC to_TO the_DT US_NNP manufacturing_NN facility_NN $_$ 19.5_CD million_CD ._.
consequently_RB it_PRP has_VBZ limited_VBN exposure_NN to_TO interest_NN rate_NN movements_NNS ._.
Dividend_NN policy_NN Historically_NNP ,_, the_DT Company_NN has_VBZ not_RB paid_VBN any_DT In_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT average_NN dividends_NNS ._.
Given_VBN the_DT stage_NN of_IN development_NN and_CC interest_NN rate_NN received_VBN on_IN cash_NN and_CC liquid_NN size_NN of_IN the_DT Company_NN and_CC related_VBN strong_JJ cash_NN investments_NNS was_VBD approximately_RB 1.44_CD %_NN per_IN flows_NNS ,_, the_DT Board_NNP announced_VBD its_PRP$ intention_NN to_TO begin_VB annum_NN ._.
The_DT largest_JJS proportion_NN of_IN investments_NNS payment_NN of_IN dividends_NNS to_TO shareholders_NNS in_IN 2004_CD ._.
was_VBD in_IN US_NNP dollar_NN liquidity_NN funds_NNS ._.
An_DT interim_JJ dividend_NN for_IN the_DT first_JJ half_NN of_IN 2004_CD of_IN one_CD penny_NN sterling_NN 1.82_CD per_IN ordinary_JJ share_NN Taxation_NNP was_VBD paid_VBN in_IN October_NNP 2004_CD and_CC an_DT interim_NN For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT tax_NN charge_NN dividend_NN for_IN the_DT second_JJ half_NN of_IN 2004_CD of_IN two_CD increased_VBN by_IN $_$ 21.7_CD million_CD to_TO $_$ 129.1_CD million_CD ._.
pence_NN sterling_NN 3.85_CD per_IN ordinary_JJ share_NN was_VBD paid_VBN in_IN April_NNP 2005_CD ._.
Shire_NNP intends_VBZ to_TO pursue_VB a_DT A_DT reconciliation_NN of_IN the_DT current_JJ tax_NN charge_NN for_IN progressive_JJ dividend_NN policy_NN ._.
It_PRP is_VBZ expected_VBN that_IN 2004_CD to_TO the_DT profit_NN before_IN tax_NN for_IN the_DT year_NN at_IN the_DT the_DT first_JJ interim_JJ payment_NN each_DT year_NN will_MD be_VB statutory_JJ tax_NN rate_NN of_IN 30_CD %_NN is_VBZ given_VBN in_IN Note_NN 26_CD maintained_VBD at_IN a_DT consistent_JJ level_NN and_CC any_DT growth_NN to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
will_MD typically_RB come_VB through_IN increasing_VBG the_DT second_JJ interim_JJ dividend_NN in_IN a_DT financial_JJ year_NN ._.
Any_DT payment_NN Cash_NN flows_VBZ of_IN dividends_NNS is_VBZ at_IN the_DT discretion_NN of_IN the_DT Board_NNP As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, cash_NN ,_, restricted_VBN of_IN Directors_NNS and_CC will_MD be_VB made_VBN in_IN Pounds_NNP sterling_NN cash_NN and_CC short-term_JJ investments_NNS totalled_VBD to_TO ordinary_JJ shareholders_NNS ,_, US_NNP dollars_NNS to_TO holders_NNS $_$ 1,457.5_CD million_CD ,_, an_DT increase_NN of_IN $_$ 43.5_CD million_CD of_IN American_JJ depositary_JJ shares_NNS and_CC Canadian_JJ from_IN $_$ 1,414.0_CD million_CD at_IN December_NNP 31_CD ,_, 2003_CD ._.
dollars_NNS to_TO exchangeable_JJ shareholders_NNS ._.
Short-term_JJ investments_NNS consisted_VBD of_IN money_NN market_NN fund_NN balances_NNS and_CC investment_NN grade_NN securities_NNS ._.
31_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 32_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_NNP Board_NNP of_IN Directors_NNS The_DT Board_NNP of_IN Directors_NNS Dr_NNP James_NNP Cavanaugh_NNP 68_CD Mr_NNP Matthew_NNP Emmens_NNP 53_CD Mr_NNP Angus_NNP Russell_NNP 49_CD Dr_NNP Barry_NNP Price_NNP 61_CD Chairman_NNP Chief_NNP Executive_NNP Officer_NNP Chief_NNP Financial_NNP Officer_NNP and_CC Non-executive_JJ Director_NNP Dr_NNP James_NNP Cavanaugh_NNP joined_VBD Matthew_NNP Emmens_NNP joined_VBD Shire_NNP Executive_NNP Vice_NNP President_NNP Dr_NNP Barry_NNP Price_NNP joined_VBD the_DT Board_NNP the_DT Board_NNP of_IN Shire_NNP on_IN March_NNP 24_CD ,_, as_IN Chief_NNP Executive_NNP Officer_NNP of_IN Global_NNP Finance_NNP of_IN Shire_NNP on_IN January_NNP 16_CD ,_, 1996_CD 1997_CD and_CC was_VBD appointed_VBN as_IN and_CC member_NN of_IN the_DT Board_NNP of_IN Angus_NNP Russell_NNP joined_VBD Shire_NNP having_VBG spent_VBN 28_CD years_NNS with_IN Chairman_NNP with_IN effect_NN from_IN Shire_NNP on_IN March_NNP 12_CD ,_, 2003_CD ._.
in_IN 1999_CD as_IN Chief_NNP Financial_NNP Glaxo_NNP holding_VBG a_DT succession_NN May_NNP 11_CD ,_, 1999_CD ._.
Dr_NNP Cavanaugh_NNP is_VBZ Mr_NNP Emmens_NNP began_VBD his_PRP$ career_NN Officer_NNP ._.
Mr_NNP Russell_NNP previously_RB of_IN executive_NN positions_NNS with_IN a_DT General_NNP Partner_NNP of_IN HealthCare_NNP in_IN international_JJ pharmaceuticals_NNS worked_VBD for_IN ICI_NNP ,_, Zeneca_NNP and_CC Glaxo_NNP Group_NNP Research_NNP ._.
He_PRP is_VBZ Partners_NNPS ,_, the_DT General_NNP Partner_NNP of_IN with_IN Merck_NNP &_CC Co_NNP ,_, Inc._NNP in_IN 1974_CD ._.
His_PRP$ last_JJ position_NN Chairman_NNP of_IN Antisoma_NNP plc_NN and_CC HealthCare_NNP Ventures_NNP ,_, a_DT venture_NN There_EX he_PRP held_VBD a_DT wide_JJ range_NN was_VBD Vice_NNP President_NNP Corporate_NNP also_RB Biowisdom_NNPS Ltd_NNP and_CC is_VBZ capital_NN fund_NN devoted_VBN exclusively_RB of_IN sales_NNS ,_, marketing_NN and_CC Finance_NNP at_IN AstraZeneca_NNP plc._NNP ._.
on_IN the_DT board_NN of_IN directors_NNS of_IN to_TO healthcare_NN ._.
Formerly_RB he_PRP administrative_JJ positions_NNS before_IN Prior_RB to_TO this_DT ,_, he_PRP held_VBD a_DT number_NN Pharmagene_NNP plc._NN ._.
Dr_NNP Price_NNP was_VBD was_VBD president_NN of_IN SmithKline_NNP volunteering_VBG in_IN 1992_CD to_TO help_VB of_IN positions_NNS within_IN the_DT Zeneca_NNP Chairman_NNP of_IN the_DT Remuneration_NNP &_CC French_NNP Laboratories_NNPS ,_, the_DT establish_VB Astra_NNP Merck_NNP ,_, the_DT Group_NNP from_IN 1993_CD until_IN 1999_CD Committee_NNP and_CC a_DT member_NN of_IN US_NNP pharmaceutical_JJ division_NN joint_JJ venture_NN between_IN Merck_NNP including_VBG Group_NNP Treasurer_NNP ,_, and_CC both_DT the_DT Audit_NNP Committee_NNP and_CC of_IN SmithKline_NNP Beecham_NNP and_CC Astra_NNP AB_NNP of_IN Sweden_NNP ._.
before_IN that_DT in_IN ICI_NNP from_IN 1980_CD the_DT Nomination_NNP Committee_NNP in_IN Corporation_NNP ._.
Prior_RB to_TO that_DT ,_, he_PRP He_PRP later_RB became_VBD President_NNP until_IN 1992_CD ._.
Dr_NNP Price_NNP is_VBZ Shires_NNP senior_JJ was_VBD president_NN of_IN SmithKline_NNP and_CC Chief_NNP Executive_NNP Officer_NNP ._.
chartered_JJ accountant_NN ,_, having_VBG non-executive_JJ Director_NNP ._.
Beecham_NNP Corporations_NNS In_IN 1999_CD he_PRP joined_VBD Merck_NNP qualified_VBD with_IN Coopers_NNP &_CC clinical_JJ laboratory_NN business_NN KGaA_NNP and_CC established_VBN EMD_NNP Lybrand_NNP ,_, and_CC is_VBZ a_DT fellow_NN of_IN and_CC ,_, before_IN that_DT ,_, President_NNP Pharmaceuticals_NNP ,_, the_DT the_DT Association_NNP of_IN Corporate_NNP of_IN Allergan_NNP International_NNP ._.
Prior_RB companys_VBZ US_NNP prescription_NN Treasurers_NNPS ._.
Mr_NNP Russell_NNP is_VBZ a_DT to_TO his_PRP$ industry_NN experience_NN ,_, pharmaceutical_JJ business_NN ._.
member_NN of_IN the_DT Executive_NNP Dr_NNP Cavanaugh_NNP served_VBD as_IN Deputy_NNP He_PRP was_VBD later_RB promoted_VBN to_TO Committee_NNP ._.
He_PRP is_VBZ also_RB a_DT nonAssistant_JJ to_TO the_DT President_NNP of_IN the_DT President_NNP of_IN the_DT global_JJ executive_NN director_NN of_IN the_DT City_NNP US_NNP on_IN the_DT White_NNP House_NNP Staff_NNP prescription_NN business_NN and_CC lived_VBD of_IN London_NNP Investment_NNP Trust_NNP plc._NN ._.
Mr_NNP Emmens_NNP is_VBZ a_DT executive_NN Chairman_NN of_IN Diversa_NNP graduate_NN of_IN Fairleigh_NNP Dickinson_NNP Corporation_NNP and_CC Vicuron_NNP ,_, Inc._NNP ._.
University_NNP New_NNP Jersey_NNP ,_, USA_NNP and_CC a_DT non-executive_JJ director_NN of_IN with_IN a_DT BS_NNP in_IN Business_NNP MedImmune_NNP Inc._NNP and_CC Advancis_NNP Management_NNP ._.
is_VBZ a_DT member_NN of_IN the_DT Board_NNP Dr_NNP Cavanaugh_NNP was_VBD a_DT member_NN of_IN Directors_NNS ,_, and_CC Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP of_IN the_DT Executive_NNP and_CC Portfolio_NNP until_IN April_NNP 2004_CD and_CC a_DT member_NN Review_NNP Committees_NNS ._.
of_IN the_DT Audit_NNP Committee_NNP until_IN November_NNP 2004_CD ._.
He_PRP acted_VBD as_IN Chairman_NNP of_IN the_DT Nomination_NNP Committee_NNP throughout_IN 2004_CD ._.
32_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 33_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_NNP Board_NNP of_IN Directors_NNS The_DT Hon_NNP James_NNP Grant_NNP ,_, Mr_NNP Ronald_NNP Nordmann_NNP 63_CD Mr_NNP Robin_NNP Buchanan_NNP 52_CD Mr_NNP David_NNP Kappler_NNP 57_CD P._NNP C._NNP C._NNP M._NNP Q._NNP C._NNP 67_CD Non-executive_JJ Director_NNP Non-executive_JJ Director_NNP Non-executive_JJ Director_NNP Non-executive_JJ Director_NNP Ronald_NNP Nordmann_NNP joined_VBD the_DT Robin_NNP Buchanan_NNP joined_VBD the_DT David_NNP Kappler_NNP joined_VBD the_DT Board_NNP The_DT Hon_NNP James_NNP Grant_NNP joined_VBD Board_NNP of_IN Shire_NNP on_IN December_NNP 23_CD ,_, Board_NNP of_IN Shire_NNP on_IN July_NNP 30_CD ,_, of_IN Shire_NNP as_IN a_DT non-executive_JJ the_DT Board_NNP of_IN Shire_NNP on_IN May_NNP 11_CD ,_, 1999_CD having_VBG previously_RB served_VBD 2003_CD ._.
He_PRP is_VBZ the_DT Senior_JJ Partner_NNP Director_NNP on_IN April_NNP 5_CD ,_, 2004_CD ._.
Mr_NNP 2001_CD as_IN a_DT non-executive_JJ as_IN a_DT non-executive_JJ director_NN of_IN the_DT UK_NNP operations_NNS and_CC Kappler_NNP retired_VBD as_IN Chief_NNP Financial_NNP Director_NNP ._.
Prior_RB to_TO its_PRP$ merger_NN of_IN Roberts_NNP Pharmaceutical_NNP director_NN of_IN the_DT global_JJ business_NN Officer_NNP of_IN Cadbury_NNP Schweppes_NNP with_IN Shire_NNP ,_, Mr_NNP Grant_NNP had_VBD been_VBN Corporation_NNP since_IN May_NNP 1999_CD ._.
consultants_NNS Bain_NNP &_CC Company_NNP plc_NN ,_, the_DT FTSE_NNP and_CC NYSE_NNP listed_VBD a_DT director_NN of_IN BioChem_NNP Pharma_NNP Mr_NNP Nordmann_NNP has_VBZ been_VBN a_DT Inc._NNP and_CC a_DT member_NN of_IN the_DT firms_NNS global_JJ confectionery_NN and_CC Inc._NNP since_IN 1986_CD ._.
He_PRP is_VBZ a_DT partner_NN financial_JJ analyst_NN in_IN healthcare_NN worldwide_NN management_NN beverages_NNS group_NN in_IN April_NNP 2004_CD ,_, and_CC Chair_NNP Emeritus_NNP with_IN the_DT equities_NNS since_IN 1971_CD ._.
Prior_RB to_TO his_PRP$ career_NN having_VBG held_VBN that_IN position_NN since_IN law_NN firm_NN Stikeman_NNP Elliott_NNP in_IN September_NNP 1994_CD to_TO January_NNP with_IN Bain_NNP &_CC Company_NNP Inc._NNP 1995_CD ._.
He_PRP worked_VBD for_IN the_DT Montreal_NNP ._.
Mr_NNP Grant_NNP sits_VBZ on_IN the_DT 2000_CD he_PRP was_VBD an_DT analyst_NN Mr_NNP Buchanan_NNP worked_VBD for_IN Cadbury_NNP Schweppes_NNP group_NN boards_NNS of_IN two_CD Canadian_JJ public_NN and_CC partner_NN at_IN Deerfield_NNP American_NNP Express_NNP International_NNP between_IN 1965_CD and_CC 1984_CD and_CC corporations_NNS ,_, in_IN addition_NN to_TO Management_NNP ._.
He_PRP is_VBZ currently_RB Banking_NNP Corporation_NNP in_IN New_NNP rejoined_VBD it_PRP in_IN 1989_CD ,_, following_VBG the_DT other_JJ private_JJ corporations_NNS and_CC Co-President_NNP of_IN Global_NNP Health_NNP York_NNP ,_, McKinsey_NNP &_CC Company_NNP acquisition_NN of_IN the_DT Trebor_NNP Group_NNP foundations_NNS and_CC councils_NNS that_WDT Associates_NNPS and_CC has_VBZ held_VBN senior_JJ and_CC Deloitte_NNP &_CC Touche_NNP where_WRB of_IN which_WDT he_PRP was_VBD Financial_NNP are_VBP not-for-profit_JJ organizations_NNS ._.
positions_NNS with_IN PaineWebber_NNP ,_, he_PRP qualified_VBD as_IN a_DT chartered_JJ Director_NNP ._.
From_IN 1989_CD to_TO 1995_CD He_PRP attended_VBD McGill_NNP University_NNP ,_, Oppenheimer_NNP &_CC Co._NNP accountant_NN FCA_NNP ._.
Mr_NNP he_PRP held_VBD a_DT number_NN of_IN senior_JJ receiving_VBG a_DT BA_NNP in_IN Arts_NNS in_IN 1958_CD F_NN Eberstadt_NNP &_CC Co._NNP and_CC Buchanan_NNP currently_RB serves_VBZ positions_NNS in_IN Cadbury_NNP and_CC a_DT BCL_NNP in_IN Law_NNP in_IN 1961_CD ._.
Warner-Chilcott_NNP Laboratories_NNPS ,_, as_IN a_DT non-executive_JJ director_NN Schweppes_NNP ,_, including_VBG director_NN Mr_NNP Grant_NNP was_VBD a_DT member_NN of_IN the_DT a_DT division_NN of_IN Warner-Lambert_NNP ._.
Mr_NNP Kappler_NNP Nomination_NNP Committee_NNP in_IN 2004_CD ._.
Mr_NNP Nordmann_NNP received_VBD his_PRP$ Mr_NNP Buchanan_NNP has_VBZ an_DT MBA_NNP with_IN has_VBZ served_VBN on_IN a_DT number_NN of_IN other_JJ undergraduate_JJ degree_NN from_IN Distinction_NNP Baker_NNP Scholar_NNP boards_NNS around_IN the_DT world_NN in_IN The_DT Johns_NNP Hopkins_NNP University_NNP from_IN Harvard_NNP Business_NNP School_NNP ._.
which_WDT Cadbury_NNP Schweppes_NNP held_VBD and_CC an_DT MBA_NNP from_IN Fairleigh_NNP Mr_NNP Buchanan_NNP was_VBD a_DT member_NN of_IN interests_NNS ._.
He_PRP was_VBD a_DT director_NN of_IN Dickinson_NNP University_NNP ._.
Mr_NNP the_DT Remuneration_NNP Committee_NNP Camelot_NNP Group_NNP plc_NN from_IN 1996_CD Nordmann_NNP is_VBZ also_RB a_DT director_NN of_IN in_IN 2004_CD ._.
to_TO 2002_CD and_CC he_PRP currently_RB serves_VBZ Guilford_NNP Pharmaceuticals_NNP Inc._NNP as_IN a_DT non-executive_JJ director_NN and_CC Neurochem_NNP Inc._NNP and_CC Par_NNP Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Mr_NNP at_IN HMV_NNP Group_NNP plc_NN and_CC Nordmann_NNP was_VBD Chairman_NNP of_IN Intercontinental_NNP Hotels_NNPS Group_NNP the_DT Audit_NNP Committee_NNP until_IN July_NNP plc._NN ._.
Additionally_RB ,_, he_PRP is_VBZ non_SYM -_: 2004_CD and_CC he_PRP remains_VBZ a_DT member_NN executive_NN Chairman_NNP at_IN Premier_NNP of_IN that_DT Committee_NNP ._.
Mr_NNP Kappler_NNP is_VBZ a_DT fellow_NN a_DT member_NN of_IN the_DT Nomination_NN of_IN the_DT Chartered_NNP Institute_NNP of_IN Committee_NNP throughout_IN 2004_CD Management_NN Accountants_NNS ._.
Mr_NNP and_CC he_PRP became_VBD a_DT member_NN of_IN Kappler_NNP became_VBD a_DT member_NN of_IN the_DT Remuneration_NNP Committee_NNP Shires_NNP Audit_NNP Committee_NNP upon_IN in_IN April_NNP 2004_CD ._.
his_PRP$ appointment_NN to_TO the_DT Board_NNP and_CC took_VBD over_RP the_DT Chairmanship_NN of_IN that_DT Committee_NNP in_IN July_NNP 2004_CD ._.
33_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 34_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT Executive_NNP Committee_NNP The_NNP Executive_NNP Committee_NNP Mr_NNP Matthew_NNP Emmens_NNP Mr_NNP Angus_NNP Russell_NNP Ms_NNP Barbara_NNP Deptula_NNP Mr_NNP Greg_NNP Flexter_NNP Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP and_CC Executive_NNP Vice_NNP President_NNP Executive_NNP Vice_NNP President_NNP Chairman_NNP of_IN the_DT Executive_NNP Executive_NNP Vice_NNP President_NNP of_IN Business_NNP Development_NNP and_CC General_NNP Manager_NNP ,_, Committee_NNP joined_VBD Shire_NNP Global_NNP Finance_NNP joined_VBD Shire_NNP joined_VBD Shire_NNP in_IN September_NNP 2004_CD North_NNP America_NNP joined_VBD Shire_NNP as_IN Chief_NNP Executive_NNP Officer_NNP in_IN 1999_CD as_IN Chief_NNP Financial_NNP from_IN Sicor_NNP Inc_NNP ,_, where_WRB she_PRP was_VBD in_IN April_NNP 2001_CD from_IN Novartis_NNP and_CC member_NN of_IN the_DT Board_NNP Officer_NNP ._.
Mr_NNP Russell_NNP previously_RB President_NNP of_IN the_DT biotechnology_NN Pharmaceuticals_NNS ,_, where_WRB he_PRP was_VBD of_IN Shire_NNP on_IN March_NNP 12_CD ,_, 2003_CD ._.
worked_VBD for_IN ICI_NNP ,_, Zeneca_NNP and_CC division_NN ._.
Prior_RB to_TO joining_VBG Sicor_NNP ,_, Vice_NNP President_NNP and_CC Head_NNP of_IN the_DT Mr_NNP Emmens_NNP began_VBD his_PRP$ career_NN AstraZeneca_NNP ._.
His_PRP$ last_JJ position_NN Ms_NNP Deptula_NNP was_VBD Senior_JJ Vice_NNP Neuroscience_NNP Business_NNP Unit_NNP in_IN international_JJ pharmaceuticals_NNS was_VBD Vice_NNP President_NNP Corporate_NNP President_NNP for_IN commercial_JJ and_CC with_IN accountability_NN for_IN US_NNP with_IN Merck_NNP &_CC Co_NNP ,_, Inc._NNP in_IN 1974_CD ._.
product_NN development_NN at_IN Coley_NNP Marketing_NNP ,_, Sales_NNS and_CC Medical_JJ There_EX he_PRP held_VBD a_DT wide_JJ range_NN Prior_RB to_TO this_DT ,_, he_PRP held_VBD a_DT number_NN Pharmaceutical_NNP Group_NNP in_IN Research_NNP ._.
Mr_NNP Flexter_NNP brought_VBD of_IN sales_NNS ,_, marketing_NN and_CC of_IN positions_NNS within_IN the_DT Zeneca_NNP Wellesley_NNP ,_, Massachusetts_NNP ,_, with_IN with_IN him_PRP over_IN 22_CD years_NNS administrative_JJ positions_NNS before_IN Group_NNP from_IN 1993_CD until_IN 1999_CD responsibility_NN for_IN key_JJ operations_NNS experience_NN in_IN global_JJ and_CC volunteering_VBG in_IN 1992_CD to_TO help_VB including_VBG Group_NNP Treasurer_NNP ,_, and_CC and_CC business_NN development_NN domestic_JJ marketing_NN ,_, business_NN establish_VB Astra_NNP Merck_NNP ,_, the_DT before_IN that_DT in_IN ICI_NNP from_IN 1980_CD activities_NNS ._.
She_PRP has_VBZ held_VBN various_JJ development_NN ,_, and_CC R&D_NNP ,_, and_CC joint_JJ venture_NN between_IN Merck_NNP until_IN 1992_CD ._.
Mr_NNP Russell_NNP is_VBZ a_DT senior_JJ management_NN positions_NNS is_VBZ also_RB a_DT qualified_VBN pharmacist_NN ._.
chartered_JJ accountant_NN ,_, having_VBG focused_VBN on_IN licensing_NN and_CC He_PRP later_RB became_VBD President_NNP qualified_VBD with_IN Coopers_NNP &_CC business_NN development_NN with_IN US_NNP and_CC Chief_NNP Executive_NNP Officer_NNP ._.
Lybrand_NNP ,_, and_CC is_VBZ a_DT fellow_NN of_IN Bioscience_NNP ,_, Schering-Plough_NNP ,_, In_IN 1999_CD he_PRP joined_VBD Merck_NNP the_DT Association_NNP of_IN Corporate_JJ American_NNP Cyanamid_NNP ,_, and_CC KGaA_NNP and_CC established_VBN EMD_NNP Treasurers_NNPS ._.
Mr_NNP Russell_NNP is_VBZ a_DT Genetics_NNP Institute_NNP ._.
Pharmaceuticals_NNS ,_, the_DT member_NN of_IN the_DT Executive_NNP companys_VBZ US_NNP prescription_NN Committee_NNP ._.
He_PRP is_VBZ also_RB a_DT nonDr_NNP Eliseo_NNP Salinas_NNP pharmaceutical_JJ business_NN ._.
executive_JJ director_NN of_IN the_DT City_NNP Chief_NNP Scientific_NNP Officer_NNP and_CC He_PRP was_VBD later_RB promoted_VBN to_TO of_IN London_NNP Investment_NNP Trust_NNP plc._NN ._.
Executive_NNP Vice_NNP President_NNP President_NNP of_IN the_DT global_JJ Global_JJ R&D_NN joined_VBD Shire_NNP in_IN June_NNP prescription_NN business_NN and_CC lived_VBD 2004_CD from_IN Wyeth_NNP Research_NNP ,_, one_CD of_IN in_IN Germany_NNP ._.
Mr_NNP Emmens_NNP is_VBZ a_DT the_DT worlds_NNS leading_VBG pharmaceutical_JJ graduate_NN of_IN Fairleigh_NNP Dickinson_NNP companies_NNS ,_, where_WRB he_PRP was_VBD Head_NNP of_IN University_NNP New_NNP Jersey_NNP ,_, USA_NNP Global_NNP Central_NNP Nervous_NNP Systems_NNPS with_IN a_DT BS_NNP in_IN Business_NNP and_CC Vice_NNP President_NNP for_IN Regional_NNP Management_NNP ._.
Mr_NNP Emmens_NNP Clinical_NNP Research_NNP &_CC Development_NNP ._.
is_VBZ a_DT member_NN of_IN the_DT Board_NNP Eliseo_NNP graduated_VBD from_IN the_DT Medical_NNP of_IN Directors_NNS ,_, and_CC Chairman_NNP School_NNP of_IN the_DT University_NNP of_IN Buenos_NNP of_IN the_DT Executive_NNP and_CC Portfolio_NNP Aires_NNP ,_, Argentina_NNP and_CC performed_VBD Review_NNP Committees_NNS ._.
a_DT residency_NN in_IN psychiatry_NN in_IN Paris_NNP ,_, where_WRB he_PRP lived_VBD for_IN 18_CD years_NNS ._.
He_PRP began_VBD his_PRP$ career_NN in_IN the_DT pharmaceutical_JJ industry_NN at_IN Synthelabo_NNP Research_NNP in_IN Paris_NNP ._.
Dr_NNP Eliseo_NNP Salinas_NNP Mr_NNP Matthew_NNP Emmens_NNP Mr_NNP Angus_NNP Russell_NNP Ms_NNP Barbara_NNP Deptula_NNP Mr_NNP Greg_NNP Flexter_NNP 34_CD 5977_CD Review_NNP 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:21_CD PM_NNP Page_NNP 35_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN The_DT Executive_NNP Committee_NNP Ms_NNP Anita_NNP Graham_NNP Mr_NNP John_NNP Lee_NNP Ms_NNP Tatjana_NNP May_NNP Mr_NNP Joseph_NNP Rus_NNP Executive_NNP Vice_NNP President_NNP Executive_NNP Vice_NNP President_NNP General_NNP Counsel_NNP ,_, Company_NNP Executive_NNP Vice_NNP President_NNP Global_NNP Human_NNP Resources_NNP Global_NNP Supply_NNP Chain_NNP &_CC Quality_NNP Secretary_NNP and_CC Executive_NNP and_CC General_NNP Manager_NNP ,_, joined_VBD Shire_NNP in_IN January_NNP 2004_CD joined_VBD Shire_NNP in_IN April_NNP 2000_CD from_IN Vice_NNP President_NNP Global_NNP Legal_NNP International_NNP joined_VBD Shire_NNP from_IN Cytyc_NNP Corporation_NNP ,_, where_WRB Schwarz_NNP Pharma_NNP ,_, where_WRB he_PRP Affairs_NNPS joined_VBD Shire_NNP in_IN May_NNP in_IN 1999_CD following_VBG more_JJR than_IN she_PRP was_VBD Vice_NNP President_NNP of_IN was_VBD Vice_NNP President_NNP ,_, Operations_NNP ._.
2001_CD from_IN AstraZeneca_NNP plc_NN 25_CD years_NNS experience_NN with_IN Human_NNP Resources_NNPS ._.
Prior_RB to_TO this_DT ,_, Prior_RB to_TO this_DT he_PRP held_VBD supply_NN where_WRB she_PRP was_VBD Assistant_NNP other_JJ leading_JJ international_JJ she_PRP held_VBD senior_JJ HR_NNP positions_NNS chain_NN responsibilities_NNS for_IN Central_NNP General_NNP Counsel_NNP in_IN Corporate_NNP pharmaceutical_JJ companies_NNS ,_, with_IN Serono_NNP ,_, Inc._NNP and_CC Scudder_NNP Pharmaceuticals_NNP ,_, The_DT Vitarine_NNP Headquarters_NNP ._.
Prior_RB to_TO joining_VBG both_DT in_IN Canada_NNP and_CC abroad_RB ._.
Kemper_NNP Investments_NNP ,_, Inc._NNP ._.
Company_NN now_RB Eon_NNP ,_, and_CC AstraZeneca_NNP in_IN 1995_CD ,_, Ms_NNP May_NNP With_IN the_DT merger_NN of_IN Shire_NNP now_RB part_NN of_IN Deutsche_NNP Bank_NNP ._.
worked_VBN at_IN Slaughter_NNP and_CC May_NNP ._.
Pharmaceuticals_NNS and_CC BioChem_NNP Her_PRP$ experience_NN spans_NNS all_DT He_PRP brought_VBD with_IN him_PRP Pharma_NNP in_IN May_NNP 2001_CD ,_, he_PRP was_VBD aspects_NNS of_IN HR_NNP including_VBG 31_CD years_NNS experience_NN in_IN the_DT appointed_VBN President_NNP and_CC managing_VBG mergers_NNS and_CC pharmaceutical_JJ industry_NN ._.
CEO_NNP of_IN Shire_NNP BioChem_NNP Inc._NNP acquisitions_NNS ,_, organizational_JJ development_NN ,_, employee_NN relations_NNS and_CC compensation_NN and_CC benefits_NNS ._.
She_PRP has_VBZ worked_VBN both_DT in_IN Europe_NNP and_CC in_IN the_DT United_NNP States_NNPS ._.
Ms_NNP Anita_NNP Graham_NNP Mr_NNP John_NNP Lee_NNP Ms_NNP Tatjana_NNP May_NNP Mr_NNP Joseph_NNP Rus_NNP 35_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 36_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Directors_NNS remuneration_JJ report_NN This_DT Report_NNP sets_VBZ out_RP the_DT Companys_NNPS approach_NN to_TO Directors_NNS remuneration_NN ._.
It_PRP complies_VBZ with_IN :_: Dear_RB Shareholder_NN During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD the_DT Remuneration_NNP the_DT 2003_CD Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP :_: Committee_NNP continued_VBD its_PRP$ work_NN ,_, on_IN behalf_NN of_IN the_DT Board_NNP ,_, on_IN Directors_NNS remuneration_NN ._.
the_DT Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD :_: and_CC The_DT Company_NN operates_VBZ in_IN a_DT highly_RB competitive_JJ multinational_JJ the_DT requirements_NNS of_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS environment_NN ._.
In_IN 2004_CD approximately_RB 90_CD %_NN of_IN Shires_NNP revenues_NNS Authority_NNP ._.
and_CC more_RBR than_IN 80_CD %_NN of_IN its_PRP$ employees_NNS were_VBD based_VBN outside_IN the_DT UK_NNP ._.
Indeed_RB most_JJS of_IN Shires_NNP revenues_NNS come_VBP from_IN the_DT US_NNP and_CC Unaudited_JJ information_NN most_JJS of_IN its_PRP$ employees_NNS are_VBP located_VBN there_RB ._.
The_DT Remuneration_NNP Committee_NNP Shire_NNP largely_RB completed_VBD a_DT major_JJ internal_JJ reorganisation_NN in_IN 2004_CD The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN all_DT elements_NNS which_WDT resulted_VBD in_IN the_DT introduction_NN of_IN a_DT new_JJ organisational_NN of_IN the_DT executive_NN Directors_NNS remuneration_NN ,_, as_RB well_RB as_IN their_PRP$ structure_NN and_CC in_IN the_DT consolidation_NN of_IN its_PRP$ US_NNP sites_NNS from_IN 14_CD to_TO 6_CD ._.
performance_NN management_NN ._.
During_IN the_DT year_NN ,_, the_DT Committee_NNP initiated_VBD a_DT review_NN of_IN the_DT Companys_NNP compensation_NN and_CC benefits_NNS philosophy_NN and_CC practice_NN The_DT constitution_NN of_IN the_DT Committee_NNP was_VBD reviewed_VBN in_IN 2004_CD and_CC to_TO ensure_VB that_IN remuneration_JJ arrangements_NNS support_VBP the_DT needs_NNS of_IN changes_NNS were_VBD made_VBN to_TO ensure_VB compliance_NN with_IN the_DT 2003_CD the_DT Company_NN as_IN it_PRP adapts_VBZ to_TO its_PRP$ new_JJ business_NN model_NN ._.
The_DT Company_NN considers_VBZ all_DT members_NNS of_IN the_DT is_VBZ ongoing_JJ ._.
The_DT Committee_NNP will_MD consult_VB with_IN its_PRP$ major_JJ shareholders_NNS Committee_NNP to_TO be_VB independent_JJ ._.
on_IN the_DT outcomes_NNS of_IN the_DT review_NN later_RB in_IN the_DT year_NN ._.
The_DT importance_NN of_IN the_DT US_NNP to_TO the_DT growth_NN of_IN the_DT Company_NN ,_, coupled_VBN with_IN the_DT fact_NN The_DT Chief_NNP Executive_NNP Officer_NNP attends_VBZ meetings_NNS of_IN the_DT Committee_NNP that_IN most_JJS of_IN its_PRP$ senior_JJ executives_NNS are_VBP based_VBN in_IN the_DT US_NNP ,_, presents_VBZ at_IN its_PRP$ invitation_NN ,_, but_CC is_VBZ not_RB involved_VBN in_IN any_DT decisions_NNS relating_VBG to_TO his_PRP$ the_DT Committee_NNP with_IN particular_JJ challenges_NNS ._.
While_IN the_DT Committee_NNP own_JJ remuneration_NN ._.
does_VBZ not_RB espouse_VB a_DT US_NNP pay_NN policy_NN ,_, it_PRP does_VBZ take_VB this_DT operating_NN environment_NN into_IN account_NN ._.
The_DT members_NNS of_IN the_DT Remuneration_NNP Committee_NNP during_IN 2004_CD were_VBD :_: As_IN part_NN of_IN the_DT compensation_NN review_NN ,_, the_DT Committee_NNP has_VBZ already_RB Dr_NNP Barry_NNP Price_NNP ,_, the_DT Senior_JJ Independent_NNP Director_NNP of_IN the_DT Company_NN decided_VBD to_TO phase_VB out_RP the_DT Deferred_NNP Bonus_NNP Plan_NNP and_CC to_TO modify_VB the_DT and_CC Chairman_NNP of_IN the_DT Committee_NNP :_: structure_NN of_IN the_DT Annual_JJ Incentive_NNP Plan_NNP ._.
The_DT changes_NNS are_VBP described_VBN below_IN ._.
The_DT modified_VBN incentive_NN structure_NN enables_VBZ Shire_NNP to_TO operate_VB Mr_NNP Robin_NNP Buchanan_NNP ,_, an_DT independent_JJ non-executive_JJ Director_NNP :_: a_DT common_JJ framework_NN for_IN the_DT senior_JJ executive_NN team_NN ,_, irrespective_RB of_IN location_NN ,_, and_CC to_TO be_VB competitive_JJ in_IN both_DT the_DT UK_NNP and_CC US_NNP ._.
Under_IN Mr_NNP Ronald_NNP Nordmann_NNP ,_, an_DT independent_JJ non-executive_JJ Director_NNP ,_, the_DT revised_VBN Annual_JJ Incentive_NNP Plan_NNP ,_, target_NN incentives_NNS will_MD be_VB earned_VBN who_WP joined_VBD the_DT Committee_NNP in_IN April_NNP 2004_CD :_: and_CC only_RB where_WRB executives_NNS have_VBP achieved_VBN Board-approved_JJ corporate_JJ objectives_NNS and_CC Committee-approved_JJ individual_JJ objectives_NNS ._.
Dr_NNP James_NNP Cavanaugh_NNP ,_, the_DT Chairman_NNP of_IN the_DT Company_NN ,_, who_WP stepped_VBD down_RP as_IN a_DT Committee_NNP member_NN in_IN April_NNP 2004_CD ._.
The_DT Remuneration_NNP Committee_NNP is_VBZ committed_VBN to_TO a_DT continuing_VBG dialogue_NN with_IN shareholders_NNS and_CC we_PRP strive_VBP to_TO accommodate_VB your_PRP$ Details_NNS of_IN the_DT number_NN of_IN Committee_NNP meetings_NNS in_IN 2004_CD and_CC the_DT views_NNS ._.
We_PRP hope_VBP that_IN this_DT report_NN provides_VBZ helpful_JJ context_NN and_CC attendance_NN at_IN those_DT meetings_NNS is_VBZ set_VBN out_RP in_IN the_DT section_NN headed_VBD explanation_NN about_IN the_DT policies_NNS and_CC practical_JJ considerations_NNS that_WDT Corporate_JJ governance_NN statements_NNS ._.
The_DT Remuneration_NNP Committee_NNP was_VBD materially_RB assisted_VBN in_IN 2004_CD by_IN Mrs_NNP Anita_NNP Graham_NNP ,_, EVP_NNP Global_NNP Human_NNP Resources_NNPS ,_, Ms_NNPS Tatjana_NNP May_NNP ,_, EVP_NNP ,_, General_NNP Counsel_NNP and_CC Mr_NNP Matthew_NNP Emmens_NNP ,_, the_DT Chief_NNP Executive_NNP Officer_NNP ._.
No_DT individual_NN is_VBZ involved_VBN in_IN the_DT determination_NN of_IN their_PRP$ own_JJ remuneration_NN ._.
The_DT following_VBG external_JJ advisers_NNS were_VBD Dr_NNP Barry_NNP Price_NNP appointed_VBN by_IN and_CC materially_RB assisted_VBD the_DT Committee_NNP :_: Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Towers_NNP Perrin_NNP :_: and_CC Slaughter_NNP and_CC May_NNP ,_, who_WP provided_VBD general_JJ legal_JJ advice_NN to_TO the_DT Company_NN ._.
Remuneration_NNP policy_NN The_DT Remuneration_NNP Committee_NNP considers_VBZ that_IN an_DT effective_JJ remuneration_NN policy_NN is_VBZ an_DT important_JJ contributor_NN to_TO the_DT Companys_NNPS success_NN ._.
It_PRP directly_RB impacts_VBZ the_DT Companys_NNP ability_NN to_TO recruit_VB ,_, retain_VB and_CC motivate_VB high_JJ calibre_NN executives_NNS who_WP embody_VBP the_DT Companys_NNPS values_NNS and_CC deliver_VB value_NN to_TO shareholders_NNS ._.
36_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 37_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN developing_VBG ,_, 10-K_NNP under_IN US_NNP GAAP_NNP ._.
The_DT detailed_JJ objectives_NNS and_CC performance_NN reviewing_VBG and_CC overseeing_VBG the_DT implementation_NN of_IN the_DT Companys_NNP standards_NNS contain_VBP commercially_RB sensitive_JJ information_NN and_CC compensation_NN and_CC benefits_NNS policy_NN ._.
The_DT effectiveness_NN of_IN the_DT current_JJ therefore_RB are_VBP not_RB summarised_VBN here_RB ._.
However_RB ,_, the_DT 2004_CD corporate_JJ policy_NN is_VBZ regularly_RB monitored_VBN by_IN the_DT Remuneration_NNP Committee_NNP ._.
objectives_NNS included_VBD specific_JJ targets_NNS in_IN the_DT following_VBG areas_NNS :_: The_DT existing_VBG policy_NN is_VBZ based_VBN on_IN the_DT following_VBG principles_NNS ,_, which_WDT growth_NN in_IN revenue_NN :_: are_VBP currently_RB under_IN review_NN :_: growth_NN in_IN net_JJ income_NN :_: Base_NNP pay_NN is_VBZ market-driven_JJ and_CC is_VBZ targeted_VBN at_IN or_CC around_IN the_DT median_NN relative_JJ to_TO the_DT appropriate_JJ comparator_NN groups_NNS ._.
progression_NN of_IN R&D_NNP portfolio_NN :_: The_DT Annual_JJ Incentive_NNP Plan_NNP is_VBZ performance-based_JJ and_CC is_VBZ linked_VBN operational_JJ objectives_NNS ,_, including_VBG the_DT sale_NN of_IN Shires_NNP vaccines_NNS to_TO the_DT achievement_NN of_IN an_DT appropriate_JJ mix_NN of_IN corporate_JJ and_CC business_NN :_: and_CC individual_JJ performance_NN targets_NNS ._.
minimizing_VBG disruption_NN to_TO the_DT business_NN while_IN implementing_VBG The_DT Committee_NNP currently_RB aims_VBZ for_IN the_DT performance-related_JJ the_DT Companys_NNPS internal_JJ reorganisation_NN ._.
elements_NNS of_IN executive_NN Director_NNP compensation_NN to_TO represent_VB over_IN half_NN of_IN total_JJ remuneration_NN ._.
The_DT Remuneration_NNP Committee_NNP assesses_VBZ performance_NN against_IN objectives_NNS in_IN the_DT first_JJ quarter_NN of_IN the_DT following_JJ year_NN ._.
The_DT annual_JJ Share-based_JJ compensation_NN is_VBZ a_DT key_JJ element_NN of_IN the_DT Companys_NNP incentive_NN is_VBZ payable_JJ in_IN cash_NN and_CC is_VBZ not_RB pensionable_JJ ._.
The_DT target_NN remuneration_NN policy_NN as_IN it_PRP aligns_VBZ the_DT interests_NNS of_IN the_DT Companys_NNP incentive_NN is_VBZ paid_VBN where_WRB executive_JJ Directors_NNS have_VBP fully_RB achieved_VBN executives_NNS with_IN the_DT interests_NNS of_IN its_PRP$ shareholders_NNS ._.
their_PRP$ individual_JJ objectives_NNS and_CC the_DT corporate_JJ objectives_NNS have_VBP been_VBN met_VBN in_IN full_JJ ._.
The_DT maximum_NN incentive_NN is_VBZ paid_VBN only_RB if_IN the_DT The_DT remuneration_NN package_NN Remuneration_NNP Committee_NNP determines_VBZ that_IN individual_JJ and_CC or_CC The_DT main_JJ elements_NNS of_IN the_DT remuneration_NN package_NN for_IN executive_JJ corporate_JJ performance_NN has_VBZ been_VBN exceptional_JJ ._.
Maximum_NNP incentive_NN Directors_NNS and_CC senior_JJ management_NN are_VBP :_: payments_NNS for_IN 2004_CD were_VBD capped_VBN at_IN 100_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC 75_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Financial_NNP Officer_NNP ._.
1_CD Salary_NNP Target_NNP Maximum_NNP Weighting_NN of_IN target_NN incentive_NN incentive_NN incentive_NN objectives_NNS 2_CD Annual_JJ Incentive_NNP Plan_NNP as_IN a_DT %_NN as_IN a_DT %_NN of_IN salary_NN of_IN salary_NN Corporate_JJ Individual_JJ 3_CD Long-term_JJ incentives_NNS Mr_NNP Matthew_NNP Emmens_NNP a_DT Share_NN options_NNS Chief_NNP Executive_NNP Officer_NNP 55_CD %_NN 100_CD %_NN 80_CD %_NN 20_CD %_NN b_NN Long_NNP Term_NNP Incentive_NNP Plan_NNP c_NN Deferred_NNP Bonus_NNP Plan_NNP Mr_NNP Angus_NNP Russell_NNP Chief_NNP Financial_NNP Officer_NNP 50_CD %_NN 75_CD %_NN 60_CD %_NN 40_CD %_NN 4_CD Pension_NN and_CC other_JJ benefits_NNS The_DT incentive_NN payments_NNS awarded_VBD to_TO each_DT executive_NN Director_NNP for_IN 2004_CD 1_CD Salary_NNP reflects_VBZ the_DT corporate_JJ and_CC individual_JJ achievements_NNS and_CC amounted_VBD The_DT Remuneration_NNP Committee_NNP reviews_VBZ salaries_NNS annually_RB ._.
In_IN doing_VBG to_TO 80_CD %_NN of_IN salary_NN for_IN Mr_NNP Emmens_NNP and_CC 75_CD %_NN of_IN salary_NN for_IN Mr_NNP Russell_NNP ._.
so_RB ,_, it_PRP looks_VBZ at_IN a_DT range_NN of_IN factors_NNS such_JJ as_IN competitive_JJ market_NN These_DT incentive_NN awards_NNS are_VBP consistent_JJ with_IN the_DT overall_JJ performance_NN data_NNS provided_VBN by_IN independent_JJ external_JJ consultants_NNS ,_, local_JJ market_NN of_IN the_DT Company_NN in_IN 2004_CD which_WDT included_VBD achieving_VBG 13_CD %_NN revenue_NN conditions_NNS ,_, performance-related_JJ pay_NN increases_NNS across_IN the_DT growth_NN ,_, 12_CD %_NN growth_NN in_IN income_NN from_IN continuing_VBG operations_NNS and_CC Company_NN and_CC individual_JJ skills_NNS and_CC performance_NN ._.
The_DT Remuneration_NNP the_DT highly_RB successful_JJ implementation_NN of_IN all_DT objectives_NNS focused_VBD on_IN Committees_NNS policy_NN is_VBZ for_IN salary_NN to_TO be_VB targeted_VBN at_IN or_CC around_IN the_DT realignment_NN of_IN the_DT Companys_NNPS business_NN model_NN ._.
the_DT median_NN of_IN the_DT relevant_JJ comparator_NN groups_NNS ,_, with_IN appropriate_JJ differentiation_NN based_VBN upon_IN skills_NNS and_CC experience_NN as_RB well_RB as_IN As_IN part_NN of_IN the_DT broader_JJR compensation_NN and_CC benefits_NNS review_NN which_WDT is_VBZ individual_JJ performance_NN ._.
continuing_VBG into_IN 2005_CD ,_, the_DT Annual_JJ Incentive_NNP Plan_NNP has_VBZ been_VBN modified_VBN ._.
For_IN the_DT financial_JJ year_NN 2005_CD ,_, the_DT target_NN incentive_NN amounts_NNS for_IN the_DT 2_CD Annual_JJ Incentive_NNP Plan_NNP Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP are_VBP Shire_NNP operates_VBZ an_DT Annual_JJ Incentive_NNP Plan_NNP which_WDT rewards_VBZ respectively_RB 65_CD %_NN and_CC 55_CD %_NN of_IN salary_NN and_CC the_DT maximum_NN incentive_NN performance_NN dependent_JJ on_IN achievement_NN of_IN pre-defined_JJ Boardamounts_NNS are_VBP respectively_RB 115_CD %_NN and_CC 100_CD %_NN of_IN salary_NN ._.
The_DT levels_NNS approved_VBD corporate_JJ objectives_NNS and_CC Committee_NNP approved_VBD of_IN target_NN and_CC maximum_NN incentives_NNS have_VBP been_VBN set_VBN to_TO be_VB individual_JJ objectives_NNS ._.
The_DT objectives_NNS are_VBP determined_VBN at_IN the_DT start_NN of_IN competitive_JJ in_IN both_DT the_DT UK_NNP and_CC US_NNP and_CC to_TO enable_VB Shire_NNP to_TO operate_VB each_DT financial_JJ year_NN to_TO ensure_VB alignment_NN ._.
The_DT corporate_JJ objectives_NNS a_DT common_JJ framework_NN for_IN the_DT senior_JJ executive_NN team_NN irrespective_RB apply_VB to_TO all_DT employees_NNS participating_VBG in_IN the_DT Companys_NNP Annual_JJ of_IN location_NN ._.
The_DT weighting_NN between_IN corporate_JJ and_CC individual_JJ Incentive_NNP Plan_NNP ._.
Each_DT objective_NN ,_, whether_IN corporate_JJ or_CC individual_JJ ,_, objectives_NNS remains_VBZ the_DT same_JJ for_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC is_VBZ weighted_JJ and_CC is_VBZ described_VBN in_IN specific_JJ and_CC measurable_JJ terms_NNS shifts_NNS from_IN 60_CD %_NN corporate_JJ and_CC 40_CD %_NN individual_NN to_TO 70_CD %_NN corporate_JJ with_IN allocated_VBN deadlines_NNS ._.
Performance_NNP standards_NNS are_VBP set_VBN for_IN and_CC 30_CD %_NN individual_NN for_IN the_DT Chief_NNP Financial_NNP Officer_NNP ._.
each_DT objective_NN so_RB that_IN target_NN incentives_NNS are_VBP awarded_VBN only_RB when_WRB exacting_VBG levels_NNS of_IN performance_NN have_VBP been_VBN achieved_VBN ._.
Objectives_NNS measured_VBN by_IN the_DT Companys_NNPS financial_JJ performance_NN are_VBP assessed_VBN on_IN the_DT Companys_NNPS results_NNS ,_, as_IN reported_VBN in_IN the_DT Companys_NNP Form_NN 37_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 38_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN 3_CD Long-term_JJ incentives_NNS Retesting_NNP has_VBZ been_VBN retained_VBN so_RB far_RB on_IN this_DT limited_JJ basis_NN in_IN order_NN to_TO a_DT Share_NN options_NNS maintain_VBP the_DT Schemes_NNPS international_JJ competitiveness_NN ._.
In_IN particular_JJ ,_, Executive_NNP Directors_NNS are_VBP eligible_JJ to_TO participate_VB in_IN the_DT Companys_NNPS the_DT Committee_NNP is_VBZ conscious_JJ of_IN the_DT fact_NN that_IN performance_NN tests_NNS 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN ._.
Share_NN options_NNS ,_, which_WDT are_VBP not_RB attached_VBN to_TO the_DT vesting_NN of_IN options_NNS in_IN many_JJ markets_NNS ,_, form_NN part_NN of_IN the_DT executive_NN Directors_NNS long-term_JJ compensation_NN ,_, including_VBG the_DT US_NNP ,_, and_CC that_IN phased_VBD vesting_NN of_IN options_NNS is_VBZ also_RB are_VBP used_VBN to_TO align_VB Directors_NNS interests_NNS with_IN those_DT of_IN shareholders_NNS common_JJ in_IN the_DT US_NNP ._.
and_CC to_TO promote_VB sustained_VBN long-term_JJ Company_NN performance_NN ._.
Any_DT new_JJ share_NN option_NN scheme_NN established_VBN in_IN the_DT future_NN will_MD The_DT grant_NN of_IN options_NNS to_TO executive_JJ Directors_NNS is_VBZ wholly_RB at_IN the_DT not_RB contain_VB a_DT retesting_NN feature_NN ._.
discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP ._.
The_DT face_NN value_NN of_IN annual_JJ option_NN grants_NNS under_IN the_DT Scheme_NNP is_VBZ capped_VBN at_IN three_CD times_NNS The_DT table_NN below_IN sets_NNS out_IN the_DT share_NN options_NNS that_WDT were_VBD granted_VBN salary_NN per_IN year_NN for_IN executive_NN Directors_NNS and_CC senior_JJ managers_NNS ._.
This_DT to_TO executive_JJ Directors_NNS during_IN 2004_CD ._.
annual_JJ grant_NN level_NN is_VBZ consistent_JJ with_IN the_DT Companys_NNP emphasis_NN on_IN Number_NN of_IN Exercise_NNP performance-linked_JJ share-based_JJ remuneration_NN for_IN its_PRP$ executives_NNS ._.
Executive_NNP Director_NNP and_CC ordinary_JJ price_NN The_DT Committee_NNP recognizes_VBZ that_IN the_DT total_NN expected_VBN value_NN of_IN share_NN option_NN scheme_NN Date_NNP of_IN grant_NN shares_NNS Shires_VBZ long-term_JJ incentive_NN arrangements_NNS is_VBZ above_IN upper_JJ quartile_NN Mr_NNP Matthew_NNP Emmens_NNP in_IN the_DT UK_NNP ._.
However_RB it_PRP is_VBZ satisfied_VBN with_IN this_DT on_IN the_DT basis_NN that_WDT 2000_CD Executive_NNP Scheme_NNP 25.03.04_CD 315,777_CD 5.26_CD executive_NN Directors_NNS will_MD only_RB benefit_VB from_IN the_DT arrangements_NNS when_WRB shareholder_NN interests_NNS have_VBP been_VBN met_VBN ._.
Mr_NNP Angus_NNP Russell_NNP 2000_CD Executive_NNP Scheme_NNP 25.03.04_CD 195,285_CD 5.26_CD The_DT current_JJ performance_NN measure_NN for_IN the_DT vesting_NN of_IN options_NNS was_VBD introduced_VBN in_IN 2002_CD following_VBG consultation_NN with_IN major_JJ institutional_JJ Where_WRB accounting_NN changes_NNS have_VBP an_DT impact_NN on_IN the_DT calculation_NN shareholders_NNS ._.
The_DT performance_NN tests_NNS for_IN executive_NN Directors_NNS of_IN EPS_NNP ,_, the_DT Remuneration_NNP Committee_NNP will_MD seek_VB at_IN all_DT times_NNS to_TO options_NNS were_VBD toughened_VBN following_VBG this_DT consultation_NN process_NN ._.
The_DT ensure_VB consistency_NN of_IN measurement_NN when_WRB determining_VBG whether_IN performance_NN tests_NNS are_VBP based_VBN on_IN real_JJ growth_NN in_IN diluted_JJ earnings_NNS performance_NN tests_NNS have_VBP been_VBN met_VBN ._.
per_IN share_NN EPS_NNP as_IN measured_VBN by_IN diluted_JJ EPS_NNP and_CC as_IN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN under_IN US_NNP GAAP_NNP ._.
This_DT measure_NN Details_NNS of_IN the_DT Companys_NNP share_NN option_NN schemes_NNS are_VBP set_VBN out_RP in_IN is_VBZ favored_VBN by_IN the_DT Remuneration_NNP Committee_NNP because_IN it_PRP is_VBZ Note_NN 28_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
Performance_NNP transparent_JJ and_CC is_VBZ a_DT relevant_JJ indicator_NN of_IN financial_JJ performance_NN ._.
conditions_NNS attaching_VBG to_TO previous_JJ executive_NN option_NN grants_NNS are_VBP detailed_VBN on_IN page_NN 44_CD in_IN the_DT audited_JJ section_NN of_IN this_DT report_NN ._.
The_DT minimum_JJ performance_NN test_NN attaching_VBG to_TO the_DT exercise_NN of_IN share_NN options_NNS for_IN executive_NN Directors_NNS is_VBZ higher_JJR than_IN for_IN other_JJ employees_NNS ._.
b_NN Long_NNP Term_NNP Incentive_NNP Plan_NNP No_NNP options_NNS vest_NN unless_IN Shires_NNP EPS_NNP meets_VBZ the_DT minimum_JJ growth_NN The_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP the_DT Plan_NN was_VBD adopted_VBN at_IN the_DT threshold_NN set_NN of_IN 15_CD %_NN in_IN excess_NN of_IN the_DT Retail_NNP Price_NNP Index_NNP RPI_NNP Companys_NNPS 1998_CD Annual_JJ General_NNP Meeting_VBG and_CC amended_VBN in_IN 2000_CD ._.
or_CC 5_CD %_NN on_IN average_NN a_DT year_NN in_IN the_DT three_CD years_NNS following_VBG the_DT date_NN of_IN Under_IN the_DT Plan_NN ,_, the_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN grant_NN ._.
In_IN the_DT case_NN of_IN an_DT annual_JJ grant_NN of_IN options_NNS worth_JJ three_CD times_NNS to_TO make_VB awards_NNS of_IN shares_NNS ,_, subject_JJ to_TO a_DT maximum_NN of_IN 100_CD %_NN salary_NN ,_, Shires_NNP EPS_NNP must_MD grow_VB by_IN 21_CD %_NN in_IN excess_NN of_IN RPI_NNP or_CC on_IN of_IN salary_NN a_DT year_NN ._.
Awards_NNS are_VBP made_VBN to_TO executive_JJ Directors_NNS and_CC average_JJ 7_CD %_NN a_DT year_NN in_IN the_DT three_CD years_NNS following_VBG the_DT date_NN of_IN grant_NN senior_JJ managers_NNS ._.
for_IN all_PDT the_DT options_NNS to_TO vest_NN ._.
The_DT performance_NN condition_NN attached_VBN to_TO the_DT vesting_NN of_IN the_DT share_NN Options_NNS with_IN a_DT value_NN on_IN grant_NN as_IN a_DT %_NN of_IN salary_NN Three-year_JJ EPS_NNP growth_NN awards_NNS made_VBN under_IN the_DT Plan_NN is_VBZ Shires_NNP Total_NNP Shareholder_NN Return_NN TSR_NNP relative_JJ to_TO the_DT FTSE_NNP 100_CD Index_NNP over_IN a_DT three-year_JJ period_NN ._.
Up_IN to_TO 100_CD %_NN Retail_NNP Price_NNP Index_NNP RPI_NNP plus_CC 15_CD %_NN The_DT Committee_NNP considers_VBZ that_IN this_DT measure_NN is_VBZ a_DT reliable_JJ and_CC for_IN executive_JJ Directors_NNS appropriate_JJ measure_NN of_IN the_DT Companys_NNP performance_NN and_CC that_IN the_DT RPI_NNP plus_CC 9_CD %_NN for_IN all_DT other_JJ employees_NNS FTSE_VBP 100_CD is_VBZ an_DT appropriate_JJ benchmark_NN given_VBN that_IN the_DT Company_NN 101_CD %_NN to_TO 200_CD %_NN RPI_NNP plus_CC 15_CD %_NN is_VBZ a_DT member_NN of_IN the_DT Index_NN ._.
201_CD %_NN to_TO 300_CD %_NN RPI_NNP plus_CC 21_CD %_NN Under_IN the_DT current_JJ Plan_NN :_: Over_IN 301_CD %_NN RPI_NNP plus_CC 27_CD %_NN all_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ in_IN the_DT top_JJ 10_CD %_NN of_IN the_DT FTSE_NNP 100_CD :_: The_DT 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, which_WDT was_VBD approved_VBN 20_CD %_NN of_IN the_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ at_IN the_DT median_NN of_IN the_DT by_IN shareholders_NNS in_IN 2000_CD ,_, contains_VBZ an_DT unlimited_JJ retesting_NN feature_NN FTSE_NNP 100_CD ,_, with_IN vesting_VBG between_IN these_DT points_NNS on_IN a_DT linear_JJ basis_NN :_: from_IN the_DT date_NN of_IN grant_NN ._.
The_DT Remuneration_NNP Committee_NNP decided_VBD ,_, and_CC after_IN consultation_NN with_IN some_DT of_IN the_DT Companys_NNP major_JJ institutional_JJ shareholders_NNS in_IN 2003_CD ,_, that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN no_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ below_IN the_DT median_NN of_IN the_DT from_IN 2004_CD onwards_NNS ,_, the_DT performance_NN condition_NN should_MD be_VB retested_VBN FTSE_NNP 100_CD ._.
once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
The_DT retest_NN will_MD be_VB applied_VBN only_RB where_WRB Shires_NNP EPS_NNP growth_NN has_VBZ not_RB met_VBN the_DT minimum_JJ performance_NN test_NN described_VBN above_IN ._.
The_DT annual_JJ average_JJ growth_NN required_VBN over_IN the_DT first_JJ three_CD years_NNS must_MD be_VB achieved_VBN over_IN the_DT extended_JJ performance_NN period_NN ._.
38_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 39_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN The_DT Remuneration_NNP Committee_NNP determines_VBZ whether_IN and_CC to_TO what_WP 4_CD Pension_NN and_CC other_JJ benefits_NNS extent_NN the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN on_IN the_DT basis_NN of_IN The_DT Companys_NNPS policy_NN is_VBZ to_TO ensure_VB that_IN pension_NN benefits_NNS are_VBP data_NNS provided_VBN by_IN an_DT independent_JJ third_JJ party_NN ._.
To_TO date_NN ,_, all_DT awards_NNS competitive_JJ in_IN the_DT markets_NNS in_IN which_WDT Shire_NNP operates_VBZ ._.
Shire_NNP made_VBD under_IN the_DT Plan_NN have_VBP been_VBN made_VBN as_IN a_DT conditional_JJ allocation_NN ,_, contributes_VBZ 30_CD %_NN of_IN the_DT Chief_NNP Executive_NNP Officers_NNPS annual_JJ salary_NN thereby_RB allowing_VBG ,_, at_IN the_DT Remuneration_NNP Committees_NNS discretion_NN ,_, to_TO a_DT SERP_NNP and_CC 401_CD k_NN Plan_NN in_IN the_DT US_NNP ._.
In_IN the_DT UK_NNP ,_, Shire_NNP operates_VBZ for_IN a_DT cash_NN equivalent_NN to_TO be_VB paid_VBN on_IN maturity_NN of_IN the_DT award_NN ._.
The_DT Company_NN contributes_VBZ 25_CD %_NN the_DT performance_NN period_NN is_VBZ measured_VBN over_IN three_CD years_NNS ,_, an_DT award_NN of_IN salary_NN for_IN the_DT Chief_NNP Financial_NNP Officer_NNP to_TO pension_NN benefits_NNS ._.
The_DT is_VBZ normally_RB transferred_VBN after_IN the_DT fourth_JJ anniversary_NN of_IN grant_NN ,_, to_TO the_DT implications_NNS of_IN the_DT forthcoming_JJ UK_NNP pension_NN tax_NN reforms_NNS which_WDT extent_NN the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN ._.
become_VBN effective_JJ in_IN 2006_CD will_MD be_VB considered_VBN during_IN the_DT course_NN of_IN the_DT year_NN and_CC the_DT Committee_NNP will_MD agree_VB any_DT policy_NN changes_NNS Directors_NNS were_VBD granted_VBN awards_NNS under_IN the_DT Plan_NN in_IN 2004_CD as_RB necessary_JJ in_IN respect_NN of_IN the_DT pension_NN arrangements_NNS of_IN the_DT a_DT conditional_JJ allocation_NN as_IN defined_VBN in_IN the_DT Plan_NN ,_, as_IN follows_VBZ :_: Chief_NNP Financial_NNP Officer_NNP and_CC other_JJ UK_NNP executives_NNS ._.
Earliest_JJS date_NN In_IN addition_NN to_TO salary_NN ,_, the_DT executive_NN Directors_NNS receive_VBP certain_JJ on_IN which_WDT benefits_NNS in_IN kind_NN ,_, principally_RB a_DT car_NN or_CC car_NN allowance_NN ,_, life_NN insurance_NN ,_, Value_NNP of_IN an_DT award_NN conditional_JJ Total_NNP can_MD be_VB private_JJ medical_JJ insurance_NN and_CC dental_JJ cover_NN ._.
These_DT benefits_NNS are_VBP award_NN at_IN number_NN of_IN transferred_VBN not_RB pensionable_JJ ._.
Date_NN of_IN grant_NN date_NN ordinary_JJ to_TO a_DT award_NN shares_NNS Director_NNP Service_NNP contracts_NNS Mr_NNP Matthew_NNP Emmens_NNP 25.03.04_CD 563,136_CD 105,259_CD 25.03.08_CD The_DT Remuneration_NNP Committee_NNP continues_VBZ to_TO believe_VB that_IN executive_JJ Directors_NNS service_NN contracts_NNS should_MD be_VB for_IN a_DT rolling_VBG Mr_NNP Angus_NNP Russell_NNP 25.03.04_CD 348,258_CD 65,095_CD 25.03.08_CD term_NN and_CC ,_, for_IN UK_NNP contracts_NNS ,_, incorporate_VB notice_NN periods_NNS of_IN 12_CD months_NNS ._.
The_DT Committee_NNP also_RB believes_VBZ that_IN the_DT Company_NN c_NN Deferred_NNP Bonus_NNP Plan_NNP should_MD retain_VB the_DT right_NN to_TO make_VB a_DT payment_NN in_IN lieu_NN of_IN notice_NN to_TO The_DT Deferred_NNP Bonus_NNP Plan_NNP ,_, in_IN which_WDT executive_JJ Directors_NNS can_MD a_DT Director_NNP ._.
The_DT contracts_NNS contain_VBP obligations_NNS on_IN the_DT executive_NN participate_VB ,_, provides_VBZ for_IN participants_NNS to_TO use_VB up_RP to_TO 50_CD %_NN of_IN their_PRP$ Directors_NNS in_IN respect_NN of_IN intellectual_JJ property_NN ,_, together_RB with_IN postannual_JJ incentive_NN to_TO buy_VB shares_NNS in_IN the_DT Company_NN ._.
The_DT Committees_NNS view_VBP is_VBZ that_IN ,_, in_IN the_DT will_MD match_VB any_DT shares_NNS bought_VBD ,_, but_CC the_DT matched_VBN shares_NNS will_MD vest_NN ,_, event_NN of_IN early_JJ termination_NN ,_, executive_NN Directors_NNS should_MD be_VB treated_VBN for_IN executive_NN Directors_NNS ,_, only_RB if_IN the_DT Companys_NNPS EPS_NNP as_IN measured_VBN fairly_RB but_CC paid_VBD no_RB more_JJR than_IN is_VBZ necessary_JJ ._.
Moreover_RB ,_, there_EX by_IN diluted_JJ EPS_NNP and_CC as_IN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN should_MD be_VB no_DT element_NN of_IN reward_NN for_IN failure_NN ._.
under_IN US_NNP GAAP_NNP grows_VBZ by_IN more_JJR than_IN 15_CD %_NN in_IN excess_NN of_IN RPI_NNP over_IN a_DT three-year_JJ period_NN 9_CD %_NN in_IN excess_NN of_IN RPI_NNP for_IN other_JJ eligible_JJ The_DT executive_NN Directors_NNS contracts_NNS of_IN employment_NN ,_, which_WDT employees_NNS ._.
Diluted_VBN EPS_NNP was_VBD chosen_VBN since_IN it_PRP is_VBZ consistent_JJ with_IN were_VBD revised_VBN following_VBG consultation_NN with_IN some_DT of_IN the_DT Companys_NNPS the_DT minimum_JJ performance_NN test_NN that_WDT applies_VBZ to_TO the_DT vesting_NN of_IN major_JJ shareholders_NNS in_IN 2003_CD ,_, are_VBP dated_VBN 10_CD March_NNP 2004_CD in_IN the_DT options_NNS see_VBP above_IN ._.
case_NN of_IN Mr_NNP Russell_NNP and_CC 12_CD March_NNP 2004_CD in_IN the_DT case_NN of_IN Mr_NNP Emmens_NNP ._.
Mr_NNP Russells_NNPS contract_NN requires_VBZ him_PRP to_TO give_VB the_DT Company_NN This_DT Plan_NN was_VBD designed_VBN to_TO deliver_VB value_NN to_TO shareholders_NNS by_IN 12_CD months_NNS notice_NN and_CC expires_VBZ on_IN him_PRP reaching_VBG 65_CD ._.
Mr_NNP Emmens_NNP encouraging_JJ executive_NN share_NN ownership_NN ._.
However_RB ,_, recent_JJ contract_NN requires_VBZ him_PRP to_TO give_VB the_DT Company_NN six_CD months_NNS notice_VBP fiscal_JJ changes_NNS in_IN the_DT US_NNP have_VBP made_VBN the_DT Plan_NNP less_RBR attractive_JJ to_TO and_CC no_DT age_NN is_VBZ specified_VBN for_IN retirement_NN ._.
The_DT Company_NN is_VBZ required_VBN participants_NNS and_CC the_DT Remuneration_NNP Committee_NNP has_VBZ determined_VBN to_TO give_VB Mr_NNP Russell_NNP 12_CD months_NNS notice_NN of_IN termination_NN ,_, other_JJ than_IN that_IN it_PRP will_MD discontinue_VB the_DT Plan_NN after_IN bonus_NN awards_NNS for_IN the_DT 2004_CD if_IN termination_NN is_VBZ for_IN cause_NN ,_, whereas_IN it_PRP is_VBZ not_RB obliged_VBN to_TO give_VB financial_JJ year_NN ._.
The_DT Committee_NNP is_VBZ reviewing_VBG the_DT design_NN and_CC implementation_NN of_IN its_PRP$ In_IN the_DT event_NN of_IN termination_NN of_IN employment_NN within_IN 12_CD months_NNS current_JJ long_JJ term_NN incentive_NN plans_NNS as_IN part_NN of_IN its_PRP$ compensation_NN and_CC of_IN a_DT change_NN of_IN control_NN ,_, the_DT amount_NN payable_JJ is_VBZ one_CD years_NNS salary_NN benefits_NNS review_NN ._.
Shareholders_NNS will_MD be_VB consulted_VBN on_IN this_DT during_IN the_DT and_CC the_DT cash_NN equivalent_NN of_IN one_CD years_NNS pension_NN ,_, car_NN and_CC other_JJ course_NN of_IN the_DT year_NN ._.
Any_DT incentive_NN payable_JJ is_VBZ at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ capped_VBN at_IN the_DT contractual_JJ maximum_NN incentive_NN ._.
The_DT amount_NN of_IN incentive_NN payable_JJ upon_IN termination_NN of_IN employment_NN in_IN any_DT other_JJ circumstances_NNS ,_, other_JJ than_IN for_IN cause_NN ,_, is_VBZ at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ capped_VBN at_IN the_DT contractual_JJ target_NN incentive_NN ._.
39_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 40_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Non-executive_JJ Directors_NNS and_CC the_DT Chairman_NNP Performance_NNP graph_NN Each_DT non-executive_JJ Director_NNP is_VBZ paid_VBN a_DT fee_NN for_IN serving_VBG as_IN a_DT Director_NNP The_NNP graph_NN below_IN sets_NNS out_IN the_DT Total_JJ Shareholder_NN Return_NN TSR_NNP for_IN and_CC additional_JJ fees_NNS are_VBP paid_VBN for_IN membership_NN or_CC chairmanship_NN the_DT five_CD years_NNS ending_VBG 31_CD December_NNP 2004_CD ._.
The_DT graph_NN compares_VBZ of_IN the_DT Audit_NNP ,_, Remuneration_NNP and_CC Nomination_NNP Committees_NNS ._.
The_DT the_DT performance_NN of_IN a_DT holding_NN of_IN the_DT Companys_NNP shares_NNS with_IN Chairman_NNP of_IN the_DT Company_NN receives_VBZ an_DT inclusive_JJ fee_NN ._.
Fees_NNS are_VBP that_IN of_IN a_DT holding_NN of_IN shares_NNS in_IN the_DT FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP determined_VBN by_IN the_DT Board_NNP ,_, with_IN the_DT exception_NN of_IN the_DT Chairmans_NNP Index_NNP over_IN the_DT relevant_JJ period_NN ,_, calculated_VBN in_IN accordance_NN with_IN fee_NN ,_, which_WDT is_VBZ determined_VBN by_IN the_DT Remuneration_NNP Committee_NNP and_CC the_DT Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD ._.
The_DT confirmed_VBN by_IN the_DT Board_NNP ._.
Fees_NNS are_VBP benchmarked_VBN against_IN nonFTSE_JJ UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP has_VBZ been_VBN selected_VBN to_TO show_VB executive_JJ Director_NNP fees_NNS of_IN comparable_JJ companies_NNS ._.
The_DT fees_NNS shareholders_NNS how_WRB Shires_NNP TSR_NNP has_VBZ performed_VBN relative_JJ to_TO other_JJ paid_VBN to_TO non-executive_JJ Directors_NNS are_VBP not_RB performance-related_JJ ._.
companies_NNS in_IN its_PRP$ sector_NN over_IN a_DT five-year_JJ period_NN ._.
Details_NNS of_IN fees_NNS paid_VBN to_TO the_DT Chairman_NNP and_CC non-executive_JJ Directors_NNS in_IN 2004_CD are_VBP set_VBN out_RP in_IN the_DT table_NN on_IN page_NN 41_CD ._.
Change_NNP in_IN the_DT Value_NN of_IN a_DT Hypothetical_JJ 100_CD Holding_NNP Over_IN Five_CD Years_NNS ._.
The_DT non-executive_JJ Directors_NNS are_VBP not_RB eligible_JJ to_TO join_VB the_DT Companys_NNPS FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP Comparison_NNP Based_VBD pension_NN scheme_NN ._.
200_CD Non-executive_JJ Directors_NNS do_VBP not_RB participate_VB in_IN any_DT of_IN the_DT Company_NN share_NN schemes_NNS or_CC other_JJ employee_NN benefit_NN schemes_NNS and_CC no_DT options_NNS have_VBP been_VBN granted_VBN to_TO non-executive_JJ Directors_NNS in_IN their_PRP$ capacity_NN as_IN non-executive_JJ Directors_NNS of_IN Shire_NNP ._.
On_IN the_DT merger_NN of_IN Shire_NNP with_IN BioChem_NNP Pharma_NNP Inc._NNP in_IN 2001_CD ,_, options_NNS were_VBD granted_VBN 150_CD to_TO The_DT Hon_NNP James_NNP Grant_NNP in_IN replacement_NN for_IN Mr_NNP Grants_NNPS BioChem_NNP Pharma_NNP options_NNS ._.
The_DT grant_NN of_IN these_DT replacement_NN options_NNS and_CC the_DT original_JJ BioChem_NNP Pharma_NNP option_NN grant_NN were_VBD made_VBN on_IN the_DT same_JJ terms_NNS as_IN applied_VBN to_TO other_JJ employees_NNS at_IN the_DT time_NN ,_, including_VBG that_IN 100_CD these_DT options_NNS are_VBP not_RB subject_JJ to_TO any_DT performance_NN conditions_NNS ._.
The_DT Chairman_NNP and_CC the_DT non-executive_JJ Directors_NNS have_VBP letters_NNS of_IN appointment_NN detailing_VBG their_PRP$ specific_JJ terms_NNS of_IN engagement_NN which_WDT ,_, other_JJ than_IN for_IN Dr_NNP Price_NNP ,_, are_VBP for_IN a_DT two-year_JJ term_NN which_WDT may_MD be_VB 50_CD renewed_VBN ._.
Dr_NNP Prices_NNS re-appointment_NN in_IN January_NNP 2005_CD is_VBZ for_IN a_DT oneDec_JJ 1999_CD Dec_NNP 2000_CD Dec_NNP 2001_CD Dec_NNP 2002_CD Dec_NNP 2003_CD Dec_NNP 2004_CD year_NN term_NN which_WDT may_MD be_VB renewed_VBN ._.
Details_NNS of_IN the_DT unexpired_JJ terms_NNS of_IN the_DT letters_NNS of_IN appointment_NN and_CC notice_NN periods_NNS are_VBP as_IN follows_VBZ :_: Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN FTSE_NNP UK_NNP Pharma_NNP and_CC Biotech_NNP Index_NNP Date_NNP of_IN Date_NNP of_IN Notice_NNP Director_NNP appointment_NN term_NN expiry_JJ period_NN Termination_NN payments_NNS Dr_NNP James_NNP Cavanaugh_NNP 24.03.05_CD 23.03.07_CD 3_CD months_NNS Dr_NNP Wilson_NNP Totten_NNP stepped_VBD down_RP as_IN Chief_NNP Scientific_NNP Officer_NNP in_IN May_NNP 2004_CD ._.
He_PRP remained_VBD an_DT employee_NN of_IN the_DT Company_NN responsible_JJ Dr_NNP Barry_NNP Price_NNP 25.01.05_CD 24.01.06_CD 3_CD months_NNS for_IN special_JJ corporate_JJ projects_NNS ,_, including_VBG M&A_NNP and_CC the_DT continued_VBN The_DT Hon_NNP James_NNP Grant_NNP 11.05.03_CD 10.05.05_CD 3_CD months_NNS development_NN of_IN FOSRENOL_NNP until_IN his_PRP$ contract_NN was_VBD terminated_VBN by_IN the_DT Company_NN ._.
No_DT change_NN was_VBD made_VBN to_TO Dr_NNP Tottens_NNP terms_NNS and_CC Mr_NNP Ronald_NNP Nordmann_NNP 23.12.03_CD 22.12.05_CD 3_CD months_NNS conditions_NNS of_IN employment_NN on_IN his_PRP$ ceasing_VBG to_TO be_VB a_DT Director_NNP and_CC Mr_NNP Robin_NNP Buchanan_NNP 30.07.03_CD 29.07.05_CD 3_CD months_NNS he_PRP was_VBD paid_VBN no_DT compensation_NN for_IN loss_NN of_IN his_PRP$ office_NN as_IN a_DT Director_NNP ._.
Mr_NNP David_NNP Kappler_NNP 06.04.04_CD 05.04.06_CD 3_CD months_NNS Dr_NNP Tottens_NNP employment_NN ended_VBD on_IN 31_CD August_NNP 2004_CD ._.
Payment_NN was_VBD made_VBN to_TO him_PRP in_IN accordance_NN with_IN the_DT payment_NN in_IN lieu_NN of_IN notice_NN Related_VBN party_NN transactions_NNS provisions_NNS in_IN his_PRP$ contract_NN of_IN employment_NN ,_, amounting_VBG to_TO 639,265_CD ._.
Details_NNS of_IN transactions_NNS relating_VBG to_TO The_DT Hon_NNP James_NNP Grant_NNP ,_, who_WP is_VBZ a_DT partner_NN of_IN a_DT Canadian_JJ law_NN firm_NN with_IN which_WDT the_DT Company_NN incurred_VBN Details_NNS of_IN Dr_NNP Tottens_NNP options_NNS ,_, LTIP_NNP awards_NNS ,_, emoluments_NNS for_IN 2004_CD professional_JJ fees_NNS during_IN the_DT year_NN ,_, and_CC with_IN Mr_NNP Ronald_NNP Nordmann_NNP and_CC pension_NN contributions_NNS are_VBP set_VBN out_RP in_IN the_DT next_JJ part_NN of_IN this_DT and_CC Dr_NNP Francesco_NNP Bellini_NNP ,_, a_DT former_JJ non-executive_JJ Director_NNP ,_, are_VBP report_NN ,_, under_IN Audited_NNP Information_NNP ._.
given_VBN in_IN Note_NN 21_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
Other_JJ remuneration_NN Mr_NNP Emmens_NNP was_VBD appointed_VBN a_DT non-executive_JJ director_NN of_IN Vertex_NNP Pharmaceuticals_NNP Inc._NNP during_IN 2004_CD ._.
In_IN this_DT capacity_NN he_PRP was_VBD paid_VBN $_$ 14,000_CD in_IN 2004_CD ,_, which_WDT he_PRP will_MD retain_VB ._.
Mr_NNP Russell_NNP is_VBZ a_DT non-executive_JJ director_NN of_IN The_DT City_NNP of_IN London_NNP Investment_NNP Trust_NNP plc_NN and_CC its_PRP$ associated_VBN companies_NNS ,_, The_DT City_NNP of_IN London_NNP European_NNP Trust_NNP Limited_NNP ,_, The_NNP City_NNP of_IN London_NNP Investments_NNPS Limited_NNP and_CC The_NNP City_NNP of_IN London_NNP Finance_NNP Company_NNP Limited_NNP ._.
In_IN this_DT capacity_NN ,_, he_PRP was_VBD paid_VBN 16,500_CD in_IN 2004_CD ,_, which_WDT he_PRP will_MD retain_VB ._.
40_CD Value_NN of_IN Hypothetical_JJ 100_CD Holding_NNP 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 41_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Audited_VBN information_NN Aggregate_NNP Directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN were_VBD as_IN follows_VBZ :_: 2004 2003 000 000_CD Emoluments_NNP 2,592_CD 2,256_CD Money_NN purchase_NN pension_NN contributions_NNS 278_CD 4,676_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 118_CD 114_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 86_CD 276_CD Compensation_NNP for_IN loss_NN of_IN office_NN 1,335_CD 3,074_CD 8,657_CD Directors_NNS emoluments_VBZ Cash_NNP Non-cash_JJ benefits_NNS benefits_NNS Total_JJ Total_JJ Salary_NNP Incentive_NNP Fees_NNS in_IN kind_NN in_IN kind_NN 2004_CD 2003_CD Director_NNP 000 000 000 000_CD 000 000 000_CD Executive_NNP i_FW ii_FW Mr_NNP Matthew_NNP Emmens_NNP 545 437 437_CD 1,419_CD 699_CD Mr_NNP Angus_NNP Russell_NNP 342_CD 257_CD 11_CD 4_CD 614_CD 499_CD iii_FW Dr_FW Wilson_NNP Totten_NNP 142_CD 107_CD 4_CD 3_CD 256_CD 531_CD iv_NN Mr_NNP Rolf_NNP Stahel_NNP 311_CD 1,029_CD 801_CD 452_CD 7_CD 2,289_CD 2,040_CD Non-executive_JJ v_NN Dr_NNP James_NNP Cavanaugh_NNP 75_CD 75_CD 54_CD Dr_NNP Barry_NNP Price_NNP 60_CD 60_CD 43_CD The_DT Hon_NNP James_NNP Grant_NNP 40_CD 40_CD 35_CD Mr_NNP Ronald_NNP Nordmann_NNP 54_CD 54_CD 45_CD Mr_NNP Robin_NNP Buchanan_NNP 40_CD 40_CD 16_CD vi_FW Mr_NNP David_NNP Kappler_NNP 34_CD 34_CD vii_NN Dr_NNP Francesco_NNP Bellini_NNP 11_CD vii_FW Mr_NNP Gerard_NNP Veilleux_NNP 12 303 303 216_CD Total_JJ 1,029_CD 801 303 452_CD 7_CD 2,592_CD 2,256_CD Notes_NNP i_FW Paid_NNP in_IN US$_$ ,_, Mr_NNP Emmens_NNP annual_JJ salary_NN in_IN 2004_CD was_VBD $_$ 999,319_CD ._.
ii_FW The_DT Company_NN underwent_VBD a_DT major_JJ internal_JJ reorganisation_NN in_IN 2004_CD ,_, which_WDT resulted_VBD in_IN the_DT Company_NN selecting_VBG Philadelphia_NNP as_IN its_PRP$ US_NNP corporate_JJ headquarters_NNS ._.
Mr_NNP Emmens_NNP was_VBD paid_VBN 420,339_CD in_IN connection_NN with_IN costs_NNS associated_VBN with_IN his_PRP$ relocation_NN to_TO the_DT Philadelphia_NNP area_NN ._.
iii_FW Dr_FW Totten_FW stepped_VBD down_RP as_IN a_DT Director_NNP of_IN the_DT Company_NN on_IN 25_CD May_NNP 2004_CD ._.
iv_VB Mr_NNP Stahel_NNP stepped_VBD down_RP as_IN a_DT Director_NNP of_IN the_DT Company_NN on_IN 19_CD March_NNP 2003_CD ._.
v_FW The_DT Chairmans_NNPS fee_NN in_IN 2004_CD was_VBD 100,000_CD ._.
Dr_NNP Cavanaugh_NNP elected_VBD to_TO receive_VB 75,000_CD ._.
vi_FW Mr_NNP Kappler_NNP was_VBD appointed_VBN a_DT non-executive_JJ Director_NNP on_IN 6_CD April_NNP 2004_CD ._.
vii_FW Dr_FW Bellini_NNP and_CC Mr_NNP Veilleux_NNP stepped_VBD down_RP as_IN non-executive_JJ Directors_NNS of_IN the_DT Company_NN on_IN 10_CD May_NNP 2003_CD ._.
Cash_NN benefits_NNS in_IN kind_NN represent_VBP expense_NN allowances_NNS including_VBG dental_JJ costs_NNS and_CC ,_, in_IN the_DT case_NN of_IN Mr_NNP Emmens_NNP ,_, relocation_NN costs_NNS and_CC non-cash_JJ benefits_NNS represent_VBP emoluments_NNS ._.
Non-cash_JJ benefits_NNS in_IN kind_NN consist_VBP of_IN private_JJ medical_JJ insurance_NN ._.
Details_NNS of_IN the_DT exercise_NN of_IN share_NN options_NNS are_VBP disclosed_VBN on_IN page_NN 43_CD ._.
Non-executive_JJ Director_NNP remuneration_NN is_VBZ to_TO from_IN the_DT date_NN of_IN resignation_NN appointment_NN ._.
41_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 42_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN Dr_NNP Totten_NNP Directors_NNS shareholdings_NNS Dr_NNP Totten_NNP stepped_VBD down_RP as_IN the_DT Chief_NNP Scientific_NNP Officer_NNP on_IN 25_CD May_NNP Directors_NNS who_WP held_VBD office_NN at_IN the_DT end_NN of_IN the_DT year_NN had_VBD interests_NNS in_IN the_DT 2004_CD ._.
The_DT table_NN above_IN details_NNS Dr_NNP Tottens_NNP emoluments_VBZ for_IN the_DT share_NN capital_NN of_IN the_DT Company_NN as_IN follows_VBZ :_: period_NN of_IN 2004_CD while_IN he_PRP was_VBD a_DT Director_NNP of_IN the_DT Company_NN ._.
These_DT 31_CD December_NNP 31_CD December_NNP emoluments_NNS include_VBP incentive_NN ._.
The_DT Remuneration_NNP Committee_NNP 2004_CD 2003_CD awarded_VBN Dr_NNP Totten_NNP the_DT maximum_NN incentive_NN ,_, of_IN 75_CD %_NN of_IN salary_NN ,_, for_IN Number_NNP of_IN Number_NNP of_IN that_DT part_NN of_IN 2004_CD he_PRP worked_VBD both_DT as_IN a_DT Director_NNP and_CC then_RB as_IN an_DT Name_NN of_IN Director_NNP shares_NNS shares_NNS employee_NN in_IN recognition_NN of_IN Dr_NNP Tottens_NNP significant_JJ contribution_NN to_TO i_FW Dr_FW James_NNP Cavanaugh_NNP 412,849_CD 8,806,368_CD the_DT Company_NN ._.
106,690_CD of_IN this_DT incentive_NN is_VBZ included_VBN in_IN the_DT table_NN above_IN ._.
Dr_NNP Totten_NNP continued_VBD as_IN an_DT employee_NN of_IN the_DT Company_NN Mr_NNP Matthew_NNP Emmens_NNP responsible_JJ for_IN special_JJ corporate_JJ projects_NNS ,_, including_VBG the_DT continued_VBN Mr_NNP Angus_NNP Russell_NNP development_NN of_IN FOSRENOL_NNP ,_, from_IN 25_CD May_NNP until_IN 31_CD August_NNP 2004_CD ,_, at_IN which_WDT point_VBP the_DT Company_NN terminated_VBD his_PRP$ employment_NN in_IN Dr_NNP Barry_NNP Price_NNP 31,350_CD 31,350_CD accordance_NN with_IN his_PRP$ service_NN contract_NN ._.
No_DT change_NN was_VBD made_VBN to_TO ii_VB The_DT Hon_NNP James_NNP Grant_NNP 36,410_CD 4,551_CD Dr_NNP Tottens_NNP terms_NNS and_CC conditions_NNS of_IN employment_NN on_IN his_PRP$ ceasing_VBG to_TO Mr_NNP Ronald_NNP Nordmann_NNP 46,966_CD 46,966_CD be_VB a_DT Director_NNP or_CC whilst_NN he_PRP remained_VBD an_DT employee_NN ._.
Upon_IN termination_NN of_IN Dr_NNP Tottens_NNP employment_NN ,_, the_DT total_JJ amount_NN paid_VBN to_TO Dr_NNP Totten_NNP ,_, Mr_NNP Robin_NNP Buchanan_NNP in_IN accordance_NN with_IN the_DT payment_NN in_IN lieu_NN of_IN notice_NN provisions_NNS in_IN Mr_NNP David_NNP Kappler_NNP 5,000_CD his_PRP$ contract_NN of_IN employment_NN ,_, was_VBD 639,265_CD ._.
This_DT comprises_VBZ one_CD years_NNS salary_NN and_CC contractual_JJ benefits_NNS and_CC target_NN incentive_NN of_IN 50_CD %_NN of_IN salary_NN ,_, which_WDT the_DT Remuneration_NNP Committee_NNP determined_VBD ,_, in_IN All_DT interests_NNS are_VBP beneficial_JJ unless_IN otherwise_RB stated_VBN ._.
accordance_NN with_IN the_DT terms_NNS of_IN Dr_NNP Tottens_NNP contract_NN ,_, to_TO award_NN him_PRP ._.
Notes_NNP Directors_NNS pension_NN entitlements_NNS i_FW Dr_FW Cavanaugh_NNP is_VBZ a_DT general_JJ partner_NN of_IN HealthCare_NNP Ventures_NNP LLC_NNP ,_, The_DT following_VBG Directors_NNS are_VBP members_NNS of_IN money_NN purchase_NN which_WDT is_VBZ the_DT management_NN company_NN for_IN a_DT number_NN of_IN limited_JJ schemes_NNS ._.
Contributions_NNS paid_VBN by_IN the_DT Company_NN in_IN respect_NN of_IN 2004_CD partnerships_NNS ._.
On_IN 11_CD November_NNP 2004_CD investment_NN partnerships_NNS were_VBD as_IN follows_VBZ :_: managed_VBN by_IN HealthCare_NNP Ventures_NNP LLC_NNP distributed_VBN to_TO their_PRP$ general_JJ and_CC limited_JJ partners_NNS 8,666,090_CD ordinary_JJ shares_NNS of_IN the_DT 2004_CD 2003_CD Company_NN ._.
7,125,560_CD of_IN these_DT shares_NNS were_VBD purchased_VBN from_IN time_NN Name_NN of_IN Director_NNP 000_CD 000_CD to_TO time_NN from_IN 1993_CD to_TO 1996_CD ._.
An_DT additional_JJ 1,534,530_CD shares_NNS Mr_NNP Matthew_NNP Emmens_NNP 156_CD 138_CD were_VBD purchased_VBN in_IN 1998_CD ._.
Dr_NNP Cavanaugh_NNP and_CC members_NNS of_IN his_PRP$ family_NN received_VBD 296,571_CD of_IN the_DT shares_NNS distributed_VBN ._.
None_NN of_IN the_DT Mr_NNP Angus_NNP Russell_NNP 86_CD 80_CD 270,277_CD shares_NNS received_VBN by_IN Dr_NNP Cavanaugh_NNP in_IN the_DT distribution_NN Dr_NNP Wilson_NNP Totten_NNP 36_CD 85_CD have_VBP been_VBN sold_VBN ._.
stepped_VBD down_RP as_IN a_DT Director_NNP on_IN 25_CD May_NNP 2004_CD ii_FW On_IN 15_CD June_NNP 2004_CD ,_, The_DT Hon_NNP James_NNP Grant_NNP exercised_VBD an_DT option_NN granted_VBN to_TO him_PRP under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN for_IN 31,859_CD Mr_NNP Rolf_NNP Stahel_NNP 4,347_CD shares_NNS at_IN the_DT option_NN price_NN of_IN 1.24_CD per_IN share_NN ._.
stepped_VBD down_RP as_IN a_DT Director_NNP on_IN 19_CD March_NNP 2003_CD Directors_NNS share_VBP options_NNS Dr_NNP Francesco_NNP Bellini_NNP 26_CD Aggregate_NNP emoluments_NNS disclosed_VBD above_IN do_VBP not_RB include_VB any_DT stepped_VBD down_RB as_IN a_DT non-executive_JJ amounts_NNS for_IN the_DT value_NN of_IN options_NNS to_TO acquire_VB ordinary_JJ shares_NNS in_IN the_DT Director_NNP on_IN 10_CD May_NNP 2003_CD Company_NN granted_VBN to_TO or_CC held_VBN by_IN the_DT Directors_NNS ._.
278_CD 4,676_CD Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Holdings_NNP Limited_NNP Share_NNP Option_NN Scheme_NN SHL_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plan_NNP Roberts_NNP Plan_NNP and_CC the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ._.
For_IN those_DT options_NNS which_WDT remained_VBD unexercised_JJ during_IN the_DT year_NN ,_, no_DT payment_NN was_VBD made_VBN by_IN any_DT Director_NNP in_IN consideration_NN of_IN the_DT grant_NN award_NN ._.
There_EX have_VBP been_VBN no_DT variations_NNS to_TO the_DT terms_NNS and_CC conditions_NNS or_CC performance_NN criteria_NNS for_IN share_NN options_NNS during_IN 2004_CD ,_, except_IN as_IN stated_VBN in_IN note_NN iii_NN below_IN as_IN regards_VBZ retesting_NN ._.
Notes_NNP i_FW Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN the_DT Companys_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
ii_FW Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
iii_FW Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP vest_NN six_CD weeks_NNS prior_RB to_TO the_DT expiry_NN date_NN ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS were_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD become_VB exercisable_JJ in_IN full_JJ only_RB if_IN Shires_NNP EPS_NNP growth_NN over_IN a_DT three-year_JJ period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Price_NNP Index_NNP RPI_NNP on_IN average_NN a_DT year_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN Directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN The_DT new_JJ EPS_NNP performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
iv_NN Following_VBG the_DT acquisition_NN of_IN BioChem_NNP on_IN 11_CD May_NNP 2001_CD ,_, the_DT BioChem_NNP Plan_NNP was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChems_NNPS common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN the_DT Company_NN ._.
v_FW Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
44_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 45_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Directors_NNS remuneration_JJ report_NN vi_FW In_IN connection_NN with_IN the_DT termination_NN of_IN Dr_NNP Tottens_NNP employment_NN ,_, the_DT Remuneration_NNP Committee_NNP agreed_VBD to_TO exercise_VB its_PRP$ discretion_NN under_IN the_DT Rules_NNS of_IN the_DT respective_JJ option_NN schemes_NNS to_TO allow_VB Dr_NNP Totten_NNP to_TO retain_VB these_DT options_NNS for_IN up_RB to_TO 24_CD months_NNS following_VBG his_PRP$ termination_NN ._.
The_DT market_NN price_NN of_IN the_DT ordinary_JJ shares_NNS at_IN 31_CD December_NNP 2004_CD was_VBD 5.47_CD and_CC the_DT range_NN during_IN the_DT year_NN was_VBD 4.36_CD to_TO 5.71_CD ._.
Long_NNP Term_NNP Incentive_NNP Plan_NNP LTIP_NNP Long_NNP Term_NNP Incentive_NNP Plan_NNP maturities_NNS during_IN the_DT year_NN 2004_CD are_VBP as_IN follows_VBZ :_: Market_NN price_NN Actual_NNP Market_NNP price_NN Value_NN at_IN Initial_JJ award_NN at_IN grant_NN date_NN performanceat_NN maturity_NN maturity_NN Date_NNP of_IN Director_NNP Date_NNP of_IN award_NN made_VBN related_JJ award_NN maturity_NN i_FW Mr_NNP Angus_NNP Russell_NNP 01.03.00_CD 1,789_CD 10.06_CD 1,296_CD 5.515_CD 7,147_CD 01.03.04_CD i_FW ii_FW Dr_FW Wilson_NNP Totten_NNP 01.03.00_CD 19,881_CD 10.06_CD 14,398_CD 5.515_CD 79,405_CD 01.03.04_CD Total_JJ 86,552_CD Notes_NNS i_FW For_IN awards_NNS made_VBN under_IN the_DT LTIP_NNP prior_RB to_TO June_NNP 2001_CD ,_, performance_NN is_VBZ measured_VBN over_IN a_DT three-year_JJ period_NN but_CC the_DT performance_NN conditions_NNS are_VBP based_VBN on_IN criteria_NNS of_IN i_FW 50_CD %_NN TSR_NNP benchmarked_VBD against_IN FTSE_NNP mid-250_CD index_NN and_CC ii_FW 50_CD %_NN subject_NN to_TO an_DT EPS_NNP condition_NN measured_VBN against_IN the_DT diluted_VBN EPS_NNP of_IN the_DT Company_NN for_IN the_DT financial_JJ year_NN ended_VBD before_IN the_DT commencement_NN of_IN the_DT performance_NN period_NN and_CC the_DT diluted_VBN EPS_NNP of_IN the_DT Company_NN for_IN the_DT financial_JJ year_NN ended_VBN on_IN or_CC before_IN the_DT end_NN of_IN the_DT performance_NN period_NN ._.
For_IN awards_NNS made_VBN on_IN 1_CD March_NNP 2000_CD ,_, the_DT Committee_NNP determined_VBD that_IN 44.84_CD %_NN of_IN the_DT part_NN of_IN the_DT award_NN subject_NN to_TO TSR_NNP performance_NN measures_NNS and_CC 100_CD %_NN of_IN the_DT part_NN of_IN the_DT award_NN subject_NN to_TO EPS_NNP performance_NN measures_NNS could_MD be_VB transferred_VBN ,_, resulting_VBG in_IN 72.42_CD %_NN of_IN the_DT total_JJ award_NN being_VBG transferred_VBN to_TO participants_NNS ._.
These_DT calculations_NNS were_VBD verified_VBN by_IN external_JJ advisers_NNS ._.
ii_FW On_IN Dr_NNP Tottens_NNP termination_NN of_IN employment_NN ,_, the_DT Remuneration_NNP Committee_NNP determined_VBD in_IN accordance_NN with_IN the_DT LTIP_NNP Rules_NNPS ,_, that_IN the_DT 2001_CD ,_, 2002_CD ,_, 2003_CD and_CC 2004_CD awards_NNS would_MD lapse_NN and_CC no_DT payment_NN would_MD be_VB made_VBN to_TO Dr_NNP Totten_NNP in_IN respect_NN of_IN them_PRP ._.
Performance_NNP conditions_NNS attaching_VBG to_TO awards_NNS made_VBN under_IN the_DT Long_NNP Term_NNP Incentive_NNP Plan_NNP are_VBP detailed_VBN on_IN pages_NNS 38_CD to_TO 39_CD ._.
Approval_NN This_DT report_NN was_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN 1_CD March_NNP 2005_CD and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Dr_NNP Barry_NNP Price_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP 45_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 46_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Audit_NNP Committee_NNP report_NN Audit_NNP Committee_NNP report_NN ensure_VB clarity_NN of_IN disclosure_NN in_IN financial_JJ reporting_NN and_CC the_DT presentation_NN of_IN a_DT balanced_JJ and_CC understandable_JJ assessment_NN Audit_NNP Committee_NNP membership_NN of_IN the_DT Companys_NNPS financial_JJ position_NN :_: The_DT members_NNS of_IN the_DT Audit_NNP Committee_NNP as_IN at_IN 31_CD December_NNP 2004_CD were_VBD David_NNP Kappler_NNP Chairman_NNP ,_, Ronald_NNP Nordmann_NNP and_CC Barry_NNP have_VBP the_DT primary_JJ responsibility_NN for_IN making_VBG a_DT recommendation_NN Price_NN ._.
They_PRP are_VBP all_DT independent_JJ non-executive_JJ Directors_NNS for_IN the_DT to_TO be_VB put_VBN to_TO shareholders_NNS for_IN approval_NN at_IN the_DT Annual_JJ General_NNP purposes_NNS of_IN The_DT UK_NNP Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP Meeting_VBG in_IN relation_NN to_TO the_DT appointment_NN ,_, re-appointment_NN ,_, the_DT Combined_NNP Code_NNP ._.
Dr_NNP James_NNP Cavanaugh_NNP the_DT Chairman_NNP of_IN removal_NN and_CC remuneration_NN of_IN the_DT external_JJ auditor_NN and_CC to_TO the_DT Company_NN was_VBD a_DT member_NN of_IN the_DT Audit_NNP Committee_NNP until_IN he_PRP assess_VB at_IN least_JJS annually_RB ,_, the_DT objectivity_NN and_CC independence_NN stood_VBD down_RP on_IN 30_CD November_NNP 2004_CD ._.
Dr_NNP Cavanaugh_NNP stepped_VBD down_RB of_IN the_DT external_JJ auditor_NN :_: as_IN in_IN his_PRP$ capacity_NN as_IN Chairman_NNP of_IN the_DT Company_NN ,_, he_PRP is_VBZ no_RB longer_RB considered_VBN to_TO be_VB independent_JJ under_IN the_DT new_JJ Combined_NNP Code_NNP ._.
review_NN and_CC discuss_VB issues_NNS and_CC recommendations_NNS arising_VBG from_IN the_DT external_JJ audit_NN ,_, and_CC any_DT matters_NNS the_DT external_JJ auditor_NN may_MD wish_VB Mr_NNP Ronald_NNP Nordmann_NNP chaired_VBD the_DT Audit_NNP Committee_NNP until_IN July_NNP 2004_CD ,_, to_TO discuss_VB :_: after_IN completion_NN of_IN the_DT preparation_NN of_IN the_DT Companys_NNP second_JJ quarter_NN results_NNS ._.
Mr_NNP David_NNP Kappler_NNP ,_, who_WP joined_VBD Shires_NNP Board_NNP and_CC set_VBN and_CC apply_VB a_DT formal_JJ policy_NN in_IN relation_NN to_TO the_DT provision_NN of_IN nonbecame_NN a_DT member_NN of_IN Shires_NNP Audit_NNP Committee_NNP on_IN 5_CD April_NNP 2004_CD ,_, audit_NN services_NNS by_IN the_DT external_JJ auditor_NN with_IN a_DT view_NN to_TO preserving_VBG took_VBD over_RP the_DT chairmanship_NN of_IN the_DT Audit_NNP Committee_NNP from_IN the_DT external_JJ auditors_NNS independence_NN and_CC objectivity_NN :_: Mr_NNP Nordmann_NNP ._.
The_DT Board_NNP is_VBZ satisfied_VBN that_IN both_DT Mr_NNP Nordmann_NNP and_CC Mr_NNP Kappler_NNP ,_, in_IN their_PRP$ capacity_NN as_IN Chairmen_NNS of_IN the_DT Committee_NNP ,_, establish_VB procedures_NNS for_IN the_DT receipt_NN ,_, retention_NN and_CC treatment_NN have_VBP recent_JJ and_CC relevant_JJ financial_JJ experience_NN ._.
The_DT Board_NNP has_VBZ of_IN complaints_NNS received_VBN by_IN the_DT Company_NN regarding_VBG accounting_NN ,_, determined_VBD that_IN Mr_NNP Kappler_NNP is_VBZ the_DT Audit_NNP Committee_NNP financial_JJ expert_NN internal_JJ accounting_NN controls_NNS or_CC auditing_NN matters_NNS :_: for_IN the_DT purposes_NNS of_IN the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD ._.
Mr_NNP Kappler_NNP retired_VBD as_IN Chief_NNP Financial_NNP Officer_NNP of_IN Cadbury_NNP Schweppes_NNP plc_NN ,_, the_DT review_NN at_IN least_JJS annually_RB the_DT effectiveness_NN of_IN the_DT Companys_NNPS FTSE_NNP and_CC NYSE_NNP listed_VBD global_JJ confectionery_NN and_CC beverages_NNS group_NN internal_JJ control_NN system_NN in_IN the_DT overall_JJ context_NN of_IN the_DT Companys_NNPS in_IN April_NNP 2004_CD having_VBG held_VBN that_IN position_NN since_IN 1995_CD ._.
He_PRP worked_VBD risk_NN management_NN system_NN :_: for_IN the_DT Cadbury_NNP Schweppes_NNP group_NN between_IN 1965_CD and_CC 1984_CD and_CC rejoined_VBD it_PRP in_IN 1989_CD ,_, following_VBG the_DT acquisition_NN of_IN the_DT Trebor_NNP Group_NNP oversee_VBP the_DT Companys_NNPS anti-fraud_JJ programs_NNS and_CC controls_NNS of_IN which_WDT he_PRP was_VBD Finance_NNP Director_NNP ._.
From_IN 1989_CD to_TO 1995_CD he_PRP held_VBD and_CC to_TO oversee_VB the_DT investigation_NN and_CC remediation_NN of_IN any_DT alleged_VBN a_DT number_NN of_IN senior_JJ positions_NNS in_IN Cadbury_NNP Schweppes_NNP ,_, including_VBG or_CC suspected_VBN fraud_NN :_: and_CC Director_NNP of_IN Corporate_NNP Finance_NNP ._.
Mr_NNP Kappler_NNP has_VBZ served_VBN on_IN a_DT number_NN of_IN other_JJ boards_NNS around_IN the_DT world_NN in_IN which_WDT Cadbury_NNP Schweppes_NNP monitor_NN and_CC review_VB the_DT internal_JJ operational_JJ audit_NN program_NN ,_, held_VBD interests_NNS ._.
He_PRP was_VBD a_DT director_NN of_IN Camelot_NNP Group_NNP plc_NN from_IN 1996_CD consider_VBP the_DT findings_NNS of_IN internal_JJ operational_JJ audit_NN reviews_NNS and_CC to_TO 2002_CD and_CC he_PRP currently_RB serves_VBZ as_IN a_DT non-executive_JJ Director_NNP managements_NNS response_NN to_TO them_PRP ._.
and_CC Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP at_IN HMV_NNP Group_NNP plc_NN and_CC Intercontinental_NNP Hotels_NNPS Group_NNP plc._NN ._.
Additionally_RB ,_, he_PRP is_VBZ non-executive_JJ The_DT Audit_NNP Committee_NNP reports_VBZ to_TO the_DT Board_NNP on_IN any_DT matter_NN on_IN which_WDT Chairman_NNP at_IN Premier_NNP Foods_NNP plc._NN ._.
Mr_NNP Kappler_NNP is_VBZ a_DT fellow_NN of_IN the_DT it_PRP considers_VBZ that_IN action_NN is_VBZ required_VBN and_CC makes_VBZ recommendations_NNS Chartered_NNP Institute_NNP of_IN Management_NNP Accountants_NNPS ._.
The_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Committee_NNP give_VB it_PRP authority_NN to_TO investigate_VB any_DT activity_NN within_IN its_PRP$ Terms_NNS of_IN The_DT members_NNS of_IN the_DT Committee_NNP are_VBP chosen_VBN from_IN amongst_IN the_DT Reference_NNP and_CC to_TO be_VB responsible_JJ for_IN the_DT resolution_NN of_IN non-executive_JJ Directors_NNS of_IN the_DT Company_NN who_WP are_VBP independent_JJ disagreements_NNS between_IN management_NN and_CC the_DT auditor_NN regarding_VBG for_IN the_DT purposes_NNS of_IN the_DT Combined_NNP Code_NNP and_CC the_DT NASDAQ_NNP the_DT Companys_NNPS financial_JJ reporting_NN ._.
The_DT Committee_NNP is_VBZ also_RB rules_NNS and_CC are_VBP selected_VBN on_IN the_DT basis_NN of_IN their_PRP$ knowledge_NN and_CC authorised_VBN to_TO seek_VB any_DT information_NN it_PRP requires_VBZ from_IN any_DT employee_NN experience_NN of_IN financial_JJ matters_NNS and_CC financial_JJ reporting_NN ._.
Committee_NNP of_IN the_DT Company_NN in_IN order_NN to_TO perform_VB its_PRP$ duties_NNS and_CC to_TO call_VB any_DT members_NNS hold_VBP office_NN for_IN an_DT initial_JJ period_NN of_IN two_CD years_NNS ,_, subject_JJ employee_NN to_TO be_VB questioned_VBN at_IN a_DT meeting_NN of_IN the_DT Committee_NNP ._.
to_TO continuing_VBG as_IN a_DT Director_NNP of_IN the_DT Company_NN ,_, for_IN such_JJ duration_NN as_IN determined_VBN by_IN the_DT Board_NNP ._.
Details_NNS of_IN the_DT fees_NNS paid_VBN to_TO members_NNS The_DT Audit_NNP Committee_NNP met_VBD on_IN 4_CD occasions_NNS in_IN 2004_CD ._.
Each_DT meeting_NN of_IN the_DT Committee_NNP are_VBP set_VBN out_RP in_IN the_DT Directors_NNS remuneration_NN report_NN was_VBD attended_VBN by_IN all_DT members_NNS of_IN the_DT Committee_NNP ._.
At_IN the_DT invitation_NN on_IN page_NN 41_CD ._.
of_IN the_DT Chairman_NNP ,_, the_DT Chief_NNP Executive_NNP Officer_NNP ,_, the_DT Chief_NNP Financial_NNP Officer_NNP ,_, the_DT Group_NNP Financial_NNP Controller_NNP and_CC the_DT Chief_NNP Risk_NNP Officer_NNP Role_NNP of_IN Audit_NNP Committee_NNP attended_VBD all_DT of_IN the_DT Committees_NNS meetings_NNS in_IN 2004_CD ,_, save_VB that_IN the_DT In_IN the_DT latter_JJ part_NN of_IN 2004_CD ,_, the_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Audit_NNP Group_NNP Financial_NNP Controller_NNP was_VBD unable_JJ to_TO attend_VB one_CD meeting_NN Committee_NNP were_VBD reviewed_VBN and_CC updated_VBN ._.
The_DT amended_VBN Terms_NNS due_JJ to_TO a_DT previous_JJ commitment_NN ._.
of_IN Reference_NNP were_VBD approved_VBN by_IN the_DT Board_NNP on_IN 22_CD February_NNP 2005_CD ._.
The_DT revised_VBN Terms_NNS of_IN Reference_NNP of_IN the_DT Audit_NNP Committee_NNP are_VBP In_IN accordance_NN with_IN its_PRP$ Terms_NNS of_IN Reference_NNP ,_, the_DT Committee_NNP met_VBD available_JJ for_IN review_NN on_IN Shires_NNP website_NN ._.
The_DT key_JJ functions_NNS of_IN the_DT with_IN the_DT external_JJ and_CC internal_JJ auditors_NNS during_IN the_DT course_NN of_IN the_DT Audit_NNP Committee_NNP under_IN the_DT revised_VBN Terms_NNS of_IN Reference_NNP are_VBP to_TO :_: year_NN without_IN any_DT executive_NN member_NN of_IN the_DT Board_NNP in_IN attendance_NN ._.
monitor_VB the_DT integrity_NN of_IN the_DT financial_JJ statements_NNS of_IN the_DT Company_NN ,_, Auditor_NNP services_NNS including_VBG its_PRP$ annual_JJ and_CC quarterly_JJ reports_NNS ,_, preliminary_JJ results_NNS The_DT Audit_NNP Committee_NNP has_VBZ adopted_VBN a_DT formal_JJ policy_NN in_IN relation_NN to_TO announcements_NNS and_CC any_DT other_JJ Board_NNP announcement_NN relating_VBG the_DT provision_NN of_IN non-audit_JJ services_NNS by_IN the_DT external_JJ auditor_NN ,_, which_WDT to_TO its_PRP$ financial_JJ performance_NN or_CC other_JJ financial_JJ information_NN to_TO be_VB was_VBD most_RBS recently_RB revised_VBN in_IN March_NNP 2004_CD ._.
The_DT Sarbanes-Oxley_NNP made_VBD public_NN :_: Act_NNP 2002_CD and_CC accordingly_RB the_DT Committees_NNS policy_NN prohibits_VBZ the_DT provision_NN of_IN certain_JJ non-audit_JJ services_NNS to_TO the_DT Company_NN by_IN the_DT external_JJ auditor_NN ,_, including_VBG :_: 46_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 47_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Audit_NNP Committee_NNP report_NN bookkeeping_NN or_CC other_JJ services_NNS related_VBN to_TO the_DT accounting_NN records_NNS audit_VBP adjustments_NNS proposed_VBN and_CC whether_IN they_PRP were_VBD corrected_VBN or_CC financial_JJ statements_NNS of_IN the_DT Company_NN :_: by_IN management_NN :_: and_CC design_NN and_CC implementation_NN of_IN financial_JJ information_NN systems_NNS :_: significant_JJ accounting_NN policies_NNS and_CC unusual_JJ transactions_NNS ._.
appraisal_NN or_CC valuation_NN services_NNS ,_, fairness_NN opinions_NNS or_CC contribution_NN -_: 2_CD Internal_NNP financial_JJ control_NN and_CC risk_NN management_NN systems_NNS in-kind_JJ reports_NNS :_: and_CC The_DT Audit_NNP Committee_NNP reviewed_VBD the_DT risk_NN management_NN strategy_NN ,_, the_DT corporate_JJ risk_NN schedules_NNS ,_, the_DT internal_JJ audit_NN strategy_NN and_CC plan_NN and_CC actuarial_JJ or_CC internal_JJ audit_NN outsourcing_VBG services_NNS ._.
progress_NN in_IN complying_VBG with_IN Section_NN 404_CD of_IN the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD and_CC the_DT effectiveness_NN of_IN the_DT system_NN of_IN internal_JJ control_NN The_DT Committees_NNS policy_NN requires_VBZ all_DT audit_NN and_CC permissible_JJ non-audit_JJ during_IN the_DT year_NN ._.
The_DT risk_NN management_NN and_CC internal_JJ financial_JJ control_NN services_NNS proposed_VBN to_TO be_VB provided_VBN by_IN the_DT Companys_NNP auditor_NN to_TO systems_NNS were_VBD the_DT subject_NN of_IN significant_JJ focus_NN at_IN all_PDT the_DT meetings_NNS be_VB approved_VBN by_IN the_DT Audit_NNP Committee_NNP ._.
Certain_JJ audit_NN and_CC non-audit_JJ held_VBN throughout_IN the_DT year_NN ,_, with_IN in_IN depth_NN discussions_NNS held_VBD between_IN services_NNS have_VBP been_VBN pre-approved_VBN by_IN the_DT Audit_NNP Committee_NNP and_CC may_MD the_DT Audit_NNP Committee_NNP ,_, Shire_NNP management_NN ,_, internal_JJ audit_NN and_CC the_DT therefore_RB be_VB provided_VBN by_IN the_DT auditor_NN provided_VBD that_DT management_NN external_JJ auditors_NNS ._.
does_VBZ not_RB need_VB to_TO exercise_VB any_DT discretion_NN in_IN determining_VBG whether_IN a_DT proposed_JJ service_NN falls_VBZ within_IN one_CD of_IN the_DT pre-approved_JJ categories_NNS ._.
In_IN addition_NN and_CC as_IN part_NN of_IN the_DT work_NN in_IN this_DT area_NN ,_, a_DT revised_VBN treasury_NN In_IN all_DT cases_NNS ,_, the_DT Audit_NNP Committee_NNP is_VBZ notified_VBN of_IN any_DT pre-approved_JJ policy_NN was_VBD approved_VBN in_IN July_NNP and_CC reports_NNS on_IN the_DT treasury_NN service_NN provided_VBN ._.
Certain_JJ services_NNS have_VBP been_VBN pre-approved_VBN by_IN investments_NNS were_VBD discussed_VBN each_DT quarter_NN ._.
At_IN the_DT same_JJ July_NNP the_DT Audit_NNP Committee_NNP as_IN part_NN of_IN its_PRP$ pre-approval_JJ policy_NN ,_, including_VBG :_: meeting_VBG the_DT Audit_NNP Committee_NNP also_RB approved_VBD the_DT insurance_NN renewal_NN program_NN for_IN 2004_CD 5_CD ._.
audit_NN services_NNS and_CC audit_NN related_VBN services_NNS ,_, such_JJ as_IN audit_NN work_NN performed_VBN in_IN the_DT preparation_NN of_IN financial_JJ statements_NNS ,_, work_NN The_DT Audit_NNP Committee_NNP also_RB received_VBD reports_NNS from_IN management_NN ,_, that_IN generally_RB only_RB the_DT auditors_NNS can_MD reasonably_RB be_VB expected_VBN the_DT internal_JJ audit_NN function_NN ,_, and_CC the_DT external_JJ auditor_NN on_IN the_DT to_TO provide_VB ,_, including_VBG comfort_NN letters_NNS ,_, statutory_JJ audits_NN and_CC effectiveness_NN of_IN the_DT Companys_NNP system_NN of_IN internal_JJ controls_NNS ._.
consultation_NN regarding_VBG financial_JJ accounting_NN and_CC or_CC reporting_VBG standards_NNS ,_, due_JJ diligence_NN related_VBN to_TO mergers_NNS and_CC acquisitions_NNS ,_, 3_CD External_NNP auditor_NN employee_NN benefit_NN plan_NN audits_NN and_CC special_JJ procedures_NNS required_VBN The_DT Audit_NNP Committee_NNP reviewed_VBD the_DT performance_NN of_IN the_DT external_JJ to_TO meet_VB certain_JJ regulatory_JJ requirements_NNS :_: auditor_NN following_VBG the_DT completion_NN of_IN the_DT 2003_CD audit_NN process_NN ,_, which_WDT resulted_VBD in_IN the_DT Audit_NNP Committee_NNP resolving_VBG to_TO recommend_VB tax_NN services_NNS ,_, such_JJ as_IN tax_NN compliance_NN services_NNS ,_, tax_NN advice_NN on_IN that_IN the_DT Company_NN submit_VB a_DT resolution_NN to_TO the_DT 2004_CD Annual_JJ General_NNP the_DT tax_NN consequences_NNS of_IN proposed_VBN transactions_NNS and_CC tax_NN advice_NN Meeting_VBG to_TO re-appoint_VB Deloitte_NNP &_CC Touche_NNP LLP_NNP as_IN the_DT Companys_NNPS on_IN employee_NN remuneration_NN strategies_NNS ,_, and_CC external_JJ auditor_NN ._.
At_IN forthcoming_JJ meetings_NNS in_IN 2005_CD ,_, the_DT Audit_NNP Committee_NNP will_MD conduct_VB a_DT formal_JJ review_NN of_IN the_DT performance_NN of_IN the_DT advice_NN on_IN internal_JJ reorganisations_NNS ,_, group_NN financing_NN external_JJ auditor_NN and_CC the_DT effectiveness_NN of_IN the_DT audit_NN process_NN in_IN arrangements_NNS ,_, share_NN schemes_NNS and_CC VAT_NNP compliance_NN ._.
connection_NN with_IN the_DT 2004_CD financial_JJ year_NN audit_NN ._.
Any_DT services_NNS proposed_VBN to_TO be_VB provided_VBN by_IN the_DT auditor_NN which_WDT is_VBZ not_RB In_IN March_NNP 2004_CD the_DT Audit_NNP Committee_NNP revised_VBD its_PRP$ pre-approval_JJ a_DT pre-approved_JJ service_NN must_MD be_VB approved_VBN in_IN advance_NN by_IN the_DT Audit_NNP process_NN of_IN all_DT audit_NN services_NNS and_CC permitted_VBD non-audit_JJ services_NNS Committee_NNP ,_, which_WDT will_MD consider_VB whether_IN the_DT skills_NNS and_CC experience_NN undertaken_VBN by_IN the_DT external_JJ auditor_NN ._.
The_DT Audit_NNP Committee_NNP of_IN the_DT auditor_NN make_VB it_PRP a_DT suitable_JJ supplier_NN of_IN the_DT proposed_VBN audit_NN approved_VBD all_DT non-audit_JJ services_NNS during_IN 2004_CD and_CC there_EX is_VBZ now_RB or_CC non-audit_JJ service_NN ._.
a_DT standing_NN agenda_NN item_NN at_IN Audit_NNP Committee_NNP meetings_NNS covering_VBG the_DT operation_NN of_IN the_DT procedures_NNS ._.
Audit_NNP Committee_NNP activities_NNS During_IN 2004_CD ,_, the_DT business_NN discussed_VBN by_IN the_DT Audit_NNP Committee_NNP Throughout_IN the_DT year_NN ,_, the_DT Audit_NNP Committee_NNP has_VBZ kept_VBN the_DT objectivity_NN included_VBD the_DT matters_NNS set_VBN out_RP below_IN ._.
and_CC independence_NN of_IN the_DT external_JJ auditor_NN under_IN review_NN and_CC has_VBZ obtained_VBN reports_NNS from_IN the_DT Companys_NNP external_JJ auditor_NN 1_CD Financial_NNP statements_NNS describing_VBG all_DT relationships_NNS between_IN the_DT auditor_NN and_CC the_DT Company_NN ._.
The_DT financial_JJ disclosures_NNS contained_VBN in_IN the_DT Companys_NNP annual_JJ and_CC The_DT Audit_NNP Committee_NNP has_VBZ remained_VBN satisfied_JJ that_IN the_DT level_NN quarterly_JJ reports_NNS to_TO shareholders_NNS were_VBD discussed_VBN by_IN the_DT Audit_NNP of_IN non-audit_JJ services_NNS or_CC the_DT nature_NN of_IN the_DT work_NN performed_VBN by_IN the_DT Committee_NNP each_DT quarter_NN and_CC at_IN year-end_NN ._.
Various_JJ accounting_NN external_JJ auditors_NNS has_VBZ not_RB in_IN any_DT way_NN impaired_VBN their_PRP$ objectivity_NN and_CC matters_NNS were_VBD also_RB discussed_VBN by_IN the_DT Audit_NNP Committee_NNP ,_, including_VBG independence_NN ._.
The_DT detail_NN of_IN the_DT fees_NNS paid_VBN to_TO the_DT external_JJ auditors_NNS the_DT application_NN of_IN the_DT critical_JJ accounting_NN policies_NNS applied_VBN by_IN the_DT is_VBZ disclosed_VBN in_IN Note_NN 4_CD to_TO the_DT summary_NN financial_JJ statements_NNS ._.
The_DT application_NN of_IN new_JJ accounting_NN standards_NNS was_VBD also_RB discussed_VBN ,_, where_WRB appropriate_JJ ,_, during_IN these_DT meetings_NNS ._.
Quarterly_JJ reports_NNS from_IN the_DT external_JJ auditors_NNS were_VBD received_VBN by_IN the_DT Audit_NNP Committee_NNP and_CC discussed_VBN ._.
The_DT reports_NNS addressed_VBD the_DT following_VBG key_JJ additional_JJ areas_NNS :_: David_NNP Kappler_NNP Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP auditor_NN responsibility_NN and_CC independence_NN :_: significant_JJ accounting_NN estimates_NNS and_CC judgements_NNS made_VBN by_IN management_NN :_: 47_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 48_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statements_NNS Corporate_JJ governance_NN statements_NNS The_DT Board_NNP has_VBZ taken_VBN into_IN consideration_NN that_IN The_DT Hon_NNP James_NNP Grant_NNP is_VBZ a_DT partner_NN of_IN Stikeman_NNP Elliot_NNP ,_, a_DT Canadian_JJ law_NN firm_NN which_WDT ,_, from_IN time_NN The_DT Company_NN is_VBZ committed_VBN to_TO high_JJ standards_NNS to_TO time_NN ,_, provides_VBZ legal_JJ advice_NN to_TO the_DT Group_NNP ._.
The_DT Board_NNP considers_VBZ of_IN corporate_JJ governance_NN Mr_NNP Grant_NNP to_TO be_VB independent_JJ notwithstanding_IN his_PRP$ position_NN as_IN he_PRP is_VBZ The_DT Board_NNP is_VBZ committed_VBN to_TO high_JJ standards_NNS of_IN corporate_JJ not_RB involved_VBN in_IN the_DT provision_NN of_IN legal_JJ advice_NN to_TO the_DT Company_NN and_CC governance_NN and_CC supports_VBZ the_DT provisions_NNS and_CC principles_NNS set_VBN out_RP in_IN is_VBZ not_RB engaged_VBN in_IN marketing_VBG the_DT services_NNS of_IN Stikeman_NNP Elliott_NNP to_TO the_DT The_DT Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP issued_VBN by_IN the_DT UK_NNP Company_NN ._.
Stikeman_NNP Elliott_NNP is_VBZ one_CD of_IN a_DT range_NN of_IN legal_JJ and_CC other_JJ Financial_JJ Reporting_NNP Council_NNP in_IN July_NNP 2003_CD the_DT Combined_NNP Code_NNP ._.
professional_JJ advisors_NNS engaged_VBN by_IN the_DT Company_NN from_IN time_NN to_TO time_NN ._.
The_DT Combined_NNP Code_NNP took_VBD full_JJ effect_NN for_IN the_DT first_JJ time_NN for_IN the_DT Accordingly_RB ,_, the_DT Board_NNP does_VBZ not_RB consider_VB the_DT relationship_NN between_IN Company_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
the_DT Company_NN and_CC Stikeman_NNP Elliott_NNP to_TO be_VB material_JJ and_CC accordingly_RB the_DT fact_NN that_IN Mr_NNP Grant_NNP is_VBZ a_DT partner_NN at_IN that_DT firm_NN does_VBZ not_RB ,_, in_IN the_DT Statement_NN of_IN compliance_NN with_IN the_DT Combined_NNP Code_NNP Boards_NNP assessment_NN ,_, affect_VB his_PRP$ independence_NN ._.
Mr_NNP Grant_NNP was_VBD a_DT Throughout_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD the_DT Company_NNP Board_NNP member_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP prior_RB to_TO its_PRP$ merger_NN with_IN the_DT has_VBZ ,_, in_IN the_DT Directors_NNS opinion_NN ,_, complied_VBN with_IN the_DT provisions_NNS set_VBN Company_NN in_IN 2001_CD ._.
Mr_NNP Grant_NNP has_VBZ an_DT extensive_JJ knowledge_NN of_IN Shires_NNP out_IN in_IN Section_NN 1_CD of_IN the_DT Combined_NNP Code_NNP ,_, save_VB that_IN the_DT Chairman_NNP business_NN and_CC he_PRP brings_VBZ a_DT wealth_NN of_IN expertise_NN to_TO the_DT Board_NNP ._.
of_IN the_DT Company_NN ,_, Dr_NNP James_NNP Cavanaugh_NNP ,_, sat_VBD on_IN the_DT Remuneration_NNP Committee_NNP until_IN 28_CD April_NNP 2004_CD and_CC on_IN the_DT Audit_NNP Committee_NNP until_IN Board_NNP and_CC Committee_NNP changes_NNS 30_CD November_NNP 2004_CD ._.
2.1_CD and_CC C._NNP 3.1_CD of_IN the_DT Combined_VBN There_EX were_VBD changes_NNS to_TO the_DT Board_NNP and_CC to_TO certain_JJ of_IN the_DT Board_NNP Code_NNP require_VBP each_DT of_IN these_DT committees_NNS to_TO be_VB comprised_VBN entirely_RB Committees_NNS in_IN 2004_CD ._.
Dr_NNP Wilson_NNP Totten_NNP ,_, the_DT Companys_NNP former_JJ Chief_NNP of_IN independent_JJ directors_NNS and_CC under_IN the_DT Combined_NNP Code_NNP as_IN Scientific_NNP Officer_NNP ,_, stepped_VBD down_RB from_IN the_DT Board_NNP on_IN 25_CD May_NNP 2004_CD ._.
revised_VBN ,_, a_DT Chairman_NNP is_VBZ no_RB longer_RB considered_VBN to_TO be_VB independent_JJ ._.
Mr_NNP David_NNP Kappler_NNP joined_VBD the_DT Board_NNP as_IN a_DT non-executive_JJ Director_NNP Dr_NNP Cavanaugh_NNP sat_VBD on_IN the_DT Audit_NNP and_CC Remuneration_NNP Committees_NNS and_CC a_DT member_NN of_IN the_DT Audit_NNP Committee_NNP on_IN 5_CD April_NNP 2004_CD ._.
With_IN for_IN part_NN of_IN 2004_CD pending_VBG the_DT appointment_NN of_IN an_DT additional_JJ noneffect_NN from_IN July_NNP 2004_CD ,_, Mr_NNP Kappler_NNP took_VBD over_RP the_DT Chairmanship_NN executive_NN Director_NNP which_WDT occurred_VBD in_IN April_NNP with_IN David_NNP Kapplers_NNP of_IN the_DT Audit_NNP Committee_NNP from_IN Mr_NNP Ronald_NNP Nordmann_NNP ._.
He_PRP remained_VBD on_IN the_DT Audit_NNP Committee_NNP for_IN a_DT Nordmann_NNP joined_VBD the_DT Remuneration_NNP Committee_NNP in_IN place_NN of_IN transitional_JJ period_NN to_TO ensure_VB a_DT smooth_JJ handover_NN of_IN responsibilities_NNS ._.
Dr_NNP James_NNP Cavanaugh_NNP on_IN 28_CD April_NNP 2004_CD ._.
Dr_NNP James_NNP Cavanaugh_NNP stepped_VBD down_RB from_IN the_DT Remuneration_NNP Committee_NNP on_IN 28_CD April_NNP The_NNP Board_NNP 2004_CD and_CC from_IN the_DT Audit_NNP Committee_NNP on_IN 30_CD November_NNP 2004_CD ._.
The_DT Board_NNP comprises_VBZ the_DT Chairman_NNP ,_, two_CD executive_NN and_CC five_CD non-executive_JJ Directors_NNS and_CC meets_VBZ at_IN least_JJS six_CD times_NNS a_DT year_NN ._.
The_DT Board_NNP meetings_NNS non-executive_JJ Directors_NNS bring_VBP judgement_NN which_WDT is_VBZ independent_JJ During_IN 2004_CD ,_, there_EX were_VBD 11_CD Board_NNP meetings_NNS of_IN which_WDT six_CD were_VBD of_IN management_NN to_TO Board_NNP deliberations_NNS ._.
The_DT executive_NN Directors_NNS face-to-face_JJ meetings_NNS and_CC five_CD held_VBN by_IN telephone_NN ._.
Board_NNP meetings_NNS have_VBP responsibility_NN for_IN day-to-day_JJ business_NN operations_NNS ._.
The_DT record_NN of_IN attendance_NN by_IN Directors_NNS at_IN Board_NNP meetings_NNS is_VBZ set_VBN out_RP below_IN :_: The_NNP Board_NNP has_VBZ overall_JJ responsibility_NN for_IN managing_VBG the_DT Company_NN Number_NN of_IN and_CC its_PRP$ strategic_JJ direction_NN and_CC seeks_VBZ to_TO provide_VB effective_JJ leadership_NN meetings_NNS Out_IN of_IN Attendance_NNP and_CC the_DT control_NN required_VBN for_IN a_DT listed_VBN company_NN ._.
The_DT Board_NNP has_VBZ Directors_NNS attended_VBD possible_JJ %_NN formally_RB reserved_VBD specific_JJ matters_NNS to_TO itself_PRP for_IN determination_NN which_WDT James_NNP Cavanaugh_NNP 11_CD 11_CD 100_CD include_VBP strategic_JJ issues_NNS ,_, budgeting_NN ,_, changes_NNS in_IN share_NN capital_NN ,_, Chairman_NNP approval_NN of_IN the_DT Companys_NNPS financial_JJ statements_NNS and_CC entry_NN into_IN material_NN contracts_NNS ._.
Matters_NNS not_RB formally_RB reserved_VBN to_TO the_DT Board_NNP Matthew_NNP Emmens_NNP 11_CD 11_CD 100_CD are_VBP delegated_VBN to_TO the_DT Executive_NNP Committee_NNP and_CC to_TO various_JJ other_JJ Chief_NNP Executive_NNP Officer_NNP Board_NNP committees_NNS whose_WP$ functions_NNS are_VBP described_VBN below_IN ._.
Angus_NNP Russell_NNP 11_CD 11_CD 100_CD Chief_NNP Financial_NNP Officer_NNP The_NNP Board_NNP members_NNS receive_VBP detailed_VBN information_NN from_IN executive_JJ Directors_NNS ,_, the_DT Company_NNP Secretary_NNP and_CC other_JJ senior_JJ managers_NNS Barry_NNP Price_NNP 10_CD 11_CD 91_CD to_TO enable_VB them_PRP to_TO discharge_VB their_PRP$ responsibilities_NNS efficiently_RB Senior_JJ non-executive_JJ Director_NNP and_CC effectively_RB ._.
The_DT Hon_NNP James_NNP Grant_NNP 10_CD 11_CD 91_CD non-executive_JJ Director_NNP All_NNP Directors_NNS have_VBP access_NN to_TO the_DT advice_NN and_CC guidance_NN of_IN the_DT Company_NNP Secretary_NNP and_CC are_VBP encouraged_VBN to_TO seek_VB independent_JJ Ronald_NNP Nordmann_NNP 11_CD 11_CD 100_CD advice_NN at_IN the_DT Companys_NNP expense_NN ,_, where_WRB they_PRP feel_VBP it_PRP is_VBZ appropriate_JJ ._.
non-executive_JJ Director_NNP The_NNP Board_NNP is_VBZ of_IN the_DT opinion_NN that_IN each_DT of_IN its_PRP$ members_NNS has_VBZ the_DT Robin_NNP Buchanan_NNP 10_CD 11_CD 91_CD knowledge_NN ,_, aptitude_NN and_CC experience_NN to_TO perform_VB the_DT functions_NNS non-executive_JJ Director_NNP required_VBN of_IN a_DT director_NN of_IN a_DT listed_VBN company_NN ._.
David_NNP Kappler_NNP non-executive_JJ Director_NNP 8_CD 8_CD 100_CD Biographical_NNP details_NNS of_IN the_DT members_NNS of_IN the_DT Board_NNP are_VBP shown_VBN appointed_VBN 5_CD April_NNP 2004_CD on_IN pages_NNS 32_CD to_TO 33_CD ._.
Wilson_NNP Totten_NNP Chief_NNP Scientific_NNP Officer_NNP 5_CD 5_CD 100_CD stepped_VBD down_RB as_IN a_DT Director_NNP on_IN Independent_NNP Directors_NNS 25_CD May_NNP 2004_CD The_NNP Board_NNP considers_VBZ Dr_NNP Barry_NNP Price_NNP ,_, Mr_NNP Ronald_NNP Nordmann_NNP ,_, The_DT Hon_NNP James_NNP Grant_NNP ,_, Mr_NNP Robin_NNP Buchanan_NNP and_CC Mr_NNP David_NNP Kappler_NNP to_TO be_VB independent_JJ non-executive_JJ Directors_NNS ._.
The_DT Board_NNP views_VBZ The_DT Chairman_NNP and_CC the_DT non-executive_JJ Directors_NNS met_VBD during_IN the_DT each_DT of_IN these_DT non-executive_JJ Directors_NNS to_TO be_VB independent_JJ of_IN year_NN without_IN the_DT executive_NN Directors_NNS being_VBG present_JJ ._.
management_NN ,_, independent_JJ in_IN judgement_NN and_CC character_NN and_CC free_JJ from_IN any_DT business_NN or_CC other_JJ relationship_NN which_WDT could_MD materially_RB interfere_VB with_IN the_DT exercise_NN of_IN their_PRP$ independent_JJ judgement_NN ._.
48_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 49_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statements_NNS Chairman_NNP and_CC Chief_NNP Executive_NNP Officer_NNP refreshening_NN of_IN the_DT Board_NNP ._.
In_IN this_DT regard_NN it_PRP should_MD be_VB noted_VBN that_IN The_DT offices_NNS of_IN Chairman_NNP and_CC Chief_NNP Executive_NNP Officer_NNP are_VBP held_VBN there_EX have_VBP been_VBN substantial_JJ changes_NNS to_TO the_DT Board_NNP membership_NN separately_RB ._.
The_DT Chairman_NNP ,_, Dr_NNP James_NNP Cavanaugh_NNP ,_, is_VBZ responsible_JJ over_IN this_DT period_NN of_IN time_NN ,_, including_VBG the_DT appointments_NNS since_IN 2003_CD for_IN the_DT conduct_NN of_IN the_DT Board_NNP and_CC ensures_VBZ that_IN Board_NNP discussions_NNS of_IN Mr_NNP Buchanan_NNP ,_, Mr_NNP Kappler_NNP and_CC Mr_NNP Emmens_NNP ._.
In_IN addition_NN ,_, there_EX are_VBP conducted_VBN in_IN such_JJ a_DT way_NN that_IN all_DT views_NNS are_VBP taken_VBN into_IN account_NN ,_, have_VBP been_VBN recent_JJ significant_JJ changes_NNS to_TO the_DT Companys_NNP Executive_NNP so_IN that_IN no_DT individual_JJ Director_NNP or_CC small_JJ group_NN of_IN Directors_NNS Committee_NNP ,_, such_JJ that_IN most_JJS of_IN its_PRP$ members_NNS have_VBP been_VBN appointed_VBN dominates_VBZ proceedings_NNS ._.
The_DT Chief_NNP Executive_NNP Officer_NNP has_VBZ the_DT in_IN the_DT last_JJ two_CD years_NNS ._.
Having_VBG deliberated_JJ carefully_RB on_IN the_DT issue_NN ,_, general_JJ responsibility_NN for_IN running_VBG the_DT business_NN on_IN a_DT day-to-day_JJ and_CC taken_VBN into_IN account_NN recent_JJ performance_NN evaluations_NNS basis_NN and_CC chairs_VBZ the_DT Executive_NNP Committee_NNP ._.
conducted_VBN with_IN the_DT assistance_NN of_IN an_DT external_JJ consultant_NN ,_, the_DT Board_NNP has_VBZ no_DT hesitation_NN in_IN asking_VBG Dr_NNP Price_NNP to_TO remain_VB on_IN the_DT Board_NNP ._.
The_DT roles_NNS and_CC responsibilities_NNS of_IN the_DT Chairman_NNP and_CC the_DT Chief_NNP Dr_NNP Prices_NNS commitment_NN to_TO the_DT Company_NN is_VBZ undiminished_JJ and_CC his_PRP$ Executive_NNP Officer_NNP are_VBP clearly_RB defined_VBN ,_, separate_JJ and_CC have_VBP been_VBN performance_NN continues_VBZ to_TO be_VB effective_JJ ._.
Further_JJ information_NN concerning_VBG the_DT Directors_NNS standing_VBG for_IN Senior_JJ non-executive_JJ Director_NNP re-election_NN at_IN the_DT Annual_JJ General_NNP Meeting_VBG ,_, including_VBG their_PRP$ Dr_NNP Barry_NNP Price_NNP is_VBZ the_DT Senior_JJ independent_JJ non-executive_JJ Director_NNP ._.
biographies_NNS ,_, will_MD be_VB included_VBN in_IN the_DT Notice_NNP of_IN Meeting_VBG to_TO Dr_NNP Price_NNP is_VBZ the_DT Companys_NNP longest-serving_JJ Director_NNP and_CC as_IN such_JJ Shareholders_NNS ._.
he_PRP has_VBZ significant_JJ knowledge_NN of_IN the_DT Company_NN and_CC its_PRP$ business_NN ._.
Dr_NNP Prices_NNS in-depth_JJ knowledge_NN of_IN the_DT Company_NN in_IN particular_JJ and_CC The_DT terms_NNS of_IN appointment_NN of_IN each_DT of_IN the_DT non-executive_JJ the_DT pharmaceutical_JJ industry_NN in_IN general_JJ is_VBZ acknowledged_VBN by_IN the_DT Directors_NNS will_MD be_VB made_VBN available_JJ for_IN inspection_NN at_IN the_DT Companys_NNP Board_NNP and_CC he_PRP is_VBZ consulted_VBN by_IN other_JJ non-executive_JJ Directors_NNS on_IN Annual_JJ General_NNP Meeting_VBG in_IN 2005_CD ._.
matters_NNS pertaining_VBG to_TO the_DT Company_NN ._.
Dr_NNP Price_NNP chairs_VBZ meetings_NNS held_VBN by_IN the_DT non-executive_JJ Directors_NNS during_IN the_DT year_NN in_IN the_DT absence_NN Performance_NNP appraisals_NNS of_IN the_DT executive_NN Directors_NNS and_CC the_DT Chairman_NNP ._.
Dr_NNP Price_NNP is_VBZ available_JJ The_DT Company_NN conducted_VBN evaluations_NNS of_IN the_DT performance_NN as_IN required_VBN for_IN consultation_NN with_IN major_JJ shareholders_NNS on_IN any_DT of_IN the_DT Board_NNP ,_, its_PRP$ committees_NNS and_CC each_DT of_IN its_PRP$ Directors_NNS in_IN 2004_CD ._.
matter_NN of_IN concern_NN ._.
An_DT external_JJ consultant_NN was_VBD engaged_VBN to_TO facilitate_VB this_DT process_NN ._.
The_DT consultant_NN designed_VBN and_CC conducted_VBN a_DT series_NN of_IN one-on-one_JJ Supply_NN of_IN information_NN appraisal_NN interviews_NNS with_IN each_DT Director_NNP and_CC presented_VBD the_DT results_NNS The_DT executive_NN Directors_NNS and_CC the_DT Company_NNP Secretary_NNP are_VBP to_TO the_DT Chairman_NNP and_CC the_DT Board_NNP ._.
It_PRP was_VBD concluded_VBN that_IN each_DT of_IN responsible_JJ for_IN ensuring_VBG that_IN detailed_VBN information_NN is_VBZ provided_VBN to_TO the_DT members_NNS of_IN the_DT Board_NNP had_VBD demonstrated_VBN commitment_NN to_TO his_PRP$ Board_NNP members_NNS in_IN advance_NN of_IN any_DT scheduled_VBN Board_NNP meeting_NN ._.
role_NN and_CC that_IN the_DT performance_NN of_IN each_DT Director_NNP continues_VBZ to_TO be_VB Before_IN decisions_NNS are_VBP made_VBN ,_, consideration_NN is_VBZ given_VBN to_TO the_DT adequacy_NN effective_JJ ._.
As_IN a_DT result_NN of_IN the_DT evaluation_NN the_DT Board_NNP discussed_VBD areas_NNS of_IN information_NN available_JJ to_TO the_DT Board_NNP and_CC ,_, if_IN necessary_JJ ,_, decisions_NNS where_WRB improvement_NN could_MD be_VB made_VBN and_CC these_DT areas_NNS will_MD be_VB the_DT are_VBP deferred_VBN if_IN further_JJ information_NN is_VBZ required_VBN ._.
Re-election_NN of_IN Directors_NNS Committees_NNS of_IN the_DT Board_NNP Non-executive_JJ Directors_NNS are_VBP appointed_VBN for_IN a_DT term_NN of_IN two_CD years_NNS ,_, The_DT Board_NNP has_VBZ established_VBN the_DT Audit_NNP Committee_NNP ,_, the_DT subject_JJ to_TO shareholder_NN approval_NN ._.
Re-appointment_NN of_IN non-executive_JJ Remuneration_NNP Committee_NNP ,_, the_DT Nomination_NNP Committee_NNP and_CC the_DT Directors_NNS following_VBG the_DT expiry_NN of_IN such_JJ two-year_JJ period_NN is_VBZ subject_JJ Executive_NNP Committee_NNP ._.
Each_DT committee_NN has_VBZ its_PRP$ own_JJ written_VBN terms_NNS to_TO satisfactory_JJ performance_NN and_CC to_TO Board_NNP approval_NN ._.
of_IN reference_NN that_WDT have_VBP been_VBN approved_VBN by_IN the_DT Board_NNP ._.
The_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Audit_NNP ,_, Nomination_NNP and_CC Remuneration_NNP At_IN each_DT Annual_JJ General_NNP Meeting_VBG ,_, any_DT Director_NNP who_WP has_VBZ been_VBN Committees_NNS are_VBP available_JJ on_IN the_DT Companys_NNP website_NN ._.
Details_NNS appointed_VBN by_IN the_DT Board_NNP is_VBZ required_VBN to_TO seek_VB re-election_NN ,_, together_RB of_IN each_DT committee_NN are_VBP as_IN follows_VBZ :_: with_IN ,_, but_CC not_RB exceeding_VBG ,_, one_CD third_NN of_IN the_DT other_JJ Directors_NNS ._.
Accordingly_RB ,_, no_DT Director_NNP should_MD serve_VB for_IN more_JJR than_IN three_CD years_NNS 1_CD Audit_NNP Committee_NNP without_IN being_VBG subject_JJ to_TO re-election_NN by_IN shareholders_NNS ._.
The_DT Audit_NNP Committee_NNP has_VBZ been_VBN established_VBN for_IN the_DT purpose_NN of_IN overseeing_VBG the_DT accounting_NN and_CC financial_JJ reporting_NN processes_VBZ At_IN the_DT Annual_JJ General_NNP Meeting_VBG to_TO be_VB held_VBN in_IN 2005_CD ,_, Mr_NNP Ronald_NNP of_IN the_DT Company_NN and_CC the_DT audit_NN of_IN its_PRP$ financial_JJ statements_NNS ._.
For_IN Nordmann_NNP and_CC Mr_NNP Matthew_NNP Emmens_NNP will_MD retire_VB by_IN rotation_NN and_CC further_JJ information_NN about_IN the_DT Audit_NNP Committee_NNP ,_, its_PRP$ membership_NN offer_VBP themselves_PRP for_IN re-election_NN ._.
In_IN addition_NN ,_, in_IN accordance_NN with_IN and_CC activities_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ,_, please_VB the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP ,_, Dr_NNP Barry_NNP Price_NNP ,_, who_WP has_VBZ refer_VBP to_TO the_DT Audit_NNP Committee_NNP Report_NNP on_IN pages_NNS 46_CD and_CC 47_CD ._.
now_RB served_VBN on_IN the_DT Board_NNP for_IN nine_CD years_NNS ,_, will_MD offer_VB himself_PRP for_IN annual_JJ re-election_NN by_IN shareholders_NNS ._.
2_CD Remuneration_NNP Committee_NNP The_NNP Remuneration_NNP Committee_NNP determines_VBZ on_IN behalf_NN of_IN the_DT Board_NNP Dr_NNP Price_NNP is_VBZ the_DT Companys_NNP longest-serving_JJ Director_NNP and_CC as_IN such_JJ the_DT policy_NN for_IN the_DT setting_NN of_IN remuneration_NN and_CC incentivisation_NN of_IN he_PRP has_VBZ significant_JJ knowledge_NN of_IN the_DT Company_NN and_CC its_PRP$ business_NN ._.
the_DT executive_NN Directors_NNS and_CC other_JJ senior_JJ executives_NNS and_CC the_DT fixing_VBG In_IN addition_NN to_TO his_PRP$ experience_NN at_IN Shire_NNP ,_, Dr_NNP Price_NNP has_VBZ many_JJ years_NNS of_IN of_IN the_DT terms_NNS of_IN their_PRP$ employment_NN ._.
The_DT remuneration_NN of_IN the_DT nonexperience_NN in_IN the_DT pharmaceutical_JJ industry_NN ,_, including_VBG 28_CD years_NNS with_IN executive_JJ Directors_NNS is_VBZ determined_VBN by_IN the_DT Board_NNP ._.
The_DT remuneration_NN the_DT Glaxo_NNP group_NN ._.
The_DT Board_NNP ,_, when_WRB making_VBG its_PRP$ determination_NN on_IN of_IN the_DT members_NNS of_IN the_DT Executive_NNP Committee_NNP ,_, other_JJ than_IN the_DT the_DT independence_NN of_IN Dr_NNP Price_NNP ,_, gave_VBD particular_JJ consideration_NN to_TO the_DT executive_NN Directors_NNS ,_, is_VBZ determined_VBN by_IN the_DT Chief_NNP Executive_NNP Officer_NNP fact_NN that_IN Dr_NNP Price_NNP has_VBZ been_VBN a_DT serving_VBG member_NN of_IN the_DT Board_NNP for_IN nine_CD following_VBG discussion_NN with_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ years_NNS ,_, that_IN the_DT Combined_NNP Code_NNP suggests_VBZ that_IN length_NN of_IN service_NN of_IN dependent_JJ on_IN performance_NN ._.
The_DT remuneration_NN of_IN the_DT executive_NN nine_CD years_NNS or_CC more_JJR is_VBZ relevant_JJ to_TO a_DT determination_NN of_IN independence_NN Directors_NNS and_CC the_DT Chairman_NNP is_VBZ determined_VBN by_IN the_DT Remuneration_NNP and_CC that_IN re-appointment_JJ should_MD be_VB subject_JJ to_TO rigorous_JJ review_NN ._.
Committee_NNP and_CC confirmed_VBN by_IN the_DT Board_NNP ._.
The_DT Board_NNP were_VBD also_RB mindful_JJ of_IN the_DT need_NN to_TO ensure_VB progressive_JJ 49_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 50_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statements_NNS The_DT Remuneration_NNP Committee_NNP may_MD engage_VB external_JJ consultants_NNS Directors_NNS remuneration_NN to_TO advise_VB on_IN any_DT aspects_NNS of_IN remuneration_NN ._.
The_DT Companys_NNP remuneration_NN policy_NN is_VBZ described_VBN in_IN the_DT Directors_NNS remuneration_NN report_NN on_IN pages_NNS 36_CD to_TO 45_CD ._.
The_DT report_NN details_NNS the_DT level_NN The_DT Remuneration_NNP Committee_NNP met_VBD on_IN 11_CD occasions_NNS in_IN 2004_CD ._.
of_IN remuneration_NN for_IN Directors_NNS and_CC the_DT basis_NN upon_IN which_WDT executive_JJ Dr_NNP Barry_NNP Price_NNP chaired_VBD the_DT Remuneration_NNP Committee_NNP throughout_IN remuneration_NN is_VBZ fixed_VBN ._.
the_DT year_NN and_CC Mr_NNP Robin_NNP Buchanan_NNP was_VBD a_DT member_NN of_IN this_DT committee_NN throughout_IN 2004_CD ._.
Dr_NNP James_NNP Cavanaugh_NNP was_VBD a_DT member_NN until_IN he_PRP Relations_NNPS with_IN shareholders_NNS stepped_VBD down_RP on_IN 28_CD April_NNP 2004_CD ._.
Mr_NNP Ronald_NNP Nordmann_NNP joined_VBD the_DT The_DT Company_NN is_VBZ committed_VBN to_TO maintaining_VBG constructive_JJ Remuneration_NNP Committee_NNP on_IN 28_CD April_NNP 2004_CD ._.
Mr_NNP Buchanan_NNP was_VBD relationships_NNS with_IN shareholders_NNS ._.
The_DT Chief_NNP Executive_NNP Officer_NNP and_CC unable_JJ to_TO attend_VB one_CD of_IN the_DT 11_CD Remuneration_NNP Committee_NNP meetings_NNS the_DT Chief_NNP Financial_NNP Officer_NNP ,_, supported_VBN by_IN other_JJ senior_JJ executives_NNS ,_, which_WDT took_VBD place_NN in_IN 2004_CD due_JJ to_TO a_DT previous_JJ commitment_NN ,_, but_CC arrange_VBP individual_JJ and_CC group_NN meetings_NNS with_IN major_JJ shareholders_NNS otherwise_RB all_DT members_NNS attended_VBD all_DT meetings_NNS ._.
throughout_IN the_DT year_NN to_TO discuss_VB the_DT Companys_NNPS strategy_NN and_CC performance_NN and_CC to_TO understand_VB the_DT views_NNS of_IN major_JJ shareholders_NNS ,_, For_IN further_JJ information_NN about_IN the_DT Remuneration_NNP Committee_NNP ,_, which_WDT are_VBP then_RB communicated_VBN to_TO the_DT Board_NNP as_IN a_DT whole_NN ._.
The_DT its_PRP$ membership_NN and_CC activities_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP Chairman_NNP and_CC the_DT Senior_JJ independent_JJ non-executive_JJ Director_NNP 2004_CD ,_, please_VB refer_VBP to_TO the_DT Directors_NNS remuneration_NN report_NN on_IN also_RB are_VBP available_JJ to_TO meet_VB with_IN major_JJ shareholders_NNS ._.
The_DT Company_NN maintains_VBZ a_DT flow_NN of_IN information_NN to_TO its_PRP$ shareholders_NNS 3_CD Nomination_NNP Committee_NNP through_IN the_DT announcement_NN of_IN quarterly_JJ results_NNS and_CC the_DT provision_NN The_DT Nomination_NNP Committee_NNP is_VBZ responsible_JJ for_IN identifying_VBG and_CC of_IN annual_JJ reports_NNS ._.
The_DT Companys_NNP website_NN at_IN www_NN ._.
com_NN also_RB nominating_VBG ,_, for_IN the_DT approval_NN of_IN the_DT Board_NNP ,_, candidates_NNS to_TO fill_VB provides_VBZ information_NN about_IN the_DT Company_NN and_CC its_PRP$ business_NN and_CC is_VBZ vacancies_NNS to_TO the_DT Board_NNP ._.
Before_IN any_DT appointment_NN is_VBZ made_VBN ,_, the_DT regularly_RB updated_VBN ._.
The_DT Companys_NNP Investor_NNP Relations_NNPS department_NN Nomination_NNP Committee_NNP evaluates_VBZ the_DT balance_NN of_IN skills_NNS ,_, knowledge_NN acts_NNS as_IN a_DT contact_NN point_NN for_IN investors_NNS throughout_IN the_DT year_NN ._.
and_CC experience_NN on_IN the_DT Board_NNP and_CC ,_, in_IN light_NN of_IN this_DT evaluation_NN ,_, identifies_VBZ the_DT capabilities_NNS required_VBN for_IN a_DT particular_JJ appointment_NN ._.
The_DT Company_NN holds_VBZ its_PRP$ Annual_JJ General_NNP Meeting_VBG in_IN London_NNP The_NNP Committee_NNP is_VBZ required_VBN to_TO consider_VB candidates_NNS from_IN a_DT wide_JJ at_IN which_WDT shareholders_NNS are_VBP given_VBN the_DT opportunity_NN to_TO ask_VB questions_NNS range_NN of_IN backgrounds_NNS ,_, on_IN merit_NN and_CC against_IN objective_JJ criteria_NNS ._.
It_PRP is_VBZ also_RB required_VBN to_TO ensure_VB that_IN candidates_NNS have_VBP sufficient_JJ time_NN to_TO devote_VB to_TO the_DT position_NN ._.
This_DT Committee_NNP meets_VBZ as_IN required_VBN Balanced_NNP and_CC timely_JJ assessment_NN of_IN positions_NNS and_CC prospects_NNS and_CC in_IN 2004_CD was_VBD chaired_VBN by_IN Dr_NNP James_NNP Cavanaugh_NNP ._.
Mr_NNP Ronald_NNP The_NNP Company_NNP strives_VBZ to_TO give_VB timely_JJ assessments_NNS of_IN matters_NNS Nordmann_NNP ,_, The_DT Hon_NNP James_NNP Grant_NNP and_CC Dr_NNP Barry_NNP Price_NNP also_RB that_IN impact_NN on_IN its_PRP$ business_NN and_CC financial_JJ position_NN and_CC to_TO present_VB served_VBN on_IN this_DT Committee_NNP in_IN 2004_CD ._.
All_DT members_NNS participated_VBD scientific_JJ and_CC other_JJ price-sensitive_JJ data_NNS in_IN a_DT balanced_JJ way_NN ._.
in_IN all_DT discussions_NNS of_IN this_DT Committee_NNP in_IN 2004_CD ._.
Corporate_JJ Social_NNP Responsibility_NNP CSR_NNP The_NNP Nomination_NNP Committee_NNP retains_VBZ the_DT services_NNS of_IN executive_NN The_DT Company_NN recognizes_VBZ the_DT impact_NN that_IN its_PRP$ business_NN may_MD have_VB search_NN consultants_NNS to_TO assist_VB it_PRP in_IN the_DT identification_NN and_CC nomination_NN on_IN people_NNS and_CC the_DT environment_NN as_RB well_RB as_IN the_DT social_JJ implications_NNS of_IN new_JJ Board_NNP candidates_NNS ._.
of_IN its_PRP$ operations_NNS on_IN the_DT general_JJ community_NN ._.
The_DT Company_NN therefore_RB attaches_VBZ great_JJ importance_NN to_TO social_JJ and_CC environmental_JJ 4_CD Executive_NNP Committee_NNP issues_NNS and_CC to_TO ethical_JJ business_NN practices_NNS ._.
Accordingly_RB ,_, ultimate_JJ The_NNP Board_NNP has_VBZ delegated_VBN the_DT day-to-day_JJ management_NN of_IN the_DT responsibility_NN for_IN them_PRP is_VBZ taken_VBN at_IN the_DT highest_JJS levels_NNS ._.
The_DT Board_NNP Company_NN to_TO the_DT Executive_NNP Committee_NNP ,_, which_WDT operates_VBZ within_IN reviews_NNS and_CC is_VBZ satisfied_VBN with_IN the_DT Companys_NNP approach_NN to_TO clear_JJ and_CC formal_JJ parameters_NNS ._.
The_DT Executive_NNP Committee_NNP meets_VBZ corporate_JJ social_JJ responsibility_NN generally_RB ._.
The_DT Board_NNP also_RB reviews_VBZ at_IN least_JJS 11_CD times_NNS per_IN year_NN ._.
The_DT Chief_NNP Executive_NNP is_VBZ the_DT Chairman_NNP of_IN the_DT specific_JJ business_NN risks_NNS related_VBN to_TO Social_NNP ,_, Environmental_NNP and_CC the_DT Executive_NNP Committee_NNP ,_, which_WDT on_IN 31_CD December_NNP 2004_CD consisted_VBD Ethical_NNP SEE_VB matters_NNS annually_RB ._.
of_IN nine_CD Executive_NNP Vice_NNP Presidents_NNP including_VBG the_DT two_CD executive_NN Directors_NNS ._.
The_DT Executive_NNP Committee_NNP reports_VBZ to_TO and_CC seeks_VBZ guidance_NN The_DT Board_NNP receives_VBZ advice_NN and_CC information_NN from_IN the_DT Corporate_JJ from_IN the_DT Board_NNP on_IN a_DT regular_JJ basis_NN ._.
Social_NNP Responsibility_NNP Committee_NNP CSR_NNP Committee_NNP to_TO make_VB this_DT assessment_NN ._.
The_DT CSR_NNP Committee_NNP ,_, which_WDT is_VBZ chaired_VBN by_IN the_DT Chief_NNP The_DT Members_NNS of_IN the_DT Executive_NNP Committee_NNP as_IN at_IN 31_CD December_NNP Financial_NNP Officer_NNP ,_, meets_VBZ three_CD times_NNS a_DT year_NN and_CC is_VBZ responsible_JJ 2004_CD were_VBD Matthew_NNP Emmens_NNP Chief_NNP Executive_NNP Officer_NNP ,_, Angus_NNP for_IN setting_VBG the_DT policies_NNS and_CC procedures_NNS that_WDT manage_VBP SEE_VB issues_NNS ,_, Russell_NNP Chief_NNP Financial_NNP Officer_NNP and_CC Executive_NNP Vice_NNP President_NNP of_IN risks_NNS and_CC opportunities_NNS ._.
SEE_VB risks_NNS are_VBP managed_VBN within_IN the_DT overall_JJ Global_JJ Finance_NNP ,_, Tatjana_NNP May_NNP General_NNP Counsel_NNP and_CC Executive_NNP Vice_NNP framework_NN of_IN risk_NN management_NN ,_, explained_VBD below_IN under_IN the_DT President_NNP of_IN Global_NNP Legal_NNP Affairs_NNP ,_, Anita_NNP Graham_NNP Executive_NNP Vice_NNP heading_VBG internal_JJ control_NN ._.
President_NNP of_IN Human_NNP Resources_NNPS ,_, Eliseo_NNP Salinas_NNP Executive_NNP Vice_NNP President_NNP of_IN Global_NNP R&D_NNP ,_, Greg_NNP Flexter_NNP Executive_NNP Vice_NNP President_NNP This_DT year_NN the_DT Company_NN has_VBZ again_RB decided_VBN to_TO produce_VB a_DT standof_JJ Sales_NNS and_CC Marketing_NNP ,_, North_NNP America_NNP ,_, Joseph_NNP Rus_NNP Executive_NNP alone_RB report_NN on_IN Corporate_JJ Social_NNP Responsibility_NN ._.
This_DT is_VBZ available_JJ Vice_NNP President_NNP of_IN Sales_NNS and_CC Marketing_NNP ,_, International_NNP ,_, Barbara_NNP on_IN request_NN or_CC from_IN the_DT Shire_NNP website_NN ._.
Deptula_NNP Executive_NNP Vice_NNP President_NNP of_IN Business_NNP Development_NNP ,_, John_NNP Lee_NNP Executive_NNP Vice_NNP President_NNP of_IN Supply_NNP Chain_NNP and_CC Quality_NNP ._.
Code_NNP of_IN Ethics_NNPS The_DT Company_NN is_VBZ committed_VBN to_TO the_DT maintenance_NN of_IN high_JJ ethical_JJ The_DT Executive_NNP Committee_NNP normally_RB meets_VBZ once_RB a_DT month_NN to_TO standards_NNS in_IN its_PRP$ dealings_NNS with_IN all_DT persons_NNS with_IN whom_WP it_PRP is_VBZ involved_VBN ._.
deliberate_JJ on_IN major_JJ business_NN issues_NNS ._.
It_PRP also_RB considers_VBZ those_DT The_DT Groups_NNS Code_NNP of_IN Ethics_NNPS applies_VBZ to_TO all_DT Directors_NNS and_CC employees_NNS matters_NNS that_WDT are_VBP of_IN a_DT size_NN and_CC significance_NN as_IN to_TO require_VB referral_NN and_CC is_VBZ available_JJ for_IN review_NN on_IN the_DT Companys_NNP website_NN ._.
to_TO the_DT Board_NNP before_IN such_JJ matters_NNS are_VBP referred_VBN to_TO the_DT Board_NNP for_IN final_JJ consideration_NN and_CC decision_NN ._.
50_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 51_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statements_NNS Dividends_NNP Following_VBG the_DT enactment_NN of_IN the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD in_IN the_DT The_NNP Company_NNP announced_VBD in_IN July_NNP 2004_CD its_PRP$ intention_NN to_TO commence_VB United_NNP States_NNPS ,_, the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP the_DT payment_NN of_IN a_DT semi-annual_JJ dividend_NN with_IN the_DT aim_NN to_TO grow_VB the_DT Officer_NNP are_VBP required_VBN to_TO complete_VB formal_JJ certifications_NNS ,_, which_WDT total_VBP dividend_NN paid_VBN for_IN each_DT year_NN progressively_RB ._.
As_IN a_DT result_NN of_IN the_DT confirm_VBP ,_, inter_VBP alia_NN ,_, that_WDT :_: adoption_NN of_IN this_DT dividend_NN policy_NN ,_, the_DT Company_NN intends_VBZ to_TO declare_VB interim_JJ dividends_NNS twice_RB per_IN year_NN ,_, with_IN the_DT first_JJ payment_NN made_VBD the_DT annual_JJ report_NN on_IN Form_NN 10-K_NN in_IN the_DT United_NNP States_NNPS does_VBZ not_RB around_IN September_NNP October_NNP ,_, following_VBG determination_NN of_IN first-half_JJ contain_VBP any_DT material_NN misstatements_NNS or_CC omissions_NNS :_: results_NNS ,_, and_CC the_DT second_JJ payment_NN around_IN April_NNP May_NNP of_IN each_DT year_NN ,_, following_VBG finalisation_NN of_IN the_DT full-year_JJ results_NNS ._.
If_IN the_DT Company_NN was_VBD financial_JJ information_NN reported_VBN in_IN Form_NN 10-K_JJ fairly_RB presents_VBZ the_DT to_TO delay_VB payment_NN of_IN the_DT second-half_JJ final_JJ dividend_NN by_IN seeking_VBG financial_JJ condition_NN ,_, results_NNS of_IN operations_NNS and_CC cash_NN flows_NNS of_IN the_DT shareholder_NN approval_NN for_IN the_DT payment_NN at_IN the_DT Annual_JJ General_NNP Company_NNP :_: Meeting_VBG which_WDT is_VBZ held_VBN in_IN June_NNP each_DT year_NN ,_, the_DT Company_NN would_MD not_RB be_VB able_JJ to_TO maintain_VB an_DT even_JJ payment_NN cycle_NN at_IN approximately_RB the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP are_VBP six_CD month_NN intervals_NNS unless_IN first-half_JJ dividend_NN payments_NNS were_VBD responsible_JJ for_IN determining_VBG and_CC maintaining_VBG disclosure_NN controls_NNS also_RB delayed_VBN ._.
Accordingly_RB ,_, the_DT Company_NN does_VBZ not_RB intend_VB to_TO put_VB a_DT and_CC procedures_NNS for_IN the_DT purposes_NNS of_IN US_NNP financial_JJ reporting_NN :_: resolution_NN to_TO shareholders_NNS at_IN the_DT Annual_JJ General_NNP Meeting_VBG approving_VBG the_DT payment_NN of_IN the_DT second-half_JJ dividend_NN ._.
This_DT is_VBZ beneficial_JJ for_IN the_DT the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP have_VBP Company_NN ,_, both_DT from_IN a_DT cash_NN flow_NN planning_NN and_CC from_IN an_DT accounting_NN evaluated_VBD the_DT effectiveness_NN of_IN those_DT disclosure_NN controls_NNS and_CC perspective_NN and_CC beneficial_JJ for_IN shareholders_NNS as_IN dividends_NNS are_VBP paid_VBN procedures_NNS :_: promptly_RB and_CC a_DT smooth_JJ payment_NN cycle_NN is_VBZ maintained_VBN ._.
the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP have_VBP Financial_JJ disclosure_NN ,_, internal_JJ control_NN and_CC the_DT role_NN indicated_VBD in_IN Form_NN 10-K_JJ whether_IN there_EX were_VBD any_DT significant_JJ of_IN the_DT auditors_NNS changes_NNS in_IN the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ The_NNP Board_NNP has_VBZ ,_, through_IN the_DT Audit_NNP Committee_NNP ,_, established_VBD formal_JJ reporting_NN :_: and_CC and_CC transparent_JJ arrangements_NNS for_IN financial_JJ reporting_NN ,_, internal_JJ control_NN and_CC external_JJ auditing_NN ._.
The_DT Audit_NNP Committees_NNS terms_NNS based_VBN on_IN the_DT evaluation_NN of_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT of_IN reference_NN extend_VBP to_TO the_DT Companys_NNPS risk_NN management_NN activities_NNS Chief_NNP Financial_NNP Officer_NNP ,_, all_DT significant_JJ deficiencies_NNS and_CC material_NN as_IN a_DT whole_JJ and_CC not_RB just_RB the_DT financial_JJ aspects_NNS of_IN internal_JJ control_NN ._.
weaknesses_NNS in_IN the_DT design_NN or_CC operation_NN of_IN internal_JJ control_NN over_IN financial_JJ reporting_NN which_WDT are_VBP reasonably_RB likely_JJ to_TO affect_VB adversely_RB All_DT employees_NNS can_MD raise_VB any_DT concerns_NNS in_IN any_DT of_IN these_DT areas_NNS with_IN the_DT Companys_NNP ability_NN to_TO record_NN ,_, process_NN ,_, summarise_NN and_CC report_VB the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP in_IN the_DT strictest_JJS confidence_NN ._.
financial_JJ information_NN included_VBD in_IN Form_NN 10-K_NN have_VBP been_VBN disclosed_VBN The_DT Company_NN operates_VBZ a_DT whistle-blowing_JJ policy_NN ,_, which_WDT is_VBZ the_DT to_TO the_DT Companys_NNPS auditors_NNS ._.
framework_NN for_IN a_DT confidential_JJ process_NN through_IN which_WDT all_DT employees_NNS are_VBP able_JJ to_TO report_VB concerns_NNS relating_VBG to_TO financial_JJ disclosure_NN ,_, internal_JJ The_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP have_VBP control_NN and_CC other_JJ compliance_NN issues_NNS in_IN good_JJ faith_NN without_IN fear_NN completed_VBN these_DT certifications_NNS and_CC they_PRP have_VBP been_VBN filed_VBN with_IN the_DT of_IN discrimination_NN or_CC reprisal_NN ._.
In_IN addition_NN ,_, the_DT Audit_NNP Committee_NNP SEC_NNP in_IN the_DT United_NNP States_NNPS as_IN part_NN of_IN the_DT Companys_NNP annual_JJ report_NN has_VBZ introduced_VBN a_DT procedure_NN for_IN the_DT receipt_NN and_CC monitoring_NN of_IN in_IN the_DT United_NNP States_NNPS on_IN Form_NN 10-K_NN ._.
complaints_NNS relating_VBG to_TO internal_JJ controls_NNS ._.
2_CD Risk_NN management_NN and_CC internal_JJ control_NN 1_CD Financial_NNP reporting_VBG The_DT Board_NNP ,_, in_IN accordance_NN with_IN the_DT Turnbull_NNP Guidance_NNP on_IN internal_JJ The_NNP Board_NNP has_VBZ ultimate_JJ responsibility_NN for_IN the_DT preparation_NN of_IN control_NN ,_, recognizes_VBZ its_PRP$ overall_JJ responsibility_NN to_TO maintain_VB a_DT sound_JJ accounts_NNS and_CC for_IN the_DT monitoring_NN of_IN systems_NNS of_IN internal_JJ financial_JJ system_NN of_IN internal_JJ control_NN to_TO safeguard_VB shareholders_NNS investments_NNS control_NN ._.
The_DT Board_NNP strives_VBZ to_TO present_VB a_DT balanced_JJ and_CC and_CC the_DT Companys_NNPS assets_NNS and_CC to_TO regularly_RB review_VB its_PRP$ effectiveness_NN ._.
understandable_JJ assessment_NN of_IN the_DT Companys_NNP position_NN and_CC its_PRP$ Whilst_NNP the_DT Board_NNP acknowledges_VBZ its_PRP$ responsibility_NN for_IN the_DT system_NN prospects_NNS and_CC endeavors_NNS to_TO present_VB scientific_JJ and_CC other_JJ priceof_JJ internal_JJ control_NN ,_, there_EX are_VBP limitations_NNS in_IN any_DT system_NN of_IN internal_JJ sensitive_JJ information_NN in_IN a_DT balanced_JJ way_NN ._.
The_DT Company_NN publishes_VBZ control_NN and_CC accordingly_RB even_RB the_DT most_RBS effective_JJ system_NN can_MD quarterly_RB financial_JJ reports_NNS so_IN that_IN its_PRP$ shareholders_NNS can_MD monitor_VB provide_VB only_JJ reasonable_JJ and_CC not_RB absolute_JJ assurance_NN ._.
Such_JJ the_DT Companys_NNPS financial_JJ position_NN regularly_RB ._.
a_DT system_NN is_VBZ designed_VBN to_TO manage_VB rather_RB than_IN eliminate_VB the_DT risk_NN of_IN failure_NN to_TO achieve_VB business_NN objectives_NNS and_CC can_MD provide_VB On_IN behalf_NN of_IN the_DT Board_NNP ,_, the_DT Audit_NNP Committee_NNP has_VBZ the_DT responsibility_NN only_RB reasonable_JJ and_CC not_RB absolute_JJ assurance_NN against_IN material_NN for_IN reviewing_VBG the_DT effectiveness_NN of_IN the_DT system_NN of_IN internal_JJ financial_JJ misstatement_NN or_CC loss_NN ._.
controls_NNS and_CC the_DT audit_NN process_NN ._.
The_DT Audit_NNP Committee_NNP has_VBZ independent_JJ access_NN to_TO the_DT auditor_NN throughout_IN the_DT year_NN in_IN The_DT Board_NNP has_VBZ reviewed_VBN both_DT the_DT key_JJ risks_NNS faced_VBN by_IN the_DT Company_NN addition_NN to_TO presentations_NNS from_IN the_DT auditor_NN on_IN a_DT quarterly_JJ basis_NN ._.
and_CC the_DT effectiveness_NN of_IN the_DT Companys_NNP internal_JJ control_NN systems_NNS Any_DT significant_JJ findings_NNS or_CC identified_VBN risks_NNS are_VBP closely_RB examined_VBN in_IN 2004_CD ._.
Outside_IN of_IN its_PRP$ review_NN ,_, the_DT Board_NNP delegates_NNS responsibility_NN and_CC are_VBP reported_VBN to_TO the_DT Board_NNP with_IN recommendations_NNS for_IN action_NN ._.
to_TO the_DT Audit_NNP Committee_NNP for_IN more_RBR regular_JJ review_NN of_IN both_DT key_JJ risks_NNS and_CC internal_JJ controls_NNS and_CC for_IN monitoring_VBG the_DT activities_NNS of_IN the_DT The_DT Company_NN has_VBZ established_VBN a_DT Disclosure_NNP Committee_NNP ,_, which_WDT is_VBZ internal_JJ audit_NN function_NN ._.
The_DT Audit_NNP Committee_NNP has_VBZ kept_VBN these_DT areas_NNS chaired_VBN by_IN the_DT Chief_NNP Financial_NNP Officer_NNP ._.
Its_PRP$ membership_NN comprises_VBZ under_IN review_NN in_IN 2004_CD ._.
senior_JJ managers_NNS from_IN the_DT legal_JJ ,_, finance_NN and_CC risk_NN departments_NNS ._.
Its_PRP$ responsibility_NN is_VBZ to_TO establish_VB and_CC maintain_VB controls_NNS and_CC other_JJ procedures_NNS to_TO ensure_VB that_IN information_NN disclosed_VBN to_TO investors_NNS is_VBZ recorded_VBN ,_, summarised_VBN and_CC reported_VBN accurately_RB and_CC to_TO monitor_VB the_DT effectiveness_NN of_IN these_DT procedures_NNS ._.
The_DT Disclosure_NNP Committee_NNP also_RB has_VBZ the_DT responsibility_NN for_IN review_NN and_CC oversight_NN of_IN the_DT Companys_NNP periodic_JJ reporting_NN ._.
51_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 52_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Corporate_JJ governance_NN statements_NNS The_DT Company_NN has_VBZ an_DT integrated_JJ risk_NN management_NN and_CC internal_JJ Effective_JJ internal_JJ audit_NN audit_NN strategy_NN that_WDT was_VBD reviewed_VBN ,_, updated_VBN and_CC approved_VBN by_IN the_DT The_DT internal_JJ review_NN of_IN the_DT Companys_NNPS control_VBP procedures_NNS and_CC Audit_NNP Committee_NNP during_IN 2004_CD ._.
Following_VBG this_DT review_NN ,_, the_DT roles_NNS compliance_NN with_IN them_PRP is_VBZ mostly_RB undertaken_VBN through_IN internal_JJ audit_NN ._.
of_IN Chief_NNP Risk_NNP Officer_NNP and_CC Director_NNP of_IN Internal_NNP Audit_NNP were_VBD split_VBN ._.
The_DT The_DT Audit_NNP Committee_NNP monitors_VBZ and_CC reviews_VBZ the_DT internal_JJ audit_NN two_CD positions_NNS ,_, both_DT of_IN which_WDT have_VBP been_VBN confirmed_VBN by_IN the_DT Audit_NNP program_NN ,_, considers_VBZ the_DT findings_NNS of_IN internal_JJ audit_NN reviews_NNS and_CC Committee_NNP ,_, report_NN to_TO the_DT Chief_NNP Financial_NNP Officer_NNP but_CC have_VBP direct_JJ managements_NNS response_NN to_TO them_PRP ,_, and_CC ensures_VBZ efficient_JJ coaccess_NN to_TO the_DT Chairman_NNP ,_, the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP ordination_NN between_IN the_DT Companys_NNP internal_JJ and_CC external_JJ auditors_NNS ._.
and_CC the_DT other_JJ members_NNS of_IN the_DT Audit_NNP Committee_NNP ._.
They_PRP also_RB both_DT The_DT Companys_NNP internal_JJ audit_NN function_NN ,_, comprising_VBG a_DT mixture_NN of_IN attend_VB and_CC present_VB regularly_RB at_IN Audit_NNP Committee_NNP meetings_NNS ._.
internal_JJ and_CC out-sourced_JJ resource_NN ,_, was_VBD operational_JJ throughout_IN 2004_CD ._.
A_DT new_JJ Director_NNP of_IN Internal_NNP Audit_NNP was_VBD appointed_VBN in_IN 2004_CD and_CC The_DT Companys_NNPS risk_NN management_NN and_CC internal_JJ audit_NN strategy_NN is_VBZ this_DT appointment_NN was_VBD approved_VBN by_IN the_DT Audit_NNP Committee_NNP ._.
The_DT based_VBN on_IN a_DT risk_NN and_CC control_NN framework_NN containing_VBG the_DT following_VBG majority_NN of_IN internal_JJ audit_NN work_NN during_IN 2004_CD has_VBZ been_VBN concentrated_VBN key_JJ elements_NNS :_: on_IN internal_JJ financial_JJ controls_NNS and_CC on_IN achieving_VBG compliance_NN with_IN Sarbanes-Oxley_NNP Act_NNP requirements_NNS ._.
The_DT Audit_NNP Committee_NNP ,_, which_WDT is_VBZ an_DT effective_JJ control_NN environment_NN :_: responsible_JJ for_IN monitoring_VBG the_DT activity_NN of_IN the_DT internal_JJ audit_NN function_NN ,_, has_VBZ reviewed_VBN the_DT effectiveness_NN of_IN the_DT internal_JJ audit_NN during_IN 2004_CD ._.
an_DT effective_JJ process_NN to_TO identify_VB ,_, assess_VB and_CC manage_VB risks_NNS :_: 3_CD External_NNP auditing_NN effective_JJ internal_JJ control_NN procedures_NNS :_: and_CC The_DT Audit_NNP Committee_NNP has_VBZ the_DT primary_JJ responsibility_NN for_IN determining_VBG the_DT remuneration_NN of_IN and_CC overseeing_VBG the_DT work_NN of_IN effective_JJ internal_JJ audit_NN ._.
any_DT accounting_NN firm_NN engaged_VBD to_TO conduct_VB the_DT external_JJ audit_NN ._.
The_DT Audit_NNP Committee_NNP assesses_VBZ at_IN least_JJS annually_RB the_DT objectivity_NN and_CC Effective_JJ control_NN environment_NN independence_NN of_IN the_DT external_JJ auditor_NN taking_VBG into_IN account_NN relevant_JJ The_DT key_JJ elements_NNS of_IN the_DT Companys_NNPS control_VBP environment_NN are_VBP regulatory_JJ requirements_NNS ._.
The_DT Audit_NNP Committee_NNP reviews_VBZ and_CC as_IN follows_VBZ :_: i_FW the_DT Board_NNP has_VBZ overall_JJ responsibility_NN to_TO maintain_VB the_DT approves_VBZ the_DT annual_JJ external_JJ audit_NN plan_NN each_DT year_NN and_CC ensures_VBZ internal_JJ control_NN system_NN and_CC has_VBZ delegated_VBN certain_JJ responsibilities_NNS it_PRP is_VBZ consistent_JJ with_IN the_DT scope_NN of_IN the_DT auditors_NNS engagement_NN ._.
The_DT to_TO the_DT Executive_NNP Committee_NNP and_CC or_CC the_DT Audit_NNP Committee_NNP :_: Audit_NNP Committee_NNP also_RB considers_VBZ whether_IN the_DT skills_NNS and_CC experience_NN ii_VBP a_DT framework_NN of_IN Corporate_JJ Values_NNS and_CC Company-wide_JJ Code_NNP of_IN the_DT external_JJ audit_NN firm_NN make_VBP it_PRP a_DT suitable_JJ supplier_NN of_IN non-audit_NN of_IN Ethics_NNS which_WDT sets_VBZ appropriate_JJ standards_NNS of_IN ethical_JJ behavior_NN services_NNS ._.
The_DT Audit_NNP Committee_NNP set_NN and_CC apply_VB a_DT formal_JJ policy_NN is_VBZ operational_JJ throughout_IN the_DT Group_NNP :_: iii_VB the_DT internal_JJ structure_NN in_IN relation_NN to_TO the_DT provision_NN of_IN non-audit_JJ services_NNS by_IN the_DT external_JJ of_IN the_DT organization_NN is_VBZ well_RB documented_VBN with_IN clear_JJ reporting_NN lines_NNS auditor_NN specifying_VBG the_DT types_NNS of_IN non-audit_JJ work_NN :_: i_FW for_IN which_WDT the_DT and_CC clear_JJ limits_NNS of_IN authority_NN for_IN different_JJ matters_NNS :_: iv_VB a_DT range_NN external_JJ auditors_NNS are_VBP excluded_VBN :_: ii_VB for_IN which_WDT the_DT external_JJ auditors_NNS of_IN corporate_JJ policies_NNS and_CC procedures_NNS have_VBP been_VBN implemented_VBN :_: can_MD be_VB engaged_VBN without_IN referral_NN to_TO the_DT Committee_NNP :_: and_CC iii_FW for_IN v_NN the_DT internal_JJ audit_NN department_NN ,_, overseen_VBN by_IN the_DT Director_NNP of_IN which_WDT a_DT case_NN by_IN case_NN decision_NN is_VBZ necessary_JJ ,_, with_IN a_DT view_NN to_TO Internal_NNP Audit_NNP ,_, carries_VBZ out_RP regular_JJ reviews_NNS of_IN control_NN activities_NNS preserving_VBG the_DT auditors_NNS independence_NN and_CC objectivity_NN ._.
The_DT Audit_NNP and_CC report_NN findings_NNS to_TO management_NN :_: vi_VB the_DT Audit_NNP Committee_NNP Committee_NNP also_RB considers_VBZ the_DT fees_NNS paid_VBN to_TO the_DT external_JJ auditors_NNS considers_VBZ the_DT major_JJ findings_NNS of_IN any_DT internal_JJ investigations_NNS and_CC and_CC whether_IN the_DT fee_NN levels_NNS for_IN non-audit_JJ services_NNS ,_, individually_RB and_CC managements_NNS response_NN to_TO them_PRP ._.
in_IN aggregate_NN ,_, relative_JJ to_TO the_DT audit_NN fee_NN are_VBP appropriate_JJ to_TO enable_VB a_DT proper_JJ audit_NN to_TO be_VB conducted_VBN ._.
Effective_JJ identification_NN ,_, assessment_NN and_CC management_NN of_IN risks_NNS The_DT management_NN of_IN business_NN risk_NN is_VBZ essential_JJ for_IN ensuring_VBG that_IN the_DT Going_VBG concern_NN basis_NN Company_NN creates_VBZ and_CC preserves_VBZ shareholder_NN value_NN ._.
Accordingly_RB ,_, After_IN making_VBG enquiries_NNS ,_, the_DT Directors_NNS have_VBP formed_VBN a_DT judgement_NN ,_, the_DT Company_NN has_VBZ an_DT ongoing_JJ process_NN for_IN identifying_VBG ,_, evaluating_VBG at_IN the_DT time_NN of_IN approving_VBG the_DT financial_JJ statements_NNS ,_, that_IN there_EX is_VBZ a_DT and_CC managing_VBG the_DT significant_JJ risks_NNS that_IN it_PRP faces_VBZ ._.
This_DT process_NN has_VBZ reasonable_JJ expectation_NN that_IN the_DT Group_NNP has_VBZ adequate_JJ resources_NNS been_VBN in_IN operation_NN throughout_IN the_DT period_NN under_IN review_NN and_CC up_RB to_TO to_TO continue_VB in_IN operational_JJ existence_NN for_IN the_DT foreseeable_JJ future_NN ._.
the_DT date_NN of_IN the_DT signing_NN of_IN the_DT accounts_NNS ._.
All_DT risks_NNS are_VBP recorded_VBN on_IN For_IN this_DT reason_NN the_DT Directors_NNS continue_VBP to_TO adopt_VB the_DT going_VBG concern_NN a_DT corporate_JJ risk_NN schedule_NN which_WDT allocates_VBZ specific_JJ responsibility_NN basis_NN in_IN preparing_VBG the_DT financial_JJ statements_NNS ._.
to_TO members_NNS of_IN the_DT Executive_NNP Committee_NNP ._.
This_DT schedule_NN has_VBZ been_VBN reviewed_VBN by_IN the_DT Audit_NNP Committee_NNP during_IN 2004_CD ._.
Effective_JJ internal_JJ control_NN procedures_NNS The_DT Company_NN has_VBZ a_DT system_NN of_IN control_NN procedures_NNS ._.
Compliance_NN with_IN these_DT procedures_NNS is_VBZ monitored_VBN through_IN a_DT system_NN of_IN internal_JJ review_NN and_CC regular_JJ reports_NNS on_IN financial_JJ performance_NN ._.
Any_DT significant_JJ issues_NNS arising_VBG are_VBP reported_VBN to_TO the_DT Audit_NNP Committee_NNP ._.
During_IN 2004_CD ,_, the_DT Company_NN has_VBZ made_VBN a_DT significant_JJ investment_NN in_IN its_PRP$ internal_JJ financial_JJ control_NN procedures_NNS as_IN part_NN of_IN compliance_NN with_IN s404_CD Sarbanes-Oxley_NNP Act_NNP requirements_NNS ._.
This_DT has_VBZ included_VBN the_DT review_NN ,_, documentation_NN and_CC testing_NN of_IN all_DT key_JJ internal_JJ financial_JJ controls_NNS ._.
The_DT conclusion_NN of_IN this_DT exercise_NN is_VBZ that_IN the_DT Company_NN had_VBD an_DT effective_JJ system_NN of_IN internal_JJ controls_NNS over_IN its_PRP$ US_NNP GAAP_NNP Form_NN 10-K_JJ financial_JJ reporting_NN at_IN 31_CD December_NNP 2004_CD ._.
52_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 53_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Statement_NN of_IN Directors_NNS responsibilities_NNS Statement_NN of_IN Directors_NNS responsibilities_NNS The_DT Companys_NNP management_NN assessed_VBD the_DT effectiveness_NN of_IN the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ reporting_NN as_IN of_IN United_NNP Kingdom_NNP company_NN law_NN requires_VBZ the_DT Directors_NNS to_TO prepare_VB December_NNP 31_CD ,_, 2004_CD ._.
In_IN making_VBG this_DT assessment_NN ,_, the_DT Companys_NNPS financial_JJ statements_NNS for_IN each_DT financial_JJ year_NN which_WDT give_VBP a_DT true_JJ and_CC management_NN used_VBD the_DT criteria_NNS set_VBN forth_RB by_IN the_DT Committee_NNP of_IN fair_JJ view_NN of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Company_NN and_CC the_DT Group_NNP Sponsoring_NNP Organizations_NNP of_IN the_DT Treadway_NNP Commission_NNP COSO_NNP as_IN at_IN the_DT end_NN of_IN the_DT financial_JJ year_NN and_CC of_IN the_DT profit_NN or_CC loss_NN of_IN the_DT in_IN Internal_NNP Control-Integrated_NNP Framework_NNP ._.
In_IN preparing_VBG those_DT financial_JJ statements_NNS ,_, the_DT Directors_NNS are_VBP required_VBN to_TO :_: Based_VBN on_IN its_PRP$ assessment_NN ,_, management_NN believes_VBZ that_IN ,_, as_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ select_JJ suitable_JJ accounting_NN policies_NNS and_CC then_RB apply_VB them_PRP reporting_VBG is_VBZ effective_JJ based_VBN on_IN those_DT criteria_NNS ._.
consistently_RB :_: Deloitte_NNP &_CC Touche_NNP LLP_NNP ,_, an_DT independent_JJ registered_JJ public_NN make_VBP judgments_NNS and_CC estimates_NNS that_WDT are_VBP reasonable_JJ and_CC accounting_JJ firm_NN ,_, has_VBZ issued_VBN an_DT audit_NN report_NN on_IN managements_NNS prudent_JJ :_: and_CC assessment_NN of_IN the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ reporting_NN ._.
This_DT report_NN appears_VBZ on_IN page_NN 54_CD of_IN this_DT Annual_JJ Review_NNP ._.
state_NN whether_IN applicable_JJ accounting_NN standards_NNS have_VBP been_VBN followed_VBN ._.
Changes_NNS in_IN internal_JJ control_NN over_IN financial_JJ reporting_NN In_IN 2004_CD ,_, the_DT Company_NN commenced_VBD the_DT implementation_NN of_IN a_DT new_JJ The_DT Directors_NNS are_VBP responsible_JJ for_IN keeping_VBG proper_JJ accounting_NN integrated_VBN information_NN system_NN covering_VBG financial_JJ processes_NNS ,_, records_NNS which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT time_NN the_DT production_NN ,_, logistics_NNS and_CC quality_NN management_NN ._.
As_IN of_IN December_NNP 31_CD ,_, financial_JJ position_NN of_IN the_DT Company_NN and_CC enable_VB them_PRP to_TO ensure_VB that_IN 2004_CD ,_, a_DT number_NN of_IN the_DT Companys_NNPS business_NN units_NNS were_VBD using_VBG the_DT the_DT financial_JJ statements_NNS comply_VBP with_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
new_JJ system_NN ._.
Further_JJ implementations_NNS have_VBP already_RB been_VBN made_VBN They_PRP are_VBP also_RB responsible_JJ for_IN the_DT system_NN of_IN internal_JJ control_NN ,_, for_IN in_IN 2005_CD and_CC more_JJR are_VBP planned_VBN for_IN 2006_CD ._.
The_DT implementations_NNS safeguarding_VBG the_DT assets_NNS of_IN the_DT Company_NN and_CC hence_RB for_IN taking_VBG have_VBP involved_VBN changes_NNS in_IN the_DT Companys_NNPS information_NN systems_NNS reasonable_JJ steps_NNS for_IN the_DT prevention_NN and_CC detection_NN of_IN fraud_NN and_CC that_IN included_VBD aspects_NNS of_IN the_DT Companys_NNP internal_JJ control_NN other_JJ irregularities_NNS ._.
over_IN financial_JJ reporting_NN and_CC ,_, accordingly_RB ,_, these_DT changes_NNS have_VBP required_VBN changes_NNS to_TO the_DT Companys_NNPS internal_JJ control_NN over_IN financial_JJ reporting_NN ._.
The_DT Company_NN has_VBZ reviewed_VBN each_DT system_NN Controls_NNP and_CC procedures_NNS as_IN it_PRP is_VBZ being_VBG implemented_VBN and_CC the_DT controls_NNS affected_VBN by_IN the_DT implementation_NN of_IN the_DT new_JJ systems_NNS and_CC made_VBN appropriate_JJ Disclosure_NN controls_NNS and_CC procedures_NNS changes_NNS to_TO affected_JJ internal_JJ controls_NNS as_IN it_PRP implemented_VBD the_DT new_JJ The_DT Company_NN ,_, under_IN the_DT supervision_NN and_CC with_IN the_DT participation_NN systems_NNS ._.
Management_NNP believes_VBZ that_IN the_DT controls_NNS as_IN modified_VBN of_IN the_DT Companys_NNP management_NN ,_, including_VBG the_DT Chief_NNP Executive_NNP are_VBP appropriate_JJ and_CC functioning_VBG effectively_RB ._.
Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP ,_, has_VBZ performed_VBN an_DT evaluation_NN of_IN the_DT effectiveness_NN of_IN the_DT Companys_NNP disclosure_NN In_IN addition_NN ,_, during_IN the_DT first_JJ quarter_NN of_IN 2005_CD the_DT Companys_NNPS controls_NNS and_CC procedures_NNS ,_, as_IN of_IN December_NNP 31_CD ,_, 2004_CD ._.
The_DT Finance_NNP Shared_NNP Services_NNPS operations_NNS in_IN Newport_NNP ,_, Kentucky_NNP will_MD Companys_NNPS management_NN necessarily_RB applied_VBD its_PRP$ judgement_NN in_IN be_VB moved_VBN to_TO Philadelphia_NNP ,_, as_IN part_NN of_IN the_DT relocation_NN of_IN the_DT majority_NN assessing_VBG the_DT costs_NNS and_CC benefits_NNS of_IN such_JJ controls_NNS and_CC procedures_NNS ,_, of_IN the_DT Companys_NNPS US_NNP operations_NNS to_TO Philadelphia_NNP ._.
As_IN part_NN of_IN this_DT which_WDT by_IN their_PRP$ nature_NN can_MD provide_VB only_JJ reasonable_JJ assurance_NN transition_NN ,_, the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ reporting_NN regarding_VBG managements_NNS control_VBP objectives_NNS ._.
Based_VBN on_IN this_DT will_MD be_VB reviewed_VBN and_CC changes_NNS may_MD be_VB made_VBN ._.
evaluation_NN ,_, the_DT Companys_NNP Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP concluded_VBD that_IN the_DT Companys_NNP disclosure_NN controls_NNS and_CC procedures_NNS are_VBP effective_JJ at_IN the_DT reasonable_JJ level_NN of_IN assurance_NN for_IN gathering_NN ,_, analyzing_VBG and_CC disclosing_VBG the_DT information_NN that_IN the_DT Company_NN is_VBZ required_VBN to_TO disclose_VB in_IN the_DT reports_NNS it_PRP files_VBZ under_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD ,_, within_IN the_DT time_NN periods_NNS specified_VBN in_IN the_DT SECs_NNS rules_NNS and_CC forms_NNS ._.
Managements_NNS report_VBP on_IN internal_JJ control_NN over_IN financial_JJ reporting_NN The_DT Companys_NNPS management_NN is_VBZ responsible_JJ for_IN establishing_VBG and_CC maintaining_VBG adequate_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN as_IN defined_VBN in_IN Rule_NNP 13_CD a_DT to_TO 15_CD f_SYM or_CC 15_CD d_SYM to_TO 15_CD f_SYM promulgated_VBN under_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD ._.
Because_IN of_IN its_PRP$ inherent_JJ limitations_NNS ,_, internal_JJ control_NN over_IN financial_JJ reporting_NN may_MD not_RB prevent_VB or_CC detect_VB misstatements_NNS ._.
Projections_NNS of_IN any_DT evaluation_NN of_IN effectiveness_NN to_TO future_JJ periods_NNS are_VBP subject_JJ to_TO the_DT risk_NN that_IN controls_NNS may_MD become_VB inadequate_JJ because_IN of_IN changes_NNS in_IN conditions_NNS ,_, or_CC that_IN the_DT degree_NN of_IN compliance_NN with_IN the_DT policies_NNS or_CC procedures_NNS may_MD deteriorate_VB ._.
53_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 54_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Report_NNP of_IN independent_JJ registered_JJ public_JJ accounting_NN firm_NN Report_NNP of_IN independent_JJ registered_JJ public_JJ accounting_NN firm_NN directors_NNS of_IN the_DT company_NN :_: and_CC 3_CD provide_VBP reasonable_JJ assurance_NN regarding_VBG prevention_NN or_CC timely_JJ detection_NN of_IN unauthorized_JJ To_TO the_DT Board_NNP of_IN Directors_NNS and_CC Stockholders_NNP of_IN acquisition_NN ,_, use_NN ,_, or_CC disposition_NN of_IN the_DT companys_NNS assets_NNS that_WDT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN ,_, Basingstoke_NNP ,_, England_NNP could_MD have_VB a_DT material_NN effect_NN on_IN the_DT financial_JJ statements_NNS ._.
We_PRP have_VBP audited_VBN the_DT accompanying_VBG consolidated_JJ balance_NN sheets_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC subsidiaries_NNS the_DT Because_IN of_IN the_DT inherent_JJ limitations_NNS of_IN internal_JJ control_NN over_IN financial_JJ Company_NN as_IN of_IN December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD ,_, and_CC the_DT related_JJ reporting_NN ,_, including_VBG the_DT possibility_NN of_IN collusion_NN or_CC improper_JJ consolidated_JJ statements_NNS of_IN operations_NNS ,_, stockholders_NNS equity_NN ,_, management_NN override_NN of_IN controls_NNS ,_, material_NN misstatements_NNS due_RB comprehensive_JJ income_NN and_CC cash_NN flows_NNS for_IN each_DT of_IN the_DT three_CD to_TO error_NN or_CC fraud_NN may_MD not_RB be_VB prevented_VBN or_CC detected_VBN on_IN a_DT timely_JJ years_NNS in_IN the_DT period_NN to_TO December_NNP 31_CD ,_, 2004_CD ._.
We_PRP also_RB have_VBP audited_VBN basis_NN ._.
Also_RB ,_, projections_NNS of_IN any_DT evaluation_NN of_IN the_DT effectiveness_NN of_IN the_DT managements_NNS assessment_NN ,_, included_VBD in_IN the_DT accompanying_VBG internal_JJ control_NN over_IN financial_JJ reporting_NN to_TO future_JJ periods_NNS are_VBP subject_JJ Management_NNP Report_NNP on_IN Internal_NNP Controls_NNP over_IN Financial_NNP Reporting_NNP ,_, to_TO the_DT risk_NN that_IN the_DT controls_NNS may_MD become_VB inadequate_JJ because_IN of_IN that_IN the_DT Company_NN maintained_VBD effective_JJ internal_JJ control_NN over_IN changes_NNS in_IN conditions_NNS ,_, or_CC that_IN the_DT degree_NN of_IN compliance_NN with_IN the_DT financial_JJ reporting_NN as_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, based_VBN on_IN criteria_NNS policies_NNS or_CC procedures_NNS may_MD deteriorate_VB ._.
established_VBN in_IN Internal_NNP Control_NNP Integrated_NNP Framework_NNP issued_VBN by_IN the_DT Committee_NNP of_IN Sponsoring_NNP Organizations_NNP of_IN the_DT Treadway_NNP In_IN our_PRP$ opinion_NN ,_, the_DT consolidated_JJ financial_JJ statements_NNS referred_VBD to_TO Commission_NNP ._.
The_DT Companys_NNP management_NN is_VBZ responsible_JJ for_IN above_IN present_JJ fairly_RB ,_, in_IN all_DT material_NN respects_VBZ ,_, the_DT financial_JJ position_NN these_DT financial_JJ statements_NNS and_CC the_DT financial_JJ statement_NN schedule_NN ,_, of_IN the_DT Company_NN as_IN of_IN December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD ,_, and_CC the_DT for_IN maintaining_VBG effective_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN ,_, results_NNS of_IN its_PRP$ operations_NNS and_CC its_PRP$ cash_NN flows_VBZ for_IN each_DT of_IN the_DT three_CD and_CC for_IN its_PRP$ assessment_NN of_IN the_DT effectiveness_NN of_IN internal_JJ control_NN over_IN years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, 2004_CD ,_, in_IN conformity_NN with_IN financial_JJ reporting_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO express_VB an_DT opinion_NN on_IN accounting_NN principles_NNS generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN these_DT financial_JJ statements_NNS and_CC the_DT financial_JJ statement_NN schedule_NN ,_, America_NNP ._.
Also_RB ,_, in_IN our_PRP$ opinion_NN ,_, such_JJ financial_JJ statement_NN schedule_NN ,_, an_DT opinion_NN on_IN managements_NNS assessment_NN ,_, and_CC an_DT opinion_NN on_IN when_WRB considered_VBN in_IN relation_NN to_TO the_DT basic_JJ consolidated_JJ financial_JJ the_DT effectiveness_NN of_IN the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ statements_NNS taken_VBN as_IN a_DT whole_NN ,_, presents_VBZ fairly_RB ,_, in_IN all_DT material_NN reporting_NN based_VBN on_IN our_PRP$ audits_NN ._.
respects_NNS ,_, the_DT information_NN set_VBN forth_RB therein_RB ._.
Also_RB ,_, in_IN our_PRP$ opinion_NN ,_, managements_NNS assessment_NN that_IN the_DT Company_NN maintained_VBD We_PRP conducted_VBD our_PRP$ audits_NN in_IN accordance_NN with_IN the_DT standards_NNS of_IN effective_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN as_IN of_IN December_NNP 31_CD ,_, the_DT Public_NNP Company_NNP Accounting_NNP Oversight_NNP Board_NNP United_NNP States_NNPS ._.
2004_CD ,_, is_VBZ fairly_RB stated_VBN ,_, in_IN all_DT material_NN respects_VBZ ,_, based_VBN on_IN the_DT criteria_NNS Those_DT standards_NNS require_VBP that_IN we_PRP plan_VBP and_CC perform_VBP the_DT audit_NN to_TO established_VBN in_IN Internal_NNP Control_NNP Integrated_NNP Framework_NNP issued_VBD obtain_VB reasonable_JJ assurance_NN about_IN whether_IN the_DT financial_JJ by_IN the_DT Committee_NNP of_IN Sponsoring_NNP Organizations_NNP of_IN the_DT Treadway_NNP statements_NNS are_VBP free_JJ of_IN material_NN misstatement_NN and_CC whether_IN effective_JJ Commission_NNP ._.
Furthermore_RB ,_, in_IN our_PRP$ opinion_NN ,_, the_DT Company_NN internal_JJ control_NN over_IN financial_JJ reporting_NN was_VBD maintained_VBN in_IN all_DT maintained_VBN ,_, in_IN all_DT material_NN respects_VBZ ,_, effective_JJ internal_JJ control_NN material_NN respects_VBZ ._.
Our_PRP$ audit_NN of_IN financial_JJ statements_NNS included_VBD over_IN financial_JJ reporting_NN as_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, based_VBN on_IN the_DT examining_VBG ,_, on_IN a_DT test_NN basis_NN ,_, evidence_NN supporting_VBG the_DT amounts_NNS and_CC criteria_NNS established_VBN in_IN Internal_NNP Control_NNP Integrated_NNP Framework_NNP disclosures_NNS in_IN the_DT financial_JJ statements_NNS ,_, assessing_VBG the_DT accounting_NN issued_VBN by_IN the_DT Committee_NNP of_IN Sponsoring_NNP Organizations_NNP of_IN the_DT principles_NNS used_VBN and_CC significant_JJ estimates_NNS made_VBN by_IN management_NN ,_, Treadway_NNP Commission_NNP ._.
and_CC evaluating_VBG the_DT overall_JJ financial_JJ statement_NN presentation_NN ._.
Our_PRP$ audit_NN of_IN internal_JJ control_NN over_IN financial_JJ reporting_NN included_VBD Deloitte_NNP &_CC Touche_NNP LLP_NNP obtaining_VBG an_DT understanding_NN of_IN internal_JJ control_NN over_IN financial_JJ Reading_VBG ,_, England_NNP reporting_NN ,_, evaluating_VBG managements_NNS assessment_NN ,_, testing_NN and_CC March_NNP 15_CD ,_, 2005_CD evaluating_VBG the_DT design_NN and_CC operating_VBG effectiveness_NN of_IN internal_JJ control_NN ,_, and_CC performing_VBG such_JJ other_JJ procedures_NNS as_IN we_PRP considered_VBD necessary_JJ in_IN the_DT circumstances_NNS ._.
We_PRP believe_VBP that_IN our_PRP$ audits_NN provide_VB a_DT reasonable_JJ basis_NN for_IN our_PRP$ opinions_NNS ._.
A_DT companys_NNS internal_JJ control_NN over_IN financial_JJ reporting_NN is_VBZ a_DT process_NN designed_VBN by_IN ,_, or_CC under_IN the_DT supervision_NN of_IN ,_, the_DT companys_NNS principal_JJ executive_NN and_CC principal_JJ financial_JJ officers_NNS ,_, or_CC persons_NNS performing_VBG similar_JJ functions_NNS ,_, and_CC effected_VBN by_IN the_DT companys_NNS board_NN of_IN directors_NNS ,_, management_NN ,_, and_CC other_JJ personnel_NNS to_TO provide_VB reasonable_JJ assurance_NN regarding_VBG the_DT reliability_NN of_IN financial_JJ reporting_NN and_CC the_DT preparation_NN of_IN financial_JJ statements_NNS for_IN external_JJ purposes_NNS in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS ._.
A_DT companys_NNS internal_JJ control_NN over_IN financial_JJ reporting_NN includes_VBZ those_DT policies_NNS and_CC procedures_NNS that_WDT 1_CD pertain_NN to_TO the_DT maintenance_NN of_IN records_NNS that_IN ,_, in_IN reasonable_JJ detail_NN ,_, accurately_RB and_CC fairly_RB reflect_VBP the_DT transactions_NNS and_CC dispositions_NNS of_IN the_DT assets_NNS of_IN the_DT company_NN :_: 2_CD provide_VBP reasonable_JJ assurance_NN that_WDT transactions_NNS are_VBP recorded_VBN as_RB necessary_JJ to_TO permit_VB preparation_NN of_IN financial_JJ statements_NNS in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS and_CC that_IN receipts_NNS and_CC expenditures_NNS of_IN the_DT company_NN are_VBP being_VBG made_VBN only_RB in_IN accordance_NN with_IN authorizations_NNS of_IN management_NN and_CC 54_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 55_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP balance_NN sheets_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS Restated_VBN December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD Notes_NNS $_$ 000_CD $_$ 000_CD Assets_NNPS Current_JJ assets_NNS :_: Cash_NN and_CC cash_NN equivalents_NNS 1,111,477_CD 1,063,362_CD Restricted_VBN cash_NN 21,627_CD 46,474_CD Short-term_JJ investments_NNS 9_CD 324,411_CD 304,129_CD Accounts_NNPS receivable_NN ,_, net_JJ 6_CD 222,546_CD 194,583_CD Inventories_NNS 7_CD 41,230_CD 43,128_CD Deferred_JJ tax_NN asset_NN 26_CD 70,387_CD 64,532_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 8_CD 137,271_CD 53,814_CD Current_JJ assets_NNS from_IN continuing_VBG operations_NNS 1,928,949_CD 1,770,022_CD Current_JJ assets_NNS from_IN discontinued_VBN operations_NNS 3_CD 24,096_CD Total_JJ current_JJ assets_NNS 1,928,949_CD 1,794,118_CD Investments_NNP 10_CD 63,267_CD 72,975_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 11_CD 131,351_CD 94,495_CD Goodwill_NNP 12_CD 235,396_CD 221,231_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ 12_CD 309,297_CD 307,882_CD Deferred_JJ tax_NN asset_NN 26_CD 7,724_CD Other_JJ non-current_JJ assets_NNS 13_CD 38,895_CD 22,420_CD Long-term_JJ assets_NNS from_IN continuing_VBG operations_NNS 785,930_CD 719,003_CD Long-term_JJ assets_NNS from_IN discontinued_VBN operations_NNS 3_CD 72,070_CD Total_JJ assets_NNS 2,714,879_CD 2,585,191_CD Liabilities_NNS and_CC shareholders_NNS equity_NN Current_JJ liabilities_NNS :_: Current_JJ installments_NNS of_IN long-term_JJ debt_NN 17_CD 290_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 14_CD 311,231_CD 205,779_CD Loan_NN facility_NN 16_CD 43,162_CD Other_JJ current_JJ liabilities_NNS 15_CD 77,558_CD 37,127_CD Total_JJ current_JJ liabilities_NNS from_IN continuing_VBG operations_NNS 431,951_CD 243,196_CD Current_JJ liabilities_NNS from_IN discontinued_VBN operations_NNS 3_CD 10,479_CD Total_JJ current_JJ liabilities_NNS 431,951_CD 253,675_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ installments_NNS 17 116 376_CD ,017_CD Deferred_JJ tax_NN liability_NN 26_CD 1,400_CD Other_JJ non-current_JJ liabilities_NNS 18_CD 32,159_CD 30,194_CD Long-term_JJ liabilities_NNS from_IN continuing_VBG operations_NNS 32,275_CD 407,611_CD Long-term_JJ liabilities_NNS from_IN discontinued_VBN operations_NNS 3_CD 779_CD Total_JJ liabilities_NNS 464,226_CD 662,065_CD Shareholders_NNS equity_NN :_: Common_JJ stock_NN of_IN 5p_JJ par_JJ value_NN :_: 800,000,000_CD shares_NNS authorized_VBN :_: and_CC 484,916,034_CD shares_NNS issued_VBN and_CC outstanding_JJ 2003_CD :_: 477,894,726_CD 40,064_CD 39,521_CD Exchangeable_JJ shares_NNS :_: 4,226,476_CD shares_NNS issued_VBN and_CC outstanding_JJ 2003_CD :_: 5,839,559_CD 195,830_CD 270,667_CD Treasury_NNP stock_NN 264_CD Additional_JJ paid-in_JJ capital_NN 1,072,407_CD 983,356_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 131,939_CD 79,007_CD Retained_VBN earnings_NNS 810,677_CD 550,575_CD Total_JJ shareholders_NNS equity_NN 2,250,653_CD 1,923,126_CD Total_JJ liabilities_NNS and_CC shareholders_NNS equity_NN 2,714,879_CD 2,585,191_CD The_DT balance_NN sheet_NN for_IN December_NNP 31_CD ,_, 2003_CD has_VBZ been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN that_WDT has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT discontinued_VBN operation_NN ._.
The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
55_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 56_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN operations_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS Restated_VBN Restated_VBN 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Revenues_NNS Product_NNP sales_NNS 1,112,457_CD 1,004,307_CD 845,340_CD Royalties_NNS 230,364_CD 203,573_CD 174,812_CD Licensing_NN and_CC development_NN 13,479_CD 3,677_CD 3,064_CD Other_JJ revenues_NNS 6,907_CD 13_CD 34_CD Total_JJ revenues_NNS 1,363,207_CD 1,211,570_CD 1,023,250_CD Costs_NNS and_CC expenses_NNS Cost_NN of_IN product_NN sales_NNS 141,909_CD 143,160_CD 120,435_CD Research_NNP and_CC development_NN 196,265_CD 187,677_CD 173,380_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 516,645_CD 409,717_CD 361,699_CD Intangible_JJ asset_NN impairment_NN 12_CD 13,477_CD 27,489_CD 18,777_CD Reorganization_NN costs_NNS 3_CD 48,469_CD 23,940_CD Total_JJ operating_NN expenses_NNS 916,765_CD 791,983_CD 674,291_CD Operating_NN income_NN 446,442_CD 419,587_CD 348,959_CD Interest_NN income_NN 21,901_CD 16,856_CD 19,536_CD Interest_NN expense_NN 12,294_CD 9,451_CD 9,169_CD Other_JJ income_NN expense_NN ,_, net_JJ 24_CD 3,845_CD 20,645_CD 12,499_CD Total_JJ other_JJ income_NN expense_NN ,_, net_JJ 13,452_CD 13,240_CD 2,132_CD Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS ,_, equity_NN in_IN earnings_NNS losses_NNS of_IN equity-method_JJ investees_NNS and_CC discontinued_VBN operations_NNS 459,894_CD 406,347_CD 346,827_CD Income_NN taxes_NNS 26_CD 129,103_CD 107,353_CD 88,350_CD Equity_NN in_IN earnings_NNS losses_NNS of_IN equity-method_JJ investees_NNS 27_CD 2,508_CD 1,057_CD 1,668_CD Income_NN from_IN continuing_VBG operations_NNS 333,299_CD 297,937_CD 260,145_CD Loss_NN from_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ nil_CD ,_, $_$ nil_JJ and_CC $_$ 3,588_CD respectively_RB 3,5_CD 20,135_CD 21,886_CD 11,659_CD Loss_NN gain_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ nil_CD ,_, nil_NN and_CC $_$ 1,224_CD respectively_RB 3,5_CD 44,157_CD 2,083_CD Net_JJ income_NN 269,007_CD 276,051_CD 250,569_CD Earnings_NNS per_IN share_NN basic_JJ 22_CD Income_NN from_IN continuing_VBG operations_NNS 67.2_CD 59.8_CD 51.9_CD Loss_NN from_IN discontinued_VBN operations_NNS 4.1_CD 4.4_CD 2.3_CD Loss_NN gain_NN on_IN disposal_NN of_IN discontinued_VBN operations_NNS 8.9_CD 0.4_CD 54.2_CD 55.4_CD 50.0_CD Earnings_NNS per_IN share_NN diluted_VBN 22_CD Income_NN from_IN continuing_VBG operations_NNS 65.9_CD 58.4_CD 50.8_CD Loss_NN from_IN discontinued_VBN operations_NNS 4.0_CD 4.2_CD 2.2_CD Loss_NN gain_NN on_IN disposal_NN of_IN discontinued_VBN operations_NNS 8.6_CD 0.4_CD 53.3_CD 54.2_CD 49.0_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS Basic_JJ 496,306,604_CD 498,212,826_CD 500,687,594_CD Diluted_NNP 511,267,432_CD 518,967,395_CD 522,418,246_CD The_DT results_NNS for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN in_IN 2004_CD ._.
The_DT results_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2002_CD reflect_VBP the_DT disposal_NN of_IN the_DT Over-The-Counter_NNP OTC_NNP business_NN in_IN 2002_CD ,_, that_DT was_VBD accounted_VBN for_IN as_IN a_DT discontinued_VBN operation_NN ._.
56_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 57_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN changes_NNS in_IN shareholders_NNS equity_NN in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN share_NN data_NNS Accumulated_VBN other_JJ Common_JJ Exchangeable_JJ comprestock_NN shares_NNS Additionalhensive_NNP Total_NNP Common_NNP number_NN Exchangeable_JJ number_NN Treasury_NNP paid-in_JJ income_NN Retained_VBN shareholders_NNS stock_NN shares_NNS shares_NNS shares_NNS stock_NN capital_NN losses_NNS earnings_NNS equity_NN $_$ 000_CD 000s_CD $_$ 000_CD 000s_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD As_IN of_IN December_NNP 31_CD ,_, 2001_CD 39,861_CD 481,817_CD 277,386_CD 5,979_CD 1,014,796_CD 93,009_CD 23,955_CD 1,262,989_CD Net_JJ income_NN 250,569250,569_CD Foreign_JJ currency_NN translation_NN 50,314_CD 50,314_CD Issue_NN of_IN common_JJ stock_NN for_IN conversion_NN of_IN loan_NN note_NN 21_CD 268_CD 1,479_CD 1,500_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 22_CD 315_CD 4,863_CD 105_CD 4,841_CD Options_NNS exercised_VBN 147_CD 1,944_CD 5,861_CD 6,008_CD Stock_NN option_NN compensation_NN 166_CD 166_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 688_CD 688_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ securities_NNS 1,264_CD 1,264_CD As_IN of_IN December_NNP 31_CD ,_, 2002_CD 40,051_CD 484,344_CD 272,523_CD 5,874_CD 1,027,499_CD 41,431_CD 274,524_CD 1,573,166_CD Net_JJ income_NN 276,051_CD 276,051_CD Foreign_JJ currency_NN translation_NN 114,116_CD 114,116_CD Redemption_NN of_IN common_JJ stock_NN 625_CD 7,593_CD 51,767_CD 52,392_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 8_CD 104_CD 1,856_CD 34_CD 1,848_CD Options_NNS exercised_VBN 87_CD 1,040_CD 5,108_CD 5,195_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 24_CD 24_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 692_CD 692_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ securities_NNS 6,322_CD 6,322_CD As_IN of_IN December_NNP 31_CD ,_, 2003_CD 39,521_CD 477,895_CD 270,667_CD 5,840_CD 983,356_CD 79,007_CD 550,575_CD 1,923,126_CD Net_JJ income_NN 269,007_CD 269,007_CD Foreign_JJ currency_NN translation_NN 46,801_CD 46,801_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 344_CD 4,839_CD 74,837_CD 1,614_CD 74,493_CD Options_NNS exercised_VBN 191_CD 2,098_CD 13,225_CD 13,416_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 216_CD 216_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 354_CD 354_CD New_NNP shares_NNS issued_VBD 8_CD 84 763 771_CD Treasury_NNP stock_NN 51,286_CD shares_NNS 264_CD 264_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ securities_NNS 27,01127,011_CD Realized_VBN gain_NN on_IN available-for-sale_JJ securities_NNS 20,880_CD 20,880_CD Dividends_NNPS 8,905_CD 8,905_CD As_IN of_IN December_NNP 31_CD ,_, 2004_CD 40,064_CD 484,916_CD 195,830_CD 4,226_CD 264_CD 1,072,407_CD 131,939_CD 810,677_CD 2,250,653_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
57_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 58_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN comprehensive_JJ income_NN in_IN thousands_NNS of_IN US_NNP dollars_NNS 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN 269,007_CD 276,051_CD 250,569_CD Other_JJ comprehensive_JJ income_NN :_: Foreign_JJ currency_NN translation_NN 46,801_CD 114,116_CD 50,314_CD Unrealized_JJ holding_NN gains_NNS on_IN available-for-sale_JJ securities_NNS 27,011_CD 6,322_CD 1,264_CD Realized_VBN gain_NN on_IN available-for-sale_JJ securities_NNS 20,880_CD Comprehensive_JJ income_NN 321,939_CD 396,489_CD 302,147_CD The_DT components_NNS of_IN accumulated_VBN other_JJ comprehensive_JJ income_NN as_IN of_IN December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Foreign_JJ currency_NN translation_NN 118,222_CD 71,421_CD Unrealized_JJ holding_NN gains_NNS on_IN available-for-sale_JJ securities_NNS 13,717_CD 7,586_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 131,939_CD 79,007_CD There_EX are_VBP no_DT material_NN tax_NN effects_NNS related_VBN to_TO the_DT items_NNS included_VBD above_RB ._.
58_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 59_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS Restated_NNP Restated_NNP 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS Net_JJ income_NN from_IN continuing_VBG operations_NNS 333,299_CD 297,937_CD 260,145_CD Adjustments_NNS to_TO reconcile_VB net_JJ income_NN to_TO net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS Depreciation_NN and_CC amortization_NN 61,253_CD 38,192_CD 33,093_CD Increase_VBP decrease_NN in_IN provision_NN for_IN sales_NNS reductions_NNS 50,746_CD 20,357_CD 3,436_CD Stock_NN option_NN compensation_NN 216_CD 24_CD 166_CD Movement_NNP in_IN deferred_JJ taxes_NNS 14,979_CD 22,193_CD 9,904_CD Equity_NN in_IN earnings_NNS losses_NNS of_IN equity-method_JJ investees_NNS 2,508_CD 1,057_CD 1,668_CD Investments_NNP 552_CD 15,616_CD 7,686_CD Movements_NNS in_IN long-term_JJ assets_NNS 14,601_CD 44,035_CD 20,153_CD Other_JJ 1,468_CD Changes_NNS in_IN operating_VBG assets_NNS and_CC liabilities_NNS ,_, net_NN of_IN acquisitions_NNS :_: Increase_VB decrease_NN in_IN accounts_NNS receivable_JJ 28,066_CD 45,408_CD 70,588_CD Decrease_NN increase_NN in_IN inventory_NN 2,185_CD 6,261_CD 3,924_CD Decrease_NN increase_NN in_IN prepayments_NNS and_CC other_JJ current_JJ assets_NNS 2,509_CD 11,765_CD 11,666_CD Increase_VBP in_IN property_NN plant_NN and_CC equipment_NN held_VBN for_IN sale_NN 12,470_CD Decrease_NN in_IN other_JJ assets_NNS 13,520_CD 291_CD 3,618_CD Increase_VBP decrease_NN in_IN accounts_NNS and_CC notes_NNS payable_JJ and_CC other_JJ liabilities_NNS 76,793_CD 890_CD 14,635_CD Increase_VBP decrease_NN in_IN deferred_JJ revenue_NN 6,151_CD 19,372_CD 11,394_CD Dividends_NNPS received_VBD from_IN investments_NNS 5,493_CD 2,289_CD Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS 520,661_CD 379,065_CD 361,822_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Net_JJ increase_NN decrease_NN in_IN short-term_JJ investments_NNS 20,282_CD 11,997_CD 407,653_CD Movements_NNS in_IN restricted_JJ cash_NN 24,847_CD 5,531_CD 52,005_CD Loans_NNPS made_VBD to_TO IDB_NNP 56,838_CD Purchase_NN of_IN subsidiary_NN undertakings_NNS 17,300_CD Purchase_NN of_IN long-term_JJ investments_NNS 6,124_CD 5,643_CD 5,933_CD Purchase_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 57,603_CD 44,681_CD 18,881_CD Purchase_NN of_IN intangible_JJ assets_NNS 30,209_CD 47,049_CD 24,032_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 34,912_CD 71,000_CD Proceeds_NNS from_IN sale_NN of_IN long-term_JJ investments_NNS 26,733_CD 1,000_CD 4,108_CD Proceeds_NNS from_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 3,527_CD 1,262_CD 721_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ assets_NNS 3,701_CD Proceeds_NNS from_IN sale_NN of_IN assets_NNS held_VBN for_IN sale_NN 11,289_CD Net_JJ cash_NN used_VBN in_IN provided_VBN by_IN investing_VBG activities_NNS 66,047_CD 77,583_CD 365,331_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Redemption_NN of_IN 2_CD %_NN convertible_JJ loan_NN notes_NNS 370,109_CD 29,775_CD Repayment_NN of_IN long-term_JJ debt_NN ,_, capital_NN leases_NNS and_CC notes_NNS 6,079_CD 231_CD 172_CD Proceeds_NNS from_IN issue_NN of_IN common_JJ stock_NN ,_, net_JJ 771_CD Proceeds_NNS from_IN exercise_NN of_IN options_NNS 13,416_CD 5,195_CD 6,008_CD Tax_NNP benefit_NN of_IN stock_NN option_NN compensation_NN ,_, charged_VBN directly_RB to_TO equity_NN 354 692 688_CD Payments_NNS for_IN redemption_NN of_IN common_JJ stock_NN 264_CD 52,392_CD Payment_NN of_IN dividend_NN 8,905_CD Net_JJ cash_NN used_VBN in_IN provided_VBN by_IN financing_VBG activities_NNS 370,816_CD 76,511_CD 6,868_CD Effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS from_IN continuing_VBG operations_NNS 7,567_CD 25,133_CD 6,957_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 91,365_CD 250,104_CD 740,978_CD Cash_NN flows_NNS used_VBN in_IN discontinued_VBN operations_NNS 43,250_CD 31,883_CD 13,689_CD Net_JJ increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 48,115_CD 218,221_CD 727,289_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN period_NN 1,063,362_CD 845,141_CD 117,852_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN period_NN 1,111,477_CD 1,063,362_CD 845,141_CD 59_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 60_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS Supplemental_NNP information_NN associated_VBN with_IN continuing_VBG operations_NNS :_: Restated_VBN Restated_VBN 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Interest_NN paid_VBN 4,849_CD 7,716_CD 8,101_CD Income_NN taxes_NNS paid_VBD 123,510_CD 118,527_CD 101,779_CD Non-cash_JJ activities_NNS Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN :_: 4,931,864_CD shares_NNS of_IN IDB_NNP 60,000_CD Escrow_NNP funds_NNS 30,000_CD Common_JJ stock_NN issued_VBN on_IN conversion_NN of_IN zero-coupon_JJ note_NN 1,500_CD Capital_NNP leases_NNS assumed_VBD on_IN acquisition_NN of_IN subsidiaries_NNS 6,266_CD The_DT results_NNS for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN in_IN 2004_CD ._.
60_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 61_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 1_CD Description_NN of_IN operations_NNS General_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC its_PRP$ subsidiaries_NNS collectively_RB referred_VBD to_TO as_IN Shire_NNP or_CC the_DT Company_NN is_VBZ a_DT global_JJ pharmaceutical_JJ company_NN with_IN a_DT strategic_JJ focus_NN on_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN ._.
The_DT Company_NN has_VBZ a_DT particular_JJ interest_NN in_IN innovative_JJ therapies_NNS that_WDT are_VBP prescribed_VBN by_IN specialist_NN doctors_NNS as_IN opposed_VBN to_TO primary-care_JJ physicians_NNS ._.
The_DT Company_NN is_VBZ focused_VBN on_IN the_DT development_NN of_IN late-stage_JJ projects_NNS and_CC marketing_NN products_NNS in_IN the_DT areas_NNS of_IN Central_NNP Nervous_NNP System_NNP CNS_NNP ,_, Gastro-Intestinal_NNP GI_NNP and_CC General_NNP Products_NNPS GP_NNP ._.
Geographically_NNP ,_, the_DT Company_NN has_VBZ operations_NNS in_IN the_DT worlds_NNS key_JJ pharmaceutical_JJ markets_NNS ,_, namely_RB North_NNP America_NNP and_CC Europe_NNP ._.
The_DT Companys_NNPS business_NN is_VBZ organized_VBN across_IN four_CD operating_NN segments_NNS :_: US_NNP ,_, International_NNP covering_VBG territories_NNS outside_IN of_IN the_DT US_NNP ,_, Research_NNP &_CC Development_NNP R&D_NNP and_CC Corporate_NNP ._.
Revenues_NNS are_VBP derived_VBN primarily_RB from_IN three_CD sources_NNS :_: sales_NNS of_IN the_DT Companys_NNP own_JJ products_NNS ,_, royalties_NNS where_WRB Shire_NNP has_VBZ out-licensed_JJ products_NNS to_TO third_JJ parties_NNS and_CC licensing_NN and_CC development_NN fees_NNS ._.
Strategic_NNP review_NN and_CC reorganization_NN In_IN 2003_CD ,_, the_DT Company_NN conducted_VBD a_DT detailed_JJ strategic_JJ review_NN resulting_VBG in_IN revised_VBN strategic_JJ priorities_NNS ,_, namely_RB that_IN the_DT Company_NN will_MD :_: search_NN ,_, develop_VB and_CC market_VB but_CC not_RB invent_VB :_: seek_VB to_TO acquire_VB products_NNS with_IN substantive_JJ patent_NN protection_NN rather_RB than_IN just_RB three_CD years_NNS Hatch-Waxman_NNP exclusivity_NN :_: focus_VB its_PRP$ in-licensing_JJ and_CC merger_NN and_CC acquisition_NN efforts_NNS on_IN the_DT US_NNP market_NN and_CC obtain_VB European_JJ rights_NNS whenever_WRB possible_JJ ._.
As_IN part_NN of_IN this_DT process_NN ,_, Shire_NNP refocused_VBD its_PRP$ R&D_NNP efforts_NNS and_CC technology_NN to_TO concentrate_VB on_IN areas_NNS where_WRB it_PRP had_VBD a_DT commercial_JJ presence_NN and_CC to_TO create_VB the_DT flexibility_NN to_TO add_VB new_JJ therapeutic_JJ areas_NNS based_VBN on_IN product_NN acquisition_NN opportunities_NNS ._.
This_DT approach_NN aimed_VBN to_TO deliver_VB the_DT combined_VBN benefit_NN of_IN increased_VBN returns_NNS and_CC lower_JJR risks_NNS ._.
In_IN connection_NN with_IN the_DT refocused_VBN R&D_NNP efforts_NNS ,_, the_DT Company_NN decided_VBD to_TO exit_NN from_IN early-stage_JJ therapeutic_JJ research_NN Lead_JJ Optimization_NN in_IN 2003_CD ,_, to_TO dispose_VB of_IN certain_JJ facilities_NNS in_IN Canada_NNP see_VBP Note_NN 3_CD and_CC announced_VBD the_DT planned_VBN disposal_NN of_IN the_DT vaccines_NNS business_NN ._.
During_IN 2004_CD ,_, the_DT Company_NN announced_VBD that_IN it_PRP would_MD continue_VB to_TO focus_VB on_IN its_PRP$ new_JJ business_NN strategy_NN ,_, including_VBG taking_VBG the_DT following_JJ actions_NNS :_: a_DT North_JJ American_JJ site_NN consolidation_NN ,_, decreasing_VBG the_DT number_NN of_IN operational_JJ sites_NNS from_IN 14_CD to_TO 6_CD in_IN 2004_CD and_CC the_DT opening_NN of_IN a_DT new_JJ US_NNP headquarters_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP :_: the_DT disposal_NN of_IN the_DT Companys_NNP vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP ,_, a_DT Canadian_JJ biotechnology_NN company_NN ,_, which_WDT was_VBD completed_VBN in_IN the_DT third_JJ quarter_NN of_IN 2004_CD see_VBP Note_NN 3_CD :_: and_CC the_DT out-licensing_NN of_IN non-core_JJ projects_NNS including_VBG the_DT acute_JJ myelogenous_JJ leukemia_NN treatment_NN TROXATYL_NNP troxacitabine_NN to_TO Structural_NNP GenomiX_NNP Inc._NNP during_IN the_DT third_JJ quarter_NN of_IN 2004_CD and_CC SPD754_CD for_IN the_DT treatment_NN of_IN HIV_NNP to_TO Avexa_NNP Limited_NNP in_IN January_NNP 2005_CD ._.
These_DT changes_NNS have_VBP had_VBN implications_NNS for_IN both_DT Shires_NNP organizational_JJ structure_NN and_CC operating_VBG sites_NNS ._.
The_DT Company_NN has_VBZ a_DT new_JJ global_JJ management_NN structure_NN aimed_VBN at_IN close_JJ interaction_NN between_IN development_NN ,_, marketing_NN and_CC sales_NNS ,_, and_CC new_JJ people_NNS in_IN key_JJ positions_NNS reporting_VBG directly_RB to_TO the_DT Chief_NNP Executive_NNP Officer_NNP ._.
The_DT Company_NN expects_VBZ to_TO complete_VB the_DT North_JJ American_JJ site_NN consolidation_NN in_IN 2005_CD ._.
To_TO date_VB the_DT Company_NN has_VBZ recorded_VBN $_$ 48.5_CD million_CD of_IN costs_NNS associated_VBN with_IN this_DT site_NN consolidation_NN ._.
Substantial_JJ progress_NN has_VBZ been_VBN made_VBN and_CC the_DT Company_NN anticipates_VBZ completing_VBG the_DT remaining_VBG actions_NNS in_IN 2005_CD ._.
Remaining_VBG costs_NNS associated_VBN with_IN the_DT reorganization_NN are_VBP estimated_VBN to_TO be_VB approximately_RB $_$ 12_CD million_CD see_VBP Note_NN 3_CD ._.
There_EX are_VBP inherent_JJ risks_NNS associated_VBN with_IN any_DT significant_JJ organizational_JJ change_NN ,_, including_VBG the_DT possibility_NN of_IN disruption_NN to_TO the_DT Companys_NNPS business_NN or_CC the_DT loss_NN of_IN key_JJ personnel_NNS ._.
Although_IN a_DT project_NN team_NN has_VBZ been_VBN set_VBN up_RP to_TO actively_RB manage_VB the_DT process_NN and_CC the_DT associated_VBN risks_NNS ,_, delays_NNS to_TO R&D_NNP projects_NNS ,_, failure_NN to_TO attain_VB sales_NNS targets_NNS or_CC other_JJ disruption_NN to_TO the_DT business_NN could_MD occur_VB as_IN a_DT result_NN of_IN the_DT reorganization_NN ._.
61_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 62_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 1_CD Description_NN of_IN operations_NNS continued_VBD Markets_NNS The_DT Companys_NNPS principal_JJ sources_NNS of_IN revenue_NN from_IN its_PRP$ primary_JJ markets_NNS include_VBP :_: in_IN the_DT US_NNP ,_, ADDERALL_NNP XR_NNP for_IN the_DT treatment_NN of_IN ADHD_NNP ,_, AGRYLIN_NNP for_IN the_DT treatment_NN of_IN elevated_JJ blood_NN platelets_NNS ,_, PENTASA_NNP for_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS and_CC CARBATROL_NNP for_IN the_DT treatment_NN of_IN epilepsy_NN ._.
In_IN addition_NN ,_, the_DT Company_NN receives_VBZ royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP for_IN the_DT treatment_NN of_IN Alzheimers_NNP disease_NN ,_, marketed_VBN by_IN Janssen_NNP Pharmaceutica_NNP NV_NNP Janssen_NNP ,_, and_CC on_IN EPIVIR_NNP ,_, COMBIVIR_NNP and_CC TRIZIVIR_NNP for_IN the_DT treatment_NN of_IN HIV_NNP AIDS_NNP ,_, marketed_VBN by_IN GSK_NNP :_: in_IN the_DT UK_NNP and_CC the_DT Republic_NNP of_IN Ireland_NNP ,_, the_DT CALCICHEW_NNP range_NN ,_, used_VBN primarily_RB as_IN adjuncts_NNS in_IN the_DT treatment_NN of_IN osteoporosis_NN ,_, and_CC REMINYL_NNP ,_, which_WDT was_VBD co-promoted_VBN with_IN Janssen-Cilag_NNP until_IN May_NNP 3_CD ,_, 2004_CD ._.
On_IN May_NNP 3_CD ,_, 2004_CD ,_, the_DT Company_NN acquired_VBN from_IN Janssen-Cilag_NNP the_DT exclusive_JJ commercialization_NN rights_NNS to_TO REMINYL_NNP in_IN the_DT UK_NNP and_CC Ireland_NNP :_: in_IN Canada_NNP ,_, 3TC_NNP and_CC COMBIVIR_NNP for_IN the_DT treatment_NN of_IN HIV_NNP AIDS_NNP ,_, HEPTOVIR_NNP for_IN the_DT treatment_NN of_IN hepatitis_NN all_DT marketed_VBN in_IN partnership_NN with_IN GSK_NNP and_CC AGRYLIN_NNP for_IN the_DT treatment_NN of_IN elevated_JJ blood_NN platelets_NNS :_: and_CC in_IN the_DT Rest_VB of_IN the_DT World_NNP ,_, royalties_NNS on_IN the_DT sales_NNS of_IN ZEFFIX_NNP for_IN the_DT treatment_NN of_IN Hepatitis_NNP B_NNP ,_, marketed_VBN by_IN GSK_NNP ,_, and_CC royalties_NNS on_IN sales_NNS of_IN REMINYL_NNP ,_, marketed_VBN by_IN Janssen_NNP ._.
In_IN addition_NN to_TO the_DT above_JJ ,_, the_DT Company_NN has_VBZ a_DT number_NN of_IN products_NNS that_WDT have_VBP been_VBN recently_RB approved_VBN and_CC projects_NNS that_WDT are_VBP currently_RB in_IN registration_NN or_CC late-stage_JJ development_NN ._.
These_DT include_VBP :_: Recently_RB approved_VBN PENTASA_NNP for_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS ._.
On_IN July_NNP 8_CD ,_, 2004_CD Shire_NNP received_VBD FDA_NNP approval_NN to_TO market_VB the_DT 500mg_JJ dosage_NN strength_NN of_IN PENTASA_NNP in_IN the_DT US_NNP :_: ADDERALL_NNP XR_NNP for_IN the_DT treatment_NN of_IN adults_NNS with_IN ADHD_NNP ._.
On_IN August_NNP 12_CD ,_, 2004_CD ,_, the_DT FDA_NNP approved_VBD a_DT once-daily_JJ treatment_NN for_IN adults_NNS with_IN ADHD_NNP :_: FOSRENOL_NNP for_IN the_DT treatment_NN of_IN high_JJ blood_NN phosphate_NN levels_NNS associated_VBN with_IN end-stage_JJ renal_JJ disease_NN ._.
On_IN October_NNP 26_CD ,_, 2004_CD Shire_NNP received_VBD FDA_NNP approval_NN to_TO market_NN FOSRENOL_NNP in_IN 250mg_CD and_CC 500mg_CD dosage_JJ strength_NN in_IN the_DT US_NNP ._.
Approval_NN was_VBD also_RB gained_VBN in_IN Sweden_NNP on_IN March_NNP 19_CD ,_, 2004_CD ,_, and_CC further_JJ regulatory_JJ approvals_NNS have_VBP been_VBN sought_VBN in_IN a_DT number_NN of_IN other_JJ EU_NNP Member_NNP States_NNPS pursuant_JJ to_TO the_DT Mutual_JJ Recognition_NNP Process_NNP ._.
Following_VBG pricing_NN and_CC reimbursement_NN discussions_NNS with_IN individual_JJ countries_NNS ,_, the_DT launch_NN of_IN FOSRENOL_NNP in_IN Europe_NNP will_MD be_VB phased_VBN during_IN 2005_CD :_: ADDERALL_NNP XR_NNP for_IN the_DT treatment_NN of_IN ADHD_NNP ._.
On_IN October_NNP 28_CD ,_, 2004_CD the_DT FDA_NNP granted_VBD an_DT additional_JJ six_CD months_NNS of_IN market_NN exclusivity_NN in_IN the_DT US_NNP under_IN the_DT Hatch-Waxman_NNP regulations_NNS ._.
The_DT additional_JJ exclusivity_NN period_NN will_MD expire_VB on_IN April_NNP 11_CD ,_, 2005_CD ._.
The_DT extension_NN followed_VBD submission_NN of_IN data_NNS from_IN a_DT clinical_JJ program_NN examining_VBG the_DT effects_NNS of_IN ADDERALL_NNP XR_NNP in_IN adolescent_JJ pediatric_JJ patients_NNS ._.
This_DT data_NN was_VBD submitted_VBN in_IN response_NN to_TO a_DT Written_VBN Request_NN by_IN the_DT FDA_NNP :_: XAGRID_NNP trade_NN name_NN for_IN AGRYLIN_NNP in_IN EU_NNP for_IN the_DT treatment_NN of_IN elevated_JJ blood_NN platelets_NNS ._.
EU_NNP approval_NN was_VBD received_VBN in_IN November_NNP 2004_CD :_: launch_NN commenced_VBD in_IN January_NNP 2005_CD and_CC will_MD be_VB phased_VBN through_IN certain_JJ countries_NNS in_IN Europe_NNP in_IN 2005_CD :_: and_CC EQUETRO_NNP previously_RB called_VBD SPD417_NNP and_CC BIPOTROL_NNP for_IN bipolar_JJ disorder_NN ._.
FDA_NNP approval_NN was_VBD granted_VBN in_IN December_NNP 2004_CD ._.
Registration_NN MTS_NNP METHYPATCH_NNP ,_, a_DT transdermal_JJ delivery_NN system_NN for_IN the_DT once-daily_JJ treatment_NN of_IN ADHD_NNP ._.
In_IN April_NNP 2003_CD Shire_NNP received_VBD a_DT not_RB approvable_JJ letter_NN from_IN the_DT FDA_NNP ._.
A_DT program_NN has_VBZ been_VBN agreed_VBN with_IN the_DT FDA_NNP to_TO address_VB issues_NNS raised_VBN in_IN this_DT letter_NN and_CC this_DT work_NN is_VBZ currently_RB ongoing_JJ :_: and_CC ADDERALL_NNP XR_NNP adolescent_JJ ._.
In_IN September_NNP 2004_CD a_DT supplemental_JJ new_JJ drug_NN application_NN for_IN the_DT use_NN of_IN ADDERALL_NNP XR_NNP in_IN the_DT adolescent_JJ population_NN was_VBD submitted_VBN to_TO the_DT FDA_NNP ._.
It_PRP is_VBZ anticipated_VBN that_IN a_DT response_NN to_TO this_DT submission_NN will_MD be_VB received_VBN during_IN the_DT second_JJ half_NN of_IN 2005_CD ._.
Late-stage_JJ development_NN SPD503_CD guanfacine_NN for_IN ADHD_NNP ,_, which_WDT is_VBZ in_IN Phase_NN III_NNP clinical_JJ trials_NNS :_: SPD476_CD for_IN ulcerative_JJ colitis_NNS ,_, which_WDT is_VBZ in_IN Phase_NN III_NNP clinical_JJ trials_NNS :_: SPD465_NNS for_IN ADHD_NNP ,_, which_WDT is_VBZ in_IN Phase_NN II_NNP clinical_JJ trials_NNS :_: SPD480_CD ,_, which_WDT is_VBZ a_DT 5-ASA_JJ based_VBN product_NN formulated_VBN in_IN a_DT single_JJ dose_NN ,_, 2g_CD and_CC 4g_CD ,_, foam_NN for_IN rectal_JJ delivery_NN in_IN the_DT treatment_NN of_IN ulcerative_JJ colitis_NNS ._.
Rights_NNS to_TO key_JJ global_JJ markets_NNS were_VBD licensed_VBN from_IN Giuliani_NNP SpA_NNP in_IN October_NNP 2002_CD ._.
This_DT product_NN will_MD provide_VB an_DT alternative_JJ treatment_NN for_IN distal_JJ rectal_JJ ulcerative_JJ colitis_NN and_CC has_VBZ reached_VBN Phase_NN II_NNP development_NN :_: and_CC NRP104_NNP for_IN ADHD_NNP which_WDT is_VBZ in_IN Phase_NN III_NNP clinical_JJ trials_NNS ._.
62_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 63_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS a_DT Basis_NN of_IN preparation_NN The_DT accompanying_VBG consolidated_JJ financial_JJ statements_NNS include_VBP the_DT accounts_NNS of_IN Shire_NNP and_CC all_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS after_IN elimination_NN of_IN intercompany_NN accounts_NNS and_CC transactions_NNS ._.
b_NN Use_NN of_IN estimates_NNS in_IN consolidated_JJ financial_JJ statements_NNS The_DT preparation_NN of_IN consolidated_JJ financial_JJ statements_NNS ,_, in_IN conformity_NN with_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS ,_, requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS ,_, the_DT disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC reported_VBD amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
Estimates_NNS and_CC assumptions_NNS are_VBP primarily_RB made_VBN in_IN relation_NN to_TO provisions_NNS for_IN sales_NNS deductions_NNS ,_, valuation_NN of_IN intangible_JJ assets_NNS and_CC fixed_VBN asset_NN investments_NNS ,_, contingent_JJ liabilities_NNS and_CC the_DT valuation_NN of_IN tax_NN assets_NNS and_CC liabilities_NNS ._.
c_NN Revenue_NN recognition_NN The_DT Company_NN recognizes_VBZ revenue_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT agreement_NN or_CC arrangement_NN :_: delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN :_: the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ fixed_VBN or_CC determinable_JJ :_: and_CC collectability_NN is_VBZ reasonably_RB assured_VBN ._.
The_DT Companys_NNPS principal_JJ revenue_NN streams_NNS and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP discussed_VBN below_IN :_: i_FW Product_NNP sales_NNS Revenue_NN for_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS or_CC at_IN the_DT time_NN of_IN delivery_NN depending_VBG on_IN the_DT terms_NNS of_IN sale_NN ._.
Provisions_NNS for_IN rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
The_DT Company_NN monitors_NNS and_CC tracks_VBZ the_DT amount_NN of_IN rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS based_VBN on_IN historical_JJ experience_NN to_TO estimate_VB the_DT amount_NN of_IN reduction_NN to_TO revenue_NN ._.
ii_FW Licensing_NN and_CC development_NN fees_NNS Licensing_VBG and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN product_NN out-licensing_JJ agreements_NNS and_CC from_IN contract_NN R&D_NNP agreements_NNS ._.
Initial_JJ license_NN fees_NNS received_VBN in_IN connection_NN with_IN product_NN out-licensing_JJ agreements_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP non-refundable_JJ and_CC not_RB creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT license_NN term_NN ,_, or_CC the_DT period_NN of_IN the_DT associated_VBN collaborative_JJ assistance_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ license_NN fees_NNS are_VBP not_RB for_IN a_DT defined_VBN period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT license_NN relates_VBZ ._.
Revenue_NN from_IN contract_NN R&D_NNP agreements_NNS is_VBZ recognized_VBN as_IN the_DT services_NNS are_VBP performed_VBN ._.
iii_FW Royalty_NN income_NN Royalty_NN income_NN relating_VBG to_TO licensed_JJ technology_NN is_VBZ recognized_VBN when_WRB the_DT licensee_NN sells_VBZ the_DT underlying_JJ product_NN ._.
The_DT Company_NN receives_VBZ sales_NNS information_NN from_IN the_DT licensee_NN on_IN a_DT monthly_JJ basis_NN ._.
For_IN any_DT period_NN that_IN the_DT information_NN is_VBZ not_RB available_JJ ,_, the_DT Company_NN estimates_VBZ sales_NNS amounts_NNS based_VBN on_IN the_DT historical_JJ product_NN information_NN ._.
Where_WRB applicable_JJ ,_, all_DT revenues_NNS are_VBP stated_VBN net_NN of_IN value_NN added_VBD tax_NN and_CC similar_JJ taxes_NNS ,_, and_CC trade_NN discounts_NNS ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
iv_NN Milestones_NNS During_IN the_DT term_NN of_IN certain_JJ R&D_NNP agreements_NNS and_CC licensing_NN agreements_NNS ,_, the_DT Company_NN receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenues_NNS are_VBP recognized_VBN on_IN achievement_NN of_IN such_JJ milestones_NNS ._.
The_DT Company_NN also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB receivable_JJ i._NN e._NN on_IN completion_NN of_IN the_DT relevant_JJ phase_NN ._.
63_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 64_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD d_SYM Cost_NN of_IN product_NN sales_NNS Cost_NN of_IN sales_NNS includes_VBZ both_DT the_DT cost_NN of_IN purchasing_VBG finished_JJ product_NN for_IN sale_NN ,_, together_RB with_IN the_DT cost_NN of_IN raw_JJ materials_NNS and_CC manufacturing_VBG for_IN those_DT products_NNS that_WDT are_VBP manufactured_VBN by_IN Shire_NNP ._.
Royalties_NNS that_WDT are_VBP payable_JJ on_IN those_DT products_NNS that_WDT Shire_VBP does_VBZ not_RB own_VB the_DT rights_NNS to_TO are_VB also_RB included_VBN in_IN cost_NN of_IN sales_NNS ._.
e_LS R&D_NNP R&D_NNP expenditures_NNS include_VBP funded_VBN and_CC unfunded_JJ expenditures_NNS and_CC are_VBP charged_VBN to_TO operations_NNS in_IN the_DT period_NN in_IN which_WDT the_DT expense_NN is_VBZ incurred_VBN ._.
f_LS Leased_VBN assets_NNS The_DT costs_NNS of_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO operations_NNS on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ,_, even_RB if_IN rental_JJ payments_NNS are_VBP not_RB made_VBN on_IN such_PDT a_DT basis_NN ._.
Assets_NNS acquired_VBN under_IN capital_NN leases_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN as_IN property_NN ,_, plant_NN and_CC equipment_NN are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN the_DT lease_NN or_CC their_PRP$ useful_JJ lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN payments_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN element_NN is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT period_NN of_IN the_DT lease_NN to_TO produce_VB a_DT level_NN yield_NN on_IN the_DT balance_NN of_IN the_DT capital_NN lease_NN obligation_NN ._.
g_NN Finance_NNP costs_NNS of_IN debt_NN Finance_NNP costs_NNS of_IN debt_NN are_VBP recorded_VBN as_IN a_DT deferred_JJ asset_NN and_CC then_RB amortized_VBD to_TO the_DT statement_NN of_IN operations_NNS over_IN the_DT term_NN of_IN the_DT debt_NN ,_, using_VBG the_DT effective_JJ interest_NN rate_NN method_NN ._.
Deferred_JJ financing_NN costs_NNS relating_VBG to_TO debt_NN extinguishments_NNS are_VBP written_VBN off_RP and_CC reflected_VBN in_IN interest_NN expense_NN in_IN the_DT consolidated_JJ statements_NNS of_IN operations_NNS ._.
h_NN Income_NN taxes_NNS The_DT Company_NN provides_VBZ for_IN income_NN taxes_NNS in_IN accordance_NN with_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP No._NN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP provided_VBN for_IN differences_NNS between_IN the_DT carrying_VBG amounts_NNS of_IN assets_NNS and_CC liabilities_NNS in_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC the_DT tax_NN bases_NNS of_IN assets_NNS and_CC liabilities_NNS that_WDT will_MD result_VB in_IN future_JJ taxable_JJ or_CC deductible_JJ amounts_NNS ._.
The_DT deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP measured_VBN using_VBG the_DT enacted_VBN tax_NN laws_NNS and_CC rates_NNS applicable_JJ to_TO the_DT periods_NNS in_IN which_WDT the_DT differences_NNS are_VBP expected_VBN to_TO affect_VB taxable_JJ income_NN ._.
Income_NNP tax_NN expense_NN is_VBZ computed_VBN as_IN the_DT tax_NN payable_JJ or_CC refundable_JJ for_IN the_DT period_NN ,_, plus_CC or_CC minus_CC the_DT change_NN during_IN the_DT period_NN in_IN deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP reduced_VBN by_IN a_DT valuation_NN allowance_NN when_WRB ,_, in_IN the_DT opinion_NN of_IN management_NN ,_, it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN some_DT portion_NN or_CC all_DT of_IN the_DT deferred_JJ tax_NN assets_NNS will_MD not_RB be_VB realized_VBN ._.
i_FW Earnings_NNS per_IN share_NN Earnings_NNS per_IN share_NN is_VBZ computed_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
Basic_JJ earnings_NNS per_IN share_NN is_VBZ based_VBN upon_IN net_JJ income_NN available_JJ to_TO ordinary_JJ shareholders_NNS divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT period_NN ._.
Diluted_JJ earnings_NNS per_IN share_NN is_VBZ based_VBN upon_IN adjusted_JJ net_JJ income_NN available_JJ to_TO ordinary_JJ shareholders_NNS divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ share_NN equivalents_NNS outstanding_JJ during_IN the_DT period_NN ,_, adjusted_VBN for_IN the_DT effect_NN of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS that_WDT were_VBD outstanding_JJ during_IN the_DT year_NN ._.
Such_JJ potentially_RB dilutive_JJ shares_NNS are_VBP excluded_VBN when_WRB the_DT effect_NN would_MD be_VB to_TO increase_VB earnings_NNS per_IN share_NN or_CC reduce_VB a_DT loss_NN per_IN share_NN ._.
j_NN Advertising_NN expense_NN The_DT Company_NN expenses_NNS the_DT cost_NN of_IN advertising_NN as_IN incurred_VBN ._.
Advertising_NN costs_NNS amounted_VBD to_TO $_$ 47.6_CD million_CD ,_, $_$ 40.7_CD million_CD ,_, and_CC $_$ 45.6_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD respectively_RB ._.
k_NN Foreign_JJ currency_NN Monetary_NNP assets_NNS and_CC liabilities_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Transaction_NN gains_NNS and_CC losses_NNS are_VBP recognized_VBN in_IN arriving_VBG at_IN operating_VBG net_JJ income_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS ,_, whose_WP$ functional_JJ currency_NN is_VBZ not_RB US_NNP dollars_NNS ,_, are_VBP translated_VBN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT cumulative_JJ effect_NN of_IN exchange_NN rate_NN movements_NNS is_VBZ included_VBN in_IN a_DT separate_JJ component_NN of_IN other_JJ comprehensive_JJ income_NN ._.
Foreign_JJ currency_NN exchange_NN transaction_NN gains_NNS and_CC losses_NNS on_IN an_DT after-tax_JJ basis_NN included_VBD in_IN consolidated_JJ net_JJ income_NN in_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD ,_, amounted_VBD to_TO a_DT $_$ 2.5_CD million_CD loss_NN ,_, $_$ 6.7_CD million_CD loss_NN and_CC $_$ 0.3_CD million_CD loss_NN ,_, respectively_RB ._.
64_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 65_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD l_NN Employee_NN stock_NN plans_VBZ The_DT Company_NN accounts_NNS for_IN its_PRP$ stock_NN options_NNS using_VBG the_DT intrinsic-value_JJ method_NN prescribed_VBN in_IN Accounting_NNP Principles_NNP Board_NNP Opinion_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS APB_NNP No._NN ._.
Accordingly_RB ,_, compensation_NN cost_NN of_IN stock_NN options_NNS is_VBZ measured_VBN as_IN the_DT excess_NN ,_, if_IN any_DT ,_, of_IN the_DT quoted_VBN market_NN price_NN of_IN Shires_NNP ordinary_JJ shares_NNS at_IN the_DT measurement_NN date_NN over_IN the_DT option_NN exercise_NN price_NN and_CC is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT vesting_JJ period_NN ._.
For_IN plans_NNS where_WRB the_DT measurement_NN date_NN occurs_VBZ after_IN the_DT grant_NN date_NN ,_, referred_VBD to_TO as_IN variable_JJ plans_NNS ,_, compensation_NN cost_NN is_VBZ re-measured_JJ on_IN the_DT basis_NN of_IN the_DT current_JJ market_NN value_NN of_IN Shires_NNP ordinary_JJ shares_NNS at_IN the_DT end_NN of_IN each_DT reporting_NN period_NN ._.
The_DT Company_NN recognizes_VBZ compensation_NN expense_NN for_IN variable_JJ plans_NNS with_IN performance_NN conditions_NNS if_IN achievement_NN of_IN those_DT conditions_NNS becomes_VBZ probable_JJ ._.
123_CD ,_, Accounting_NNP for_IN Stock-Based_NNP Compensation_NNP SFAS_NNP No._NN ._.
123_CD ,_, the_DT Company_NN has_VBZ included_VBN in_IN these_DT financial_JJ statements_NNS the_DT required_JJ pro-forma_FW disclosures_NNS as_IN if_IN the_DT fair-value_JJ method_NN of_IN accounting_NN had_VBD been_VBN applied_VBN ._.
As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD six_CD stock-based_JJ employee_NN compensation_NN plans_NNS ,_, which_WDT are_VBP described_VBN more_RBR fully_RB in_IN Note_NN 28_CD ._.
The_DT following_VBG table_NN illustrates_VBZ the_DT effect_NN on_IN net_JJ income_NN and_CC earnings_NNS per_IN share_NN if_IN the_DT Company_NN had_VBD applied_VBN the_DT fair_JJ value_NN recognition_NN provisions_NNS of_IN SFAS_NNP No._NN ._.
2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ income_NN ,_, as_IN reported_VBN 269,007_CD 276,051_CD 250,569_CD Add_VBP Stock-based_JJ employee_NN compensation_NN charge_NN credit_NN included_VBN in_IN reported_JJ net_JJ income_NN ,_, net_NN of_IN related_JJ tax_NN effects_NNS 216_CD 24_CD 166_CD Deduct_NNP Total_NNP stock-based_JJ employee_NN compensation_NN expense_NN determined_VBN under_IN fair_JJ value-based_JJ method_NN for_IN all_DT awards_NNS 32,966_CD 31,956_CD 24,084_CD Pro-forma_JJ net_JJ income_NN 236,257_CD 244,071_CD 226,319_CD 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, Earnings_NNS per_IN share_NN As_IN reported_VBN basic_JJ 54.2_CD 55.4_CD 50.0_CD As_IN reported_VBN diluted_VBN 53.3_CD 54.2_CD 49.0_CD Pro-forma_JJ basic_JJ 47.6_CD 49.0_CD 45.2_CD Pro-forma_JJ diluted_VBN 46.9_CD 48.0_CD 44.4_CD The_DT fair_JJ value_NN of_IN stock_NN options_NNS used_VBN to_TO compute_VB pro-forma_FW net_JJ income_NN and_CC per_IN share_NN disclosures_NNS represents_VBZ the_DT estimated_VBN present_JJ value_NN at_IN grant_NN date_NN using_VBG the_DT Black-Scholes_NNP option-pricing_NN model_NN with_IN the_DT following_VBG weighted_JJ average_JJ assumptions_NNS :_: Year_NN to_TO December_NNP 31_CD ,_, 2004 2003 2002_CD Risk-free_JJ interest_NN rate_NN 2.46-4_CD .19_CD %_NN 1.89-3_CD .40_CD %_NN 1.90-5_CD .33_CD %_NN Expected_VBN dividend_NN yield_NN 0_CD %_NN :_: 0.6_CD %_NN 0_CD %_NN 0_CD %_NN Expected_VBN life_NN 5_CD years_NNS 5_CD years_NNS 5_CD years_NNS Expected_VBN volatility_NN 48.8_CD %_NN 60.0_CD %_NN 55.2_CD %_NN m_NN Cash_NN and_CC cash_NN equivalents_NNS Cash_NN and_CC cash_NN equivalents_NNS are_VBP defined_VBN as_IN short-term_JJ highly_RB liquid_JJ investments_NNS with_IN original_JJ maturities_NNS of_IN 90_CD days_NNS or_CC less_JJR ._.
n_JJ Short-term_JJ investments_NNS Short-term_JJ investments_NNS consist_VBP of_IN commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS ._.
In_IN accordance_NN with_IN SFAS_NNP No._NN ._.
115_CD ,_, Accounting_NNP for_IN Certain_NNP Investments_NNP in_IN Debt_NNP and_CC Equity_NNP Securities_NNPS SFAS_NNP No._NN ._.
115_CD ,_, and_CC based_VBN on_IN the_DT Companys_NNP intentions_NNS regarding_VBG these_DT instruments_NNS ,_, the_DT Company_NN has_VBZ classified_VBN all_DT short-term_JJ investments_NNS as_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, as_IN available-for-sale_JJ ._.
Institutional_JJ and_CC managed_VBD cash_NN funds_NNS are_VBP short-term_JJ money_NN market_NN instruments_NNS ,_, including_VBG bank_NN and_CC building_NN society_NN term_NN deposits_NNS and_CC other_JJ debt_NN securities_NNS from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
o_NN Inventories_NNS Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN including_VBG manufacturing_NN overheads_NNS ,_, where_WRB appropriate_JJ or_CC net_JJ realizable_JJ value_NN ._.
Net_JJ realizable_JJ value_NN is_VBZ based_VBN on_IN estimated_VBN normal_JJ selling_NN price_NN less_RBR further_JJ costs_NNS expected_VBN to_TO be_VB incurred_VBN to_TO completion_NN and_CC disposal_NN ._.
65_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 66_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD p_JJ Investments_NNPS The_DT Company_NN has_VBZ certain_JJ investments_NNS in_IN pharmaceutical_JJ and_CC biotechnology_NN companies_NNS ._.
Investments_NNP are_VBP accounted_VBN for_IN using_VBG the_DT equity-method_NN of_IN accounting_NN if_IN the_DT investment_NN gives_VBZ the_DT Company_NN the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN ,_, but_CC not_RB control_VB over_RP ,_, the_DT investee_NN ._.
Significant_JJ influence_NN is_VBZ generally_RB deemed_VBN to_TO exist_VB if_IN the_DT Company_NN has_VBZ an_DT ownership_NN interest_NN in_IN the_DT voting_NN stock_NN of_IN the_DT investee_NN between_IN 20_CD %_NN and_CC 50_CD %_NN ,_, although_IN other_JJ factors_NNS ,_, such_JJ as_IN representation_NN on_IN the_DT investees_NNS Board_NNP of_IN Directors_NNS and_CC the_DT impact_NN of_IN commercial_JJ arrangements_NNS ,_, are_VBP considered_VBN in_IN determining_VBG whether_IN the_DT equity-method_NN of_IN accounting_NN is_VBZ appropriate_JJ ._.
Under_IN the_DT equity-method_NN of_IN accounting_NN ,_, the_DT Company_NN records_NNS its_PRP$ investments_NNS in_IN equity-method_JJ investees_NNS in_IN the_DT consolidated_JJ balance_NN sheet_NN as_IN Investments_NNP equity-method_JJ investments_NNS and_CC its_PRP$ share_NN of_IN the_DT investees_NNS earnings_NNS or_CC losses_NNS together_RB with_IN other-than-temporary_JJ impairments_NNS in_IN value_NN as_IN Equity_NN in_IN losses_NNS earnings_NNS of_IN equity-method_JJ investees_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
All_DT other_JJ equity_NN investments_NNS ,_, which_WDT consist_VBP of_IN investments_NNS for_IN which_WDT the_DT Company_NN does_VBZ not_RB have_VB the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN ,_, are_VBP accounted_VBN for_IN under_IN the_DT cost_NN method_NN or_CC at_IN fair_JJ value_NN ._.
Investments_NNP in_IN private_JJ companies_NNS are_VBP carried_VBN at_IN cost_NN ,_, less_JJR provisions_NNS for_IN other-than-temporary_JJ impairment_NN in_IN value_NN ._.
For_IN public_JJ companies_NNS that_WDT have_VBP readily_RB determinable_JJ fair_JJ values_NNS ,_, the_DT Company_NN classifies_VBZ its_PRP$ equity_NN investments_NNS as_IN available-for-sale_JJ and_CC ,_, accordingly_RB ,_, records_NNS these_DT investments_NNS at_IN their_PRP$ fair_JJ values_NNS with_IN unrealized_JJ gains_NNS and_CC losses_NNS included_VBD in_IN the_DT consolidated_JJ statements_NNS of_IN comprehensive_JJ income_NN ,_, net_NN of_IN any_DT related_JJ tax_NN effect_NN ._.
Realized_VBN gains_NNS and_CC losses_NNS and_CC declines_NNS in_IN value_NN judged_VBN to_TO be_VB other-than-temporary_JJ on_IN available-for-sale_JJ securities_NNS are_VBP included_VBN in_IN other_JJ expense_NN ,_, net_JJ see_VBP Note_NN 24_CD ._.
The_DT cost_NN of_IN securities_NNS sold_VBN is_VBZ based_VBN on_IN the_DT specific_JJ identification_NN method_NN ._.
Interest_NN and_CC dividends_NNS on_IN securities_NNS classified_VBN as_IN available-forsale_NN are_VBP included_VBN as_IN interest_NN income_NN ._.
q_NN Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS i_FW Goodwill_NNP In_IN a_DT business_NN combination_NN ,_, goodwill_NN represents_VBZ the_DT excess_NN of_IN the_DT fair_JJ value_NN of_IN the_DT consideration_NN given_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ assets_NNS and_CC liabilities_NNS acquired_VBN ._.
Goodwill_NN and_CC other_JJ intangibles_NNS with_IN indefinite_JJ lives_NNS are_VBP not_RB amortized_VBN to_TO operations_NNS ,_, but_CC instead_RB are_VBP reviewed_VBN for_IN impairment_NN ,_, at_IN least_JJS annually_RB ,_, or_CC when_WRB there_EX is_VBZ an_DT indicator_NN of_IN impairment_NN ._.
The_DT Company_NN has_VBZ no_DT intangible_JJ assets_NNS with_IN indefinite_JJ useful_JJ lives_NNS ,_, other_JJ than_IN goodwill_NN ._.
The_DT Company_NN has_VBZ determined_VBN that_IN there_EX are_VBP no_DT impairment_NN losses_NNS for_IN any_DT of_IN the_DT reporting_NN periods_NNS covered_VBN by_IN these_DT financial_JJ statements_NNS ._.
ii_FW Other_JJ intangible_JJ assets_NNS Other_JJ intangible_JJ assets_NNS ,_, which_WDT comprise_VBP intellectual_JJ property_NN including_VBG trade_NN marks_NNS for_IN products_NNS with_IN a_DT defined_VBN revenue_NN stream_NN namely_RB commercial_JJ products_NNS or_CC rights_NNS to_TO products_NNS awaiting_VBG final_JJ regulatory_JJ approval_NN ,_, are_VBP recorded_VBN at_IN cost_NN and_CC amortized_VBN over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT related_JJ product_NN ,_, which_WDT ranges_VBZ from_IN 5_CD to_TO 35_CD years_NNS weighted_VBN average_JJ 23_CD years_NNS ._.
Intellectual_NNP property_NN with_IN no_DT defined_VBN revenue_NN stream_NN ,_, where_WRB the_DT related_JJ product_NN has_VBZ not_RB yet_RB completed_VBN the_DT necessary_JJ approval_NN process_NN ,_, is_VBZ written_VBN off_RP to_TO operations_NNS on_IN acquisition_NN ._.
The_DT following_VBG factors_NNS are_VBP considered_VBN in_IN estimating_VBG useful_JJ lives_NNS ._.
Where_WRB an_DT intangible_JJ asset_NN is_VBZ a_DT composite_NN of_IN a_DT number_NN of_IN factors_NNS ,_, the_DT period_NN of_IN amortization_NN is_VBZ determined_VBN from_IN considering_VBG these_DT factors_NNS together_RB :_: expected_VBN use_NN of_IN the_DT asset_NN :_: regulatory_JJ ,_, legal_JJ or_CC contractual_JJ provisions_NNS ,_, including_VBG the_DT regulatory_JJ approval_NN and_CC review_NN process_NN ,_, patent_NN issues_NNS and_CC actions_NNS by_IN government_NN agencies_NNS :_: the_DT effects_NNS of_IN obsolescence_NN ,_, changes_NNS in_IN demand_NN ,_, competing_VBG products_NNS and_CC other_JJ economic_JJ factors_NNS ,_, including_VBG the_DT stability_NN of_IN the_DT market_NN ,_, known_VBN technological_JJ advances_NNS ,_, development_NN of_IN competing_VBG drugs_NNS that_WDT are_VBP more_RBR effective_JJ clinically_RB or_CC economically_RB :_: and_CC actions_NNS of_IN competitors_NNS ,_, suppliers_NNS ,_, regulatory_JJ agencies_NNS or_CC others_NNS that_WDT may_MD eliminate_VB current_JJ competitive_JJ advantages_NNS ._.
66_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 67_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD r_NN Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN is_VBZ shown_VBN at_IN cost_NN ,_, less_JJR accumulated_VBN depreciation_NN and_CC any_DT impairment_NN ._.
The_DT cost_NN of_IN significant_JJ assets_NNS includes_VBZ capitalized_JJ interest_NN incurred_VBN during_IN the_DT construction_NN period_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight-line_JJ basis_NN at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN as_IN follows_VBZ :_: Buildings_NNS 20-50_CD years_NNS Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 4-10_CD years_NNS Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 4-10_CD years_NNS The_DT cost_NN of_IN land_NN is_VBZ not_RB depreciated_VBN ._.
Expenditures_NNS for_IN maintenance_NN and_CC repairs_NNS are_VBP charged_VBN to_TO operations_NNS as_IN incurred_VBN ._.
The_DT costs_NNS of_IN major_JJ renewals_NNS and_CC improvements_NNS are_VBP capitalized_VBN ._.
At_IN the_DT time_NN property_NN ,_, plant_NN and_CC equipment_NN is_VBZ retired_VBN or_CC otherwise_RB disposed_JJ of_IN ,_, the_DT cost_NN and_CC accumulated_VBN depreciation_NN are_VBP eliminated_VBN from_IN the_DT asset_NN and_CC accumulated_VBN depreciation_NN accounts_NNS ._.
The_DT profit_NN or_CC loss_NN on_IN such_JJ disposition_NN is_VBZ reflected_VBN in_IN operating_VBG income_NN ._.
s_PRP Valuation_NNP and_CC impairment_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS The_DT Company_NN evaluates_VBZ the_DT carrying_VBG value_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS for_IN impairment_NN whenever_WRB events_NNS or_CC changes_NNS in_IN circumstances_NNS indicate_VBP that_IN the_DT carrying_VBG amounts_NNS of_IN the_DT assets_NNS may_MD not_RB be_VB recoverable_JJ ._.
When_WRB such_PDT a_DT determination_NN is_VBZ made_VBN ,_, managements_NNS estimate_NN of_IN undiscounted_JJ cash_NN flows_VBZ to_TO be_VB generated_VBN by_IN the_DT assets_NNS is_VBZ compared_VBN to_TO the_DT carrying_VBG value_NN of_IN the_DT assets_NNS to_TO determine_VB whether_IN an_DT impairment_NN has_VBZ occurred_VBN ._.
If_IN an_DT impairment_NN is_VBZ indicated_VBN ,_, the_DT amount_NN of_IN the_DT impairment_NN recognized_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS is_VBZ determined_VBN by_IN estimating_VBG the_DT fair_JJ value_NN of_IN the_DT assets_NNS and_CC recording_VBG a_DT loss_NN for_IN the_DT amount_NN that_IN the_DT carrying_VBG value_NN exceeds_VBZ the_DT estimated_VBN fair_JJ value_NN ._.
This_DT fair_JJ value_NN is_VBZ usually_RB determined_VBN based_VBN on_IN estimated_VBN discounted_JJ cash_NN flows_NNS ._.
t_NN Assets_NNS held_VBN for_IN sale_NN An_DT asset_NN is_VBZ classified_VBN as_IN held_VBN for_IN sale_NN when_WRB ,_, amongst_IN other_JJ things_NNS ,_, the_DT Company_NN has_VBZ committed_VBN to_TO a_DT plan_NN of_IN disposition_NN ,_, the_DT asset_NN is_VBZ available_JJ for_IN immediate_JJ sale_NN ,_, and_CC the_DT plan_NN is_VBZ not_RB expected_VBN to_TO change_VB significantly_RB ._.
u_NNP Sales_NNS deductions_NNS i_FW Rebates_NNPS Rebates_NNPS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS and_CC contractual_JJ rebates_NNS with_IN health-maintenance_NN organizations_NNS HMOs_NNS ._.
These_DT rebates_NNS are_VBP based_VBN on_IN price_NN differentials_NNS between_IN a_DT base_NN price_NN and_CC the_DT selling_NN price_NN ._.
As_IN a_DT result_NN ,_, rebates_NNS generally_RB increase_VB as_IN a_DT percentage_NN of_IN the_DT selling_NN price_NN over_IN the_DT life_NN of_IN the_DT product_NN as_IN prices_NNS increase_NN ._.
Provisions_NNS for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS ,_, with_IN estimates_NNS of_IN future_JJ utilization_NN derived_VBN from_IN historical_JJ trends_NNS ._.
ii_FW Returns_NNPS The_DT Company_NN estimates_VBZ the_DT proportion_NN of_IN recorded_JJ revenue_NN that_WDT will_MD result_VB in_IN a_DT return_NN ,_, based_VBN on_IN historical_JJ trends_NNS and_CC ,_, when_WRB applicable_JJ ,_, specific_JJ factors_NNS affecting_VBG certain_JJ products_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT accrual_NN is_VBZ recorded_VBN as_IN a_DT reduction_NN to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
iii_FW Coupons_NNPS The_DT Company_NN uses_VBZ coupons_NNS as_IN a_DT form_NN of_IN sales_NNS incentive_NN ._.
An_DT accrual_NN is_VBZ established_VBN based_VBN on_IN the_DT Companys_NNP expectation_NN of_IN the_DT level_NN of_IN coupon_NN redemption_NN ,_, using_VBG historical_JJ trends_NNS ._.
iv_FW Discounts_NNPS The_DT Company_NN offers_VBZ cash_NN discounts_NNS to_TO customers_NNS for_IN the_DT early_JJ payment_NN of_IN receivables_NN ._.
Those_DT discounts_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN and_CC accounts_NNS receivable_NN in_IN the_DT same_JJ period_NN that_IN the_DT related_JJ sale_NN is_VBZ recorded_VBN ._.
v_FW Wholesaler_NNP chargebacks_VBZ The_DT Company_NN has_VBZ contractual_JJ agreements_NNS with_IN third_JJ parties_NNS to_TO supply_VB certain_JJ products_NNS at_IN predetermined_VBN prices_NNS ._.
Wholesalers_NNS acting_VBG as_IN intermediaries_NNS in_IN these_DT transactions_NNS are_VBP reimbursed_VBN by_IN Shire_NNP ,_, if_IN this_DT price_NN is_VBZ less_JJR than_IN the_DT price_NN paid_VBN by_IN the_DT wholesaler_NN to_TO Shire_NNP ._.
Provisions_NNS for_IN wholesaler_NN chargebacks_NNS based_VBN on_IN historical_JJ trends_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
67_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 68_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD v_JJ Shareholders_NNS equity_NN i_FW Common_JJ stock_NN The_DT authorized_VBN common_JJ stock_NN of_IN Shire_NNP as_IN of_IN December_NNP 31_CD ,_, 2004_CD was_VBD 799,999,965_CD ordinary_JJ shares_NNS and_CC 17,500,000_CD special_JJ ordinary_JJ voting_NN shares_NNS ._.
The_DT special_JJ ordinary_JJ voting_NN shares_NNS are_VBP entitled_VBN to_TO dividend_NN and_CC other_JJ rights_NNS that_WDT are_VBP economically_RB equivalent_JJ to_TO those_DT of_IN the_DT ordinary_JJ shares_NNS ._.
ii_FW Dividends_NNPS Under_IN English_NNP law_NN ,_, Shire_NNP can_MD pay_VB dividends_NNS only_RB out_IN of_IN its_PRP$ distributable_JJ profits_NNS ,_, defined_VBN as_IN the_DT accumulated_VBN realized_VBD profits_NNS under_IN UK_NNP generally_RB accepted_VBD accounting_NN principles_NNS ,_, of_IN the_DT parent_NN company_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN and_CC not_RB the_DT consolidated_JJ group_NN ,_, so_RB far_RB as_IN not_RB previously_RB utilized_VBN by_IN distribution_NN or_CC capitalization_NN ,_, less_JJR accumulated_VBN realized_VBN and_CC unrealized_JJ losses_NNS ,_, so_RB far_RB as_IN not_RB previously_RB written_VBN off_RP in_IN a_DT reduction_NN or_CC reorganization_NN of_IN capital_NN duly_RB made_VBD ._.
The_DT Company_NN can_MD make_VB a_DT distribution_NN only_RB if_IN the_DT distribution_NN does_VBZ not_RB reduce_VB net_JJ assets_NNS below_IN the_DT aggregate_NN of_IN the_DT called-up_JJ share_NN capital_NN and_CC undistributable_JJ reserves_NNS ._.
Any_DT payment_NN of_IN dividends_NNS is_VBZ at_IN the_DT discretion_NN of_IN the_DT Board_NNP of_IN Directors_NNS and_CC will_MD be_VB made_VBN in_IN Pounds_NNP sterling_NN to_TO Ordinary_NNP Shareholders_NNP ,_, US_NNP dollars_NNS to_TO ADS_NNPS holders_NNS and_CC Canadian_JJ dollars_NNS to_TO Exchangeable_JJ Shareholders_NNS ._.
At_IN December_NNP 31_CD ,_, 2004_CD ,_, Shires_NNP distributable_JJ profits_NNS were_VBD 86.4_CD million_CD $_$ 165.9_CD million_CD ._.
iii_FW Treasury_NNP stock_NN The_DT Company_NN records_NNS the_DT purchase_NN of_IN its_PRP$ own_JJ shares_NNS as_IN a_DT reduction_NN of_IN shareholders_NNS equity_NN based_VBN on_IN the_DT price_NN paid_VBN for_IN the_DT shares_NNS ._.
w_VB Concentration_NNP of_IN risk_NN Revenues_NNS are_VBP mainly_RB derived_VBN in_IN the_DT US_NNP 69_CD %_NN of_IN total_JJ revenues_NNS from_IN agreements_NNS with_IN major_JJ pharmaceutical_JJ companies_NNS and_CC relationships_NNS with_IN pharmaceutical_JJ wholesale_JJ distributors_NNS and_CC retail_JJ pharmacy_NN chains_NNS ._.
Significant_JJ customers_NNS are_VBP disclosed_VBN in_IN Note_NN 23_CD ._.
Such_JJ clients_NNS have_VBP significant_JJ cash_NN resources_NNS and_CC therefore_RB any_DT credit_NN risk_NN associated_VBN with_IN these_DT transactions_NNS is_VBZ considered_VBN minimal_JJ ._.
Excess_JJ cash_NN is_VBZ invested_VBN in_IN bank_NN and_CC building_NN society_NN term_NN deposits_NNS and_CC commercial_JJ paper_NN from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
These_DT investments_NNS typically_RB bear_VBP minimal_JJ credit_NN risk_NN ._.
A_DT significant_JJ proportion_NN of_IN revenue_NN is_VBZ derived_VBN from_IN sales_NNS of_IN ADDERALL_NNP XR_NNP and_CC royalties_NNS received_VBN on_IN 3TC_NNP ._.
During_IN 2004_CD ,_, revenues_NNS from_IN these_DT products_NNS were_VBD $_$ 606.7_CD million_CD and_CC $_$ 155.8_CD million_CD ,_, representing_VBG 45_CD %_NN and_CC 11_CD %_NN of_IN total_JJ revenues_NNS respectively_RB ._.
As_IN a_DT result_NN ,_, factors_NNS affecting_VBG the_DT sale_NN or_CC production_NN of_IN ADDERALL_NNP XR_NNP or_CC 3TC_NNP would_MD have_VB a_DT material_NN adverse_JJ effect_NN on_IN the_DT Companys_NNPS financial_JJ condition_NN and_CC results_NNS of_IN operation_NN ._.
x_LS Non-monetary_JJ transactions_NNS The_DT Company_NN enters_VBZ into_IN certain_JJ non-monetary_JJ transactions_NNS that_WDT involve_VBP either_CC the_DT granting_VBG of_IN a_DT license_NN over_IN the_DT Companys_NNP patents_NNS or_CC the_DT disposal_NN of_IN an_DT asset_NN or_CC group_NN of_IN assets_NNS in_IN exchange_NN for_IN a_DT non-monetary_JJ asset_NN ,_, usually_RB equity_NN ._.
The_DT Company_NN accounts_NNS for_IN these_DT transactions_NNS at_IN fair_JJ value_NN where_WRB the_DT Company_NN is_VBZ able_JJ to_TO determine_VB the_DT fair_JJ value_NN within_IN reasonable_JJ limits_NNS ._.
To_TO the_DT extent_NN that_IN the_DT Company_NN concludes_VBZ that_IN it_PRP is_VBZ unable_JJ to_TO determine_VB the_DT fair_JJ value_NN of_IN a_DT transaction_NN ,_, that_IN transaction_NN is_VBZ accounted_VBN for_IN at_IN the_DT recorded_JJ amounts_NNS of_IN the_DT assets_NNS ._.
Management_NN is_VBZ required_VBN to_TO exercise_VB its_PRP$ judgment_NN in_IN determining_VBG whether_IN or_CC not_RB the_DT fair_JJ value_NN of_IN the_DT asset_NN received_VBD or_CC that_DT given_VBN up_RP can_MD be_VB determined_VBN ._.
In_IN doing_VBG so_RB ,_, management_NN considers_VBZ ,_, amongst_IN other_JJ things_NNS ,_, previous_JJ license_NN agreements_NNS over_IN similar_JJ intellectual_JJ property_NN rights_NNS where_WRB there_EX is_VBZ monetary_JJ consideration_NN ._.
The_DT Company_NN has_VBZ a_DT limited_JJ number_NN of_IN comparable_JJ historical_JJ license_NN agreements_NNS ._.
Management_NN has_VBZ determined_VBN that_IN for_IN all_DT non-monetary_JJ transactions_NNS recorded_VBN to_TO date_VB the_DT fair_JJ value_NN of_IN the_DT consideration_NN is_VBZ not_RB determinable_JJ :_: consequently_RB ,_, such_JJ transactions_NNS have_VBP been_VBN recognized_VBN at_IN recorded_VBN value_NN ._.
In_IN the_DT future_NN ,_, as_IN Shire_NNP engages_VBZ in_IN further_JJ transactions_NNS ,_, there_EX may_MD be_VB a_DT fair_JJ value_NN assigned_VBN to_TO similar_JJ transactions_NNS resulting_VBG in_IN a_DT different_JJ accounting_NN treatment_NN ._.
y_RB Reclassifications_NNP Certain_NNP amounts_VBZ reported_VBN in_IN previous_JJ years_NNS have_VBP been_VBN reclassified_VBN to_TO conform_VB to_TO the_DT 2004_CD presentation_NN ._.
In_IN addition_NN the_DT 2002_CD and_CC 2003_CD financial_JJ statements_NNS have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN ,_, which_WDT has_VBZ been_VBN treated_VBN as_IN a_DT discontinued_VBN operation_NN ._.
z_SYM New_NNP accounting_NN pronouncements_NNS i_FW Adopted_VBN in_IN the_DT current_JJ year_NN FIN_NNP 46R_NNP In_IN December_NNP 2003_CD ,_, the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP issued_VBD a_DT revision_NN to_TO FASB_NNP Interpretation_NNP No._NN ._.
46_CD Consolidation_NN of_IN Variable_NNP Interest_NNP Entities_NNPS VIE_NNP ,_, an_DT interpretation_NN of_IN Accounting_NNP Research_NNP Bulletin_NNP ARB_NNP No._NN ._.
51_CD FIN_NNP 46R_NNP ,_, which_WDT requires_VBZ a_DT VIE_NNP to_TO be_VB consolidated_VBN by_IN a_DT Company_NN that_WDT will_MD absorb_VB a_DT majority_NN of_IN the_DT VIEs_NNS expected_VBN losses_NNS ,_, receive_VBP a_DT majority_NN of_IN the_DT entitys_NNS expected_VBN residual_JJ returns_NNS ,_, or_CC both_DT ,_, as_IN a_DT result_NN of_IN ownership_NN ,_, contractual_JJ or_CC other_JJ financial_JJ interest_NN in_IN the_DT VIE_NNP ._.
Prior_RB to_TO the_DT adoption_NN of_IN FIN_NNP 46R_NNP ,_, VIEs_NNS were_VBD generally_RB consolidated_VBN by_IN companies_NNS owning_VBG a_DT majority_NN voting_NN interest_NN in_IN the_DT VIE_NNP ._.
The_DT consolidation_NN requirements_NNS of_IN FIN_NNP 46R_NNP applied_VBD immediately_RB to_TO VIEs_NNS created_VBN after_IN January_NNP 31_CD ,_, 2003_CD ,_, however_RB ,_, the_DT FASB_NNP deferred_VBD the_DT effective_JJ date_NN for_IN VIEs_NNS created_VBN before_IN February_NNP 1_CD ,_, 2003_CD to_TO the_DT quarter_NN ended_VBD March_NNP 31_CD ,_, 2004_CD for_IN calendar-year_JJ companies_NNS ._.
Adoption_NN of_IN the_DT provisions_NNS of_IN FIN_NNP 46R_NNP prior_RB to_TO the_DT deferred_VBN effective_JJ date_NN was_VBD permitted_VBN ._.
The_DT adoption_NN of_IN FIN_NNP 46R_NNP did_VBD not_RB have_VB a_DT material_NN impact_NN on_IN the_DT Company_NN ._.
68_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 69_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 2_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD z_SYM New_NNP accounting_NN pronouncements_NNS continued_VBD ii_FW To_TO be_VB adopted_VBN in_IN future_NN periods_NNS EITF_NNP 03-01_CD In_IN March_NNP 2004_CD ,_, the_DT Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP reached_VBD a_DT consensus_NN on_IN Issue_NNP 03-01_CD ,_, The_DT Meaning_NNP of_IN Other-Than-Temporary_NNP Impairment_NNP and_CC Its_PRP$ Application_NN to_TO Certain_NNP Investments_NNP EITF_NNP 03-01_CD or_CC the_DT Issue_NNP ._.
EITF_NNP 03-01_CD is_VBZ applicable_JJ to_TO a_DT debt_NN and_CC equity_NN securities_NNS within_IN the_DT scope_NN of_IN FAS_NNP No._NN ._.
115_CD ,_, b_NN debt_NN and_CC equity_NN securities_NNS within_IN the_DT scope_NN of_IN SFAS_NNP No._NN ._.
124_CD and_CC that_WDT are_VBP held_VBN by_IN an_DT investor_NN that_WDT reports_VBZ a_DT performance_NN indicator_NN ,_, and_CC c_NN equity_NN securities_NNS not_RB within_IN the_DT scope_NN of_IN SFAS_NNP No._NN ._.
115_CD and_CC not_RB accounted_VBD for_IN under_IN the_DT Accounting_NNP Principles_NNP Board_NNP Opinion_NNP 18s_VBZ equity-method_JJ e._FW g._FW investments_NNS in_IN private_JJ companies_NNS ._.
EITF_NNP 03-01_CD provides_VBZ a_DT step_NN model_NN to_TO determine_VB whether_IN an_DT investment_NN is_VBZ impaired_VBN and_CC if_IN an_DT impairment_NN is_VBZ other-than-temporary_JJ ._.
In_IN addition_NN ,_, it_PRP requires_VBZ that_IN investors_NNS provide_VBP certain_JJ disclosures_NNS for_IN investments_NNS in_IN private_JJ companies_NNS and_CC ,_, if_IN applicable_JJ ,_, other_JJ information_NN related_VBN specifically_RB to_TO investments_NNS in_IN private_JJ companies_NNS ,_, such_JJ as_IN the_DT aggregate_JJ carrying_NN amount_NN of_IN investments_NNS in_IN private_JJ companies_NNS ,_, the_DT aggregate_JJ amount_NN of_IN investments_NNS in_IN private_JJ companies_NNS that_IN the_DT investor_NN did_VBD not_RB evaluate_VB for_IN impairment_NN because_IN an_DT impairment_NN indicator_NN was_VBD not_RB present_JJ ,_, and_CC the_DT situations_NNS under_IN which_WDT the_DT fair_JJ value_NN of_IN an_DT investment_NN in_IN a_DT private_JJ company_NN is_VBZ not_RB estimated_VBN ._.
The_DT disclosures_NNS relating_VBG to_TO investments_NNS in_IN private_JJ companies_NNS should_MD not_RB be_VB aggregated_VBN with_IN other_JJ types_NNS of_IN investments_NNS ._.
The_DT effective_JJ date_NN for_IN the_DT prospective_JJ application_NN of_IN EITF_NNP 03-01_CD impairment_NN model_NN to_TO all_DT current_JJ and_CC future_JJ investments_NNS has_VBZ been_VBN delayed_VBN by_IN FASB_NNP Staff_NNP Position_NNP EITF_NNP 03-01_CD ._.
The_DT disclosure_NN requirements_NNS are_VBP effective_JJ for_IN annual_JJ periods_NNS for_IN fiscal_JJ years_NNS ending_VBG after_IN June_NNP 15_CD ,_, 2004_CD ,_, therefore_RB December_NNP 31_CD ,_, 2004_CD in_IN the_DT case_NN of_IN the_DT Company_NN ._.
SFAS_NNP 123R_NNP In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
123_CD revised_VBN 2004_CD ,_, Share-Based_NNP Payment_NN SFAS_NNP No._NN ._.
123R_CD requires_VBZ that_IN the_DT cost_NN resulting_VBG from_IN all_DT share-based_JJ payment_NN transactions_NNS be_VB recognized_VBN in_IN the_DT financial_JJ statements_NNS at_IN fair_JJ value_NN and_CC that_IN excess_JJ tax_NN benefits_NNS be_VB reported_VBN as_IN a_DT financing_NN cash_NN inflow_NN rather_RB than_IN as_IN a_DT reduction_NN of_IN taxes_NNS paid_VBN ._.
123R_CD is_VBZ effective_JJ for_IN the_DT Company_NN from_IN July_NNP 1_CD ,_, 2005_CD ._.
123R_CD permits_NNS public_JJ companies_NNS to_TO account_VB for_IN share-based_JJ payments_NNS using_VBG one_CD of_IN two_CD methods_NNS :_: modified-prospective_JJ method_NN or_CC method_NN ._.
Under_IN the_DT modified-prospective_JJ method_NN ,_, from_IN the_DT effective_JJ date_NN ,_, compensation_NN cost_NN is_VBZ recognized_VBN based_VBN on_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
123R_CD for_IN all_DT new_JJ share-based_JJ awards_NNS and_CC based_VBN on_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
123_CD for_IN all_DT awards_NNS granted_VBN prior_RB to_TO the_DT effective_JJ date_NN of_IN SFAS_NNP No._NN ._.
123R_CD that_WDT remain_VBP unvested_JJ on_IN the_DT effective_JJ date_NN ._.
The_DT requirements_NNS of_IN the_DT method_NN are_VBP as_IN above_RB ,_, with_IN the_DT exception_NN that_IN companies_NNS are_VBP permitted_VBN to_TO restate_VB ,_, based_VBN on_IN the_DT amounts_NNS previously_RB recognized_VBN under_IN SFAS_NNP No._NN ._.
123_CD for_IN pro-forma_FW disclosure_NN purposes_NNS ,_, either_CC all_DT prior_RB periods_NNS presented_VBN or_CC prior_RB interim_JJ periods_NNS in_IN the_DT year_NN of_IN adoption_NN ._.
123_CD pro-forma_FW disclosures_NNS given_VBN in_IN Note_NN 2_CD above_IN show_NN the_DT impact_NN of_IN the_DT Company_NN adopting_VBG SFAS_NNP No._NN ._.
The_DT Company_NN has_VBZ yet_RB to_TO determine_VB which_WDT method_NN of_IN transition_NN will_MD be_VB adopted_VBN or_CC the_DT adoption_NN date_NN ._.
aa_NN Statutory_JJ accounts_NNS The_DT consolidated_JJ financial_JJ statements_NNS as_IN of_IN December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD and_CC for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN to_TO December_NNP 31_CD ,_, 2004_CD do_VBP not_RB comprise_VB statutory_JJ accounts_NNS within_IN the_DT meaning_NN of_IN Section_NN 240_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD ._.
Statutory_JJ accounts_NNS prepared_VBN in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT United_NNP Kingdom_NNP for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD have_VBP been_VBN delivered_VBN to_TO the_DT Registrar_NNP of_IN Companies_NNS for_IN England_NNP and_CC Wales_NNP ._.
The_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS was_VBD unqualified_JJ ._.
3_CD Reorganizations_NNPS Actions_NNPS commenced_VBD in_IN 2004_CD i_FW North_JJ American_JJ site_NN consolidation_NN As_IN previously_RB disclosed_VBN ,_, Shire_NNP began_VBD a_DT consolidation_NN of_IN its_PRP$ North_JJ American_JJ sites_NNS in_IN 2004_CD ,_, decreasing_VBG the_DT number_NN of_IN sites_NNS from_IN 14_CD to_TO 6_CD and_CC opening_VBG a_DT new_JJ US_NNP headquarters_NN office_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
The_DT Company_NN recorded_VBN costs_NNS of_IN $_$ 48.5_CD million_CD in_IN 2004_CD and_CC estimates_VBZ further_JJ costs_NNS of_IN approximately_RB $_$ 12_CD million_CD in_IN 2005_CD ._.
The_DT site_NN consolidation_NN is_VBZ expected_VBN to_TO be_VB complete_JJ by_IN the_DT end_NN of_IN 2005_CD ._.
The_DT primary_JJ costs_NNS associated_VBN with_IN the_DT site_NN consolidation_NN include_VBP :_: severance_NN costs_NNS relating_VBG to_TO 138_CD employees_NNS :_: retention_NN payments_NNS to_TO key_JJ employees_NNS :_: relocation_NN costs_NNS relating_VBG to_TO 85_CD employees_NNS who_WP were_VBD moved_VBN to_TO Wayne_NNP ,_, Pennsylvania_NNP :_: costs_NNS of_IN duplicate_VBP facilities_NNS including_VBG lease_NN exit_NN costs_NNS :_: and_CC other_JJ incremental_JJ costs_NNS associated_VBN with_IN the_DT site_NN closures_NNS ,_, such_JJ as_IN legal_JJ ,_, consultancy_NN ,_, the_DT write-down_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN and_CC information_NN technology_NN costs_NNS ._.
69_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 70_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Reorganizations_NNS continued_VBD Actions_NNS commenced_VBN in_IN 2004_CD continued_VBD i_FW North_JJ American_JJ site_NN consolidation_NN continued_VBD As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, 107_CD employees_NNS had_VBD left_VBN the_DT Company_NN ._.
The_DT cost_NN of_IN the_DT employee_NN severance_NN is_VBZ being_VBG ratably_RB recognized_VBN over_IN the_DT period_NN from_IN the_DT communication_NN date_NN to_TO the_DT termination_NN date_NN ._.
In_IN addition_NN ,_, all_DT 85_CD employees_NNS had_VBD relocated_VBN ._.
The_DT cost_NN of_IN relocation_NN is_VBZ being_VBG recorded_VBN as_IN it_PRP is_VBZ incurred_VBN ._.
The_DT following_JJ table_NN presents_VBZ the_DT cost_NN of_IN the_DT reorganization_NN recorded_VBN to_TO date_NN and_CC the_DT total_JJ estimated_JJ costs_NNS of_IN the_DT reorganization_NN ._.
After_IN the_DT plan_NN is_VBZ finalized_VBN and_CC actions_NNS are_VBP completed_VBN ,_, the_DT Company_NN will_MD continue_VB to_TO update_VB its_PRP$ reorganization_NN accruals_VBZ based_VBN on_IN changes_NNS in_IN estimates_NNS ._.
Total_JJ costs_NNS Total_JJ incurred_VBN to_TO estimated_VBN December_NNP 31_CD ,_, costs_NNS of_IN 2004_CD reorganization_NN $_$ m_CD $_$ m_CD Employee_NN severance_NN 20.0_CD 22_CD Relocation_NNP costs_VBZ 13.8_CD 14_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1_CD Consultancy_NN costs_VBZ 2.9_CD 3_CD Duplicate_NNP facilities_NNS 5.1_CD 15.5_CD Information_NN technology_NN costs_VBZ 2.1_CD 2_CD Other_JJ costs_NNS 3.4_CD 3_CD 48.5_CD 60.5_CD The_DT charges_NNS have_VBP been_VBN reflected_VBN within_IN reorganization_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS and_CC within_IN the_DT reporting_NN segments_NNS as_IN follows_VBZ :_: US_NNP International_NNP Corporate_NNP R&D_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN 7.2_CD 5.1_CD 2.0_CD 5.7_CD 20.0_CD Relocation_NNP costs_VBZ 9.8_CD 4.0_CD 13.8_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1.2_CD Consultancy_NN costs_NNS 1.7_CD 1.2_CD 2.9_CD Duplicate_NNP facilities_NNS 2.6_CD 2.5_CD 5.1_CD Information_NN technology_NN costs_VBZ 0.3_CD 1.8_CD 2.1_CD Other_JJ costs_NNS 2.4_CD 1.0_CD 3.4_CD 24.0_CD 5.1_CD 6.0_CD 13.4_CD 48.5_CD As_IN noted_VBN above_IN ,_, certain_JJ of_IN the_DT costs_NNS associated_VBN with_IN the_DT reorganization_NN will_MD be_VB paid_VBN in_IN subsequent_JJ periods_NNS ._.
The_DT following_VBG provides_VBZ a_DT reconciliation_NN of_IN the_DT liability_NN to_TO date_NN :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2004_CD 2004_CD liability_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN 20.0_CD 18.3_CD 1.7_CD Relocation_NNP costs_VBZ 13.8_CD 13.8_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1.2_CD Consultancy_NN costs_VBZ 2.9_CD 2.9_CD Duplicate_NNP facilities_NNS 5.1_CD 2.6_CD 2.5_CD Information_NN technology_NN costs_VBZ 2.1_CD 2.1_CD Other_JJ costs_NNS 3.4_CD 3.4_CD 48.5_CD 44.3_CD 4.2_CD The_DT employee_NN severance_NN costs_NNS will_MD be_VB paid_VBN in_IN 2005_CD ._.
The_DT duplicate_VBP facilities_NNS will_MD be_VB paid_VBN over_IN the_DT remaining_VBG life_NN of_IN the_DT lease_NN which_WDT is_VBZ due_JJ to_TO terminate_VB in_IN 2009_CD ._.
70_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 71_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Reorganizations_NNS continued_VBD Actions_NNS commenced_VBN in_IN 2004_CD continued_VBD ii_FW Disposal_NNP of_IN the_DT vaccines_NNS business_NN On_IN September_NNP 9_CD ,_, 2004_CD ,_, the_DT Company_NN completed_VBD its_PRP$ disposal_NN of_IN the_DT vaccines_NNS business_NN to_TO IDB_NNP ._.
The_DT total_JJ consideration_NN for_IN the_DT sale_NN was_VBD $_$ 120_CD million_CD comprising_VBG $_$ 30_CD million_CD of_IN cash_NN received_VBN at_IN completion_NN ,_, $_$ 30_CD million_CD of_IN cash_NN held_VBN in_IN escrow_NN and_CC due_JJ on_IN the_DT first_JJ anniversary_NN of_IN closing_NN and_CC $_$ 60_CD million_CD received_VBN at_IN completion_NN in_IN the_DT form_NN of_IN 4,931,864_CD subscription_NN receipts_NNS of_IN IDB_NNP ._.
Each_DT subscription_NN receipt_NN entitled_VBN Shire_NNP to_TO acquire_VB ,_, at_IN any_DT time_NN during_IN the_DT period_NN from_IN January_NNP 10_CD ,_, 2005_CD to_TO July_NNP 9_CD ,_, 2006_CD ,_, for_IN no_DT additional_JJ consideration_NN ,_, one_CD fully_RB paid_VBN common_JJ share_NN of_IN IDB_NNP ._.
Prior_RB to_TO January_NNP 10_CD ,_, 2005_CD ,_, if_IN IDB_NNP were_VBD to_TO raise_VB up_RP to_TO $_$ 60_CD million_CD from_IN equity-related_JJ issuances_NNS then_RB they_PRP were_VBD required_VBN to_TO repurchase_VB the_DT subscription_NN receipts_NNS from_IN Shire_NNP for_IN $_$ 60_CD million_CD in_IN cash_NN ._.
On_IN December_NNP 21_CD ,_, 2004_CD ,_, IDB_NNP gave_VBD notification_NN that_IN it_PRP intended_VBD to_TO complete_VB a_DT convertible_JJ debt_NN issuance_NN on_IN January_NNP 7_CD ,_, 2005_CD and_CC subsequently_RB repurchased_VBD the_DT subscription_NN receipts_NNS from_IN Shire_NNP on_IN January_NNP 7_CD ,_, 2005_CD ._.
In_IN addition_NN to_TO the_DT $_$ 120_CD million_CD consideration_NN ,_, IDB_NNP was_VBD required_VBN to_TO reimburse_VB Shire_NNP in_IN full_JJ for_IN the_DT net_JJ cost_NN of_IN operating_VBG the_DT vaccines_NNS business_NN from_IN June_NNP 30_CD ,_, 2004_CD through_IN consummation_NN of_IN the_DT sale_NN ._.
As_IN part_NN of_IN the_DT transaction_NN ,_, Shire_NNP entered_VBD into_IN an_DT agreement_NN to_TO provide_VB IDB_NNP with_IN a_DT loan_NN facility_NN of_IN up_RB to_TO $_$ 100_CD million_CD ,_, which_WDT can_MD be_VB drawn_VBN down_RB over_IN the_DT four_CD years_NNS following_VBG completion_NN ._.
Drawings_NNS under_IN the_DT loan_NN facility_NN will_MD be_VB segregated_VBN into_IN two_CD components_NNS :_: i_FW drawings_NNS for_IN injectable_JJ flu_NN development_NN of_IN up_RB to_TO $_$ 30_CD million_CD ._.
Such_JJ drawings_NNS under_IN the_DT loan_NN facility_NN will_MD be_VB repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ non-Canadian_JJ injectable_JJ flu_NN products_NNS ,_, subject_JJ to_TO minimum_JJ annual_JJ repayments_NNS in_IN respect_NN of_IN the_DT $_$ 30_CD million_CD drawing_NN ,_, to_TO be_VB made_VBN between_IN 2007_CD and_CC 2017_CD :_: and_CC ii_FW drawings_NNS for_IN pipeline_NN development_NN from_IN the_DT balance_NN of_IN the_DT $_$ 100_CD million_CD loan_NN facility_NN of_IN up_RB to_TO $_$ 70_CD million_CD ._.
Such_JJ drawings_NNS will_MD be_VB repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ pipeline_NN products_NNS and_CC will_MD have_VB no_DT fixed_VBN repayment_NN schedule_NN ._.
As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, IDB_NNP had_VBD drawn_VBN down_RB $_$ 56.8_CD million_CD :_: $_$ 30.0_CD million_CD for_IN injectable_JJ flu_NN development_NN and_CC $_$ 26.8_CD million_CD for_IN pipeline_NN development_NN ._.
The_DT transaction_NN gave_VBD rise_NN to_TO an_DT overall_JJ loss_NN on_IN disposition_NN of_IN the_DT vaccines_NNS business_NN of_IN $_$ 44_CD million_CD ,_, which_WDT comprises_VBZ a_DT gain_NN on_IN disposal_NN of_IN net_JJ assets_NNS of_IN $_$ 26_CD million_CD together_RB with_IN a_DT provision_NN for_IN a_DT loss_NN of_IN $_$ 70_CD million_CD out_IN of_IN the_DT $_$ 100_CD million_CD loan_NN facility_NN available_JJ to_TO IDB_NNP ._.
This_DT provision_NN is_VBZ made_VBN on_IN the_DT basis_NN that_WDT loan_NN repayments_NNS based_VBN solely_RB on_IN the_DT future_JJ sales_NNS of_IN pipeline_NN products_NNS in_IN development_NN provide_VBP no_DT certainty_NN of_IN recovery_NN ._.
The_DT historical_JJ consolidated_JJ financial_JJ statements_NNS have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT vaccines_NNS business_NN as_IN a_DT discontinued_VBN operation_NN for_IN all_DT periods_NNS presented_VBN ._.
The_DT results_NNS of_IN the_DT discontinued_VBN operation_NN have_VBP been_VBN removed_VBN from_IN all_DT periods_NNS on_IN a_DT line-by-line_JJ basis_NN from_IN product_NN sales_NNS revenue_NN to_TO income_NN from_IN continuing_VBG operations_NNS ._.
The_DT net_JJ loss_NN from_IN the_DT discontinued_VBN operation_NN ,_, together_RB with_IN the_DT loss_NN on_IN disposal_NN ,_, are_VBP shown_VBN as_IN separate_JJ line_NN items_NNS ._.
Operating_VBG results_NNS of_IN the_DT discontinued_VBN operations_NNS are_VBP summarized_VBN below_IN ._.
2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Revenues_NNS Product_NNP sales_NNS 3,626_CD 25,531_CD 14,048_CD Total_JJ revenues_NNS 3,626_CD 25,531_CD 14,048_CD Costs_NNS and_CC expenses_NNS Cost_NN of_IN product_NN sales_NNS 8,304_CD 19,954_CD 13,247_CD Research_NNP and_CC development_NN 9,222_CD 20,879_CD 15,799_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 5,614_CD 9,671_CD 6,923_CD Total_JJ operating_NN expenses_NNS 23,140_CD 50,504_CD 35,969_CD Operating_NN loss_NN 19,514_CD 24,973_CD 21,921_CD Other_JJ expense_NN income_NN ,_, net_JJ 621_CD 3,087_CD 4,154_CD 1_CD Loss_NN from_IN discontinued_VBN operations_NNS 20,135_CD 21,886_CD 17,767_CD Loss_NN on_IN disposition_NN 44,157_CD 64,292_CD 21,886_CD 17,767_CD 1_CD The_DT loss_NN from_IN discontinued_VBN operations_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2002_CD of_IN $_$ 11.7_CD million_CD comprises_VBZ a_DT loss_NN from_IN the_DT vaccines_NNS business_NN of_IN $_$ 17.8_CD million_CD and_CC a_DT gain_NN from_IN the_DT Over-the-Counter_NNP OTC_NNP business_NN of_IN $_$ 6.1_CD million_CD ._.
71_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 72_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Reorganizations_NNS continued_VBD Actions_NNS commenced_VBN in_IN 2004_CD continued_VBD ii_FW Disposal_NNP of_IN the_DT vaccines_NNS business_NN continued_VBD The_DT operating_NN results_NNS of_IN the_DT vaccines_NNS business_NN represented_VBD the_DT entire_JJ Biologics_NNP segment_NN as_RB well_RB as_IN certain_JJ parts_NNS of_IN the_DT International_NNP and_CC R&D_NNP segments_NNS ._.
As_IN a_DT result_NN of_IN the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN ,_, the_DT Biologics_NNPS segment_NN is_VBZ no_RB longer_RBR an_DT operating_NN segment_NN of_IN the_DT Company_NN and_CC the_DT International_NNP and_CC R&D_NNP segments_NNS have_VBP been_VBN restated_VBN accordingly_RB ._.
The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT discontinued_VBN vaccines_NNS operation_NN are_VBP summarized_VBN below_IN ._.
December_NNP 31_CD ,_, 2003_CD $_$ 000_CD Current_JJ assets_NNS Cash_NN and_CC cash_NN equivalents_NNS 245_CD Accounts_NNPS receivable_NN ,_, net_JJ 21,107_CD Inventories_NNS ,_, net_JJ 2,130_CD Prepaid_JJ expenses_NNS and_CC other_JJ current_JJ assets_NNS 614_CD Total_JJ current_JJ assets_NNS 24,096_CD Long-term_JJ assets_NNS Investments_NNP 178_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 66,730_CD Goodwill_NNP ,_, net_JJ 4,629_CD Other_JJ non-current_JJ assets_NNS 533_CD Total_JJ long-term_JJ assets_NNS 72,070_CD Total_JJ assets_NNS 96,166_CD Current_JJ liabilities_NNS Current_JJ installments_NNS of_IN long-term_JJ debt_NN 764_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 9,715_CD Total_JJ current_JJ liabilities_NNS 10,479_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ installments_NNS 764_CD Other_JJ long-term_JJ liabilities_NNS 15_CD Total_JJ long-term_JJ liabilities_NNS 779_CD Total_JJ assets_NNS less_RBR total_JJ liabilities_NNS 84,908_CD At_IN December_NNP 31_CD ,_, 2004_CD the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT discontinued_VBN vaccines_NNS operation_NN were_VBD $_$ nil_JJ ._.
Actions_NNS commenced_VBD in_IN 2003_CD i_FW Closure_NN of_IN Lead_JJ Optimization_NNP The_DT closure_NN of_IN Lead_JJ Optimization_NN resulted_VBD in_IN :_: the_DT severance_NN of_IN 134_CD employees_NNS ._.
As_IN of_IN December_NNP 2004_CD ,_, all_DT employees_NNS had_VBD left_VBN the_DT Company_NN :_: a_DT $_$ 6.0_CD million_CD write-off_NN of_IN tangible_JJ fixed_JJ assets_NNS ._.
These_DT assets_NNS ,_, primarily_RB laboratory_NN equipment_NN ,_, were_VBD used_VBN by_IN Lead_JJ Optimization_NN for_IN R&D_NNP and_CC had_VBD no_DT alternative_JJ use_NN :_: and_CC the_DT cancellation_NN ,_, to_TO the_DT extent_NN possible_JJ ,_, of_IN contracts_NNS directly_RB relating_VBG to_TO Lead_JJ Optimization_NN ._.
72_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 73_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 3_CD Reorganizations_NNS continued_VBD Actions_NNS commenced_VBN in_IN 2003_CD continued_VBD i_FW Closure_NN of_IN Lead_JJ Optimization_NN continued_VBD The_DT costs_NNS associated_VBN with_IN these_DT actions_NNS have_VBP been_VBN reflected_VBN in_IN reorganization_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD and_CC within_IN the_DT reporting_NN segments_NNS as_IN follows_VBZ :_: Allocation_NN between_IN segments_NNS R&D_NNP International_NNP $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 6,425_CD Write-off_NN of_IN tangible_JJ fixed_JJ assets_NNS 6,026_CD Other_JJ costs_NNS 800_CD 7,225_CD 6,026_CD The_DT following_VBG provides_VBZ a_DT roll-forward_NN of_IN the_DT liability_NN to_TO December_NNP 31_CD ,_, 2004_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2004_CD 2004_CD liability_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 3,452_CD 118_CD 3,570_CD Other_JJ costs_NNS 325_CD 9_CD 98_CD 236_CD 3,777_CD 127_CD 3,668_CD 236_CD The_DT following_VBG provides_VBZ a_DT roll-forward_NN of_IN the_DT liability_NN as_IN of_IN December_NNP 31_CD ,_, 2003_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2003_CD 2003_CD liability_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 6,425_CD 2,973_CD 3,452_CD Write-down_NN of_IN tangible_JJ fixed_JJ assets_NNS 6,026_CD 6,026_CD Other_JJ costs_NNS 800 475 325_CD 13,251_CD 9,474_CD 3,777_CD ii_FW Disposition_NNP of_IN Canadian_NNP facilities_NNS Subsequent_JJ to_TO the_DT closure_NN of_IN Lead_JJ Optimization_NN and_CC the_DT decision_NN to_TO dispose_VB of_IN the_DT vaccines_NNS business_NN ,_, the_DT Company_NN began_VBD an_DT assessment_NN of_IN its_PRP$ property_NN needs_VBZ in_IN Canada_NNP and_CC the_DT United_NNP States_NNPS ._.
As_IN a_DT result_NN of_IN this_DT initial_JJ process_NN the_DT Company_NN decided_VBD to_TO dispose_VB of_IN its_PRP$ building_NN in_IN Laval_NNP ,_, Canada_NNP ,_, and_CC to_TO relocate_VB the_DT employees_NNS ._.
The_DT Company_NN also_RB decided_VBD to_TO sell_VB its_PRP$ building_NN in_IN Buffalo_NNP Grove_NNP ._.
As_IN of_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN had_VBD obtained_VBN valuations_NNS of_IN the_DT properties_NNS and_CC entered_VBD into_IN sale_NN negotiations_NNS with_IN third_JJ parties_NNS on_IN the_DT Laval_NNP property_NN and_CC was_VBD actively_RB seeking_VBG buyers_NNS for_IN its_PRP$ Buffalo_NNP Grove_NNP facility_NN ._.
Based_VBN on_IN these_DT negotiations_NNS ,_, the_DT valuations_NNS obtained_VBN ,_, the_DT limitations_NNS on_IN use_NN of_IN the_DT building_NN in_IN its_PRP$ current_JJ state_NN and_CC the_DT overall_JJ real_JJ estate_NN market_NN ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN charge_NN of_IN $_$ 10.7_CD million_CD in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ,_, which_WDT is_VBZ included_VBN in_IN reorganization_NN costs_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
The_DT Company_NN reclassified_VBD to_TO prepaid_JJ expenses_NNS and_CC other_JJ current_JJ assets_NNS the_DT assets_NNS held_VBN for_IN sale_NN ._.
73_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 74_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 4_CD Business_NN combination_NN :_: Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
SUMI_NNP acquisition_NN On_IN September_NNP 27_CD ,_, 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ acquisition_NN of_IN SUMI_NNP from_IN Niro_NNP Inc._NNP for_IN a_DT cash_NN consideration_NN of_IN $_$ 17.3_CD million_CD ,_, including_VBG $_$ 0.3_CD million_CD costs_NNS of_IN acquisition_NN ._.
This_DT transaction_NN provided_VBD the_DT Company_NN with_IN an_DT in-house_JJ facility_NN in_IN which_WDT to_TO manufacture_VB several_JJ key_JJ US_NNP products_NNS ._.
The_DT acquisition_NN was_VBD accounted_VBN for_IN using_VBG the_DT purchase_NN method_NN and_CC goodwill_NN of_IN $_$ 10.2_CD million_CD was_VBD recorded_VBN ._.
The_DT results_NNS of_IN operations_NNS of_IN SUMI_NNP have_VBP been_VBN included_VBN in_IN the_DT consolidated_JJ results_NNS of_IN the_DT Company_NN since_IN the_DT date_NN of_IN acquisition_NN ._.
The_DT purchase_NN price_NN of_IN $_$ 17.3_CD million_CD was_VBD allocated_VBN as_IN follows_VBZ :_: Fair_NNP value_NN $_$ 000_CD Total_JJ current_JJ assets_NNS 3,188_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 11,620_CD Current_JJ instalments_NNS of_IN long-term_JJ debt_NN 216_CD Accounts_NNPS payable_JJ 1,367_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ instalments_NNS 6,050_CD Net_JJ assets_NNS acquired_VBN 7,175_CD Goodwill_NNP 10,175_CD 17,350_CD Represented_VBN by_IN Purchase_NNP consideration_NN 17,000_CD Acquisition_NNP fees_NNS 350_CD 17,350_CD The_DT following_VBG unaudited_JJ consolidated_JJ pro-forma_FW results_NNS of_IN operations_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2002_CD gave_VBD effect_NN to_TO the_DT acquisition_NN of_IN SUMI_NNP as_IN if_IN it_PRP were_VBD completed_VBN at_IN the_DT beginning_NN of_IN the_DT period_NN ._.
These_DT pro-forma_FW results_NNS reflect_VBP incremental_JJ financing_NN costs_NNS resulting_VBG from_IN acquisition_NN and_CC the_DT amortization_NN of_IN acquired_VBN intangible_JJ assets_NNS :_: 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD Revenues_NNS 1,042,748_CD Net_JJ income_NN 248,983_CD Earnings_NNS per_IN share_NN basic_JJ 49.7_CD Earnings_NNS per_IN share_NN diluted_VBN 48.7_CD This_DT unaudited_JJ pro-forma_FW financial_JJ information_NN has_VBZ been_VBN prepared_VBN for_IN comparative_JJ purposes_NNS only_RB and_CC does_VBZ not_RB purport_VB to_TO represent_VB the_DT results_NNS of_IN operations_NNS which_WDT would_MD actually_RB have_VB occurred_VBN had_VBD the_DT companies_NNS operated_VBD as_IN one_CD during_IN the_DT period_NN ,_, nor_CC to_TO predict_VB the_DT Companys_NNPS results_NNS of_IN future_JJ operations_NNS ._.
5_CD Disposal_NNP of_IN the_DT Over-The-Counter_NNP OTC_NNP business_NN In_IN December_NNP 1999_CD the_DT Company_NN acquired_VBD a_DT group_NN of_IN products_NNS ,_, collectively_RB referred_VBD to_TO as_IN the_DT OTC_NNP portfolio_NN ,_, through_IN its_PRP$ merger_NN with_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP Roberts_NNP ._.
The_DT OTC_NNP portfolio_NN consisted_VBD of_IN non-prescription_JJ laxatives_NNS and_CC dietary_JJ supplements_NNS sold_VBN by_IN the_DT Companys_NNPS US_NNP operating_VBG segment_NN ._.
As_IN a_DT pharmaceuticals_NNS company_NN that_WDT focuses_VBZ on_IN prescription-only_JJ products_NNS ,_, this_DT part_NN of_IN the_DT business_NN was_VBD not_RB considered_VBN to_TO be_VB a_DT core_NN part_NN of_IN the_DT Companys_NNP long-term_JJ strategy_NN and_CC hence_RB the_DT decision_NN was_VBD made_VBN to_TO divest_VB the_DT OTC_NNP portfolio_NN ._.
On_IN December_NNP 27_CD ,_, 2002_CD ,_, the_DT Company_NN completed_VBD its_PRP$ divestment_NN of_IN the_DT OTC_NNP business_NN ._.
The_DT Company_NN received_VBD sale_NN proceeds_NNS of_IN $_$ 71.0_CD million_CD and_CC recorded_VBD a_DT gain_NN on_IN disposal_NN of_IN $_$ 2.1_CD million_CD ._.
The_DT historical_JJ consolidated_JJ financial_JJ statements_NNS were_VBD restated_VBN to_TO reflect_VB the_DT OTC_NNP business_NN as_IN a_DT discontinued_VBN operation_NN for_IN all_DT periods_NNS presented_VBN ._.
Operating_VBG results_NNS of_IN the_DT discontinued_VBN operation_NN for_IN 2002_CD are_VBP summarized_VBN below_IN ._.
The_DT amounts_NNS include_VBP income_NN tax_NN provisions_NNS based_VBN on_IN the_DT stand-alone_JJ results_NNS of_IN the_DT OTC_NNP business_NN ._.
There_EX have_VBP been_VBN no_DT allocations_NNS of_IN general_JJ and_CC administrative_JJ corporate_JJ costs_NNS or_CC interest_NN expense_NN related_VBN to_TO corporate_JJ credit_NN facilities_NNS to_TO the_DT business_NN ._.
As_IN the_DT OTC_NNP business_NN functioned_VBD within_IN the_DT US_NNP ,_, which_WDT itself_PRP essentially_RB functions_NNS as_IN an_DT independent_JJ entity_NN ,_, no_DT corporate_JJ costs_NNS were_VBD eliminated_VBN upon_IN discontinuance_NN of_IN the_DT operation_NN ._.
Within_IN the_DT US_NNP ,_, the_DT OTC_NNP business_NN had_VBD few_JJ dedicated_VBN resources_NNS ._.
All_DT of_IN the_DT products_NNS were_VBD manufactured_VBN and_CC packaged_VBN by_IN third-party_JJ contract_NN manufacturers_NNS ._.
The_DT products_NNS were_VBD distributed_VBN through_IN a_DT shared_VBN warehouse_NN facility_NN and_CC sold_VBN through_IN a_DT small_JJ sales_NNS team_NN ._.
74_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 75_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 5_CD Disposal_NNP of_IN the_DT Over-The-Counter_NNP OTC_NNP business_NN continued_VBD 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD Product_NN sales_NNS 24,010_CD Cost_NN of_IN product_NN sales_NNS 5,764_CD Gross_NNP profit_NN 18,246_CD Operating_NN expenses_NNS Selling_VBG ,_, general_JJ and_CC administrative_JJ 8,550_CD Operating_NN income_NN 9,696_CD Income_NN taxes_NNS 3,588_CD 1_CD Income_NN from_IN discontinued_VBN operations_NNS net_NN of_IN tax_NN 6,108_CD Gain_NNP on_IN sale_NN net_NN of_IN tax_NN 2,083_CD 8,191_CD 1_CD The_DT loss_NN from_IN discontinued_VBN operations_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2002_CD of_IN $_$ 11.7_CD million_CD comprises_VBZ a_DT loss_NN from_IN the_DT vaccines_NNS business_NN of_IN $_$ 17.8_CD million_CD and_CC a_DT gain_NN from_IN the_DT OTC_NNP business_NN of_IN $_$ 6.1_CD million_CD ._.
6_CD Accounts_NNPS receivable_NN ,_, net_JJ Trade_NNP receivables_NN at_IN December_NNP 31_CD ,_, 2004_CD of_IN $_$ 222.5_CD million_CD December_NNP 31_CD ,_, 2003_CD :_: $_$ 194.6_CD million_CD ,_, are_VBP stated_VBN net_NN of_IN a_DT provision_NN for_IN doubtful_JJ accounts_NNS and_CC sales_NNS discounts_NNS of_IN $_$ 4.3_CD million_CD December_NNP 31_CD ,_, 2003_CD :_: $_$ 7.9_CD million_CD ._.
The_DT movement_NN in_IN the_DT provision_NN for_IN doubtful_JJ accounts_NNS and_CC sales_NNS discounts_NNS is_VBZ as_IN follows_VBZ :_: 2004 2003 2002_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD As_IN of_IN January_NNP 1_CD 7,853_CD 4,585_CD 5,724_CD Charged_VBN to_TO operations_NNS 38,218_CD 42,841_CD 35,021_CD Released_VBN to_TO income_NN 3,395_CD Utilization_NN 38,412_CD 39,573_CD 36,160_CD As_IN of_IN December_NNP 31_CD 4,264_CD 7,853_CD 4,585_CD 7_CD Inventories_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Finished_VBN goods_NNS 22,349_CD 26,226_CD Work-in-process_JJ 11,831_CD 10,104_CD Raw_NNP materials_NNS 7,050_CD 6,798_CD 41,230_CD 43,128_CD 8_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Prepaid_NN expenses_NNS 31,401_CD 26,158_CD Assets_NNS held_VBN for_IN sale_NN see_VBP Note_NN 3_CD 12,470_CD Deferred_JJ financing_NN costs_NNS see_VBP Note_NN 17_CD 1,004_CD Subscription_NN receipts_NNS see_VBP Note_NN 3_CD 60,000_CD Cash_NN held_VBN in_IN escrow_NN see_VBP Note_NN 3_CD 30,000_CD Value_NNP added_VBD taxes_NNS receivable_JJ 2,124_CD 3,819_CD Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP investment_NN see_VBP Note_NN 25_CD 1,784_CD Other_JJ current_JJ assets_NNS 11,962_CD 10,363_CD 137,271_CD 53,814_CD 75_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 76_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 9_CD Short-term_JJ investments_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Commercial_JJ paper_NN 149,659_CD 120,872_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 174,752_CD 183,257_CD 324,411_CD 304,129_CD 10_CD Investments_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD 1_CD Investments_NNP in_IN private_JJ companies_NNS 2,451_CD 46,068_CD Available-for-sale_JJ securities_NNS 29,970_CD 21,879_CD 1_CD Equity-method_JJ investments_NNS 30,846_CD 5,028_CD 63,267_CD 72,975_CD 1_CD Prior_RB to_TO the_DT adoption_NN of_IN FIN_NNP 46R_NNP the_DT Company_NN accounted_VBD for_IN its_PRP$ investments_NNS in_IN the_DT GeneChem_NNP Funds_NNPS described_VBD below_IN as_IN investments_NNS in_IN private_JJ companies_NNS and_CC did_VBD not_RB consolidate_VB these_DT investments_NNS as_IN the_DT impact_NN on_IN net_JJ assets_NNS ,_, financial_JJ position_NN and_CC results_NNS of_IN operations_NNS of_IN the_DT Company_NN were_VBD individually_RB and_CC in_IN the_DT aggregate_JJ immaterial_NN ._.
These_DT investments_NNS were_VBD appropriately_RB reclassified_VBN to_TO equity-method_JJ investments_NNS upon_IN the_DT adoption_NN of_IN FIN_NNP 46R_NNP ._.
The_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 15.4_CD million_CD on_IN its_PRP$ investments_NNS during_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD 2003_CD :_: $_$ 15.5_CD million_CD :_: 2002_CD $_$ 8.7_CD million_CD ._.
All_DT impairments_NNS in_IN the_DT three_CD years_NNS presented_VBN were_VBD recorded_VBN in_IN the_DT International_NNP segment_NN ._.
a_DT Investments_NNP in_IN private_JJ companies_NNS During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 9.8_CD million_CD against_IN these_DT investments_NNS based_VBN on_IN changes_NNS in_IN the_DT estimates_NNS of_IN their_PRP$ fair_JJ value_NN ._.
This_DT amount_NN includes_VBZ $_$ 4.2_CD million_CD to_TO reduce_VB the_DT value_NN of_IN an_DT investment_NN in_IN a_DT private_JJ company_NN that_WDT gained_VBD a_DT listing_NN on_IN March_NNP 24_CD ,_, 2004_CD :_: the_DT initial_JJ listing_NN price_NN was_VBD below_IN the_DT anticipated_JJ flotation_NN price_NN used_VBN to_TO value_VB the_DT investment_NN at_IN December_NNP 31_CD ,_, 2003_CD see_VBP below_IN and_CC the_DT Company_NN believes_VBZ the_DT decline_NN in_IN value_NN was_VBD other-than-temporary_JJ ._.
After_IN the_DT date_NN of_IN the_DT listing_VBG the_DT investment_NN was_VBD reclassified_VBN to_TO available-for-sale_JJ securities_NNS and_CC so_RB any_DT changes_NNS since_IN the_DT initial_JJ listing_NN date_NN have_VBP been_VBN recorded_VBN in_IN other_JJ comprehensive_JJ income_NN ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 15.5_CD million_CD ._.
An_DT impairment_NN of_IN $_$ 6.2_CD million_CD was_VBD recorded_VBN to_TO reduce_VB the_DT carrying_VBG value_NN of_IN the_DT investment_NN in_IN the_DT private_JJ company_NN seeking_VBG a_DT listing_NN see_VBP above_IN to_TO one_CD based_VBN on_IN the_DT anticipated_JJ flotation_NN price_NN for_IN the_DT share_NN offering_NN early_RB in_IN 2004_CD ._.
Also_RB ,_, an_DT impairment_NN of_IN $_$ 8.5_CD million_CD was_VBD recorded_VBN in_IN relation_NN to_TO the_DT GeneChem_NNP Funds_NNPS investment_NN ,_, following_VBG reviews_NNS of_IN the_DT Funds_NNPS investment_NN portfolios_NNS that_WDT identified_VBD other-than-temporary_JJ declines_NNS in_IN the_DT value_NN of_IN certain_JJ private_JJ and_CC publicly_RB quoted_VBN securities_NNS held_VBN by_IN the_DT Funds_NNS ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2002_CD ,_, the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 6.6_CD million_CD due_JJ to_TO a_DT decrease_NN in_IN the_DT market_NN value_NN of_IN its_PRP$ investment_NN in_IN private_JJ companies_NNS based_VBN on_IN changes_NNS in_IN estimates_NNS in_IN value_NN from_IN the_DT prior_JJ year_NN ._.
The_DT changes_NNS in_IN fair_JJ market_NN value_NN which_WDT resulted_VBD in_IN the_DT write-downs_NNS referred_VBD to_TO above_IN were_VBD based_VBN on_IN the_DT Companys_NNP estimates_NNS of_IN fair_JJ value_NN ._.
These_DT estimates_NNS were_VBD derived_VBN from_IN financial_JJ and_CC other_JJ publicly_RB available_JJ information_NN such_JJ as_IN press_NN releases_NNS and_CC recent_JJ capital_NN raising_VBG activities_NNS ._.
b_NN Available-for-sale_JJ securities_NNS i_FW Gain_NNP on_IN sale_NN During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN sold_VBD an_DT investment_NN in_IN an_DT available-for-sale_JJ security_NN ,_, valued_VBN at_IN $_$ 11.9_CD million_CD ,_, realizing_VBG a_DT gain_NN on_IN the_DT sale_NN of_IN $_$ 14.8_CD million_CD 2003_CD :_: $_$ nil_JJ ._.
See_VB Note_VB 24_CD ._.
ii_FW Other-than-temporary_JJ impairment_NN The_DT Company_NN recorded_VBN other-than-temporary_JJ impairments_NNS of_IN $_$ 1.6_CD million_CD ,_, $_$ nil_JJ and_CC $_$ 1.4_CD million_CD against_IN its_PRP$ available-for-sale_JJ securities_NNS in_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD respectively_RB ._.
At_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD no_DT available-for-sale_JJ investments_NNS in_IN a_DT significant_JJ unrealized_JJ loss_NN position_NN for_IN which_WDT other-thantemporary_JJ impairments_NNS have_VBP not_RB been_VBN recognized_VBN ._.
76_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 77_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBD 10_CD Investments_NNPS continued_VBD c_NN Equity-method_JJ investments_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD GSK_NNP 6,179_CD 5,028_CD GeneChem_NNP Funds_NNPS 18,343_CD Other_JJ 6,324_CD 30,846_CD 5,028_CD i_FW GSK_NNP The_NNP Company_NNP has_VBZ accounted_VBN for_IN its_PRP$ commercialization_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP ,_, using_VBG the_DT equity-method_NN of_IN accounting_NN ._.
The_DT Companys_NNP 50_CD %_NN share_NN of_IN the_DT partnership_NN is_VBZ included_VBN within_IN Equity_NN in_IN earnings_NNS of_IN equity-method_JJ investees_NNS ._.
ii_FW GeneChem_NNP Funds_NNPS The_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP and_CC the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP The_NNP Funds_NNPS are_VBP Canadian_JJ limited_JJ partnerships_NNS investing_VBG in_IN healthcare_NN research_NN and_CC development_NN companies_NNS ,_, in_IN which_WDT the_DT Company_NN owns_VBZ 30_CD %_NN and_CC 11_CD %_NN shares_NNS respectively_RB ._.
At_IN December_NNP 31_CD ,_, 2004_CD the_DT Funds_NNPS net_JJ assets_NNS totalled_VBD approximately_RB $_$ 107_CD million_CD ._.
The_DT Company_NN is_VBZ involved_VBN as_IN a_DT limited_JJ partner_NN and_CC the_DT general_JJ partner_NN of_IN the_DT Funds_NNPS :_: involvement_NN in_IN the_DT Funds_NNS dates_NNS from_IN between_IN 1997_CD and_CC 2000_CD ._.
The_DT Companys_NNP exposure_NN to_TO loss_NN as_IN a_DT result_NN of_IN its_PRP$ involvement_NN with_IN the_DT Funds_NNPS is_VBZ limited_VBN to_TO the_DT carrying_VBG value_NN of_IN the_DT investment_NN ,_, $_$ 18.3_CD million_CD at_IN December_NNP 31_CD ,_, 2004_CD 2003_CD :_: $_$ 19.8_CD million_CD ,_, 2002_CD :_: $_$ 20.0_CD million_CD and_CC its_PRP$ commitment_NN to_TO further_JJ investment_NN of_IN $_$ 2.9_CD million_CD 2003_CD :_: $_$ 4.1_CD million_CD ,_, 2002_CD :_: $_$ 1.9_CD million_CD ._.
During_IN the_DT last_JJ six_CD months_NNS of_IN 2004_CD ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 4.0_CD million_CD against_IN the_DT investment_NN in_IN the_DT Funds_NNPS following_VBG reviews_NNS of_IN the_DT Funds_NNPS investment_NN portfolios_NNS that_WDT identified_VBD other-than-temporary_JJ declines_NNS in_IN the_DT value_NN of_IN certain_JJ private_JJ and_CC publicly_RB quoted_VBN securities_NNS held_VBN by_IN the_DT Funds_NNS ._.
11_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 80,631_CD 66,314_CD Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 67,301_CD 46,257_CD Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 34,823_CD 55,186_CD 182,755_CD 167,757_CD Less_RBR :_: Accumulated_VBN depreciation_NN 51,404_CD 73,262_CD 131,351_CD 94,495_CD Depreciation_NN expense_NN for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD was_VBD $_$ 22.5_CD million_CD ,_, $_$ 14.1_CD million_CD and_CC $_$ 11.5_CD million_CD respectively_RB ._.
12_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Goodwill_NNP arising_VBG on_IN businesses_NNS acquired_VBN 296,607_CD 275,594_CD Less_RBR :_: accumulated_VBN amortization_NN 61,211_CD 54,363_CD 235,396_CD 221,231_CD Other_JJ intangible_JJ assets_NNS Intellectual_NNP property_NN rights_NNS acquired_VBD 543,969_CD 469,137_CD Less_RBR :_: accumulated_VBN amortization_NN 234,672_CD 161,255_CD 309,297_CD 307,882_CD Total_JJ 544,693_CD 529,113_CD 77_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 78_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 12_CD Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS ,_, net_JJ continued_VBD The_DT increase_NN in_IN the_DT net_JJ book_NN value_NN of_IN goodwill_NN and_CC other_JJ intangible_JJ assets_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: Other_JJ intangible_JJ Goodwill_NNP assets_NNS $_$ 000_CD $_$ 000_CD As_IN of_IN January_NNP 1_CD ,_, 2004_CD 221,231_CD 307,882_CD Acquisitions_NNPS 49,189_CD Amortization_NN charged_VBN 38,724_CD Asset_NNP impairments_NNS 13,477_CD Disposals_NNPS 2,868_CD Foreign_JJ currency_NN translation_NN 14,165_CD 7,295_CD As_IN of_IN December_NNP 31_CD ,_, 2004_CD 235,396_CD 309,297_CD The_DT acquisition_NN of_IN other_JJ intangible_JJ assets_NNS is_VBZ primarily_RB related_VBN to_TO the_DT purchase_NN of_IN the_DT exclusive_JJ commercialization_NN rights_NNS of_IN REMINYL_NNP in_IN the_DT UK_NNP and_CC Ireland_NNP $_$ 30.0_CD million_CD ,_, and_CC milestone_NN payments_NNS relating_VBG to_TO FOSRENOL_NNP $_$ 19.0_CD million_CD ._.
The_DT weighted_JJ average_JJ amortization_NN period_NN for_IN these_DT additions_NNS is_VBZ 9.5_CD years_NNS ._.
Amortization_NN charged_VBD for_IN the_DT three_CD years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD was_VBD $_$ 38.7_CD million_CD ,_, $_$ 26.4_CD million_CD and_CC $_$ 20.8_CD million_CD ,_, respectively_RB ._.
Goodwill_NN was_VBD no_RB longer_RB amortized_VBN with_IN effect_NN from_IN January_NNP 1_CD ,_, 2002_CD following_VBG the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS SFAS_NNP No._NN ._.
The_DT useful_JJ economic_JJ lives_NNS of_IN other_JJ intangible_JJ assets_NNS continue_VBP to_TO be_VB amortized_VBN under_IN SFAS_NNP No._NN ._.
Management_NNP estimates_VBZ that_IN the_DT annual_JJ amortization_NN charges_NNS in_IN respect_NN of_IN intangible_JJ fixed_VBN assets_NNS held_VBD as_IN of_IN December_NNP 31_CD ,_, 2004_CD will_MD average_VB approximately_RB $_$ 40_CD million_CD for_IN each_DT of_IN the_DT five_CD years_NNS to_TO December_NNP 31_CD ,_, 2009_CD ._.
Estimated_VBN amortization_NN expense_NN can_MD be_VB affected_VBN by_IN various_JJ factors_NNS including_VBG future_JJ acquisitions_NNS ,_, disposals_NNS of_IN product_NN rights_NNS and_CC the_DT technological_JJ advancement_NN and_CC regulatory_JJ approval_NN of_IN competitor_NN products_NNS ._.
During_IN 2004_CD ,_, the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 13.5_CD million_CD ._.
These_DT impairments_NNS resulted_VBD from_IN a_DT change_NN of_IN operational_JJ management_NN and_CC its_PRP$ views_NNS of_IN the_DT economic_JJ value_NN and_CC strategic_JJ worth_NN of_IN the_DT products_NNS concerned_VBN ,_, which_WDT decreased_VBD estimated_VBN future_JJ cash_NN flows_NNS ._.
$_$ 1.5_CD million_CD of_IN these_DT impairments_NNS were_VBD recorded_VBN in_IN the_DT US_NNP segment_NN and_CC $_$ 12.0_CD million_CD in_IN the_DT International_NNP segment_NN ._.
During_IN 2003_CD the_DT Company_NN recorded_VBN asset_NN impairments_NNS of_IN $_$ 12.1_CD million_CD 2002_CD :_: $_$ 18.8_CD million_CD and_CC an_DT asset_NN write-down_NN of_IN $_$ 15.4_CD million_CD ._.
The_DT asset_NN impairments_NNS of_IN $_$ 12.1_CD million_CD resulted_VBD from_IN a_DT decline_NN in_IN product_NN prices_NNS ,_, which_WDT decreased_VBD estimated_VBN future_JJ cash_NN flows_NNS ._.
The_DT asset_NN write-down_NN of_IN $_$ 15.4_CD million_CD resulted_VBD from_IN a_DT decision_NN not_RB to_TO renew_VB product_NN licenses_NNS that_WDT were_VBD not_RB core_NN to_TO the_DT business_NN ._.
The_DT impairments_NNS and_CC write-downs_NNS totalling_VBG $_$ 27.5_CD million_CD were_VBD recorded_VBN in_IN the_DT US_NNP segment_NN $_$ 11.7_CD million_CD and_CC the_DT International_NNP segment_NN $_$ 15.8_CD million_CD ._.
During_IN 2002_CD the_DT Company_NN reviewed_VBD its_PRP$ existing_JJ product_NN base_NN ._.
On_IN completion_NN of_IN this_DT review_NN ,_, management_NN decided_VBD to_TO cease_VB supporting_VBG certain_JJ products_NNS that_WDT were_VBD not_RB considered_VBN to_TO be_VB core_NN to_TO the_DT business_NN and_CC to_TO redirect_VB investment_NN toward_IN other_JJ more_RBR profitable_JJ products_NNS ._.
Intangible_JJ assets_NNS associated_VBN with_IN these_DT products_NNS ,_, namely_RB product_NN rights_NNS and_CC licenses_NNS ,_, were_VBD written_VBN down_RP to_TO their_PRP$ fair_JJ value_NN based_VBN on_IN discounted_JJ cash_NN flow_NN analyses_NNS ._.
This_DT resulted_VBD in_IN the_DT recording_NN of_IN an_DT impairment_NN loss_NN of_IN $_$ 18.8_CD million_CD $_$ 10.8_CD million_CD in_IN the_DT US_NNP segment_NN and_CC $_$ 8.0_CD million_CD in_IN the_DT International_NNP segment_NN ._.
The_DT net_JJ book_NN value_NN of_IN goodwill_NN by_IN operating_VBG segment_NN is_VBZ as_IN follows_VBZ :_: US_NNP International_NNP Corporate_NNP R&D_NNP Total_NNP December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000 2004 205_CD ,386_CD 30,010_CD 235,396_CD 2003_CD 193,023_CD 28,298_CD 221,321_CD There_EX were_VBD no_DT changes_NNS in_IN the_DT allocation_NN of_IN goodwill_NN in_IN either_CC period_NN ._.
All_PDT the_DT movements_NNS relate_VBP to_TO foreign_JJ exchange_NN ._.
78_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 79_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 13_CD Other_JJ non-current_JJ assets_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Deferred_VBN financing_NN costs_NNS see_VBP Note_NN 17_CD 6,441_CD SERP_NNP investment_NN see_VBP Note_NN 25_CD 7,698_CD 12,042_CD IDB_NNP loan_NN see_VBP Note_NN 3_CD 30,000_CD Other_JJ assets_NNS 1,197_CD 3,937_CD 38,895_CD 22,420_CD Further_JJ details_NNS of_IN the_DT SERP_NNP investment_NN are_VBP provided_VBN in_IN Note_NN 25_CD ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT cash_NN surrender_NN value_NN of_IN life_NN insurance_NN policies_NNS which_WDT is_VBZ backed_VBN by_IN short-term_JJ investments_NNS ._.
A_DT liability_NN of_IN $_$ 5.5_CD million_CD is_VBZ included_VBN within_IN Notes_NNP 15_CD and_CC 18_CD 2003_CD :_: $_$ 8.9_CD million_CD ._.
14_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Trade_NNP accounts_NNS payable_JJ 35,008_CD 21,301_CD Accrued_VBN rebates_NNS Medicaid_NNP 84,758_CD 46,075_CD Accrued_VBN rebates_NNS Managed_VBN care_NN 14,667_CD 13,202_CD Sales_NNS return_VBP reserve_NN 22,530_CD 8,343_CD Accrued_VBN bonuses_NNS 23,171_CD 18,920_CD Accrued_VBN coupons_NNS 15,869_CD 4,078_CD R&D_NNP accruals_NNS 10,924_CD 27,676_CD Marketing_NNP accrual_NN 26,095_CD 16,045_CD Accrued_VBN royalties_NNS 8,250_CD 3,036_CD Deferred_JJ revenue_NN 14,472_CD 4,132_CD Reorganization_NN accrual_NN see_VBP Note_NN 3_CD 1,936_CD 3,541_CD Other_JJ accrued_VBN expenses_NNS 53,551_CD 39,430_CD 311,231_CD 205,779_CD 15_CD Other_JJ current_JJ liabilities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Income_NN taxes_NNS payable_JJ 12,597_CD 19,102_CD Deferred_JJ payments_NNS 18,980_CD Interest_NN on_IN long-term_JJ debt_NN see_VBP Note_NN 17_CD 2,653_CD Social_NNP security_NN liabilities_NNS 3,062_CD 2,216_CD Value_NNP added_VBD taxes_NNS 1,503_CD SERP_NNP see_VB Note_VB 25_CD 1,904_CD 2,781_CD Other_JJ accrued_VBN liabilities_NNS 41,015_CD 8,872_CD 77,558_CD 37,127_CD 16_CD Loan_NN facility_NN As_IN part_NN of_IN the_DT transaction_NN which_WDT disposed_VBD of_IN the_DT vaccines_NNS business_NN Shire_NNP agreed_VBD to_TO provide_VB IDB_NNP with_IN a_DT loan_NN facility_NN of_IN up_RB to_TO $_$ 100_CD million_CD ._.
A_DT provision_NN of_IN $_$ 70_CD million_CD was_VBD made_VBN against_IN this_DT facility_NN representing_VBG the_DT pipeline_NN products_NNS element_NN ._.
In_IN the_DT period_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, IDB_NNP drew_VBD down_RB $_$ 26.8_CD million_CD of_IN this_DT facility_NN ._.
An_DT additional_JJ $_$ 43.2_CD million_CD is_VBZ available_JJ to_TO IDB_NNP to_TO draw_VB down_RP through_IN September_NNP 2008_CD ._.
79_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 80_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 17_CD Long-term_JJ debt_NN December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Total_JJ obligations_NNS 116_CD 376,307_CD Current_JJ maturities_NNS of_IN long-term_JJ obligations_NNS 290_CD Total_JJ long-term_JJ debt_NN 116_CD 376,017_CD An_DT analysis_NN of_IN total_JJ obligations_NNS by_IN loan_NN type_NN is_VBZ presented_VBN below_IN :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Convertible_JJ notes_NNS due_JJ 2011 116 370_CD ,225_CD Capital_NN leases_NNS 6,082_CD 116_CD 376,307_CD i_FW Convertible_JJ notes_NNS due_JJ 2011_CD The_DT guaranteed_VBN convertible_JJ notes_NNS due_JJ 2011_CD were_VBD issued_VBN in_IN August_NNP 2001_CD by_IN Shire_NNP Finance_NNP Limited_NNP the_DT Issuer_NNP ,_, a_DT wholly-owned_JJ finance_NN subsidiary_NN of_IN Shire_NNP ._.
At_IN the_DT choice_NN of_IN investors_NNS ,_, each_DT $_$ 1,000_CD of_IN nominal_JJ value_NN notes_NNS was_VBD convertible_JJ into_IN 49.62_CD Shire_NNP ordinary_JJ shares_NNS subject_JJ to_TO adjustment_NN or_CC 16.54_CD Shire_NNP ADSs_NNP subject_NN to_TO adjustment_NN at_IN any_DT time_NN up_RP to_TO August_NNP 21_CD ,_, 2011_CD ._.
Alternatively_RB ,_, investors_NNS had_VBD the_DT option_NN to_TO receive_VB repayment_NN of_IN the_DT nominal_JJ principal_NN in_IN cash_NN either_CC at_IN the_DT maturity_NN date_NN of_IN August_NNP 21_CD ,_, 2011_CD or_CC by_IN exercising_VBG a_DT put_NN option_NN on_IN any_DT of_IN the_DT three_CD put_VBD dates_NNS being_VBG August_NNP 21_CD ,_, 2004_CD ,_, August_NNP 21_CD ,_, 2006_CD and_CC August_NNP 21_CD ,_, 2008_CD ._.
On_IN August_NNP 21_CD ,_, 2004_CD ,_, upon_IN exercise_NN of_IN the_DT put_NN option_NN by_IN substantially_RB all_DT of_IN the_DT convertible_JJ note_NN holders_NNS and_CC subsequently_RB ,_, the_DT Company_NN redeemed_VBD $_$ 370.1_CD million_CD at_IN par_NN from_IN available_JJ funds_NNS 2003_CD :_: $_$ 29.8_CD million_CD ,_, recording_VBG a_DT gain_NN of_IN $_$ 0.5_CD million_CD ._.
The_DT obligation_NN to_TO pay_VB the_DT remaining_VBG $_$ 0.1_CD million_CD of_IN the_DT convertible_JJ loan_NN notes_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, 2004_CD is_VBZ due_JJ in_IN 2011_CD ._.
The_DT interest_NN expense_NN recorded_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD was_VBD $_$ 12.2_CD million_CD ,_, including_VBG the_DT write-off_NN of_IN $_$ 7.4_CD million_CD of_IN deferred_VBN financing_NN costs_NNS 2003_CD :_: $_$ 7.5_CD million_CD ,_, 2002_CD :_: $_$ 8.0_CD million_CD ._.
ii_NNP Capital_NNP leases_VBZ During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN served_VBD notice_NN to_TO buy_VB out_RP its_PRP$ remaining_VBG capital_NN leases_NNS ,_, totalling_VBG $_$ 5.7_CD million_CD ,_, relating_VBG to_TO its_PRP$ manufacturing_NN facility_NN in_IN Maryland_NNP ._.
Repayment_NN of_IN the_DT leases_NNS occurred_VBD in_IN October_NNP 2004_CD ._.
December_NNP 31_CD ,_, 2003_CD Obligations_NNS under_IN capital_NN leases_NNS $_$ 000_CD Current_JJ 290_CD Non-current_JJ 5,792_CD 6,082_CD The_DT following_NN is_VBZ an_DT analysis_NN of_IN the_DT leased_VBN property_NN under_IN capital_NN leases_NNS by_IN major_JJ asset_NN classes_NNS :_: December_NNP 31_CD ,_, 2003_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 6,645_CD Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 172_CD 6,817_CD Less_RBR :_: accumulated_VBN depreciation_NN 888_CD 5,929_CD 80_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 81_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 18_CD Other_JJ non-current_JJ liabilities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD SERP_NNP see_VB Note_VB 25_CD 3,591_CD 6,102_CD Long-term_JJ bonuses_NNS 4,425_CD 3,117_CD Deferred_JJ revenue_NN 9,074_CD 13,430_CD Insurance_NN provisions_NNS 9,274_CD 5,770_CD Reorganization_NN accrual_NN see_VBP Note_NN 3_CD 2,488_CD 236_CD Other_JJ accrued_VBN liabilities_NNS 3,307_CD 1,539_CD 32,159_CD 30,194_CD Deferred_JJ revenue_NN relates_VBZ to_TO amounts_NNS received_VBN from_IN the_DT out-licensing_NN of_IN AGRYLIN_NNP and_CC FOSRENOL_NNP in_IN Japan_NNP and_CC the_DT global_JJ out-licensing_NN of_IN TROXATYL_NNP ._.
19_CD Financial_NNP instruments_NNS The_DT estimated_VBN fair_JJ value_NN of_IN the_DT Companys_NNPS financial_JJ instruments_NNS as_IN of_IN December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD is_VBZ summarized_VBN below_IN ._.
Certain_JJ estimates_NNS and_CC judgments_NNS were_VBD required_VBN to_TO develop_VB the_DT fair_JJ value_NN amounts_NNS ._.
The_DT fair-value_JJ amounts_NNS shown_VBN below_IN are_VBP not_RB necessarily_RB indicative_JJ of_IN the_DT amounts_NNS that_IN the_DT Company_NN would_MD realize_VB upon_IN disposition_NN nor_CC do_VBP they_PRP indicate_VBP the_DT Companys_NNPS intent_NN or_CC ability_NN to_TO dispose_VB of_IN the_DT financial_JJ instrument_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD used_VBN to_TO estimate_VB the_DT fair_JJ value_NN of_IN each_DT material_NN class_NN of_IN financial_JJ instrument_NN :_: Short-term_JJ investments_NNS commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS the_DT carrying_NN value_NN approximates_VBZ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ nature_NN of_IN these_DT instruments_NNS ._.
Investments_NNP the_DT carrying_VBG value_NN of_IN non-current_JJ investments_NNS with_IN readily_RB determinable_JJ market_NN values_NNS equals_VBZ the_DT fair_JJ value_NN as_IN such_JJ instruments_NNS are_VBP marked_VBN to_TO market_NN ._.
Long-term_JJ debt_NN the_DT fair_JJ value_NN of_IN long-term_JJ debt_NN is_VBZ estimated_VBN based_VBN on_IN the_DT discounted_JJ future_JJ cash_NN flows_VBZ using_VBG currently_RB available_JJ interest_NN rates_NNS or_CC ,_, where_WRB the_DT debt_NN instrument_NN is_VBZ traded_VBN ,_, by_IN reference_NN to_TO the_DT market_NN price_NN ._.
IDB_NNP subscription_NN receipts_NNS the_DT carrying_NN value_NN equals_VBZ the_DT fair_JJ value_NN as_IN the_DT subscription_NN receipts_NNS were_VBD repurchased_VBN on_IN January_NNP 7_CD ,_, 2005_CD for_IN $_$ 60_CD million_CD ._.
The_DT carrying_VBG amounts_NNS and_CC corresponding_JJ fair_JJ values_NNS of_IN financial_JJ instruments_NNS are_VBP as_IN follows_VBZ :_: Carrying_VBG amount_NN Fair_NN value_NN December_NNP 31_CD ,_, 2004_CD $_$ 000_CD $_$ 000_CD Financial_JJ assets_NNS :_: Commercial_JJ paper_NN 149,659_CD 149,659_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 174,752_CD 175,185_CD Investments_NNP 29,970_CD 29,970_CD IDB_NNP subscription_NN receipts_NNS 60,000_CD 60,000_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 116_CD 117_CD Carrying_VBG amount_NN Fair_NN value_NN December_NNP 31_CD ,_, 2003_CD $_$ 000_CD $_$ 000_CD Financial_JJ assets_NNS :_: Commercial_JJ paper_NN 120,872_CD 120,872_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 183,257_CD 183,257_CD Investments_NNP 21,879_CD 21,879_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 376,017_CD 378,005_CD The_DT carrying_VBG amounts_NNS of_IN cash_NN and_CC cash_NN equivalents_NNS ,_, accounts_NNS receivable_JJ ,_, accounts_NNS payable_JJ and_CC accrued_VBN liabilities_NNS approximate_JJ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ maturity_NN of_IN these_DT instruments_NNS ._.
81_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 82_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 20_CD Commitments_NNS and_CC contingencies_NNS a_DT Leases_NNP Future_NNP minimum_NN lease_NN payments_NNS presented_VBD below_IN include_VBP principal_JJ lease_NN payments_NNS and_CC other_JJ fixed_VBN executory_NN fees_NNS under_IN lease_NN arrangements_NNS as_IN of_IN December_NNP 31_CD ,_, 2004_CD :_: Operating_NN leases_VBZ $_$ 000_CD 2005_CD 16,374_CD 2006_CD 15,004_CD 2007_CD 12,928_CD 2008_CD 9,839_CD 2009_CD 6,892_CD Thereafter_RB 37,708_CD 98,745_CD i_FW Operating_NN leases_VBZ The_DT Company_NN leases_VBZ facilities_NNS ,_, motor_NN vehicles_NNS and_CC certain_JJ equipment_NN under_IN operating_VBG leases_NNS expiring_VBG through_IN 2015_CD ._.
Lease_NNP and_CC rental_JJ expense_NN included_VBD in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT accompanying_VBG statements_NNS of_IN operations_NNS amounted_VBD to_TO $_$ 7.2_CD million_CD ,_, $_$ 12.2_CD million_CD and_CC $_$ 6.7_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD ,_, respectively_RB ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, Shire_NNP Inc._NNP a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, signed_VBD an_DT eleven_JJ year_NN operating_VBG lease_NN on_IN a_DT property_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
Shire_NNP US_NNP ,_, Inc._NNP another_DT wholly-owned_JJ subsidiary_NN ,_, acts_VBZ as_IN guarantor_NN in_IN respect_NN of_IN this_DT lease_NN ._.
The_DT future_JJ minimum_NN lease_NN payments_NNS under_IN the_DT lease_NN agreement_NN are_VBP $_$ 34.4_CD million_CD in_IN aggregate_NN ._.
SUMI_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, terminated_VBN certain_JJ operating_VBG leases_NNS in_IN October_NNP 2004_CD ._.
ii_FW Restricted_VBN cash_NN in_IN respect_NN of_IN leases_NNS At_IN December_NNP 31_CD ,_, 2004_CD the_DT Company_NN had_VBD $_$ 5.3_CD million_CD of_IN restricted_VBN cash_NN held_VBN as_IN collateral_NN for_IN certain_JJ equipment_NN leases_VBZ 2003_CD :_: $_$ 5.3_CD million_CD ._.
b_NN Letters_NNS of_IN credit_NN and_CC guarantees_NNS i_FW As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD outstanding_JJ an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Barclays_NNP Bank_NNP plc_NN in_IN the_DT amount_NN of_IN $_$ 15.0_CD million_CD providing_VBG security_NN on_IN the_DT recoverability_NN of_IN insurance_NN claims_NNS ._.
The_DT Company_NN had_VBD restricted_VBN cash_NN of_IN $_$ 16.0_CD million_CD in_IN connection_NN with_IN this_DT letter_NN of_IN credit_NN ._.
ii_FW The_DT Companys_NNPS acquisitions_NNS ,_, dispositions_NNS and_CC other_JJ contractual_JJ arrangements_NNS contain_VBP representations_NNS and_CC warranties_NNS ,_, which_WDT have_VBP been_VBN determined_VBN to_TO have_VB fide_NN minimis_NNS potential_JJ liability_NN ._.
c_NN Commitments_NNS i_FW As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD outstanding_JJ commitments_NNS to_TO subscribe_VB for_IN interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG $_$ 22.0_CD million_CD 2003_CD :_: $_$ 8.0_CD million_CD of_IN which_WDT $_$ 4.2_CD million_CD is_VBZ committed_VBN to_TO in_IN 2005_CD and_CC a_DT further_JJ $_$ 13.7_CD million_CD could_MD be_VB payable_JJ in_IN 2005_CD ,_, depending_VBG on_IN the_DT timing_NN of_IN capital_NN calls_NNS ._.
ii_FW MTS_FW METHYPATCH_NNP In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN MTS_NNP METHYPATCH_NNP in_IN 2003_CD ,_, the_DT Company_NN has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN milestones_NNS ._.
This_DT will_MD require_VB $_$ 50_CD million_CD upon_IN regulatory_JJ approval_NN of_IN the_DT product_NN and_CC up_RB to_TO $_$ 75_CD million_CD linked_VBN to_TO the_DT future_JJ sales_NNS performance_NN ._.
The_DT Company_NN expects_VBZ to_TO meet_VB these_DT payments_NNS with_IN cash_NN from_IN operations_NNS ._.
The_DT Company_NN expects_VBZ to_TO resubmit_VB MTS_NNP METHYPATCH_NNP for_IN approval_NN in_IN 2005_CD ._.
iii_FW FOSRENOL_NNP patent_NN rights_NNS In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN the_DT global_JJ patents_NNS for_IN FOSRENOL_NNP ,_, Shire_NNP agreed_VBD to_TO pay_VB AnorMED_NNP Inc._NNP $_$ 6_CD million_CD when_WRB it_PRP is_VBZ approved_VBN in_IN certain_JJ European_JJ countries_NNS and_CC $_$ 6_CD million_CD upon_IN receipt_NN of_IN regulatory_JJ approval_NN in_IN Japan_NNP ._.
The_DT Company_NN has_VBZ committed_VBN to_TO spend_VB a_DT further_JJ $_$ 5.1_CD million_CD by_IN the_DT end_NN of_IN 2005_CD and_CC has_VBZ an_DT additional_JJ commitment_NN of_IN $_$ 4.4_CD million_CD for_IN the_DT design_NN and_CC construction_NN of_IN a_DT technology_NN center_NN at_IN Owings_NNP Mills_NNP ,_, Maryland_NNP ,_, also_RB expected_VBN to_TO be_VB incurred_VBN in_IN 2005_CD ._.
v_FW Wayne_NNP ,_, Pennsylvania_NNP fit-out_JJ The_DT Company_NN is_VBZ in_IN the_DT process_NN of_IN fitting_JJ out_IN its_PRP$ new_JJ US_NNP headquarters_NN at_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD an_DT outstanding_JJ commitment_NN of_IN $_$ 20.4_CD million_CD relating_VBG to_TO this_DT refurbishment_NN ,_, expected_VBN to_TO be_VB incurred_VBN in_IN 2005_CD ._.
82_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 83_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 20_CD Commitments_NNS and_CC contingencies_NNS continued_VBD d_SYM Legal_NNP proceedings_NNS i_FW General_NNP The_NNP Company_NNP accounts_VBZ for_IN litigation_NN losses_NNS in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
5_CD ,_, Accounting_NNP for_IN Contingencies_NNPS SFAS_NNP No._NN ._.
5_CD ,_, loss_NN contingency_NN provisions_NNS are_VBP recorded_VBN for_IN probable_JJ losses_NNS when_WRB management_NN is_VBZ able_JJ to_TO reasonably_RB estimate_VB the_DT loss_NN ._.
Where_WRB the_DT estimated_JJ loss_NN lies_VBZ within_IN a_DT range_NN and_CC no_DT particular_JJ amount_NN within_IN that_DT range_NN is_VBZ a_DT better_JJR estimate_NN than_IN any_DT other_JJ amount_NN ,_, the_DT minimum_NN amount_NN is_VBZ recorded_VBN ._.
In_IN other_JJ cases_NNS managements_NNS best_JJS estimate_NN of_IN the_DT loss_NN is_VBZ recorded_VBN ._.
These_DT estimates_NNS are_VBP developed_VBN substantially_RB before_IN the_DT ultimate_JJ loss_NN is_VBZ known_VBN and_CC the_DT estimates_NNS are_VBP refined_VBN each_DT accounting_NN period_NN in_IN light_NN of_IN additional_JJ information_NN being_VBG known_VBN ._.
In_IN instances_NNS where_WRB the_DT Company_NN is_VBZ unable_JJ to_TO develop_VB a_DT best_JJS estimate_NN of_IN loss_NN ,_, no_DT litigation_NN loss_NN is_VBZ recorded_VBN at_IN that_DT time_NN ._.
As_IN information_NN becomes_VBZ known_VBN a_DT loss_NN provision_NN is_VBZ set_VBN up_RP when_WRB a_DT best_JJS estimate_NN can_MD be_VB made_VBN ._.
The_DT best_JJS estimates_NNS are_VBP reviewed_VBN quarterly_JJ and_CC the_DT estimates_NNS are_VBP changed_VBN when_WRB expectations_NNS are_VBP revised_VBN ._.
Any_DT outcome_NN upon_IN settlement_NN that_IN deviates_VBZ from_IN the_DT Companys_NNPS best_JJS estimate_NN may_MD result_VB in_IN an_DT additional_JJ expense_NN in_IN a_DT future_JJ accounting_NN period_NN ._.
ii_FW Phentermine_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, is_VBZ a_DT defendant_NN in_IN 260_CD lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
SUS_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB prescribed_VBN ,_, causes_VBZ the_DT alleged_JJ sideeffects_NNS and_CC that_IN SUS_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN November_NNP 30_CD ,_, 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
iii_FW ADDERALL_NNP XR_NNP a_DT Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Shires_NNP extended-release_NN once-daily_RB version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP ,_, is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ._.
In_IN January_NNP 2003_CD the_DT Company_NN was_VBD notified_VBN that_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Barr_NNP had_VBD submitted_VBN an_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP under_IN the_DT US_NNP Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD Patent_NN ._.
The_DT notification_NN alleged_VBD that_IN the_DT 819_CD Patent_NN is_VBZ not_RB infringed_VBN by_IN Barrs_NNP extended-release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, which_WDT is_VBZ the_DT subject_NN of_IN Barrs_NNP ANDA_NNP ._.
On_IN February_NNP 24_CD ,_, 2003_CD Shire_NNP Laboratories_NNPS Inc._NNP ._.
Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Barr_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP alleging_VBG that_IN Barrs_NNP ANDA_NNP infringes_VBZ the_DT 819_CD Patent_NN ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN August_NNP 12_CD ,_, 2003_CD ,_, Shire_NNP Laboratories_NNP was_VBD issued_VBN a_DT new_JJ US_NNP patent_NN No._NN ._.
In_IN August_NNP 2003_CD Shire_NNP was_VBD notified_VBN that_IN Barr_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT US_NNP Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN and_CC alleging_VBG that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 300_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
83_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 84_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 20_CD Commitments_NNS and_CC contingencies_NNS continued_VBD d_SYM Legal_NNP proceedings_NNS continued_VBD iii_FW ADDERALL_NNP XR_NNP continued_VBD a_DT Barr_NNP Laboratories_NNPS ,_, Inc._NNP continued_VBD The_DT lawsuits_NNS against_IN Barr_NNP with_IN respect_NN to_TO the_DT 819_CD and_CC 300_CD Patents_NNP were_VBD consolidated_VBN in_IN December_NNP 2003_CD and_CC a_DT trial_NN date_NN scheduled_VBN for_IN January_NNP 2006_CD ._.
On_IN September_NNP 27_CD ,_, 2004_CD ,_, Barr_NNP filed_VBD an_DT amended_VBN Answer_NNP ,_, Affirmative_NNP Defense_NNP and_CC Counterclaim_NNP in_IN which_WDT Barr_NNP added_VBD the_DT following_VBG counterclaims_NNS and_CC affirmative_JJ defenses_NNS :_: invalidity_NN of_IN the_DT 819_CD Patent_NN ,_, non-infringement_NN of_IN the_DT 300_CD Patent_NN and_CC unenforceability_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP due_JJ to_TO inequitable_JJ conduct_NN ._.
Shire_NNP has_VBZ asserted_VBN affirmative_JJ defenses_NNS ,_, alleging_VBG ,_, among_IN other_JJ things_NNS ,_, that_IN Barr_NNP has_VBZ waived_VBN its_PRP$ right_NN to_TO assert_VB the_DT counterclaims_NNS set_VBN forth_RB in_IN its_PRP$ September_NNP 27_CD ,_, 2004_CD amended_VBN answers_NNS ._.
Barr_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
Even_RB if_IN Barr_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT latest_JJS stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN Barr_NNP receives_VBZ a_DT favorable_JJ decision_NN before_IN the_DT expiration_NN of_IN the_DT stay_NN ,_, then_RB Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended-release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ,_, following_VBG the_DT expiration_NN of_IN the_DT Hatch-Waxman_NNP exclusivity_NN period_NN ._.
However_RB ,_, on_IN October_NNP 28_CD ,_, 2004_CD the_DT FDA_NNP granted_VBD an_DT additional_JJ six_CD months_NNS exclusivity_NN to_TO ADDERALL_NNP XR_NNP based_VBN upon_IN pediatric_JJ studies_NNS carried_VBD out_RP on_IN the_DT drug_NN product_NN ,_, meaning_VBG that_IN Barr_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN after_IN Hatch-Waxman_NNP exclusivity_NN expires_VBZ on_IN April_NNP 11_CD ,_, 2005_CD ._.
b_NN Impax_NNP Laboratories_NNP ,_, Inc._NNP ._.
In_IN November_NNP 2003_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Impax_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Impax_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT US_NNP Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 30mg_JJ strength_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN dates_NNS of_IN the_DT 819_CD and_CC 300_CD Patents_NNP and_CC alleging_VBG that_IN the_DT 819_CD and_CC 300_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Impaxs_NNP extended-release_NN mixed_JJ amphetamine_NN salt_NN product_NN ,_, the_DT subject_NN of_IN Impaxs_NNP ANDA_NNP ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Impax_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Impax_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
A_DT trial_NN date_NN of_IN October_NNP 11_CD ,_, 2005_CD has_VBZ been_VBN set_VBN ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP received_VBD an_DT additional_JJ notification_NN from_IN Impax_NNP advising_VBG of_IN the_DT filing_NN of_IN an_DT ANDA_NNP for_IN generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ and_CC 25mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP in_IN addition_NN to_TO the_DT 30mg_JJ strength_NN ,_, the_DT subject_NN of_IN Impaxs_NNP initial_JJ ANDA_NNP ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Impax_NNP from_IN commercializing_VBG its_PRP$ amended_VBN ANDA_NNP products_NNS before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Impax_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
Even_RB if_IN Impax_NNP receives_VBZ a_DT tentative_JJ approval_NN from_IN the_DT FDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stays_NNS May_MD 2006_CD in_IN the_DT case_NN of_IN the_DT 30mg_JJ strength_NN and_CC June_NNP 2007_CD in_IN the_DT case_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ and_CC 25mg_JJ strengths_NNS or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_WDT Impax_NNP receives_VBZ a_DT favorable_JJ decision_NN before_IN the_DT expiration_NN of_IN the_DT stays_NNS ,_, then_RB Impax_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ extended-release_NN mixed_JJ amphetamine_NN salt_NN products_NNS upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiration_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
However_RB ,_, on_IN October_NNP 28_CD ,_, 2004_CD the_DT FDA_NNP granted_VBD an_DT additional_JJ six_CD months_NNS exclusivity_NN to_TO ADDERALL_NNP XR_NNP based_VBN upon_IN pediatric_JJ studies_NNS carried_VBD out_RP on_IN the_DT drug_NN product_NN ,_, meaning_VBG that_IN Impax_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN after_IN Hatch-Waxman_NNP exclusivity_NN expires_VBZ on_IN April_NNP 11_CD ,_, 2005_CD ._.
c_NN Colony_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Colony_NNP Pharmaceuticals_NNP Inc._NNP ._.
Colony_NN had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT US_NNP Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
In_IN any_DT event_NN ,_, Colony_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiration_NN of_IN Shires_NNP existing_VBG Hatch-Waxman_NNP exclusivity_NN on_IN April_NNP 11_CD ,_, 2005_CD and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
84_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 85_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 20_CD Commitments_NNS and_CC contingencies_NNS continued_VBD d_SYM Legal_NNP proceedings_NNS continued_VBD iii_FW ADDERALL_NNP XR_NNP continued_VBD d_SYM Teva_NNP Pharmaceuticals_NNP USA_NNP ,_, Inc._NNP ._.
In_IN February_NNP 2005_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Teva_NNP Pharmaceuticals_NNP USA_NNP ,_, Inc._NNP ._.
Teva_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT US_NNP Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 10mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
In_IN any_DT event_NN ,_, Teva_NNP may_MD not_RB market_VB its_PRP$ ANDA_NNP products_NNS until_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP following_VBG the_DT expiration_NN of_IN the_DT existing_VBG Hatch-Waxman_NNP exclusivity_NN on_IN April_NNP 11_CD ,_, 2005_CD and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
iv_NN CARBATROL_NNP In_IN August_NNP 2003_CD the_DT Company_NN was_VBD notified_VBN that_IN Nostrum_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Nostrum_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT US_NNP HatchWaxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 300mg_JJ strength_NN of_IN CARBATROL_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS US_NNP patents_NNS for_IN CARBATROL_NNP ,_, US_NNP patent_NN No._NN ._.
The_DT notification_NN alleges_VBZ that_IN the_DT 013_CD and_CC 570_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP 300mg_CD extended-release_NN carbamazepine_NN product_NN ,_, the_DT subject_NN of_IN Nostrums_NNPS ANDA_NNP ._.
On_IN September_NNP 18_CD ,_, 2003_CD Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Nostrum_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP for_IN infringement_NN of_IN these_DT two_CD patents_NNS ._.
The_DT Company_NN was_VBD also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Nostrum_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Nostrum_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN January_NNP 23_CD ,_, 2004_CD the_DT Company_NN amended_VBD the_DT Complaint_NNP to_TO delete_VB the_DT allegations_NNS with_IN respect_NN to_TO the_DT 013_CD Patent_NN ._.
On_IN July_NNP 12_CD ,_, 2004_CD the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP dismissed_VBD Nostrums_NNP abuse_NN of_IN process_NN counterclaim_NN for_IN failure_NN to_TO state_VB a_DT claim_NN upon_IN which_WDT relief_NN can_MD be_VB granted_VBN ._.
On_IN December_NNP 10_CD ,_, 2004_CD Nostrum_NNP filed_VBD a_DT summary_NN judgment_NN motion_NN seeking_VBG a_DT declaration_NN of_IN non-infringement_NN of_IN the_DT 570_CD Patent_NN ._.
Shires_NNP opposition_NN to_TO this_DT motion_NN was_VBD filed_VBN on_IN January_NNP 14_CD ,_, 2005_CD ._.
Even_RB if_IN Nostrum_NNP receives_VBZ tentative_JJ approval_NN from_IN the_DT FDA_NNP for_IN its_PRP$ ANDA_NNP ,_, it_PRP can_MD not_RB lawfully_RB launch_VB its_PRP$ generic_JJ version_NN before_IN the_DT earlier_JJR of_IN the_DT expiration_NN of_IN the_DT stay_NN February_NNP 2006_CD or_CC a_DT district_NN court_NN decision_NN in_IN its_PRP$ favor_NN ._.
In_IN the_DT event_NN that_IN the_DT Company_NN does_VBZ not_RB prevail_VB ,_, then_RB Nostrum_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ 300mg_JJ extended-release_NN carbamazepine_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ._.
21_CD Related_VBN parties_NNS a_DT Professional_JJ fees_NNS The_DT Company_NN incurred_VBN professional_JJ fees_NNS with_IN Stikeman_NNP Elliott_NNP ,_, a_DT law_NN firm_NN in_IN which_WDT The_DT Hon_NNP James_NNP Grant_NNP ,_, a_DT director_NN of_IN Shire_NNP ,_, is_VBZ a_DT partner_NN ,_, totalling_VBG $_$ 2.1_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD $_$ 0.8_CD million_CD and_CC $_$ 1.2_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD ._.
b_NN NeuroChem_NNP Inc._NNP ._.
In_IN April_NNP 2004_CD Shire_NNP BioChem_NNP Inc._NNP ._.
BioChem_NNP ,_, a_DT subsidiary_NN of_IN Shire_NNP ,_, sold_VBD a_DT Canadian_JJ property_NN to_TO NeuroChem_NNP Inc._NNP for_IN $_$ 7.8_CD million_CD CAN$_NNP 10.5_CD million_CD ._.
Dr_NNP Bellini_NNP ,_, a_DT non-executive_JJ Director_NNP of_IN BioChem_NNP and_CC ,_, until_IN May_NNP 10_CD ,_, 2003_CD ,_, a_DT non-executive_JJ Director_NNP of_IN Shire_NNP ,_, and_CC Mr_NNP Nordmann_NNP ,_, a_DT non-executive_JJ Director_NNP of_IN Shire_NNP ,_, are_VBP both_DT directors_NNS of_IN NeuroChem_NNP Inc._NNP ._.
Dr_NNP Bellini_NNP had_VBD an_DT indirect_JJ substantial_JJ interest_NN in_IN the_DT issued_VBN share_NN capital_NN of_IN NeuroChem_NNP Inc._NNP at_IN the_DT time_NN of_IN the_DT transaction_NN ._.
In_IN April_NNP 2004_CD ,_, BioChem_NNP contributed_VBD cash_NN of_IN $_$ 3.7_CD million_CD CAN$_NNP 5.0_CD million_CD and_CC equipment_NN and_CC intellectual_JJ property_NN to_TO the_DT start-up_NN of_IN a_DT new_JJ Canadian-based_JJ pharmaceutical_JJ R&D_NNP organization_NN ,_, ViroChem_NNP Pharma_NNP Inc._NNP in_IN return_NN for_IN an_DT equity_NN interest_NN and_CC royalties_NNS on_IN the_DT sale_NN of_IN certain_JJ products_NNS subsequently_RB launched_VBN by_IN ViroChem_NNP ._.
BioChem_NNP has_VBZ undertaken_VBN to_TO invest_VB an_DT additional_JJ $_$ 8.3_CD million_CD CAN$_NNP 10.0_CD million_CD in_IN ViroChem_NNP in_IN two_CD equal_JJ tranches_NNS of_IN CAN$_NNP 5.0_CD million_CD in_IN April_NNP 2005_CD and_CC April_NNP 2006_CD ._.
Dr_NNP Bellini_NNP ,_, a_DT non-executive_JJ Director_NNP of_IN BioChem_NNP and_CC ,_, until_IN May_NNP 10_CD ,_, 2003_CD ,_, a_DT non-executive_JJ Director_NNP of_IN Shire_NNP ,_, had_VBD ,_, at_IN the_DT time_NN of_IN the_DT transaction_NN ,_, an_DT indirect_JJ substantial_JJ interest_NN in_IN a_DT company_NN which_WDT is_VBZ a_DT co-investor_NN in_IN ViroChem_NNP Pharma_NNP Inc._NNP 85_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 86_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 22_CD Earnings_NNS per_IN share_NN The_DT following_VBG table_NN reconciles_NNS income_NN from_IN continuing_VBG operations_NNS and_CC the_DT weighted_JJ average_JJ ordinary_JJ shares_NNS outstanding_JJ for_IN basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN for_IN the_DT periods_NNS presented_VBN :_: Restated_VBN Restated_VBN 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS 333,299_CD 297,937_CD 260,145_CD Loss_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 20,135_CD 21,886_CD 11,659_CD Loss_NN gain_NN on_IN disposal_NN of_IN discontinued_VBN operations_NNS 44,157_CD 2,083_CD Numerator_NN for_IN basic_JJ earnings_NNS per_IN share_NN 269,007_CD 276,051_CD 250,569_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN 3,421_CD 5,218_CD 5,585_CD Numerator_NN for_IN diluted_JJ earnings_NNS per_IN share_NN 272,428_CD 281,269_CD 256,154_CD Year_NN to_TO December_NNP 31_CD ,_, 2004 2003 2002_CD Weighted_JJ average_JJ number_NN of_IN shares_NNS outstanding_JJ Number_NN of_IN shares_NNS Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS Basic_JJ 496,306,604_CD 498,212,826_CD 500,687,594_CD Effect_NN of_IN dilutive_JJ shares_NNS :_: Share_NN options_NNS 3,035,620_CD 1,859,076_CD 1,883,475_CD Convertible_JJ debt_NN 11,858,416_CD 18,895,493_CD 19,847,177_CD Warrants_NNS 66,792_CD 14,960,828_CD 20,754,569_CD 21,730,652_CD Diluted_NNP 511,267,432_CD 518,967,395_CD 522,418,246_CD Basic_JJ earnings_NNS per_IN share_NN :_: Income_NN from_IN continuing_VBG operations_NNS 67.2_CD 59.8_CD 51.9_CD Loss_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 4.1_CD 4.4_CD 2.3_CD Loss_NN gain_NN on_IN disposal_NN of_IN discontinued_VBN operations_NNS 8.9_CD 0.4_CD 54.2_CD 55.4_CD 50.0_CD Diluted_VBN earnings_NNS per_IN share_NN :_: Income_NN from_IN continuing_VBG operations_NNS 65.9_CD 58.4_CD 50.8_CD Loss_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 4.0_CD 4.2_CD 2.2_CD Loss_NN gain_NN on_IN disposal_NN of_IN discontinued_VBN operations_NNS 8.6_CD 0.4_CD 53.3_CD 54.2_CD 49.0_CD The_DT warrants_NNS and_CC share_NN options_NNS not_RB included_VBD within_IN the_DT calculation_NN of_IN the_DT diluted_VBN weighted_JJ average_JJ number_NN of_IN shares_NNS ,_, because_IN the_DT exercise_NN prices_NNS exceeded_VBD the_DT Companys_NNPS average_JJ share_NN price_NN during_IN the_DT calculation_NN period_NN ,_, are_VBP shown_VBN below_IN :_: 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS Share_NN options_NNS 16,640,724_CD 17,006,093_CD 17,492,575_CD Warrants_NNS 1,346,407_CD 1,346,407_CD 16,640,724_CD 18,352,500_CD 18,838,982_CD During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN recorded_VBD a_DT loss_NN on_IN redemption_NN of_IN the_DT convertible_JJ loan_NN notes_NNS of_IN $_$ 7.4_CD million_CD ,_, which_WDT resulted_VBD from_IN the_DT write-off_NN of_IN unamortized_JJ debt_NN issuance_NN costs_NNS ._.
Diluted_NNP EPS_NNP would_MD have_VB been_VBN 53.9_CD ,_, or_CC 0.6_CD higher_JJR ,_, without_IN this_DT loss_NN on_IN redemption_NN ._.
86_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 87_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 23_CD Segment_NNP reporting_VBG The_DT Company_NN has_VBZ disclosed_VBN segment_NN information_NN for_IN the_DT individual_JJ reporting_NN segments_NNS of_IN the_DT business_NN ,_, based_VBN on_IN the_DT way_NN in_IN which_WDT the_DT business_NN is_VBZ managed_VBN and_CC controlled_VBN ._.
The_DT Companys_NNPS principal_JJ reporting_NN segments_NNS are_VBP by_IN operational_JJ function_NN ,_, each_DT being_VBG managed_VBN and_CC monitored_VBN separately_RB and_CC serving_VBG different_JJ markets_NNS ._.
The_DT Company_NN evaluates_VBZ performance_NN based_VBN on_IN operating_VBG income_NN ._.
The_DT Company_NN does_VBZ not_RB have_VB inter-segment_JJ transactions_NNS ._.
The_DT US_NNP segment_NN represents_VBZ the_DT Companys_NNP commercial_JJ operations_NNS in_IN the_DT United_NNP States_NNPS and_CC the_DT International_NNP segment_NN represents_VBZ the_DT commercial_JJ operations_NNS in_IN the_DT Rest_VB of_IN the_DT World_NNP ._.
The_DT R&D_NNP segment_NN represents_VBZ all_DT direct_JJ R&D_NN costs_NNS incurred_VBN by_IN the_DT Company_NN throughout_IN the_DT world_NN ._.
Corporate_JJ represents_VBZ the_DT royalty_NN business_NN that_WDT is_VBZ managed_VBN at_IN the_DT Corporate_JJ office_NN and_CC certain_JJ costs_NNS that_WDT are_VBP managed_VBN at_IN the_DT corporate_JJ office_NN and_CC not_RB allocated_VBN to_TO the_DT other_JJ segments_NNS ._.
The_DT results_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD and_CC 2002_CD have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN ,_, which_WDT had_VBD previously_RB been_VBN reported_VBN as_IN the_DT Biologics_NNPS segment_NN ._.
The_DT US_NNP and_CC International_NNP reportable_JJ segments_NNS have_VBP also_RB been_VBN restated_VBN as_IN certain_JJ components_NNS of_IN the_DT vaccines_NNS business_NN previously_RB formed_VBD part_NN of_IN these_DT segments_NNS ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 2.7_CD million_CD is_VBZ included_VBN in_IN cost_NN of_IN product_NN sales_NNS ._.
Depreciation_NN and_CC amortization_NN relating_VBG to_TO R&D_NNP assets_NNS are_VBP included_VBN in_IN US_NNP and_CC International_NNP segments_NNS ._.
87_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 88_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 23_CD Segment_NN reporting_NN continued_VBD Restated_NNP Restated_NNP Restated_NNP Restated_NNP Restated_NNP US_NNP International_NNP Corporate_NNP R&D_NNP Total_NNP Year_NN to_TO December_NNP 31_CD ,_, 2003_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD External_NNP revenues_NNS :_: Product_NN sales_NNS 846,438_CD 157,869_CD 1,004,307_CD Royalties_NNS 14_CD 10,314_CD 193,245_CD 203,573_CD Licensing_NN and_CC development_NN 3,376_CD 301_CD 3,677_CD Other_JJ revenues_NNS 13_CD 13_CD Total_JJ revenues_NNS 849,841_CD 168,484_CD 193,245_CD 1,211,570_CD Cost_NN of_IN product_NN sales_NNS 94,597_CD 48,563_CD 143,160_CD 2_CD Research_NNP and_CC development_NN 194,902_CD 194,902_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 234,091_CD 80,968_CD 56,755_CD 371,814_CD 1_CD ,_, 2_CD Depreciation_NN and_CC amortization_NN 30,965_CD 24,338_CD 26,804_CD 82,107_CD Total_JJ operating_NN expenses_NNS 359,653_CD 153,869_CD 83,559_CD 194,902_CD 791,983_CD Operating_NN income_NN loss_NN 490,188_CD 14,615_CD 109,686_CD 194,902_CD 419,587_CD US_NNP International_NNP Corporate_NNP R&D_NNP Total_NNP Year_NN to_TO December_NNP 31_CD ,_, 2003_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Total_JJ assets_NNS from_IN continuing_VBG operations_NNS 697,460_CD 413,134_CD 1,269,300_CD 109,131_CD 2,489,025_CD Long-lived_JJ assets_NNS 238,774_CD 233,313_CD 200,225_CD 46,691_CD 719,003_CD Capital_NN expenditure_NN on_IN long-lived_JJ assets_NNS 18,324_CD 46,368_CD 15,827_CD 16,854_CD 97,373_CD 1_CD Included_VBN in_IN depreciation_NN and_CC amortization_NN are_VBP the_DT write-downs_NNS of_IN intangible_JJ assets_NNS of_IN $_$ 27.5_CD million_CD $_$ 15.8_CD million_CD in_IN the_DT International_NNP segment_NN and_CC $_$ 11.7_CD million_CD in_IN the_DT US_NNP segment_NN ,_, property_NN ,_, plant_NN and_CC equipment_NN of_IN $_$ 6.0_CD million_CD Corporate_JJ segment_NN and_CC assets_NNS held_VBN for_IN resale_NN of_IN $_$ 10.7_CD million_CD Corporate_JJ segment_NN ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 2.6_CD million_CD is_VBZ included_VBN within_IN cost_NN of_IN product_NN sales_NNS ._.
Depreciation_NN and_CC amortization_NN relating_VBG to_TO R&D_NNP assets_NNS are_VBP included_VBN within_IN US_NNP and_CC International_NNP segments_NNS ._.
2_CD Costs_NNS associated_VBN with_IN the_DT closure_NN of_IN the_DT Lead_JJ Optimization_NN division_NN and_CC other_JJ related_JJ activities_NNS in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD are_VBP :_: Research_NNP and_CC development_NN $_$ 7.2_CD million_CD and_CC depreciation_NN and_CC amortization_NN $_$ 16.7_CD million_CD ._.
These_DT amounts_NNS are_VBP reflected_VBN in_IN reorganization_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS is_VBZ included_VBN within_IN cost_NN of_IN product_NN sales_NNS $_$ 0.8_CD million_CD ._.
88_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 89_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 23_CD Segment_NN reporting_NN continued_VBD Material_NNP customers_NNS In_IN the_DT periods_NNS set_VBN out_RP below_IN ,_, certain_JJ customers_NNS ,_, all_DT within_IN the_DT US_NNP operating_NN segment_NN ,_, accounted_VBD for_IN greater_JJR than_IN 10_CD %_NN of_IN the_DT Companys_NNPS total_VBP revenues_NNS :_: 2004 2004 2003 2003_CD 2002_CD 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN Customer_NN A_DT 339,136_CD 25_CD %_NN 274,771_CD 23_CD %_NN 231,270_CD 23_CD %_NN Customer_NN B_NNP 303,965_CD 22_CD %_NN 269,364_CD 22_CD %_NN 197,184_CD 19_CD %_NN Customer_NN C_NNP 167,998_CD 12_CD %_NN 175,856_CD 15_CD %_NN 160,210_CD 16_CD %_NN Customer_NN D_NNP 156,578_CD 11_CD %_NN 158,689_CD 13_CD %_NN 149,613_CD 15_CD %_NN Amounts_NNS outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, in_IN respect_NN of_IN these_DT material_NN customers_NNS were_VBD as_IN follows_VBZ :_: 2004_CD 2003_CD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Customer_NN A_DT 28,178_CD 23,793_CD Customer_NN B_NNP 23,535_CD 25,676_CD Customer_NN C_NNP 8,515_CD 45,712_CD Customer_NN D_NNP 16,975_CD 8,212_CD 77,203_CD 103,393_CD 24_CD Other_JJ income_NN expense_NN ,_, net_JJ 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD SERP_NNP valuation_NN adjustment_NN see_VBP Note_NN 25 264 175_CD 2,301_CD Impairment_NN of_IN long-term_JJ investments_NNS see_VBP Note_NN 10_CD 15,364_CD 15,540_CD 8,680_CD GeneChem_NNP Funds_NNPS management_NN fee_NN 4,036_CD 3,755_CD 3,333_CD Gain_NN on_IN sale_NN of_IN available-for-sale_JJ security_NN see_VBP Note_NN 10_CD 14,805_CD Foreign_JJ exchange_NN 2,467_CD 6,716_CD 344_CD Other_JJ 2,571_CD 2,319_CD 4,507_CD 3,845_CD 20,645_CD 12,499_CD 25_CD Retirement_NNP benefits_NNS a_DT Personal_JJ defined_VBN contribution_NN pension_NN plans_VBZ The_DT Company_NN makes_VBZ contributions_NNS to_TO defined_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
For_IN the_DT defined_VBN contribution_NN retirement_NN plans_NNS ,_, the_DT level_NN of_IN the_DT Companys_NNP contribution_NN is_VBZ fixed_VBN at_IN a_DT set_VBN percentage_NN of_IN employees_NNS pay_VBP ._.
Company_NN contributions_NNS to_TO personal_JJ defined_VBN contribution_NN pension_NN plans_NNS totaled_VBD $_$ 9.0_CD million_CD ,_, $_$ 16.1_CD million_CD and_CC $_$ 6.8_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD respectively_RB ,_, and_CC were_VBD charged_VBN to_TO operations_NNS as_IN they_PRP became_VBD payable_JJ ._.
b_NN Defined_VBN benefit_NN pension_NN plan_NN Roberts_NNP ,_, a_DT company_NN with_IN which_WDT the_DT Company_NN merged_VBD in_IN December_NNP 1999_CD ,_, operated_VBD a_DT defined_VBN SERP_NNP for_IN certain_JJ US_NNP employees_NNS ,_, which_WDT was_VBD established_VBN in_IN 1998_CD ._.
This_DT plan_NN was_VBD available_JJ to_TO former_JJ employees_NNS of_IN Roberts_NNP who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
As_IN part_NN of_IN the_DT restructuring_NN of_IN the_DT Company_NN following_VBG the_DT Roberts_NNP merger_NN ,_, the_DT SERP_NNP was_VBD closed_VBN to_TO new_JJ members_NNS and_CC contributions_NNS ceased_VBD being_VBG paid_VBN into_IN the_DT plan_NN for_IN existing_VBG members_NNS ._.
As_IN part_NN of_IN this_DT arrangement_NN ,_, the_DT Company_NN paid_VBD a_DT lump_NN sum_NN contribution_NN into_IN the_DT plan_NN of_IN $_$ 18.0_CD million_CD ,_, the_DT result_NN of_IN which_WDT is_VBZ that_IN the_DT Company_NN has_VBZ no_DT future_JJ contributions_NNS to_TO make_VB under_IN the_DT plan_NN ._.
In_IN accordance_NN with_IN EITF_NNP 97-14_CD ,_, the_DT asset_NN and_CC liability_NN of_IN $_$ 7.7_CD million_CD and_CC $_$ 5.5_CD million_CD ,_, respectively_RB ,_, are_VBP shown_VBN on_IN the_DT balance_NN sheet_NN within_IN the_DT categories_NNS Other_JJ non-current_JJ assets_NNS ,_, Other_JJ current_JJ liabilities_NNS and_CC Other_JJ non-current_JJ liabilities_NNS ._.
89_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 90_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 26_CD Income_NN taxes_NNS The_DT components_NNS of_IN pre_NN tax_NN income_NN from_IN continuing_VBG operations_NNS are_VBP as_IN follows_VBZ :_: 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD UK_NNP 67,363_CD 76,267_CD 50,520_CD US_NNP 265,770_CD 285,221_CD 218,139_CD Other_JJ jurisdictions_NNS 261,487_CD 197,393_CD 179,208_CD Sub-total_JJ 459,894_CD 406,347_CD 346,827_CD Equity_NN investees_NNS 2,508_CD 1,057_CD 1,668_CD The_DT provision_NN for_IN income_NN taxes_NNS by_IN location_NN of_IN the_DT taxing_VBG jurisdiction_NN for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, consisted_VBN of_IN the_DT following_NN :_: 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Current_JJ income_NN taxes_NNS :_: UK_NNP corporation_NN tax_NN 746_CD US_NNP federal_JJ tax_NN 98,668_CD 101,174_CD 67,686_CD US_NNP state_NN and_CC local_JJ taxes_NNS 5,107_CD 4,313_CD 9,561_CD Other_JJ jurisdictions_NNS 36,417_CD 18,792_CD 19,864_CD Total_JJ current_JJ taxes_NNS 140,938_CD 124,279_CD 97,111_CD Deferred_JJ taxes_NNS :_: UK_NNP corporation_NN tax_NN 482_CD 9,696_CD US_NNP federal_JJ tax_NN 12,171_CD 3,647_CD 1,136_CD US_NNP state_NN and_CC local_JJ taxes_NNS 104_CD 180_CD 34_CD Other_JJ jurisdictions_NNS 922_CD 30,449_CD 9,931_CD Total_JJ deferred_JJ taxes_NNS 11,835_CD 16,926_CD 8,761_CD Total_JJ income_NN taxes_NNS attributable_JJ to_TO continuing_VBG operations_NNS 129,103_CD 107,353_CD 88,350_CD Total_JJ incomes_NNS taxes_NNS attributable_JJ to_TO discontinued_VBN operations_NNS 4,812_CD Total_JJ income_NN taxes_NNS 129,103_CD 107,353_CD 93,162_CD The_DT reconciliation_NN of_IN income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ income_NN losses_NNS of_IN associates_NNS and_CC discontinued_VBN operations_NNS to_TO the_DT provision_NN for_IN income_NN taxes_NNS is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ income_NN losses_NNS of_IN associates_NNS and_CC discontinued_VBN operations_NNS 459,894_CD 406,347_CD 346,827_CD UK_NNP corporation_NN tax_NN rate_NN 30_CD %_NN 30_CD %_NN 30_CD %_NN Adjustments_NNS to_TO derive_VB effective_JJ rate_NN :_: Non-deductible_JJ items_NNS :_: Permanent_JJ differences_NNS 2.0_CD %_NN 1.1_CD %_NN 1.2_CD %_NN Other_JJ items_NNS :_: Change_NNP in_IN valuation_NN allowance_NN 3.3_CD %_NN 7.1_CD %_NN 4.0_CD %_NN Difference_NN in_IN taxation_NN rates_NNS 0.6_CD %_NN 11.2_CD %_NN 10.5_CD %_NN Prior_RB year_NN adjustment_NN 4.5_CD %_NN 2.1_CD %_NN 0.7_CD %_NN Other_JJ 0.5_CD %_NN 2.7_CD %_NN 0.1_CD %_NN Provision_NNP for_IN income_NN taxes_NNS on_IN continuing_VBG operations_NNS 28.1_CD %_NN 26.4_CD %_NN 25.5_CD %_NN 90_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 91_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 26_CD Income_NN taxes_NNS continued_VBD The_DT significant_JJ components_NNS of_IN deferred_JJ income_NN tax_NN assets_NNS and_CC liabilities_NNS and_CC their_PRP$ balance_NN sheet_NN classifications_NNS ,_, as_IN of_IN December_NNP 31_CD ,_, are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD Deferred_VBN tax_NN assets_NNS :_: Accrued_VBN expenses_NNS not_RB currently_RB deductible_JJ 9,708_CD 3,340_CD Losses_NNS carried_VBD forward_RB 194,523_CD 248,239_CD Provisions_NNS 32,086_CD 11,299_CD Other_JJ 32,020_CD 1,876_CD Gross_NNP deferred_VBN tax_NN assets_NNS 268,337_CD 264,754_CD Less_RBR :_: valuation_NN allowance_NN 152,915_CD 168,176_CD 115,422_CD 96,578_CD Deferred_JJ tax_NN liabilities_NNS :_: Excess_NN of_IN tax_NN value_NN over_IN book_NN value_NN of_IN assets_NNS 37,311_CD 33,446_CD Net_JJ deferred_JJ tax_NN assets_NNS 78,111_CD 63,132_CD Balance_NN sheet_NN classifications_NNS :_: Deferred_JJ tax_NN assets_NNS current_JJ 70,387_CD 64,532_CD Deferred_JJ tax_NN assets_NNS liabilities_NNS non-current_JJ 7,724_CD 1,400_CD 78,111_CD 63,132_CD The_DT approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS as_IN of_IN December_NNP 31_CD ,_, are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2004_CD 2003_CD $_$ 000_CD $_$ 000_CD US_NNP federal_JJ tax_NN NOLs_NNS 25,416_CD 23,468_CD US_NNP state_NN tax_NN NOLs_NNS 93,542_CD 130,755_CD UK_NNP NOLs_NNP 246,966_CD 146,164_CD Canadian_JJ NOLs_NNS 438,523_CD 465,476_CD Foreign_JJ tax_NN jurisdictions_NNS 100,808_CD 188,869_CD The_DT tax_NN losses_NNS shown_VBN above_IN have_VBP the_DT following_VBG expiration_NN dates_NNS :_: December_NNP 31_CD ,_, 2004_CD $_$ 000_CD Within_IN 1_CD year_NN 1,274_CD Within_IN 1-2_CD years_NNS 4,403_CD Within_IN 2-3_CD years_NNS 2,832_CD Within_IN 3-4_CD years_NNS 75,943_CD Within_IN 4-5_CD years_NNS 36,771_CD Within_IN 5-6_CD years_NNS 1,430_CD Within_IN 6-7_CD years_NNS 923_CD After_IN 7_CD years_NNS 95,493_CD Available_JJ indefinitely_RB 686,186_CD As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN had_VBD a_DT valuation_NN allowance_NN of_IN $_$ 153_CD million_CD to_TO reduce_VB its_PRP$ deferred_JJ tax_NN assets_NNS to_TO estimated_VBN realizable_JJ value_NN ._.
The_DT valuation_NN allowance_NN relates_VBZ to_TO the_DT deferred_VBN tax_NN assets_NNS arising_VBG from_IN operating_VBG loss_NN carry-forwards_NNS and_CC capital_NN loss_NN carry-forwards_NNS ,_, which_WDT have_VBP no_DT expiration_NN date_NN ._.
The_DT utilization_NN of_IN operating_VBG loss_NN carry-forwards_NNS is_VBZ ,_, however_RB ,_, restricted_VBN to_TO the_DT taxable_JJ income_NN of_IN the_DT subsidiary_NN generating_VBG the_DT losses_NNS ._.
In_IN addition_NN ,_, capital_NN loss_NN carry-forwards_NNS can_MD be_VB offset_VBN only_RB against_IN capital_NN gains_NNS ._.
As_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN over_IN the_DT periods_NNS in_IN which_WDT the_DT temporary_JJ differences_NNS are_VBP anticipated_VBN to_TO reverse_VB ,_, and_CC reasonable_JJ and_CC feasible_JJ tax-planning_JJ strategies_NNS ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Company_NN will_MD realize_VB the_DT benefits_NNS of_IN these_DT deductible_JJ differences_NNS ,_, net_NN of_IN the_DT valuation_NN allowances_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realizable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
As_IN of_IN December_NNP 31_CD ,_, 2004_CD the_DT Company_NN has_VBZ not_RB made_VBN a_DT UK_NNP tax_NN provision_NN on_IN approximately_RB $_$ 1.4_CD billion_CD of_IN unremitted_JJ earnings_NNS of_IN the_DT Companys_NNP international_JJ subsidiaries_NNS ._.
It_PRP is_VBZ not_RB practical_JJ to_TO determine_VB the_DT amount_NN of_IN unrecognized_JJ deferred_JJ tax_NN liabilities_NNS for_IN temporary_JJ differences_NNS relating_VBG to_TO these_DT investments_NNS ._.
91_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 92_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 27_CD Equity_NN in_IN earnings_NNS losses_NNS of_IN equity-method_JJ investees_NNS 2004 2003 2002_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD GSK_NNP 4,433_CD 3,495_CD 2,592_CD GeneChem_NNP Funds_NNPS see_VBP Note_NN 10_CD 75_CD Other_JJ 2,000_CD 4,552_CD 924_CD 2,508_CD 1,057_CD 1,668_CD The_DT Company_NN has_VBZ accounted_VBN for_IN its_PRP$ commercialization_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP using_VBG the_DT equity-method_NN of_IN accounting_NN ._.
The_DT Company_NN owns_VBZ ,_, but_CC does_VBZ not_RB exercise_VB control_NN over_IN ,_, a_DT 50_CD %_NN share_NN of_IN the_DT partnership_NN ._.
28_CD Stock_NNP incentive_NN plans_VBZ The_DT Company_NN has_VBZ granted_VBN options_NNS to_TO directors_NNS and_CC employees_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT following_VBG six_CD stock_NN option_NN plans_NNS :_: i_FW Shire_FW Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
On_IN February_NNP 28_CD ,_, 2000_CD ,_, the_DT Remuneration_NNP Committee_NNP of_IN the_DT Board_NNP exercised_VBD its_PRP$ powers_NNS to_TO amend_VB the_DT terms_NNS of_IN the_DT Executive_NNP Share_NNP Option_NN Scheme_NN so_RB as_IN to_TO include_VB a_DT cliff_NN vesting_VBG provision_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ._.
ii_FW Shire_FW Pharmaceuticals_NNPS Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP 2000_CD Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN this_DT scheme_NN are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT option_NN granted_VBN prior_RB to_TO August_NNP 2002_CD ,_, if_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN becomes_VBZ exercisable_JJ in_IN full_JJ ._.
If_IN it_PRP increases_VBZ by_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN the_DT same_JJ three-year_JJ period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS granted_VBN become_VBN exercisable_JJ ._.
Given_VBN Shires_NNPS development_NN ,_, it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT earnings_NNS per_IN share_NN based_VBN measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS were_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP fully_RB diluted_VBD earnings_NNS per_IN share_NN growth_NN over_IN a_DT three-year_JJ period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Price_NNP Index_NNP RPI_NNP on_IN average_NN a_DT year_NN for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 3_CD %_NN per_IN annum_NN directors_NNS ,_, RPI_NNP plus_CC 5_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 5_CD %_NN per_IN annum_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 7_CD %_NN per_IN annum_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN per_IN annum_NN The_DT new_JJ earnings_NNS per_IN share_NN performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
After_IN consultation_NN with_IN certain_JJ of_IN its_PRP$ institutional_JJ shareholders_NNS ,_, the_DT Company_NN has_VBZ decided_VBN that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN from_IN 2004_CD onwards_NNS ,_, the_DT retest_NN of_IN the_DT performance_NN condition_NN if_IN Shires_NNP earnings_NNS per_IN share_NN growth_NN has_VBZ fallen_VBN short_JJ of_IN the_DT minimum_JJ annual_JJ average_JJ percentage_NN increase_NN over_IN the_DT three-year_JJ period_NN from_IN grant_NN ,_, has_VBZ been_VBN changed_VBN ._.
The_DT performance_NN condition_NN will_MD be_VB retested_VBN once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
Hence_RB the_DT level_NN of_IN earnings_NNS per_IN share_NN growth_NN in_IN the_DT next_JJ two_CD years_NNS needs_VBZ to_TO be_VB consequentially_RB higher_JJR to_TO meet_VB the_DT test_NN ._.
Six_CD weeks_NNS prior_RB to_TO the_DT expiration_NN date_NN ,_, any_DT options_NNS that_WDT have_VBP not_RB become_VB exercisable_JJ at_IN an_DT earlier_JJR date_NN ,_, automatically_RB vest_NN without_IN reference_NN to_TO the_DT performance_NN criteria_NNS ._.
92_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 93_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_NNS continued_VBD iii_NN Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
iv_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
v_NN Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP Options_NNPS issued_VBN under_IN the_DT SLI_NNP Plan_NNP were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT company_NN acquired_VBN by_IN the_DT Company_NN on_IN March_NNP 23_CD ,_, 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN Shire_NNP ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SLI_NNP Plan_NNP ._.
vi_FW BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP on_IN May_NNP 11_CD ,_, 2001_CD ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChem_NNP Pharma_NNP Inc._NNP s_VBZ common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN Shire_NNP ._.
All_DT BioChem_NNP Pharma_NNP Inc._NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN ._.
In_IN a_DT period_NN of_IN ten_CD years_NNS ,_, not_RB more_JJR than_IN 10_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN Shire_NNP may_MD be_VB placed_VBN under_IN option_NN under_IN any_DT employee_NN share_NN scheme_NN ._.
In_IN addition_NN ,_, the_DT following_VBG terms_NNS apply_VB to_TO options_NNS that_WDT may_MD be_VB granted_VBN under_IN the_DT various_JJ plans_NNS :_: 2000_CD Executive_NNP Scheme_NNP :_: the_DT maximum_JJ number_NN of_IN Shire_NNP ordinary_JJ shares_NNS over_IN which_WDT incentive_NN options_NNS may_MD be_VB granted_VBN under_IN Part_NN 3_CD of_IN the_DT scheme_NN is_VBZ 25,000,000_CD ._.
Stock_NNP Purchase_NNP Plan_NNP :_: up_RP to_TO 2,000,000_CD Shire_NNP ordinary_JJ shares_NNS ._.
The_DT following_JJ stock_NN options_NNS were_VBD outstanding_JJ as_IN of_IN December_NNP 31_CD ,_, 2004_CD :_: Expiration_NN period_NN Scheme_NNP Number_NNP of_IN options_NNS from_IN date_NN of_IN issue_NN Vesting_JJ period_NN Executive_NNP Scheme_NNP 2,274,395_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS 2000_CD Executive_NNP Scheme_NNP 20,233,565_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS Sharesave_NNP Scheme_NNP 319,432_CD 6_CD months_NNS after_IN vesting_VBG 3_CD or_CC 5_CD years_NNS Stock_NNP Purchase_NNP Plan_NNP 435,977_CD On_IN vesting_VBG date_NN 27_CD months_NNS SLI_NNP Plan_NNP 4,710_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP BioChem_NNP Plan_NNP 4,075,546_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP 27,343,625_CD 93_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 94_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_NNS continued_VBD A_DT summary_NN of_IN the_DT status_NN of_IN the_DT Companys_NNP stock_NN option_NN plans_NNS as_IN of_IN December_NNP 31_CD ,_, 2004_CD ,_, 2003_CD and_CC 2002_CD and_CC of_IN the_DT related_JJ transactions_NNS during_IN the_DT periods_NNS then_RB ended_VBD is_VBZ presented_VBN below_IN :_: Weighted_JJ average_JJ exercise_NN price_NN Year_NN to_TO December_NNP 31_CD ,_, 2004_CD $_$ Number_CD of_IN shares_NNS Outstanding_JJ as_IN of_IN beginning_NN of_IN period_NN 10.92_CD 25,995,543_CD Granted_VBN 9.92_CD 6,966,411_CD Exercised_VBN 7.16_CD 2,097,716_CD Forfeited_NNP 14.62_CD 3,520,613_CD Outstanding_JJ as_IN of_IN end_NN of_IN period_NN 11.30_CD 27,343,625_CD Exercisable_JJ as_IN of_IN end_NN of_IN period_NN 16.70_CD 8,728,709_CD 6,665,144_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
These_DT options_NNS were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT market_NN value_NN on_IN the_DT date_NN of_IN grant_NN ._.
94,861_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 3.74_CD approximately_RB $_$ 7.22_CD ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
173,613_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 3.92_CD approximately_RB $_$ 7.57_CD ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
In_IN relation_NN to_TO a_DT grant_NN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 8.06_CD in_IN 2001_CD ,_, an_DT additional_JJ 32,793_CD options_NNS were_VBD granted_VBN at_IN a_DT price_NN of_IN 4.58_CD on_IN the_DT 2004_CD maturity_NN date_NN ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD is_VBZ $_$ 9.99_CD ._.
Weighted_JJ average_JJ exercise_NN price_NN Year_NN to_TO December_NNP 31_CD ,_, 2003_CD $_$ Number_CD of_IN shares_NNS Outstanding_JJ as_IN of_IN beginning_NN of_IN period_NN 11.55_CD 20,051,297_CD Granted_VBN 6.30_CD 9,407,852_CD Exercised_VBN 5.12_CD 1,039,439_CD Forfeited_NNP 11.28_CD 2,424,167_CD Outstanding_JJ as_IN of_IN end_NN of_IN period_NN 10.92_CD 25,995,543_CD Exercisable_JJ as_IN of_IN end_NN of_IN period_NN 12.79_CD 8,989,450_CD 8,819,199_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
182,639_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 3.86_CD approximately_RB $_$ 6.91_CD ._.
406,014_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 4.09_CD approximately_RB $_$ 7.32_CD ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD is_VBZ $_$ 6.39_CD ._.
94_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 95_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN 28_CD Stock_NNP incentive_NN plans_NNS continued_VBD Weighted_JJ average_JJ exercise_NN price_NN Year_NN to_TO December_NNP 31_CD ,_, 2002_CD $_$ Number_CD of_IN shares_NNS Outstanding_JJ as_IN of_IN beginning_NN of_IN period_NN 10.80_CD 16,249,844_CD Granted_VBN 8.49_CD 6,179,894_CD Exercised_VBN 3.52_CD 1,940,546_CD Forfeited_NNP 11.07_CD 437,895_CD Outstanding_JJ as_IN of_IN end_NN of_IN period_NN 11.55_CD 20,051,297_CD Exercisable_JJ as_IN of_IN end_NN of_IN period_NN 9.24_CD 8,491,051_CD 4,539,529_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
186,052_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 5.02_CD approximately_RB $_$ 8.08_CD ._.
18,342_CD and_CC 1,435,971_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 3.19_CD and_CC 5.44_CD approximately_RB $_$ 5.14_CD and_CC $_$ 8.76_CD ,_, respectively_RB ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2002_CD is_VBZ $_$ 8.91_CD ._.
In_IN the_DT rest_NN of_IN the_DT world_NN ,_, the_DT Company_NN acquired_VBD the_DT license_NN to_TO develop_VB and_CC commercialize_VB NRP104_NNP ._.
The_DT Company_NN paid_VBD an_DT initial_JJ sum_NN of_IN $_$ 50_CD million_CD on_IN signing_NN ,_, and_CC there_EX is_VBZ a_DT further_JJ $_$ 50_CD million_CD due_JJ upon_IN acceptance_NN of_IN filing_NN of_IN the_DT New_NNP Drug_NNP Application_NNP by_IN the_DT FDA_NNP and_CC up_RB to_TO $_$ 300_CD million_CD in_IN milestone_NN payments_NNS following_VBG the_DT first_JJ commercial_JJ sale_NN depending_VBG on_IN the_DT characteristics_NNS of_IN the_DT FDA_NNP approved_VBD product_NN labeling_VBG ._.
A_DT $_$ 5_CD million_CD milestone_NN payment_NN is_VBZ payable_JJ following_VBG the_DT first_JJ commercial_JJ sale_NN in_IN specified_VBN European_JJ countries_NNS ._.
An_DT additional_JJ $_$ 100_CD million_CD milestone_NN would_MD be_VB payable_JJ as_IN a_DT sales_NNS bonus_NN upon_IN achieving_VBG a_DT significant_JJ sales_NNS target_NN ._.
The_DT Company_NN may_MD be_VB entitled_VBN to_TO refunds_NNS of_IN amounts_NNS previously_RB paid_VBN in_IN the_DT event_NN of_IN a_DT delayed_JJ product_NN approval_NN ._.
95_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 96_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN thousands_NNS of_IN US_NNP dollars_NNS ,_, except_IN where_WRB indicated_VBN Quarterly_JJ results_NNS of_IN operations_NNS unaudited_JJ The_DT following_VBG table_NN presents_NNS summarized_VBN unaudited_JJ quarterly_JJ results_NNS for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD ._.
The_DT 2003_CD results_NNS for_IN all_DT quarterly_JJ periods_NNS and_CC Q1_CD ,_, 2004_CD presented_VBN have_VBP been_VBN restated_VBN to_TO reflect_VB the_DT disposal_NN of_IN the_DT vaccines_NNS business_NN which_WDT has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT discontinued_VBN operation_NN ._.
See_VB Note_NN 3_CD for_IN further_JJ details_NNS ._.
During_IN Q3_NNP 2004_CD the_DT Company_NN recorded_VBD a_DT loss_NN on_IN redemption_NN of_IN the_DT convertible_JJ loan_NN notes_NNS of_IN $_$ 7.4_CD million_CD ,_, which_WDT resulted_VBD from_IN the_DT write-off_NN of_IN unamortized_JJ debt_NN issuance_NN costs_NNS ._.
Diluted_NNP EPS_NNP would_MD have_VB been_VBN 15.4_CD ,_, or_CC 0.1_CD higher_JJR ,_, without_IN this_DT loss_NN on_IN redemption_NN ._.
These_DT were_VBD in_IN respect_NN of_IN the_DT implementation_NN of_IN the_DT new_JJ business_NN model_NN in_IN 2004_CD and_CC the_DT closure_NN of_IN Lead_JJ Optimization_NN together_RB with_IN the_DT exit_NN of_IN certain_JJ properties_NNS in_IN 2003_CD ._.
Included_VBN in_IN 2001_CD were_VBD $_$ 29.7_CD million_CD of_IN asset_NN impairment_NN charges_NNS ,_, $_$ 83.5_CD million_CD of_IN merger_NN transaction_NN expenses_NNS and_CC $_$ 10.2_CD million_CD of_IN costs_NNS in_IN relation_NN to_TO the_DT disposition_NN of_IN certain_JJ assets_NNS ._.
All_DT of_IN these_DT costs_NNS were_VBD in_IN relation_NN to_TO the_DT merger_NN with_IN BioChem_NNP in_IN 2001_CD ._.
2_CD Total_JJ other_JJ income_NN ,_, net_JJ includes_VBZ $_$ 14.9_CD million_CD on_IN the_DT sale_NN of_IN a_DT portfolio_NN investment_NN in_IN 2004_CD ._.
In_IN 2001_CD there_EX was_VBD a_DT $_$ 55.7_CD million_CD writedown_NN of_IN investments_NNS related_VBN to_TO the_DT BioChem_NNP merger_NN ._.
3_CD As_IN a_DT consequence_NN of_IN the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
142_CD ,_, with_IN effect_NN from_IN January_NNP 1_CD ,_, 2002_CD ,_, the_DT amortization_NN expense_NN shown_VBN for_IN 2001_CD and_CC 2000_CD in_IN the_DT selected_VBN consolidated_JJ financial_JJ data_NNS presented_VBN is_VBZ not_RB on_IN a_DT consistent_JJ basis_NN of_IN accounting_NN with_IN subsequent_JJ periods_NNS ._.
Net_JJ income_NN for_IN 2001_CD and_CC 2000_CD would_MD have_VB been_VBN $_$ 49.5_CD million_CD and_CC $_$ 223.0_CD million_CD ,_, respectively_RB ._.
97_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 98_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD General_NNP Directors_NNS The_DT summary_NN financial_JJ statement_NN does_VBZ not_RB contain_VB sufficient_JJ The_DT Directors_NNS who_WP served_VBD during_IN the_DT year_NN were_VBD as_IN follows_VBZ :_: information_NN to_TO allow_VB for_IN as_RB full_JJ an_DT understanding_NN of_IN the_DT results_NNS and_CC state_NN of_IN affairs_NNS of_IN the_DT Company_NN or_CC Group_NNP and_CC of_IN the_DT policies_NNS and_CC Dr_NNP James_NNP Cavanaugh_NNP arrangements_NNS concerning_VBG directors_NNS remuneration_NN ,_, as_RB would_MD Chairman_NNP ,_, non-executive_JJ Director_NNP be_VB provided_VBN by_IN the_DT full_JJ annual_JJ financial_JJ statements_NNS and_CC reports_NNS ._.
Chairman_NNP of_IN the_DT Nomination_NNP Committee_NNP The_NNP summary_NN financial_JJ statement_NN is_VBZ prepared_VBN under_IN UK_NNP GAAP_NNP ._.
For_IN further_JJ information_NN ,_, the_DT full_JJ UK_NNP statutory_JJ accounts_NNS ,_, the_DT Mr_NNP Matthew_NNP Emmens_NNP auditors_NNS report_VBP on_IN those_DT accounts_NNS and_CC the_DT Directors_NNS report_VBP Chief_NNP Executive_NNP Officer_NNP should_MD be_VB consulted_VBN ._.
Mr_NNP Angus_NNP Russell_NNP In_IN accordance_NN with_IN Section_NN 239_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD Chief_NNP Financial_NNP Officer_NNP shareholders_NNS have_VBP a_DT right_NN and_CC can_MD elect_VB to_TO obtain_VB the_DT full_JJ report_NN and_CC accounts_NNS free_JJ of_IN charges_NNS by_IN writing_VBG to_TO :_: Dr_NNP Barry_NNP Price_NNP Senior_NNP non-executive_JJ Director_NNP The_NNP Company_NNP Secretary_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Hampshire_NNP International_NNP Business_NNP Park_NNP The_NNP Hon_NNP James_NNP Grant_NNP Chineham_NNP Non-executive_JJ Director_NNP Basingstoke_NNP Hampshire_NNP Mr_NNP Ronald_NNP Nordmann_NNP RG24_NNP 8EP_NNP Non-executive_JJ Director_NNP Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP until_IN July_NNP 2004_CD The_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS are_VBP signed_VBN on_IN behalf_NN of_IN the_DT Board_NNP by_IN AC_NNP Russell_NNP ,_, Chief_NNP Financial_NNP Officer_NNP ._.
Mr_NNP Robin_NNP Buchanan_NNP Non-executive_JJ Director_NNP The_NNP Companys_NNP auditors_NNS have_VBP given_VBN an_DT unqualified_JJ report_NN on_IN the_DT statutory_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
The_DT Mr_NNP David_NNP Kappler_NNP report_NN did_VBD not_RB contain_VB any_DT statement_NN under_IN Section_NN 237_CD 2_CD or_CC 3_CD appointed_VBN 5_CD April_NNP 2004_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Non-executive_JJ Director_NNP Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP with_IN effect_NN from_IN July_NNP 2004_CD Summary_NNP directors_NNS report_VBP Dr_NNP Wilson_NNP Totten_NNP Results_NNS and_CC dividends_NNS stepped_VBD down_RB 25_CD May_NNP 2004_CD The_DT profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN of_IN the_DT Group_NNP was_VBD Chief_NNP Scientific_NNP Officer_NNP 57.4_CD million_CD 2003_CD :_: loss_NN of_IN 298.3_CD million_CD ._.
The_DT net_JJ assets_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2004_CD were_VBD 2,232.2_CD million_CD 2003_CD :_: 2,308.5_CD million_CD ._.
Business_NNP review_NN A_DT review_NN of_IN the_DT Groups_NNS business_NN and_CC important_JJ events_NNS during_IN the_DT Mr_NNP Angus_NNP Russell_NNP year_NN and_CC likely_JJ future_NN developments_NNS is_VBZ set_VBN out_RP in_IN the_DT Chairmans_NNPS Chief_NNP Financial_NNP Officer_NNP statement_NN ,_, the_DT Chief_NNP Executive_NNP Officers_NNPS review_NN ,_, the_DT financial_JJ review_NN 15_CD April_NNP 2005_CD and_CC the_DT Directors_NNS remuneration_NN report_NN in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS ,_, which_WDT are_VBP similar_JJ to_TO the_DT statements_NNS contained_VBN in_IN the_DT annual_JJ review_NN at_IN the_DT front_NN of_IN this_DT document_NN which_WDT form_VBP part_NN of_IN this_DT summary_NN financial_JJ statement_NN ._.
98_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 99_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD Independent_NNP Auditors_NNS Statement_NN to_TO the_DT Members_NNS of_IN Shire_NNP Basis_NNP of_IN opinion_NN Pharmaceuticals_NNP Group_NNP plc_NN :_: We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN bulletin_NN 1999_CD 6_CD We_PRP have_VBP examined_VBN the_DT summary_NN financial_JJ statement_NN which_WDT The_DT Auditors_NNS Statement_NN on_IN the_DT Summary_NNP Financial_NNP Statement_NNP comprises_VBZ the_DT summary_NN Directors_NNS report_NN ,_, consolidated_JJ profit_NN and_CC issued_VBN by_IN the_DT Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT United_NNP loss_NN account_NN ,_, consolidated_JJ balance_NN sheet_NN ,_, consolidated_JJ cash_NN flow_NN Kingdom_NNP ._.
We_PRP have_VBP not_RB considered_VBN the_DT effects_NNS of_IN any_DT events_NNS statement_NN ,_, the_DT consolidated_JJ statement_NN of_IN total_JJ recognized_VBN gains_NNS between_IN the_DT date_NN on_IN which_WDT we_PRP signed_VBD our_PRP$ report_NN on_IN the_DT annual_JJ and_CC losses_NNS and_CC Notes_NNS 1_CD to_TO 4_CD of_IN the_DT summary_NN financial_JJ statements_NNS ._.
accounts_NNS 24_CD March_NNP 2005_CD and_CC the_DT date_NN of_IN this_DT statement_NN ._.
This_DT report_NN is_VBZ made_VBN solely_RB to_TO the_DT Companys_NNPS members_NNS ,_, as_IN a_DT body_NN ,_, Opinion_NNP in_IN accordance_NN with_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
In_IN our_PRP$ opinion_NN ,_, the_DT summary_NN financial_JJ statement_NN is_VBZ consistent_JJ with_IN Our_PRP$ work_NN has_VBZ been_VBN undertaken_VBN so_RB that_IN we_PRP might_MD state_VB to_TO the_DT the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS Companys_NNPS members_NNS those_DT matters_NNS we_PRP are_VBP required_VBN to_TO state_NN remuneration_NN report_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN for_IN the_DT to_TO them_PRP in_IN an_DT auditors_NNS report_NN and_CC for_IN no_DT other_JJ purpose_NN ._.
To_TO the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD and_CC complies_VBZ with_IN the_DT applicable_JJ fullest_JJS extent_NN permitted_VBN by_IN law_NN ,_, we_PRP do_VBP not_RB accept_VB or_CC assume_VB requirements_NNS of_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT responsibility_NN to_TO anyone_NN other_JJ than_IN the_DT Company_NN and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
Companys_NNS members_NNS as_IN a_DT body_NN ,_, for_IN our_PRP$ audit_NN work_NN ,_, for_IN this_DT report_NN ,_, for_IN our_PRP$ audit_NN report_NN ,_, or_CC for_IN the_DT opinions_NNS we_PRP have_VBP formed_VBN ._.
Respective_JJ responsibilities_NNS of_IN Directors_NNS and_CC auditors_NNS The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN in_IN accordance_NN with_IN applicable_JJ United_NNP Kingdom_NNP law_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN of_IN the_DT summary_NN financial_JJ statement_NN with_IN the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS remuneration_NN report_NN ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN Deloitte_NNP &_CC Touche_NNP LLP_NNP as_IN described_VBN in_IN the_DT contents_NNS section_NN ,_, and_CC consider_VB the_DT implications_NNS Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS Reading_VBG or_CC material_NN inconsistencies_NNS with_IN the_DT summary_NN financial_JJ statement_NN ._.
18_CD April_NNP 2005_CD 99_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 100_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD Consolidated_NNP profit_NN and_CC loss_NN account_NN 2004 2003 000 000_CD Turnover_NN :_: Group_NNP and_CC share_NN of_IN joint_JJ venture_NN 752,362_CD 749,853_CD Less_RBR :_: share_NN of_IN joint_JJ ventures_NNS turnover_NN 3,594_CD Continuing_VBG operations_NNS 752,362_CD 746,259_CD Discontinued_VBN operations_NNS 2,169_CD 14,809_CD Group_NNP turnover_NN 754,531_CD 761,068_CD Cost_NN of_IN sales_NNS 84,477_CD 102,384_CD Gross_NNP profit_NN 670,054_CD 658,684_CD Net_JJ operating_NN expenses_NNS 2004_CD :_: including_VBG 81,185,000_CD exceptional_JJ goodwill_NN impairment_NN ,_, 2003_CD :_: 426,362,000_CD 604,359_CD 958,619_CD Operating_NN profit_NN loss_NN 65,695_CD 299,935_CD Continuing_VBG operations_NNS Group_NNP 76,353_CD 285,303_CD Discontinued_VBN operations_NNS 10,658_CD 14,632_CD 65,695_CD 299,935_CD Share_NN of_IN joint_JJ ventures_NNS operating_VBG loss_NN 2,806_CD Share_NN of_IN associates_NNS operating_VBG profit_NN 37_CD Profit_NN on_IN disposal_NN of_IN fixed_JJ asset_NN investment_NN 8,264_CD 698_CD Loss_NN on_IN sale_NN of_IN discontinued_VBN operations_NNS 23,191_CD Finance_NNP income_NN ,_, net_JJ 6,630_CD 3,702_CD Profit_NN loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 57,435_CD 298,341_CD Tax_NNP on_IN profit_NN loss_NN on_IN ordinary_JJ activities_NNS 70,866_CD 65,014_CD Loss_NN for_IN the_DT financial_JJ year_NN 13,431_CD 363,355_CD Dividends_NNPS paid_VBD 1_CD penny_NN per_IN share_NN 4,967_CD Dividends_NNS proposed_VBN 2_CD pence_NN per_IN share_NN 9,952_CD Retained_VBN loss_NN for_IN the_DT year_NN transferred_VBN from_IN reserves_NNS 28,350_CD 363,355_CD Loss_NN per_IN share_NN Basic_JJ 2.7_CD p_NN 72.9_CD p_NN Diluted_NNP 2.7_CD p_NN 72.9_CD p_NN Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 31_CD December_NNP 2004 2003 000 000_CD Loss_NN for_IN the_DT financial_JJ year_NN 13,431_CD 363,355_CD Translation_NN of_IN the_DT financial_JJ statements_NNS of_IN overseas_JJ subsidiaries_NNS 55,510_CD 47,157_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS relating_VBG to_TO the_DT year_NN 68,941_CD 410,512_CD 100_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 101_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD Consolidated_NNP balance_NN sheet_NN 31_CD December_NNP 31_CD December_NNP 2004 2003 000 000_CD Fixed_JJ assets_NNS Intangible_JJ assets_NNS intellectual_JJ property_NN 160,033_CD 171,548_CD Intangible_JJ assets_NNS goodwill_NN 1,204,056_CD 1,365,583_CD Tangible_JJ assets_NNS 68,415_CD 97,054_CD Fixed_VBN asset_NN investments_NNS 52,721_CD 33,269_CD 1,485,225_CD 1,667,454_CD Current_JJ assets_NNS Stocks_NNS 21,475_CD 25,282_CD Debtors_NNS due_JJ within_IN one_CD year_NN excluding_VBG deferred_JJ tax_NN 157,089_CD 141,046_CD due_JJ within_IN one_CD year_NN deferred_VBN tax_NN 40,097_CD 36,049_CD due_JJ after_IN more_JJR than_IN one_CD year_NN excluding_VBG deferred_JJ tax_NN 20,259_CD 9,224_CD due_JJ after_IN more_JJR than_IN one_CD year_NN deferred_VBN tax_NN 4,023_CD Current_JJ asset_NN investments_NNS 169,199_CD 169,895_CD Restricted_VBN cash_NN 11,265_CD 25,962_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 581,500_CD 595,708_CD 1,004,907_CD 1,003,166_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN 237,446_CD 141,722_CD Net_JJ current_JJ assets_NNS 767,461_CD 861,444_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 2,252,686_CD 2,528,898_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Convertible_JJ debt_NN 60_CD 202,659_CD Other_JJ creditors_NNS 20,415_CD 17,739_CD 20,475_CD 220,398_CD Net_JJ assets_NNS 2,232,211_CD 2,308,500_CD Capital_NN and_CC reserves_NNS Called-up_JJ share_NN capital_NN 24,246_CD 23,895_CD Treasury_NNP shares_NNS 137_CD Share_NN premium_NN 3,279,593_CD 3,218,695_CD Exchangeable_JJ shares_NNS 137,825_CD 190,425_CD Capital_NN reserve_NN 3,135_CD 3,135_CD Other_JJ reserves_NNS 24,247_CD 24,247_CD Profit_NN and_CC loss_NN account_NN 1,236,698_CD 1,151,897_CD Equity_NNP shareholders_NNS funds_NNS 2,232,211_CD 2,308,500_CD 101_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 102_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Summary_NNP financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD Consolidated_NNP cash_NN flow_NN statement_NN 2004 2003 000 000_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 273,732_CD 280,275_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN :_: Interest_NN and_CC other_JJ income_NN received_VBD 14,524_CD 13,165_CD Interest_NN paid_VBN 7,856_CD 9,404_CD Interest_NN element_NN of_IN finance_NN lease_NN rentals_NNS 38_CD 59_CD Distribution_NN from_IN investments_NNS 672_CD Net_JJ cash_NN inflow_NN from_IN returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 7,302_CD 3,702_CD Taxation_NNP :_: Foreign_NNP corporation_NN tax_NN paid_VBN 65,761_CD 66,874_CD Capital_NN expenditure_NN and_CC financial_JJ investments_NNS :_: Purchase_NN of_IN investments_NNS 4,818_CD 3,447_CD Purchase_NN of_IN intangible_JJ assets_NNS 16,299_CD 30,238_CD Purchase_NN of_IN tangible_JJ fixed_JJ assets_NNS 33,445_CD 31,400_CD Proceeds_NNS from_IN sale_NN of_IN investments_NNS 15,074_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ assets_NNS 1,918_CD Proceeds_NNS from_IN sale_NN of_IN tangible_JJ fixed_JJ assets_NNS 9,587_CD 1,060_CD Net_JJ cash_NN outflow_NN for_IN capital_NN expenditure_NN and_CC financial_JJ investments_NNS 27,983_CD 64,025_CD Acquisitions_NNPS and_CC disposals_NNS :_: Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN 17,106_CD 559_CD Net_JJ cash_NN inflow_NN from_IN disposals_NNS 17,106_CD 559_CD Equity_NNP dividends_NNS paid_VBD 4,967_CD Cash_NN inflow_NN before_IN management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 199,429_CD 153,637_CD Management_NN of_IN liquid_JJ resources_NNS :_: Decrease_NN increase_NN in_IN cash_NN placed_VBN on_IN short-term_JJ deposit_NN 9,017_CD 17,848_CD Financing_NN :_: Issue_NN of_IN ordinary_JJ share_NN capital_NN 423_CD Exercise_NN of_IN share_NN options_NNS 7,285_CD 3,114_CD Repurchase_NN of_IN ordinary_JJ share_NN capital_NN 137_CD 31,808_CD Capital_NN element_NN of_IN finance_NN lease_NN rentals_NNS 3,364_CD 160_CD Net_JJ decrease_NN in_IN debt_NN during_IN the_DT year_NN 199,918_CD 18,053_CD Net_JJ cash_NN outflow_NN from_IN financing_VBG 195,711_CD 46,907_CD Decrease_NN increase_NN in_IN cash_NN in_IN the_DT year_NN 5,299_CD 124,578_CD 102_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 103_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 1_CD Basis_NN of_IN preparation_NN The_DT summary_NN financial_JJ statement_NN has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN the_DT accounting_NN policies_NNS set_VBN out_RP in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
2_CD Directors_NNS remuneration_JJ Aggregate_NNP Directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2004 2003 000 000_CD Emoluments_NNP 2,592_CD 2,256_CD Money_NN purchase_NN pension_NN contributions_NNS 278_CD 4,676_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 118_CD 114_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 86_CD 276_CD Compensation_NNP for_IN loss_NN of_IN office_NN 1,335_CD 3,074_CD 8,657_CD Directors_NNS emoluments_VBZ Cash_NNP Non-cash_JJ Total_JJ Total_JJ Salary_NNP Bonus_NNP Fees_NNS benefits_NNS in_IN kind_NN benefits_NNS in_IN kind_NN 2004_CD 2003_CD Director_NNP 000 000 000 000_CD 000 000 000_CD Executive_NNP i_FW ii_FW Mr_NNP Matthew_NNP Emmens_NNP 545 437 437_CD 1,419_CD 699_CD Mr_NNP Angus_NNP Russell_NNP 342_CD 257_CD 11_CD 4_CD 614_CD 499_CD iii_FW Dr_FW Wilson_NNP Totten_NNP 142_CD 107_CD 4_CD 3_CD 256_CD 531_CD iv_NN Mr_NNP Rolf_NNP Stahel_NNP 311_CD 1,029_CD 801_CD 452_CD 7_CD 2,289_CD 2,040_CD Non-executive_JJ v_NN Dr_NNP James_NNP Cavanaugh_NNP 75_CD 75_CD 54_CD Dr_NNP Barry_NNP Price_NNP 60_CD 60_CD 43_CD The_DT Hon_NNP James_NNP Grant_NNP 40_CD 40_CD 35_CD Mr_NNP Ronald_NNP Nordmann_NNP 54_CD 54_CD 45_CD Mr_NNP Robin_NNP Buchanan_NNP 40_CD 40_CD 16_CD vi_FW Mr_NNP David_NNP Kappler_NNP 34_CD 34_CD vii_NN Dr_NNP Francesco_NNP Bellini_NNP 11_CD vii_FW Mr_NNP Gerard_NNP Veilleux_NNP 12 303 303 216_CD Total_JJ 1,029_CD 801 303 452_CD 7_CD 2,592_CD 2,256_CD Notes_NNP i_FW Paid_NNP in_IN US$_$ ,_, Mr_NNP Emmens_NNP annual_JJ salary_NN in_IN 2004_CD was_VBD $_$ 999,319_CD ._.
ii_FW The_DT Company_NN underwent_VBD a_DT major_JJ internal_JJ reorganisation_NN in_IN 2004_CD which_WDT resulted_VBD in_IN the_DT Company_NN selecting_VBG Philadelphia_NNP as_IN its_PRP$ US_NNP corporate_JJ headquarters_NNS ._.
103_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 104_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Notes_NNS to_TO the_DT summary_NN financial_JJ statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD 3_CD Loss_NN per_IN share_NN Basic_JJ EPS_NNP is_VBZ based_VBN on_IN the_DT net_JJ profit_NN or_CC loss_NN attributable_JJ to_TO ordinary_JJ shareholders_NNS divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT year_NN ._.
Share_NN options_NNS to_TO purchase_VB approximately_RB 16.6_CD million_CD ordinary_JJ shares_NNS for_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD were_VBD not_RB dilutive_JJ and_CC were_VBD therefore_RB excluded_VBN from_IN the_DT computation_NN of_IN loss_NN earnings_NNS per_IN share_NN 2003_CD :_: 17.0_CD million_CD ._.
Warrants_NNS to_TO purchase_VB approximately_RB 1.3_CD million_CD ordinary_JJ shares_NNS for_IN the_DT year_NN to_TO 31_CD December_NNP 2003_CD were_VBD not_RB dilutive_JJ and_CC were_VBD therefore_RB excluded_VBN from_IN the_DT computation_NN of_IN loss_NN per_IN share_NN ._.
Basic_JJ and_CC diluted_JJ 2004 2003 000 000_CD Loss_NN for_IN the_DT financial_JJ year_NN 13,431_CD 363,355_CD The_DT weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN each_DT year_NN are_VBP as_IN follows_VBZ :_: 2004_CD 2003_CD Number_NNP Number_NNP For_IN basic_JJ and_CC diluted_JJ EPS_NNP 496,306,604_CD 498,212,826_CD 4_CD Operating_NN profit_NN loss_NN Operating_NN profit_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG crediting_VBG :_: 2004 2003 000 000_CD Depreciation_NN and_CC amounts_NNS written_VBN off_RP tangible_JJ fixed_JJ assets_NNS owned_VBN 12,409_CD 18,772_CD held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS 107_CD 597_CD Amortisation_NNP and_CC amounts_VBZ written_VBN off_RP intellectual_JJ property_NN 29,164_CD 30,405_CD Amortisation_NNP and_CC amounts_VBZ written_VBN off_RP goodwill_NN 158,283_CD 533,115_CD Research_NNP and_CC development_NN 112,534_CD 131,654_CD Reorganisation_NN costs_NNS 26,529_CD 14,597_CD Government_NN grants_NNS 14_CD 2,169_CD Operating_NN lease_NN rentals_NNS plant_NN and_CC machinery_NN 3,580_CD 3,591_CD other_JJ 3,541_CD 3,868_CD Auditors_NNS remuneration_NN for_IN audit_NN services_NNS 1_CD Group_NNP 1,715_CD 630_CD 1_CD Company_NN 60_CD 20_CD Auditors_NNS remuneration_NN for_IN non-audit_JJ services_NNS 2_CD Group_NNP audit_NN related_VBN 1,172_CD 1,015_CD 3_CD Group_NNP tax_NN 2,583_CD 1,145_CD 4_CD Group_NNP other_JJ 100_CD 177_CD 4_CD Company_NN other_JJ 75_CD 1_CD Audit_NNP fees_NNS consisted_VBD of_IN audit_NN work_NN only_RB the_DT Companys_NNPS auditors_NNS can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN statutory_JJ audits_NN ,_, and_CC in_IN 2004_CD included_VBD the_DT audit_NN in_IN relation_NN to_TO internal_JJ control_NN over_IN US_NNP GAAP_NNP Form_NN 10-K_JJ financial_JJ reporting_NN ._.
104_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 105_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP head_NN office_NN and_CC main_JJ operating_NN locations_NNS Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP Italia_NNP S._NNP p._NNP A._NN Suite_NNP 500_CD Ville_NNP Saint-Laurent_NNP ,_, Qubec_NNP H4S_NNP 2C9_NNP Canada_NNP Tel_NNP 1_CD 514 787 2300_CD Fax_NN 1_CD 514 787 2427 105_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 106_CD Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shareholder_NN information_NN Registered_NNP office_NN address_NN US_NNP Shareholders_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP i_FW ADSs_NNP Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP The_NNP Companys_NNP American_NNP Depository_NNP Shares_NNP ADSs_NNP ,_, each_DT United_NNP Kingdom_NNP representing_VBG three_CD ordinary_JJ shares_NNS ,_, are_VBP listed_VBN on_IN the_DT NASDAQ_NNP Registered_NNP in_IN England_NNP national_JJ market_NN under_IN the_DT symbol_NN SHPGY_NNP ._.
2883758_CD reports_NNS and_CC other_JJ documents_NNS with_IN the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP SEC_NNP which_WDT are_VBP available_JJ for_IN inspection_NN and_CC Investor_NN relations_NNS copying_VBG at_IN the_DT SECs_NNS public_JJ reference_NN facilities_NNS or_CC can_MD be_VB obtained_VBN Europe_NNP and_CC Rest_VB of_IN the_DT World_NNP :_: Cla_NNP Rosenfeld_NNP by_IN writing_VBG to_TO the_DT Company_NNP Secretary_NNP ._.
Tel_NNP 44_CD 0_CD 1256 894160_CD Fax_NNP 44_CD 0_CD 1256 894708_CD ii_FW ADS_NNPS Depositary_NNP Email_NNP investorrelations@uk_NNP ._.
com_NN Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP is_VBZ the_DT depositary_NN for_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN ADSs_NNS ._.
All_DT enquiries_NNS North_NNP America_NNP :_: Brian_NNP Piper_NNP concerning_VBG ADS_NNPS records_NNS ,_, certificates_NNS or_CC transfer_NN of_IN ordinary_JJ Tel_NNP 1_CD 484 595 8800_CD shares_NNS into_IN ADSs_NNS should_MD be_VB addressed_VBN to_TO :_: Fax_NN 1_CD 484 595 8151_CD Email_NNP bpiper@us_NNS ._.
com_NN Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP PO_NNP Box_NNP 8205_CD www_NN ._.
com_NN Boston_NNP ,_, Massachusetts_NNP 02266-8205_CD USA_NNP Registrars_NNPS and_CC transfer_VB office_NN Tel_NNP 1_CD 781 575 4328_CD All_DT administrative_JJ enquiries_NNS relating_VBG to_TO shareholdings_NNS Fax_NNP 1_CD 781 575 4088_CD should_MD be_VB addressed_VBN to_TO Lloyds_NNP TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_VBN shareholders_NNS name_NN and_CC address_NN ._.
Canadian_JJ Shareholders_NNS i_FW Exchangeable_JJ Shares_NNS of_IN Shire_NNP Acquisition_NNP Inc._NNP ._.
Lloyds_NNP TSB_NNP Registrars_NNPS Exchangeable_JJ shares_NNS in_IN Shire_NNP Acquisition_NNP Inc._NNP are_VBP convertible_JJ Customer_NN Services_NNPS ,_, The_DT Causeway_NNP into_IN three_CD ordinary_JJ shares_NNS of_IN Shire_NNP or_CC one_CD ADS_NNPS representing_VBG three_CD Worthing_JJ ,_, West_NNP Sussex_NNP BN99_NNP 6DA_NNP ordinary_JJ shares_NNS of_IN Shire_NNP ._.
Exchangeable_JJ shares_NNS trade_NN on_IN the_DT United_NNP Kingdom_NNP Toronto_NNP Stock_NNP Exchange_NNP under_IN the_DT symbol_NN SHQ_NNP ._.
Shires_NNP ordinary_JJ Tel_NNP 44 870 600 3970_CD shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP and_CC Shires_NNP ADSs_NNS are_VBP listed_VBN on_IN the_DT NASDAQ_NNP national_JJ market_NN ._.
ii_FW Trustee_NN for_IN Exchangeable_JJ Shareholders_NNS Natcan_NNP Trust_NNP Company_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN of_IN the_DT National_NNP Bank_NNP of_IN Canada_NNP ,_, acts_VBZ as_IN Trustee_NN for_IN Exchangeable_JJ Shareholders_NNS ._.
All_DT enquiries_NNS concerning_VBG Exchangeable_JJ Share_NN records_NNS or_CC conversions_NNS of_IN Exchangeable_JJ Shares_NNS into_IN ordinary_JJ shares_NNS of_IN Shire_NNP or_CC ADSs_NNS should_MD be_VB addressed_VBN to_TO :_: Natcan_NNP Trust_NNP Company_NNP 1100_CD University_NNP Street_NNP Suite_NNP 900_CD Montreal_NNP ,_, Qubec_NNP H3B_NNP 2G7_NNP Canada_NNP Tel_NNP 1_CD 514 871 7171_CD 1_CD 800 341 1419_CD Fax_NN 1_CD 514 871 7442 106_CD 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 107_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Shire_NNP Trade_NNP Marks_NNP |_NNP Cautionary_NNP statements_NNS Shire_NNP Trade_NNP Marks_NNP Cautionary_NNP statements_NNS ADDERALL_NNP XR_NNP mixed_JJ amphetamine_NN salts_VBZ Statements_NNP included_VBD herein_NN that_WDT are_VBP not_RB historical_JJ facts_NNS are_VBP ADDERALL_NNP mixed_JJ amphetamine_NN salts_VBZ forward-looking_JJ statements_NNS ._.
Such_JJ forward-looking_JJ statements_NNS AGRYLIN_NNP anagrelide_NN hydrochloride_NN involve_VBP a_DT number_NN of_IN risks_NNS and_CC uncertainties_NNS and_CC are_VBP subject_JJ AMATINE_NNP midodrine_NN hydrochloride_NN to_TO change_VB at_IN any_DT time_NN ._.
In_IN the_DT event_NN such_JJ risks_NNS or_CC uncertainties_NNS CALCICHEW_NNP calcium_NN carbonate_NN materialize_VBP ,_, Shires_NNP results_NNS could_MD be_VB materially_RB affected_VBN ._.
The_DT risks_NNS CALCICHEW_NNP D3_CD FORTE_NNP calcium_NN carbonate_NN and_CC uncertainties_NNS include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO ,_, risks_NNS associated_VBN CARBATROL_NNP carbamazepine_NN with_IN the_DT inherent_JJ uncertainty_NN of_IN pharmaceutical_JJ research_NN ,_, product_NN COLAZIDE_NNP balsalazide_NN development_NN ,_, manufacturing_NN and_CC commercialization_NN ,_, the_DT impact_NN EQUETRO_NNP carbamazepine_NN of_IN competitive_JJ products_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, the_DT impact_NN FOSRENOL_NNP lanthanum_NN carbonate_NN of_IN those_DT on_IN Shires_NNP Attention_NN Deficit_NNP Hyperactivity_NNP Disorder_NNP ADHD_NNP METHYPATCH_NNP methylphenidate_NN franchise_NN ,_, patents_NNS ,_, including_VBG but_CC not_RB limited_VBN to_TO ,_, legal_JJ challenges_NNS MICROTROL_NNP relating_VBG to_TO Shires_NNP ADHD_NNP franchise_NN ,_, government_NN regulation_NN and_CC PROAMATINE_NNP midodrine_NN hydrochloride_NN approval_NN ,_, including_VBG but_CC not_RB limited_VBN to_TO Health_NNP Canadas_NNP suspension_NN SOLARAZE_NNP diclofenac_JJ sodium_NN 3_CD %_NN of_IN ADDERALL_NNP XR_NNP sales_NNS in_IN Canada_NNP and_CC the_DT expected_VBN product_NN TROXATYL_NNP troxacitabine_NN approval_NN dates_NNS of_IN METHYPATCH_NNP MTS_NNP ADHD_NNP ,_, SPD503_NNP VANIQA_NNP eflornithine_NN hydrochloride_NN ADHD_NNP ,_, SPD465_NNP ADHD_NNP ,_, SPD476_NNP ulcerative_JJ colitis_NNS ,_, and_CC XAGRID_NNP anagrelide_NN hydrochloride_NN NRP104_NNP ADHD_NNP ,_, including_VBG its_PRP$ scheduling_NN classification_NN by_IN the_DT Drug_NNP Enforcement_NNP Agency_NNP in_IN the_DT United_NNP States_NNPS ,_, Shires_NNPS ability_NN to_TO secure_VB new_JJ products_NNS for_IN development_NN ,_, and_CC other_JJ risks_NNS and_CC Third-party_JJ Trade_NNP Marks_NNP uncertainties_NNS detailed_VBN from_IN time_NN to_TO time_NN in_IN Shires_NNP filings_NNS with_IN 3TC_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP ,_, including_VBG its_PRP$ Annual_JJ COMBIVIR_NNP trade_NN mark_NN of_IN GSK_NNP Report_NNP on_IN Form_NN 10-K_NN for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2004_CD ._.
EPIVIR_NNP trade_NN mark_NN of_IN GSK_NNP EPIVIR-HBV_NNP trade_NN mark_NN of_IN GSK_NNP The_NNP statements_NNS of_IN the_DT individuals_NNS and_CC medical_JJ practitioners_NNS HEPTOVIR_VBP trade_NN mark_NN of_IN GSK_NNP appearing_VBG in_IN the_DT operating_NN review_NN on_IN pages_NNS 8_CD to_TO 23_CD of_IN this_DT PENTASA_NNP mesalamine_NN trade_NN mark_NN of_IN Ferring_NNP AS_NNP document_NN have_VBP been_VBN made_VBN by_IN and_CC represent_VB the_DT views_NNS of_IN the_DT REMINYL_NNP galantamine_NN hydrobromide_NN named_VBN individuals_NNS ._.
The_DT views_NNS represented_VBN are_VBP those_DT of_IN the_DT trade_NN mark_NN of_IN Johnson_NNP &_CC Johnson_NNP named_VBD medical_JJ practitioners_NNS and_CC should_MD not_RB necessarily_RB be_VB TRIZIVIR_JJ trade_NN mark_NN of_IN GSK_NNP taken_VBN to_TO represent_VB the_DT views_NNS of_IN Shire_NNP ._.
ZEFFIX_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP 107_NNP 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP 108_CD Designed_VBN and_CC produced_VBN by_IN Bostock_NNP and_CC Pollitt_NNP Limited_NNP ,_, London_NNP Printed_NNP in_IN the_DT UK_NNP by_IN Butler_NNP and_CC Tanner_NNP The_DT paper_NN used_VBN in_IN this_DT publication_NN is_VBZ Elemental_JJ Chlorine_NNP Free_NNP ECF_NNP sourced_VBD from_IN sustainably_RB managed_VBN forests_NNS ._.
5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP IBC109_NNP 5977_CD Accounts_NNPS 2004_CD ._.
qxd_NN 5_CD 9_CD 05_CD 5:26_CD PM_NNP Page_NNP BC110_NNP Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP United_NNP Kingdom_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Fax_NNP 44_CD 0_CD 1256 894708_CD www_NN ._.
